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Certain recent, dramati~< developments in the field of insulin research, 
therefore, were not included in this review. Most important are the findings 
that the insulin receptor consists of two 125,000 M. W. a subunits and two 
90,000 M. W. B subunits (M. Czech, A mer. J. Med. 70: 142, 1981). The a subunit 
presumably binds insulin, while the B subunit, which is highly susceptible to 
proteolytic cleavage, possesses kinase activity and phosphorylates itself at a 
tyrosine residue in response to binding of the hormone (M. Kasuga et al., 
Science 215: 185, 1982; Roth and Cassell, Science 219: 299, 1983). Binding of 
insulin activates a membrane protease which cleaves a glycopeptide mediator 
from the receptor. This mediator stimulates glycogen synthetase and inhibits 
glycogen phosphorylase by activating glycogen synthetase phosphatase and 
inactivating glycogen synthetase kinase (phosphorylase b kinase kinase, cAMP-
dependent protein kinase), stimulates mitochondrial pyruvate dehydrogenase by 
activating the phosphatase that dephosphorylates the inactive dehydrogenase's 
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a subunit, inhibits the (Ca ++ + Mg ++ )-ATPase of adipocyte plasma meJ?brane 
by decreasing enzyme phosphorylation, and activates the endo-plasmic reticu-
lum phosphodiesterase (Czech, 1981; Chan and McDonald, J. Bioi. Chern. 257: 
7443, 1982; J. Larner et al., Rec. Prog. Horm. Res. 38: 511, 1982). 
Insertion of the human insulin gene into the genome of the bacterium 
Escherichia coli, resulting in microbial production of human insulin on an 
industrial scale, also was not reviewed. This achievement represents the first 
commercial health care product derived from recombinant DNA technology (I. 
S. Johnson, Science 219: 632, 1983). I believe, however, that these develop-
ments do not appreciably affect justification of the research described or 
evaluation of the results reported:·in this dissertation. 
M.E.K. 
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CHAPTER I 
INTRODUCTION 
ST ATE~ENT OF THE PROBLEM 
When Frederick Sanger completed the elucidation of the primary 
structure of bovine insulin in 1955, all appeared right with the world of insulin. 
The hormone had been purified to a high degree, making possible the effective 
treatment of diabetes mellitus. The physiologic effects of insulin were well 
understood and its site of biosynthesis and secretion was lmown. Many of the 
hormone's physicochemical properties, including its minimum molecular weight 
and aggregative behavior, were lmown. Sanger's accomplishment had verified 
several fundamental tenets of protein chemistry and opened new areas of 
investigation. Insulin had been crystallized in several different forms and the 
zinc atoms coordinately bonded in the hexamer were easily replaced by heavy 
metal atoms, promising another seminal accomplishment of protein chemistry: 
the elucidation of a protein's tertiary structure by x-ray diffraction. In vivo 
bioassays of increased sensitivity and a new in vitro rat diaphragm bioassy made 
possible the measurement of insulin in blood for the first time. A thorough 
understanding of the cause of diabetes as well as a possible cure for the disease 
appeared imminent. Yet, within five years, the question of circulating insulin 
and its relation to normal and diabetic physiology was characterized by a state 
of utter confusion. 
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With the introduction of in vitro bioassays for insulin, which measure what 
--
was termed insulin-like activity (ILA), a plethora of substances that mimic 
insulin effects measured by the assays (e.g_., stimulation of glucose uptake, 
glycogen synthesis or carbon dioxide production), but do not exhibit certain 
physicochemical properties of the hormone, were discovered in human serum and 
plasma. In 1958, an in vitro bioassay for insulin using rat epididymal fat pads 
was introduced (Martin et al., 1958; Ref. 393). Although this assay was at least 
ten times more sensitive than the diaphragm assay, it was immediately noted 
that serum insulin levels measured with the fat pad assay were 5-20 times higher 
than those found using the latter assay. 
Antoniades et al. (1965; Ref. 511, 512) then found that Dowex cation 
-- ~· 
exchange resin used to prepare human blood plasma, when eluted with strong 
acid or alkali, yielded significant quantities of ILA detectable by the fat pad 
assay, but not by the diaphragm assay. When this cationic serum protein fraction 
was treated with acid, alkali, acid-ethanol or an aqueous extract of adipose 
tissue, the ILA was detectable by the diaphragm assay, was found to reside in a 
soluble, anionic fraction, and was neutralized by anti-insulin serum. This 
treatment also generated an insoluble, cationic protein fraction, suggesting a 
serum insulin-binding protein dissociated from the hormone by a factor produced 
by adipose tissue (Antoniades, 1961; Antoniades and Gundersen, 1961; Ref. 509, 
514). 
The existence of an insulin-binding protein in normal human serum was 
further supported by the work of Shaw and Shuey (1963; Ref. 390), who 
demonstrated that adipose tissue extract causes a 12-fold increase of normal 
fasting human serum ILA measured by the diaphragm assay and that anti-insulin 
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serum prevents this ILA increment. Gundersen and Lin (1965; Ref. 39~) then 
found that heparin also increases diaphragm-assayable ILA in cationic serum 
protein fractions and in normal human sera to levels found with the fat pad assay 
and that this ILA increment is neutralized by anti-insulin serum. The existence 
of a human serum insulin-binding protein appeared virtually assured with the 
appearance of several reports of the electrophoretic migration of radioactivity 
with a-globulins after incubation of exogenous radiolabeled insulin with normal 
human serum (Clausen et al., 1963; Mitchell, 1960; Ref. 520, 521). 
Berson and Yalow, however, disputed the concept of ''bound insulin" on 
several grounds, contending that the only physiologically significant insulin-
binding proteins are the anti-insulin antibodies found in the blood of insulin-
treated diabetics. They observed no increase in insulin measured by 
radioimmunoassay (RIA) after treatment of human sera with adipose tissue 
extract (1961, Ref. 523) and they demonstrated that apparent association of 
radiolabeled insulin with normal serum proteins represents irreversible binding of 
damaged tracer by these proteins (1965, Ref. 515). They also pointed out that 
the behavior of ''bound insulin" is inconsistent with established physiologic insulin 
response, since total plasma insulin levels ("bound" plus "free") reported by 
Antoniades decrease after intravenous glucose administration (1965,Ref.515). 
Berson and Yalow also refuted the concept of "bound insulin" on 
theoretical grounds. They argued that rapid insulin kinetics in vivo, resulting in 
quick onset of diabetic symptoms after pancreatectomy, are inconsistent with 
the slow kinetics of hormones such as thyroxine that are lmown to be bound to 
serum carrier proteins. They pointed out that symptoms of thyroid hormone 
deficiency appears only weeks after thyroidectomy and that in cases of proven 
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insulin binding by serum proteins-formation of insulin-antibody compl~xes in 
insulin-resistant diabetics-insulin-dependent carbohydrate homeostasis is 
frankly deranged (1965,Ref.528). 
The concept of "bound insulin" is also inconsistent with the observations 
of Froesch et al., who found that about 90% of human serum ILA measured by 
the rat fat pad assay is not suppressible by anti-insulin serum (nonsuppressible 
insulin-like activity, NSILA), that levels of antiserum~uppressible ILA are very 
similar to those found with RIA, and that only about 10% of serum NSILA is 
extractable with acid-ethanol (designated NSILA-8) (Froesch et al., 1963; 
Labhart et al., 1972; Jakob et al., 1968; Ref. 527, 546, 547). Furthermore, the 
remaining serum NSILA (NSILA-P}was found to be a protein of molecular weight 
100,000-150,000 daltons that is not dissociable by acid or urea (Ref. 546, 547). 
Subsequently, NSILA-8 was found to be structurally similar to insulin, but 
to exhibit the function of a growth factor in vivo (Rinderknecht and Humbel, 
1976; Zapf et al., 1975; Ref. 549, 550, 557), while the ILA exhibited by 
supraphysiologic concentrations of NSILA-8 was demonstrated to be due to a 2% 
cross-reactivity of the factor with insulin receptors (Gavin et al., 1973; Ref. 
565). In addition, other plasma growth factors (i.e., somatomedins A and C and 
multiplication stimulating activity) were also found to exhibit ILA at 
supraphysiologic concentrations, suggesting a family of insulin-like growth 
factors (IGFs) that, with insulin, derive from a common ancestral gene and 
diverged functionally (Shields, 1977; Ref. 728). The arguments of Berson and 
Yalow and characterization of the IGFs therefore caused the concept of "bound 
insulin" to fall into disfavor. 
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Two developments, however, have again made the question of "bound 
insulin" a worthwhile object of study. 1) Guenther (1974, Ref. 387) reported that 
heparin treatment of cationic serum protein fractions causes an increase of 
insulin measured by the RIA and implicated biotin as the ILA-potentiating factor 
in adipose tissue extract. 2) IGFs have been found to have serum binding 
proteins (Zapf et al., 1975; Van Wyk et al., 1974; Ref. 557, 598), making an 
insulin-binding protein a plausible expectation. 
SPECIFIC OBJECTIVES 
Zapf et al. (1975, Ref. 5&7) elucidated the serum carrier protein for 
' 
NSILA-8 by gel chromatography and charcoal adsorption analysis of radiolabeled 
NSILA-8 incubated with human serum. They found that about 40% of 1251-
NSILA-S radioactivity added to normal human serum eluted from Sephadex G-
200 at positions corresponding to proteins of significantly higher molecular 
weights than free NSILA-8 {apprx. 7,000 daltons). Addition of excess unlabeled 
NSILA-8 to serum-tracer mixtures resulted in nearly complete abolition of two 
upfield peaks of radioactivity with a concomitant increase of free NSILA-8 peak 
activity. Acid treatment of serum, followed by dialysis and gel chromatography 
yielded fractions that exhibited reversible binding of NSILA-8. 
This kind of study, however, has not been applied to the question of serum 
insulin-binding protein. Benson and Yalow utilized electrophoretic and 
ultracentrifugation techniques, but no gel chromatography, in their experiments, 
nor did they investigate the effect of heparin on serum immunoreactive insulin 
{IRI). Therefore, I endeavored to investigate both the question of a normal 
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human serum insulin-binding protein using the approach of Zapf et al. and the 
contribution of serum growth factors to ILA using a cultured cell bioassay 
capable of discriminating between specific insulin-like activity and the effects 
of growth factors. 
Purified 1251-insulin will be incubated with normal human serum and 
plasma, followed by Sephadex G-200 gel chromatography in order to determine 
whether radioactivity becomes associated with high molecular weight fractions. 
Reversibility of association will be tested by gel chromatography of plasma-
tracer mixtures and upfield peak material incubated with excess unlabeled 
insulin and by dextran-coated charcoal analysis of upfield peak material in the 
presence of excess unlabeled insulin and 8 M urea. Initially, the verifiability of 
heparin-induced IRI in cationic serum protein fractions will be tested in order to 
determine whether heparin can also be used as a potential dissociative agent. 
The possibility of irreversible binding of damaged tracer to albumin will be 
examined by affinity chromatography using anti-albumin antibodies coupled to 
Sepharose 4B, followed by ultrafiltration of radioactivity retained by the 
immunoadsorbent. 
The appropriateness of both diploid and malignant human cell lines for use 
in an insulin bioassay will be tested based on three criteria: 1) demonstration of 
cell-surface insulin receptors by peroxidase-antiperoxidase immunocytochemical 
staining and specific adsorption of 1251-insulin by cells; 2) demonstration of a 
significant insulin-induced, dose-dependent increment in the rate of glucose 
uptake by cells, using replicate multiwell cultures and measurement of glucose 
concentration in the supernatant medium; and 3) prolonged stasis of cell 
proliferation without cell death in serum-free media (with and without insulin), 
with resumption of log-phase growth after addition of serum. 
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An insulin bioassay capable of discriminating the effects of specific ILA 
and growth factors will thus be developed to generate the following parameters 
relative to control cultures: cell number (representing stimulation of cell 
proliferation by growth factors), total glucose uptake {representing ILA 
irrespective of cell number), and rate of glucose uptake {representing specific 
ILA). This assay will be used to examine serum fractions generated by molecular 
size separations (ultrafiltration and gel chromatography) in order to determine 
the relationship of proliferative effects and specific ILA to total ILA. 
The relationship of immunoreactive insulin to specific ILA will be 
determined by radioimmunoassay of all fractions and the role of biotin and 
heparin in stimulating ILA will be ascertained by also carrying out the bioassay 
' 
of all fractions in the presence of these agents. 
The range of subjects involved in this research is broad. Examination of 
insulin structure is important to considerations of aggregation, immunochemistry 
and biologic activity. Knowledge of cellular insulin receptor properties is basic 
to evaluation of differential hormone effects relative to hormone concentration 
and to choice of cells appropriate for an insulin bioassay. Evidence pertaining to 
mechanisms of insulin action bear upon interpretation of observations that 
contradict previous reports. A survey of insulin assays, requiring an 
understanding of the hormone's physiologic and metabolic effects, is necessary 
for an appreciation of ILA in its proper historical perspective and for evaluation 
of assays employed in this work. A discussion of atypical ILA must include 
insulin precursors and, of course, serum growth factors. I review all these topics 
in what I hope is sufficient depth to enable the reader to evaluate the 
observations reported and to judge the appropriateness of the conclusions drawn 
from them. 
CHAPTER II 
INSULIN: THE ANABOLIC HORMONE 
INSULIN-OR LACK OF IT (DIABETES)-IN ANTIQUITY 
At least oblique reference to the most striking symptoms of diabetes-ex-
cessive thirst (polydipsia) and urination (polyuria)-may be found among the 
oldest human documents. The Ebers papyrus, the 16th century B.C. Egyptian 
medical treatise, contains the phrase, "A medicine to drive away the passing 
of too much urine" (1). 
Unequivocal discussions cpncerning diabetes mellitus appear in Hindu 
medical texts dating back to the first century B.C. The writers of these texts 
anticipated use of the term mellitus, a Latin word meaning "honey sweet," by 
nearly two millenia, when they referred to the disease as Iksumeha or Madhumea 
(sugar or honey urine). This designation probably derived, however, from the 
resemblance of the diabetic's almost colorless urine to the juices of the sugar 
cane or from the particular attraction it had for insects, rather than from its 
taste, since no mention is made of tasting the urine (2). The writers recognized 
that the diabetic "gradually loses strength, flesh, and healthy glow of complex-
ion." The symptoms of thirst, fatigue, diminution of sexual capacity, confusion, 
abscesses and carbuncles are also listed. 
The first century Roman medical writer Aulus Cornelius Celsus rendered 
a concise description of the disease he declined to name when he stated, "But 
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when the urine exceeds the fluid taken • • • it gives rise to wasting and 
danger"(3). Although the perceived fluid imbalance was in error, appreciation 
of the impressive polyuria is clear. During the following century, the Greek 
physician Aretaeus of Cappadocia rendered the best ancient clinical account 
of the disease, which not only contained the first mention of the term diabetes, 
a Greek word meaning "siphon" ("because the fluid does not remain in the 
body, but uses the man's body as a ladder, whereby to leave it."), but also is 
the first concise and accurate contribution to the knowledge of diabetes in 
the medical literature of the western world. He described in great detail this 
wasting disease as a "melting of the flesh," enumerating such symptoms as 
thirst and loss of body constitueqts via the urine (4). 
In analyzing two cases of diabetes, Aretaeus' renowned contemporary 
colleague and compl:ltriot, Galen, demonstrates the Greek gift for intuitive 
reasoning when he postulates a failure of the assimilatory functions and 
considers the discoloration of the urine as the result of a lack of "coction" 
(analogous to the modern concept of metabolism), which Galen describes as 
an alteration of nutrients in the body (5). 
The classic tradition of astute diagnosis was ably continued in medieval 
times by the great 12th century Jewish Aristotelian scholar, philosopher, and 
physician, Moses Maimonides, who noted twenty cases of diabetes in Egypt, 
but only two in Spain and northwest Africa (6). Thus, diabetes mellitus was 
considered a rare disease until the 17th century, when the British physician 
Thomas Willis diagnosed a considerable number of cases. Although ancient 
physicians are widely credited with knowledge of diabetic glycosuria because 
of references to honey or sugar urine in their accounts of the disease, Willis 
rendered the first true documentation of the sweet taste of the diabetic's 
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urine (5). He did not demonstrate the actual presence of sugar in the urine, 
however, but believed-like the 16th century physician and alchemist Para-
celsus-that the focus of the body's derangement is salts. 
Willis did recognize that diabetes mellitus is a metabolic disease and 
in fact was the first to implicate the blood's role in the malady, stating "the 
serum and the blood are in fault, because they lend too hastily their contents." 
It was the experiments of the British physician Matthew Dobson a century 
later that indicated excessive "saccharine matter" in both the urine and serum 
of diabetics, leading him to conclude that the glycosuria results from hypergly-
cemia (7). In 1815, the French chemist Michel-Eugene Chevreul showed that 
this saccharine matter is glucos~ (5). The foundation thus was laid for the 
general acceptance of William Cullen's earlier delineation of diabetes mellitus 
and diabetes insipidus (8). 
Several developments during the 19th century formed the real basis for 
the discovery of insulin. First, the renowned French physiologist Claude Bernard 
established the concept of homeostasis based on the effects of internal secre-
tions (9). Second, Paul Langerhans, a pupil of the German father of pathology, 
Rudolph Virchow, described in 1869 a group of cells in the pancreas that were 
different from the enzyme-secreting acinar cells (10). Third-and most impor-
tant-was the work of ~the physiologists Oskar Minkowski and Baron Joseph von 
Mering. 
In 1884, Minkowski had implicated 8-hydroxybutyric acid as a major 
cause of diabetic acidosis, demonstrated a decrease of blood carbon dioxide 
during diabetic coma, and introduced alkali therapy to counteract the condition 
(11). Five years later, at the University of Strassburg, Minkowski and Mering 
attempted to disrupt fat digestion in dogs by removing the pancreas, known 
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to secrete lipases. They found that the dogs greatly increased their urine 
output and died in ten to thirty days. The presence of large amounts of sugar 
in the urine confirmed the diagnosis of classic diabetes mellitus. Furthermore, 
replacement of the pancreas under the skin ameliorated the symptoms. Thus, 
these facts and the influence of Bernard's milieu interieur concept enabled 
Minkowski to postulate the secretion by the pancreas of a substance responsible 
for the maintenance of systemic carbohydrate homeostasis (12). 
When in 1901 the U.S. pathologist Eugene L. Opie described degenerative 
changes in the Islets of Langerhans associated with diabetes (13,14), leading 
such physiologists as Sir Edward Sharpey-Schafer to conclude that Islet cells 
are the source of the postulated l)ypoglycemic substance (15), the fundamental 
' 
mechanism of diabetes mellitus was clear. The challenge that remained for 
a series of investigators during the next twenty years was the extraction of 
this pancreatic principle in a form capable of reversing diabetic hyperglycemia 
and its deadly consequences. 
Georg Ludwig Zuelzer of Germany in 1907-1909 (16), Israel Kleiner of 
the United States in 1915-1919 (17), and Nicholas Paulesco of Romania in 1921 
(18) were able to reverse the acute symptoms of ,diabetes with relatively crude 
pancreatic extracts, but frequent febrile responses to these extracts precluded 
their usefulness as therapeutic agents. 
Zuelzer extracted calf pancreas and, after observing the extract's 
hypoglycemic effects in animals, attempted to use it to treat human diabetics. 
He was able to show that the extract reversed diabetic glycosuria, ketonuria, 
and ketonemia, but consistent hyperpyrexia forced him to abandon these efforts. 
Zuelzer was also hampered by an inability to monitor blood glucose levels in 
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humans, since micromethods for determination of the sugar ware not de:veloped 
until 1913 (5). 
Kleiner injected aqueous filtrates prepared from canine pancreases into 
depancreatized dogs and observed almost immediate hypoglycemic effects, 
consisting of decreases in blood glucose as great as 200 mg/100 ml. This 
hypoglycemic effect lasted about two hours and was accompanied by decreased 
glycosuria. Kleiner also demonstrated that extracts from organs other than 
the pancreas fail to have this effect. He was disturbed, however, not only 
by febrile reactions, but also by "tremor of the head and hind legs" (probably 
symptoms of hypoglycemia). Furthermore, the necessity of injecting 100-150 
rnl of his weak extract to obtain the observed effects presented an obstacle 
to its use in human subjects. 
In a well-controlled, thorough study, Paulesco repeated Kleiner's observa-
tions on pancreatectomized dogs and also noted a specific pancreatic extract-
induced decrease of blood and urine urea and acetone. He demonstrated dose-
response behavior of the extract-induced decrease in blood glucose and urea 
concentrations, not only in diabetic, but also in normal animals. 
Because they isolated it in a form sufficiently pure to be consistently 
effective in the treatment of human diabetes without serious side effects, the 
physiologists Frederick Grant Banting and Charles Herbert Best are generally 
credited with the discovery of the hormone they named insulin, an obvious 
reference to its origin in the islets of Langerhans. A struggling Canadian 
orthopedic surgeon, Banting accepted a lectureship at the University of Western 
Ontario, London, in 1920. It was there, while preparing a lecture, that he 
carne across a paper by Moses Barron, detailing destruction of the acinar 
pancreas in dogs after ligation of the pancreatic duct (19). At that point, 
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Banting was struck by the possibility that the proteolytic enzymes secreted 
by the acinar pancreas could have precluded the preparation of a hormone 
extract sufficiently potent to treat diabetes and that the ligation described 
by Barron might provide a solution to the problem. Destruction of the acinar 
pancreas was later found to be unnecessary for the isolation of biologically 
active insulin, but the inspiration proved fateful. 
Banting obtained permission from John Macleod, director of the physiol-
ogy laboratories at the University of Toronto, to use one of the laboratories 
at that institution and there entered into a fortuitous collaboration with Best, 
a student of biochemistry. The two worked incessantly through the summer 
of 1921, attempting to induce at~phy of the canine acinar pancreas. Finally, 
they succeeded in obtaining a potent aqueous extract that had a hypoglycemic 
effect in pancreatectomized dogs, then obtained a preparation s1.1itable for 
treatment of human diabetics using an improved acid-ethanol extraction proce-
dure (20). Immediately, Macleod put Best and J. B. Collip to work on the 
development of a large-scale bovine pancreatic insulin purification procedure 
for the Connaught Laboratories in Canada and the Eli Lilly Company in the 
United States (21,22). A grateful scientific community and public were reflected 
in the award of the 1923 Nobel Prize for physiology or medicine to Banting 
and Macleod. 
Thus, one era ended and another began. The horrifying spectacle of 
the "melting of the flesh" gave way to the first consistent reports of diabetic 
neuropathy and angiopathy in those now able to live long enough-60 or more 
years past their former life expectancy-to manifest these pathologies. The 
history of diabetes as Aretaeus' "wonderful" and hopeless disease ended; the 
history of insulin as an illustrious influence on the development of endocrinology, 
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protein chemistry, and clinical chemistry began. As will be seen, although 
not the first proven instance of hormone action, insulin was the first protein 
whose primary structure was elucidated, the first complete protein to be 
synthesized in the laboratory, the object of the first radioimmunoassay, and 
the first hormone for which a prohormone was found. Insulin research continues 
more vigorously than ever, yet the ultimate cause and eradication of diabetes 
mellitus remain as elusive as ever. Perhaps insulin will be the focus of another 
discovery that will not only open a new field of endeavour, but will finally 
eradicate one of the oldest and mo.:;t perplexing diseases to plague the human 
species. 
'•' 
PHYSiOLOGIC EFFECTS 
Islet tissue containing insulin-secreting 8-cells is found in all vertebrates, 
from cyclostomes to man (23). Insulin-producing cells have also been reported 
among vertebrate precursors, in the entodermal epithelium of certain starfishes 
and tunicates (24). Glucagon-secreting a-cells are found in vertebrates only 
beyond the cyclostomes, with the appearance of the organized proximity of 
exocrine and endocrine pancreatic tissues (25,26). 
In mammals, the islets are scattered throughout the acinar pancreas and 
consist of cords of intermingled a-cells, B -cells, and D (at)-cells, which 
probably secrete gastrin (27) and/or somatostatin (28). It is in this class of 
vertebrates that insulin appears to have its greatest integrative influence on 
systemic anabolism, governing biosynthetic processes involving carbohydrates, 
proteins, fats, and electrolytes in liver, muscle, adipose tissue, connective 
tissue, leukocytes, endothelium, and epithelium. Insulin has not been found to 
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have an effect on nervous tissue or erythrocytes, nor does it promote intestinal 
absorption or renal tubule reabsorption of glucose. 
In mammalian studies, concerning especially rats, dogs, and humans, 
insulin has been found to increase the uptake of glucose by muscle and adipose 
tissue (29-32). Although glucose uptake by liver is insulin-independent (33), 
insulin stimulates glucose utilization in that organ, as it does in muscle and 
adipose tissue, promoting glycogenesis in liver and muscle (34,35) and glucose 
oxidation in target tissues (36). At the same time, the hormone inhibits 
glycogenolysis in liver and muscle and gluconeogenesis in liver (34). The 
systemic result of insulin effects on target tissue carbohydrate metabolism 
makes it the most potent hypoglycemic agent of mammalian physiology. 
Insulin promotes amino acid uptake and protein synthesis by muscle and 
liver (37-44), while decreasing tissue proteolysis (45,46). Thus, the hormone 
creates a positive nitrogen balance. Only recently has the profound impact 
of insulin on lipid metabolism in adipose tissue and liver been appreciated. 
The hormone induces the synthesis and esterification of fatty acids while 
inhibiting the hydrolysis of triglycerides in adipocytes and liver, serving as a 
potent antagonist of such fatty acid mobilizing hormones as epinephrine, 
thyrotropin, adrenocorticotropin, glucagon, somatotropin, and glucocorticoids 
(47-52). This anti-lipolytic effect prevents the formation and appearance in 
blood of the "ketone bodies," acetoacetate, s -hydroxybutyrate, and acetone. 
Insulin-induced uptake of K+ also occurs in the absence of glucose (53) and, 
therefore, insulin is a hypokalemic, as well as a hypophosphoremic, agent (54). 
The enormous impact of insulin on mammalian metabolism is profoundly 
appreciated by observing the course of "brittle" diabetes mellitus, whether 
induced by total pancreatectomy or selective destruction of the s -cells by 
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such agents as alloxan and streptozotocin, or appearing spontaneously, usually 
in the immature animal (juvenile onset). 
Immediately after complete termination of s-cell function, the unopposed 
stimulation of liver gluconeogenesis by glucocorticoids and glucagon (if loss of 
islet function is subtotal), liver and muscle glycogenolysis by epinephrine and 
glucagon, and suppression of tissue glucose uptake by somatotropin, as well as 
a marked reduction of insulin-dependent glucose uptake and glycogenesis, results 
in general glucose mobilization and a hyperglycemic state (55,56). Within 
hours, the concentration of plasma glucose exceeds 300 mg/100 ml, twice the 
maximum attained in normal individuals (57). 
The renal tubules normally cannot reabsorb glucose in excess of 160 
.• 
mg/100 ml plasma (58) and, as this renal threshold is passed, the sugar "spills 
over" into the urine, creating glycosuria. Water is lost with the excess glucose, 
leading to polyuria. The need to replace this water causes polydipsia and, if 
replacement is insufficient, dehydration ensues. 
Thyroid hormone-induced glucose oxidation and the energy requirements 
of tissues dependent on insulin for glucose uptake quickly result in exhaustion 
of these tissues' carbohydrate reserves. Epinephrine stimulation of proteolysis 
results in muscle wasting and mobilization of amino acids, which feed gluconeo-
genesis in the liver, exacerbating the hyperglycemia. Requisite deamination 
of these metabolized amino acids drives the plasma urea concentration to 
excessively high levels (55). 
The virtual shutdown of carbohydrate utilization and the potent free 
fatty acid mobilizing, lipolytic, and anti-lipogenic effects of epinephrine, 
glucagon, somatotropin, corticotropin (ACTH), and glucocorticoids (48,49,51,59) 
force the diabetic individual to switch to the products of fatty acid catabol-
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ism-the oxybutyrates-as his primary energy currency. Thus, the plasma 
concentration of free fatty acids as well as of acetoacetate, its reduction 
product B-hydroxybutyrate, and its spontaneous decarboxylation product ace-
tone-the ketone bodies-rises precipitously, producing a striking lipemia, keto-
nemia, and a consequent ketonuria. Because two of the three ketone bodies 
are acids, a dangerous acidosis ensues, leaching K+ from tissues and causing 
a further deterioration in the insulin-dependent electrolyte balance. 
Acidosis and electrolyte imbalance have a disastrous effect on the central 
nervous system, leading to coma and death, despite the individual's attempts 
to alleviate the acidosis by conserving carbon dioxide through a deep Kussmaul 
respiration (60). Even with insufin control and non-ketogenic maturity-onset 
diabetes, the induction of normally minor pathways of carbohydrate metabolism 
by frequent hyperglycemia eventually results in thickening of vascular basement 
membranes with deposited mucopolysaccharides and abnormal intracellular 
osmolality in Schwann cells due to high concentrations of sorbitol. These 
derangements are major factors in diabetic angiopathy (including retinopathy) 
and neuropathy (61-64). 
Because of the potent insulin antagonism of such pituitary hormones as 
corticotropin, somatotropin, and thyrotropin, such hormones of the adrenal 
medulla as epinephrine, and such hormones of the adrenal cortex as glucocorti-
coids as well as the pancreatic hormone glucagon, total pancreatectomy accom-
panied by hypophysectomy (Moussay animals) and/or adrenalectomy greatly 
alleviates the consequences of insulin loss, preventing or greatly delaying the 
onset of ketogenic diabetes by throwing the animal into a precarious balance 
between hyperglycemia and hypoglycemia (65). 
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METABOLIC EFFECTS 
Most of the observed physiologic effects of insulin are necessarily based 
on some impact on the quantity or function of the enzymes governing interme-
diary metabolism. In this respect, the broad anabolic influence that insulin 
exerts on mammalian physiology can be seen to derive from the various ways 
in which the hormone affects "key" enzymes* of the major metabolic pathways. 
Insulin has been found to influence intermediary metabolism in at least 
three ways: 1) a delayed influence on enzyme biosynthesis, requiring several 
hours to several days; 2) an immediate effect on preformed enzyme activity 
within minutes by affecting the;~ intracellular concentration of one or more 
"messengers" (see Chapter III); and 3) an indirect feedback inhibition-based 
modulation of enzyme activity through changes in the concentration of insulin-
affected key enzyme reaction products. 
Insulin has been found to induce the key glycolytic enzymes glucokinase, 
phosphofructokinase, and pyruvate kinase (67-69) while suppressing the biosyn-
thesis of the key gluconeogenic enzymes phosphoenolypyruvate carboxykinase, 
pyruvate carboxylase, fructose diphosphatase, and glucose-6-phosphatase (70-72). 
Weber found that in liver the activities and quantities of the key glyco-
lytic enzymes decrease and of the key gluconeogenic enzymes increase after 
induction of alloxan diabetes in rats (73-74). These trends, including a 
precipitous rise in the ratio of key gluconeogenic enzymes to key glycolytic 
*The use of the term ''key enzyme" here is that of George Weber (66) in that 
it signifies an enzyme catalyzing an essentially irreversible reaction, which 
thus is not utilized in an opposing metabolic pathway; ~ glycogen synthetase 
for glycogenesis and glycogen phosphorylase for glycogenolysis. 
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enzymes, continue over a period of several days (66). After insulin is 
administered to these diabetic rats, the trends reverse themselves and return 
to normal levels within two days. 
The insulin-induced increase in key glycolytic enzyme activities is blocked 
by such inhibitors of protein synthesis as actinomycin, puromycin, and ethionine 
(73), while a glucocorticoid (triamcinolone)-induced increase of key gluconeo-
genic enzyme activities is prevented or reversed by inhibitors of protein 
synthesis and insulin (75). The same reciprocal relationship of the key hepatic 
enzymes was seen in starved rats that were subsequently re-fed. Increases of 
glycolytic enzyme activities and decreases of gluconeogenic enzyme activities 
upon re-feeding were blocked by ~dministration of anti-insulin serum, indicating 
that this phenomenon is insulin-dependent. Hexokinase activity, however, 
remained unchanged during starvation and re-feeding, indicating insulin indepen-
dence, although Krahl's group have reported insulin restoral of diabetes- and 
fasting-diminished hexokinase activity in rats (76-77). 
Insulin promotes glucose oxidation while providing NADPH for fatty acid 
synthesis by inducing the key enzymes of the pentose phosphate pathway, 
glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase (78-
80), and malic enzyme (NADP-malate dehydrogenase) (66, 71), providing a critical 
link in the conversion of glucose to fatty acids. The hormone also induces 
key enzymes of lipid synthesis. 
Like the key glycolytic enzymes, an insulin-induced increase of starva-
tion- and diabetes-depleted citrate cleavage enzyme and fatty acid synthetase 
was seen in rat liver (81). Evidence for an insulin-induced increase in liver 
microsomal fatty acid desaturase and glycerol kinase, leading to ·triglyceride 
formation, has also been found (82-83). Meanwhile, insulin suppresses the 
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synthesis of hydroxymethyl glutaryl CoA synthetase, the key enzyme of. aceto-
acetate formation in liver (84). 
Insulin helps conserve a pool of amino acids for protein synthesis, thus 
promoting a positive nitrogen balance, by suppressing the biosynthesis of 
transaminases and other enzymes of amino acid degradation, as well as the 
key urea cycle enzymes, ornithine carbamyl transferase (ornithine transcarbamy-
Iase), arginine synthetase, and arginosuccinase in liver (85-88). Insulin suppres-
sion of urea cycle enzymes not only accounts for the marked increase of urea 
excretion by diabetics, but also increases the quantity of aspartate available 
for protein biosynthesis by decreasing urea cycle conversion of the amino acid 
to fumarate, a substrate for glt;tconeogenesis in liver cell cytoplasm. The 
ammonium ion normally converted to urea may be utilized in the glutamine 
synthetase-catalyzed conversion of glutamate to glutamine, increasing the 
availability of the latter amino acid for protein synthesis. 
Increased glutamine and the carbon dioxide otherwise converted to urea 
may also serve as substrate for cytoplasmic formation of carbamyl phosphate, 
which can then be utilized, with aspartate (also a substrate of purine synthesis), 
in pyrimidine biosynthesis, leading to speculation that insulin causes a substrate-
driven increase of nucleic acid synthesis (89). Insulin has also been found, 
however, to induce rat liver thymidine phosphorylase, the first enzyme in the 
degradative pathway for the nucleotide (66). 
A more direct basis for insulin enhancement of nucleic acid synthesis 
may be found in evidence that the hormone induces RNA polymerase in rat 
liver (90), increases DNA polymerase activity in rat liver and mammary 
epithelium (91,92), and causes cell proliferation in severely diabetic rat liver 
(91). 
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The best example of a rapid effect of insulin on enzyme activity is 
found in hepatic glycogen metabolism, consisting of a simultaneous activation 
of glycogen synthetase and inactivation of glycogen phosphorylase within a few 
minutes {93). The hormone also causes an immediate inactivation of triglyceride 
lipase in adipose tissue {94). Evidence basing these effects on a reversal of 
the Sutherland cyclic AMP-mediated mechanism for ephinephrine and glucagon 
action is reviewed in Chapter III. 
The most profound immediate effect of insulin on target tissues other 
than liver-an increase in glucose transport across the cell membrane, followed 
by a rise in the intracellular concentration of glucose-6-phosphate-remains an 
enigma. Neither the mechanism !'nor the structures responsible for this facili-
tated sugar transport has yet been elucidated, and there exists no clear evidence 
that insulin has any effect on hexokinase biosynthesis. However, several 
investigators have reported an insulin-dependent association of type II hexoki-
nase with mitochondria in rat muscle, adipose tissue, and mammary epithelium 
{95-97), suggesting a rapid enhancement by the hormone of anabolic processes 
in these tissues through an increase of cellular energy charge, resulting from 
an accelerated rate of oxidative phosphorylation. 
Weber {98) has proposed a system of insulin integration of hepatic 
intermediary metabolism, resulting from immediate insulin effects and occurring 
before insulin-induced influence on enzyme biosynthesis. This integrative effect 
is based on immediate insulin effects on the concentration of metabolites that 
inhibit key enzymes of pathways involved in their biosynthesis. 
Free fatty acids, their oxidation product, acetyl CoA, and the substrates 
of gluconeogenesis-all decreased by insulin-have been found to inhibit the key 
enzymes of glycolysis. In addition, free fatty acids, which in high concentrations 
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nonspecifically inhibit many enzymes, are particularly inhibitory in high physio-
logic concentrations toward the key enzymes of glycolysis, the pentose phos-
phate pathway and the tricarboxylic acid cycle. 
Insulin decreases liver uptake of L-alanine (99), an inhibitor of pyruvate 
kinase, and decreases the availability of ATP (by increasing its utilization in 
glucose-6-phosphate formation and lipid biosynthesis, while decreasing liver 
adenylate kinase activity (100)), an inhibitor of phosphofructokinase and pyruvate 
kinase, free fatty acids (by inactivating lipases), and acetyl CoA (by increasing 
its utilization in fatty acid synthesis). 
Insulin's immediate effects in adipose tissue-facilitation of glucose up-
take, resulting in a substrate (glucose-6-phosphate)-induced increase in a-
' 
glycerophosphate-causes a rapid fall in plasma free fatty acids, which in turn 
alleviates the free fatty acid feedback inhibition of key enzymes of glycolysis, 
the pentose phosphate pathway, and the tricarboxylic acid cycle. These 
pathways and, consequently, lipid biosynthesis are facilitated before insulin 
effects on enzyme biosynthesis become apparent. 
Even a cursory examination of insulin's effects on mammalian interme-
diary metabolism thus reveals impressive evidence that it is indeed the master 
hormone of anabolism in this class of animals, providing all materials-enzymes, 
substrates, high-energy phosphate anhydrides, and electron donors-necessary 
for biosynthesis of complex carbohydrates, fats, proteins, and nucleic acids~ in 
liver, muscle, adipose and connective tissue, lymphoid cells, epithelium, and 
endothelium. The fact that insulin triggers an orchestrated chain of such 
events, commencing immediately after ingestion of a meal and continuing at 
different levels of metabolic regulation for several days thereafter, also argues 
for insulin's proposed pivotal role as the "feast or famine" hormone in animal 
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evolution, enabling an animal to make the most efficient use of ingested 
nutrients for further utilization in times of starvation that often require 
vigorous exercise in pursuit of another meal. 
One may thus speculate that man-made prosperity has created an 
evolutionary trap, evidenced by the apparent correlation of maturity-onset 
diabetes with consumption of fats in industrialized western nations (101). 
CHAPTER III 
INSULIN ACTIVITY ON THE MOLECULAR LEVEL 
THE INSULIN MOLECULE 
Extraction and Purification 
The first insulin used to treat a human diabetic (January 11, 1922) was 
extracted from bovine pancreases obtained from commercial sources by Banting 
and Best. They extracted the pancreatic tissue with cold acidified saline, 
followed by ethanol to a final con~entration of 60%. The filtrate was evaporated 
to dryness in a stream of warm air, the residue was washed with toluene and 
then was dissolved in saline. This material possessed an insulin activity of 
slightly more than one international unit per ml (102). 
During the previous year, Banting and Best had also found this method 
to be the most effective in producing potent insulin extracts from canine and 
fetal calf pancreas, the latter being the source of a preparation possessing 
ten times the potency of the adult bovine extract, probably because fetal calf 
pancreas of under five months' development does not contain pancreatic 
enzymes, while producing a large quantity of insulin. 
Soon after commenoement of large-scale commercial production of 
insulin in 1922, acetone wrls substituted for ethanol and the wind tunnel was 
replaced by a vacuum still. After the U.S. chemist John Jacob Abel first crys-
24 
25 
tallized insulin around 1925 {103), it was found that crystallization of the 
hormone requires zinc or another divalent metal cation, such as cobalt, nickel 
or cadmium {104). Due in large part to D.A. Scott's delineation of the role 
of zinc in the crystallization of insulin {105), protamine zinc insulin was 
introduced in 1936 as a long-acting agent that abrogated the diabetic's require-
ment for frequent injections of the hormone (106). 
As the requirement for pure insulin from a variety of animal species 
for physicochemical studies of the hormone became felt, ever more sophisticated 
biochemical separation techniques were brought to bear on the problem of 
insulin isolation and purification. Techniques used include fractional precipita-
tion with ethanol or salt, isoelectr~c precipitation, ion exchange chromatography, 
gel filtration, and partition chromatography using paper and adsorbent columns 
(104). 
For example, rat insulin has been isolated from frozen pancreas extracted 
in 8096 ethanol adjusted to pH 3 with phosphoric acid, followed by addition of 
ammonium hydroxide to pH 8. After clarification of the solution, insulin is 
precipitated first by adding ethanol and ether and again with picric acid. The 
I 
picrate is dissolved in acid acetone, precipitated with excess acetone, washed 
with ether and dried {104). Bovine insulin has been purified from pancreatic 
extracts by gel filtration on Sephadex G-50 equilibrated with 0.2 M ammonium 
bicarbonate, pH 7 .8, at 4 °C, followed by crystallization from zinc acetate, pH 
5.9 (107). Sephadex G-50 has also been used to purify feline (108) and human 
(109) insulins, using 1 M acetic acid for elution. After crystallization from 
citrate buffer, the human insulin was found to be relatively free of glucagon. 
Cellulose acetate electrophoresis has also proven to be an effective means of 
separating the two hormones (110). The proinsulin (as much as 296) 
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contaminating commercial preparations of insulin may also be removed by 
sephadex G-50 chromatography with 1 M acetic acid (111). 
Insulin has been extracted from human plasma with ethanol, normal 
butanol and toluene acidified with hydrochloric acid, resulting in recovery of 
80-9096 exogenous (35g) insulin and a forty-fold increase of endogenous insulin 
activity (112). 
Physical Properties 
The zinc-complexed insulin first crystallized by Abel was in the rhombo-
hedral form, consisting of insulin hexamers each containing 2 or 4 zinc atoms 
(113). Later, the zinc-insulin he}Camer was crystallized in monoclinic form in 
the presence of phenol and a zinc-free orthorhombic form has been crystallized 
at acid pH (104). 
It was the prevalence of the zinc-containing insulin hexamer (M.W. 
35,000-36,000) in preparations subjected to physical studies before 1948 that 
led early investigators to believe that the molecular weight of the hormone 
lay somewhere between 36,000 and 48,000. In 1948, Gutfreund concluded that 
. 
these species were aggregates of a molecular weight 12,000 subunit (114). 
Finally, in 1952, Harfenist and Craig showed that the ultimate insulin subunit, 
or monomer, was a molecule of approximately 6,000 daltons molecular weight 
(115), quickly confirmed by elucidation of the hormone's primary structure, 
which assigned to bovine insulin a molecular weight of 5, 734 daltons. Based 
on its amino acid composition, the molecular weight of human insulin is 5,808 
daltons. 
The insulin dimer of molecular weight 10,000-12,000 has been shown to 
have a sedimentation coefficient (S2o,w> of 1.85 x 10-13 sec., a diffusion 
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coefficient (D2o,w> of 13.5 x to-7 cm2/sec., and a frictional ratio (f/fo) of 
1.1, while the monomer of 6,000-7,500 molecular weight shows 
s2o,w = 1.2 x to-13 sec., D2o,w = 16 x 1o-7 cm2/sec. and f/fo=1.12 (104), 
indicating that the molecule is nearly spherical in shape. 
Both bovine pancreatic insulin and human plasma insulin derived from 
portal vein blood have been found to have an electrophoretic mobility between 
albumin and at-globulins (116), but a substantial portion of human endogenous 
plasma insulin of the peripheral circulation has been shown to migrate with 
a -globulins (see Chapter IV). 
Primary Structure 
The complete elucidation of the primary structure of bovine pancreatic 
insulin, an outstanding tour de force achieved by the biochemist Frederick 
Sanger and co-workers at Oxford University, reported in 1955 (117), was a 
watershed of protein chemistry, not only because it represented the first amino 
acid sequence determination of a protein, but also because it conclusively 
demonstrated the uniqueness and~ consistency of protein structure (be., the 
amino acid sequence of every molecule of a given protein is identical, but 
different from every other protein) and proved the veracity of the peptide 
bond hypothesis advanced by Hofmeister and Fischer in 1906 (118). 
The chain of events leading to the elucidation of the amino acid sequence 
of bovine insulin, shown in figure 1, began in 1945 when Sanger introduced 
1,2,4-fluorodinitrobenzene (FDNB, since called the Sanger reagent) for dinitro-
phenyl (DNP) labelling of amino-terminal amino acids according to the following 
reaction: 
28 
FIGURE 1. AMINO ACID SEQUENCES OF INSULINS AND CUMULATIVE 
AMINO ACID REPLACEMENTS AT POSITIONS WHERE VARIATIONS OCCUR. 
B chain insulin: 
[a] pig, dog, cattle, sheep, goat, horse; sperm, fin and sei whales 
[b) human, African elephant 
[c) rabbit 
[d), [e) rat, mouse 
[f) chicken 
[g) guinea pig 
[h) coypu 
(i] bonito* 
[j] cod fish 
(k] angler fish 
* Either B 24 or B 25 phe deleted. 
t Deletion. 
* Single component from mixture of bonito, tuna and swordfish insulins. 
(Reproduced with permission from the American Diabetes Association, Inc., 
from Ref. 128. Copyright 1972 by the American Diabetes Association, Inc.) 
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~ Q 
F NHCHC-R 1 
c$JN0 2 + Q I ®No, + HF H2 N-CH-C-R -+ 
R 
NOz N0 2 (119) 
The labelled 
~ Q I NHCHC-R 
protein was then subjected to acid hydrolysis as follows: 
c$JNO, 
N0 2 
6N HCl 
+ amino acids. 18 hrs. 
The bright yellow DNP-N-terminal amino acid was separated from other 
amino acids by extraction with ether and identified by partition chromatography 
with reference to standard DNP-amino acids. Thus, FDNB labelling of insulin 
followed by acid hydrolysis yielded the expected e:-DNP derivative of lysine 
and cx-DNP derivatives of phenylalanine and glycine. Based on the molecular 
weight of 12,000 assigned to insulin at that time, Sanger deduced that the 
hormone consists of four amino acid chains, two with N-terminal phenylalanine 
and two with N-terminal glycine (120). 
By 194 7, Sanger was able to obtain the separated chains of insulin intact 
by oxidation of the hormone with performic acid, yielding the cysteic acid 
derivatives (121). Because an accurate amino acid analysis of insulin was 
available to Sanger from the beginning of his endeavour, he knew that complica-
tions resulting from oxidation of tryptophan and methionine would be avoided 
since these amino acids are not present in bovine insulin. He found two kinds 
of polypeptide chains: one, designated A-chain, was acidic and had a simpler 
\ 
amino acid composition than the complete insulin molecule, lacking lysine, 
arginine, histidine, phenylalanine, threonine, and proline; the other, designated 
B-chain, was basic, containing all the basic amino acids of the insulin molecule. 
.. 
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The A-chain, with N-terminal glycine, was found to consist of 21 residues, 
four of which were cysteic acid, while the B-chain, with N-terminal phenylala-
nine, possessed 30 residues, two of which were cysteic acid. 
The B-chain, having a more distinctive composition than the A-chain, 
proved easier to study, and was sequenced first. Mild acid hydrolysis yielded 
about 45 peptides of varying size, which were separated and recovered by 
electrophoresis, ion-exchange chromatography, and adsorption on charcoal, fol-
lowed by two-dimensional paper chromatography. Such treatment of the DNP 
derivatives of the separated chains enabled the first four N-terminal amino 
acids of the B-chain and the first five N-terminal amino acids of the A-chain 
to be deduced. Preliminary sequ~ncing and amino acid analysis of the separated 
chains demonstrated that insulin consists of only two kinds of polypeptide 
chains. Thus, it was concluded that insulin either consists of two identical 
halves or is a molecule of molecular weight 6,000. The latter alternative was 
later found to be the case. 
Peptide fragments enabled all but four B-chain amino acids to be assigned 
their proper sequence. The complete B-chain amino acid sequence was deter-
mined in 1950 after additional, longer peptides were obtained by proteolytic 
cleavage with pepsin, trypsin, and chymotrypsin (122), which also enabled 
assignments of positions for glutamine and asparagine (123), otherwise converted 
to their corresponding acids by acid hydrolysis. 
The major problem encountered in sequencing the A-chain arose from 
the juxtaposition of two cysteine residues at positions 6 and 7, resulting in 
the formation of peptides that could not be separated adequately by paper 
chromatography. This problem was solved by paper electrophoresis at pH 2. 75, 
at which point carboxylic acids are uncharged, cysteic acid is negatively 
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charged, and amines are positively charged. Thus, the sequence of the A-chain 
was known by 1953 (124,125). 
At this time, a molecular weight of approximately 6,000 daltons hsd 
already been assigned to insulin. Thus, the hormone had to consist of one copy 
of each of the two polypeptide chains, A and B, linked by cystine disulfide 
bonds. The disparity between the number of cysteines found in the A and B 
chains indicated that they were linked by two interchain disulfide bonds and 
that the remaining two cysteines in the A-chain formed an intrachain disulfide 
bond. Because of rearrangement of disulfide bonds that occurs in acid solution, 
however, it wasn't until 1955 that the correct linkages could be determined 
after it was learned that enzymic proteolysis at neutral pH and acid hydrolysis 
in the presence of sulfhydryl compounds such as thioglycollic acid proceeds 
without disulfide rearrangement (126). 
Implications of Variations in Primary Structure 
More than twenty distinct amino acid sequences for insulin from the 
various species studied, the majority of which are depicted in figure 1, are 
now known (127). It may be seen that the insulin molecule consists of certain 
amino acids that are invariant among the different species: all the cysteines, 
A1, A2, A16, A19, B6, BS, Bll, B12, B15, B16, B18, B23, B24, and B26 
hydrophobic residues, and AS and A21 amides; other amino acids that are 
conservatively variant: A3, B1, and B2 apolar residues, A18 polar residue, and 
A4, B5, and B13 charged residues; and the remaining amino acids, that are 
freely variant, especially at positions AS, A9, A10, B20, B21, B22, B29, and 
B30. In addition, coypu (or nutria, Myocastor coypus, a large South American 
rodent) insulin A-chain has been found to have an additional amino acid, a 
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c-terminal aspartate, and B-chain one less residue at position 25, while certain 
fish insulin B-chains have an additional amino acid at the N-terminus, but are 
lacking an amino acid at the C-terminus. Because even guinea pig, coypu, 
and fish insulins exhibiting differences of 19 to 22 residues compared to bovine 
insulin have been shown to have biological activity among different species 
(128), one may conclude that the invariant residues are important to the 
biological activity of the hormone, either by insuring a molecular conformation 
that preserves the shape of the active site or by functioning in the active 
site itself. 
The results of chemical modification of the insulin molecule, summarized 
in Table I, tend to confirm that invariant amino acids play a critical role in 
the hormone's biological activity.' Specifically, oxidative or reductive cleavage 
of the disulfide bonds and removal of the Al glycine, A2 isoleucine, A21 
asparagine, and the last eight amino acids of the B-chain, which include B23 
glycine, B24 phenylalanine, and B26 tyrosine, result in serious losses of activity. 
On the other hand, removal or modification of the variable Bl, B29, and B30 
residues causes no significant reduction of insulin activity. Further confirma-
tion of the modification studies is provided by proinsulin, which possesses 1796 
insulin bioactivity (141) and 0.06-2896 insulin immunoreactivity (136). The 
proinsulin connecting peptide, which joins the amino terminus of the A-chain 
to the carboxy terminus of the B-chain, not only obscures the A-chain amino 
terminal residues, but also is known to cover the A14 and A19 tyrosines (143), 
which appear to be important to insulin immunoreactivity. 
TABLE I. EFFECTS OF CHEMICAL MODIFICATIONS ON INSULIN BIOLOGICAL 
ACTIVITY AND IMMUNOREACTIVITY 
96 Biol. Act. 96 Immunore-
Method of of Native activity of 
Altered Residues Type of Residue* Alteration Insulin Native Insulin Ref. 
Free amine-bearing 1 I, 1 C, 1 v acetylation 78-98a 129 
Free carboxy-bearing 1 I, 2 c, 3 v esterification <0.5g 130 
Cystine S2 I reduction 45-63a 131 
oxidation oa,f 132 
A 7, B7 cystine I s-car boxy- 40-1ooa,f 133 
methylation 
s-sulfonation 15a 133 
A6, All cystine I S-thionylation 1f t 134 
Tyrosine-0 H 3 I, 1 v acetylation <3a 129 
A1 glycine I removal 2-1of,h 20-30j 133 
amine removal 15h 40j 133 
arginine addition 59-ssa,h 40j 133 
lys-arg addition 20h 34j 133 
acetylation 40-1oof,h 47j 133 <;.:» 
35-4oh 135 ~ 
TABLE I (CONTINUED) 
% Biol. Act. % Immunore-
Method of of Native activity of 
Altered Residues Type of Residue* Alteration Insulin Native Insulin Ref. 
A1 glycine I t-butoxy- 17h 135 
carbonylation 
2-dimethyl-3-formyl- 13h 135 
D-thiazolidine-4-
carbonyl conjugation 
A14 tyrosine v nitration 60-70a,c 6-38j,k 136 
iodination 1ooi 93j 137 
A14, A19 tyrosines V, I iodination 7oa,c 4-59j,k 136 
A21 asparagine I removal 0-2g 138 
A-chain 10 I, 3 C, 8 v removal oa,b 139 
B1 phenylalanine c removal 9of 103j 133 
_E-iodination 60-7oh 85j 133 
fluorescein isothio- 4oa 24-56j 136 
cyanate conjugation 
(FITC) 
B29 lysine v E: -acetylation 75-1oof,h 85j 133 
B30 alanine v removal 98-lOOa,g 138,140 
<:.) 
arg2 addition 61a 141 <:.11 
TABLE I (CONTINUED) 
% Biol. Act. % Immunore-
Method of of Native activity of 
Altered Residues Type of Residue* Alteration Insulin Native Insulin Ref. 
B1 phe/B29 lys c, v gly subst./ E -acetyl- 35a 25j 133 
at ion 
B1 phe,B29 lys c, v acetylation 85-1oof,h 3oj 133 
B1-B6 1 I, 3 c, 2 v removal >44a 142 
B23-B30 3 I, 5 V removal 15d,g 138 
<0.2 143 
oa o.o8-2.oj,k 136 
<4a,g 148,149 
B-chain 12 I, 4 C, 14 v removal 0a,b 139 
A1 gly, B1 phe I, C removal 1.6-7f,h 15j 133 
FITC 4a 3-32j 136 
A1 gly, B1 phe, B29 lys I, C, V FITC oa 0-4j 136 
A1-A2, B1-B2 2 I, 2 C removal 0.2h 2j 133 
A21 asn, B30 ala I, V removal ta 0.17-3.5j,k 136 
FOOTNOTES TO TABLE I. 
a. Mouse convulsion assay 
b. Mouse hemidiaphragm assay 
c. Mouse blood sugar assay 
d. Rat hemidiaphragm assay 
e. Rat epididymal fat pad assay 
f. Rat blood sugar assay 
g. Rabbit blood sugar assay 
h. Fat cell assay (incorporation of 3-3H glucose into adipocyte lipids; 144,145) 
i. Fat cell assay (glucose oxidation) 
j. Radioimmunoassay 
k. Immunohemolysis 
* I = invariant 
C = conservatively variant 
V = variant 
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secondarY Structure 
- Calculations based on low ultraviolet optical rotatory dispersion (ORD) 
and ci:-cular dichroism (CD) spectra have led investigators to conclude that 30 
to 4096 of insulin residues are confined to tight right-handed a -helical 
conformations (146,147). This figure is in good agreement with the 35% a-helix 
found in x-ray diffraction studies, which also indicate that nearly 5096 of the 
insulin residues contribute to right-handed helices and none to left-handed 
helices (104,143). All the a-helical residues are found in two stretches of 
a -helix, one in the A-chain, between A2 isoleucine and AS alanine, and the 
other in the B-chain, between B9 serine and B19 cystine. A stretch of 
non-a-helix lies between A13 leu~ine and A21 asparagine. In addition, hydrogen 
bonds are formed between the A19 carbonyl oxygen and the B25 cx-amido 
hydrogen, the A21 a-carboxy oxygen and the B22 arginine guanidinium amino 
hydrogen, and the A4 glutamate carboxy oxygen and the B29 cr-amido hydrogen, 
while the C-terminal residues of the B-chain, from B21 glutamate to the B30 
terminus, form half of an antiparallel e -pleated sheet important in insulin 
dimer formation (143) (See Chapter IV, "Insulin Aggregates"). 
Tertiary Structure 
The elucidation of insulin's tertiary structure began in 1935, when the 
British chemist and crystallographer Dorothy Hodgkin crystallized insulin in 
the rhombohedral form, as Abel had done, and performed single-crystal x-ray 
analysis on the preparation (150). She found that the protein molecular weight 
of the unit cell of these crystals was about 36,000, the same value Svedberg 
had deduced from sedimentation velocity studies of insulin in solution (151), 
and that the crystals had trigonal symmetry. This finding meant that the unit 
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could be divided into three equivalent parts, each with a molecular weight of 
12,000, suggesting that the predominant insulin species being studied· at the 
time consisted of at least three equal subunits. It is now known that this 
species is actually the insulin hexamer. 
It was not until 1960 that Barbara Low, using the acid orthorhombic 
crystal form of insulin, demonstrated that each asymmetric unit contained two 
molecules related by a twofold (!Y-) axis perpendicular to the vertical threefold 
crystal (!-) axis (152). After Schlichtkrull's discovery that a minimum of two 
zinc ions per hexamer are necessary for crystallization of insulin in the 
rhombohedral form (153), it was concluded that these ions must lie along the 
threefold axis, equally spaced above and below the local twofold axes. After 
isomorphous replacements of these zinc atoms with heavy metal atoms were 
made, x-ray diffraction patterns were obtained that enabled the construction 
0 
of electron density maps at 2.8 A resolution. Based on the known primary 
structure of porcine insulin, a three-dimensional model of the porcine insulin 
0 0 
monomer, with a diameter of 50 A and a height of 35 A (pictured in figure 
2), was constructed (154,155). 
Examination of the tertiary structure of the insulin monomer, based on 
x-ray diffraction studies, reveals that the B-chain termini emerge from the 
central stretch of a-helix, through sharp turns at BS glycine and the 
tetrapeptide from B20 glycine to B23 glycine, in a fully extended conformation. 
The A-chain sits compactly between these arms, on the B-chain a-helix. The 
A2-A8 <>-helix runs across the top of the molecule and the A13-A21 helix 
folds across the face of the molecule to bring the C-terminal residues of the 
A-chain back beneath those of the A-chain N-terminus. Eight of 14 invariant 
hydrophobic residues-B6, Bll, B15 and A16 leucines, A2 isoleucine, B18 valine, 
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FIGURE 2. REPRESENTATION OF THE TERTIARY STRUCTURE OF THE 
INSULIN MONOMER, VIEWED PERPENDICULAR TO THE THREEFOLD AXIS 
(Reproduced with permiSSion from the American Diabetes Association, Inc., 
from Ref. 143. Copyright 1972 by the American Diabetes Association, Inc.) 
41 
42 
B24 phenylalanine, and B26 tyrosine-form the molecule's apolar core, while 
many other nonpolar residues are located on the surface with their side chains 
directed inward toward the interior of the molecule. Thus, the invariant 
hydrophobic residues appear to be critically important to the maintenance of 
the molecule's tertiary structure, which is requisite for insulin's biological 
activity, as evidenced by the fact that desoctapeptide (B23-B30 deletion) insulin, 
which has not been found to possess more than 15% insulin activity, has been 
shown by CD studies to undergo extensive conformational changes compared 
to native insulin (156). 
The B-chain a -helix is flanked by the two interchain disulfide bonds, 
the B7-A 7 cystine, which lies on ;the surface of the molecule, and the B19-A20 
cystine, which is partially concealed. The intrachain A6-A11 cystine is 
completely buried in the hydrophobic core. A number of invariant residues at 
the surface of the monomer, including several apolar amino acids with their 
side chains directed outward, appear to be important to the biological activity 
and aggregative properties of insulin. A1 glycine, AS glutamine, A19 tyrosine, 
A21 asparagine, and B25 phenylalanine are especially likely to be involved in 
the active site (135), with an important contact being made between the A19 
tyrosine phenolic hydroxy group and the A2 isoleucine side chain. Removal 
of A21 asparagine, which nearly abolishes biologic activity, has also been found 
to cause extensive conformational alterations and to reduce greatly the ability 
of the radiolabeled (1251) insulin derivative to bind to adipocyte receptors (135). 
The remainder of the insulin monomer surface consists. of two hydrophobic 
faces, one consisting of B12 valine, B16 tyrosine, and B30 alanine and the 
other of B1 phenylalanine, B14 alanine, B17 leucine, B18 valine, A13 leucine, 
and A14 tyrosine, which are involved in formation of the insulin dimer and 
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hexamer. The quaternary structure of insulin is dealt with further in .Chapter 
IV, where insulin aggregates are discussed. 
§_ynthesis 
During the 1960s, insulin was the object of yet another landmark in 
protein chemistry, the first laboratory synthesis of a complete protein, carried 
out by Katsoyannis and co-workers. The synthesis involved initial amino acid 
conjugation, peptide elongation, and joining of peptide fragments after reactive 
side chains and amino and carboxy termini had been masked with blocking 
groups easily removed under mild conditions with a minimum of racemization 
to yield a crystalline product readily separated from other reaction components. 
The A- and B-chains were synthesized separately as sulfocysteinyl derivatives 
and, after reduction of the A-chain to the cysteinyl form, they were combined 
in the presence of air, resulting in a 12-16% yield of biologically active, 
completely synthetic sheep insulin (157-158). Synthesis of insulin derivations 
has proven to be a valuable means of studying the effects on biological activity 
of the otherwise unattainable modification of specific amino acids. 
THE INSUUN RECEPTOR 
It is now widely recognized that the first event of cellular hormone 
action is the binding of the hormone to a cell "receptor." Indeed, one may 
apply equally well to any hormone receptor Pedro Cuatrecasas' operational 
definition of the insulin receptor (159), which "signifies those molecules of the 
cell which are uniquely capable of recognizing and interacting with insulin with 
a high degree of selectivity and affinity and which, in addition, possess the 
capability of conveying the occurrence of the interaction to biochemical 
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processes resulting in metabolicelly significant events. Thus, the receptor has 
at least two functions: 1) to specifically recognize insulin and 2) to somehow 
convey to other molecules the fact that insulin has been recognized." 
In relation to the first function, it is pertinent to examine where in 
the cell recognition of insulin takes place, the specificity and affinity of the 
insulin-receptor association, the nature of the insulin receptor, the fate of 
both the hormone and receptor, and the means by which the cell modulates 
its insulin response at the receptor level; regarding the second function, the 
question obviously remains how the signal generated by insulin-receptor associa-
tion is conveyed to the cell's metabolic machinery. 
Location 
Unlike steroid and thyroid hormones, which enter the cell before encoun-
tering specific receptors, protein hormones are now generally believed to trigger 
their effects at the cell surface by binding to receptors integrally associated 
with the plasma membrane. Several lines of evidence strongly suggest that 
insulin receptors are situated exclusively at the surface of the cell: 
1. Specific binding of insulin to fat cell homogenate fractions is almost 
exclusively limited to particulate, or plasma membrane, fractions, which exhibit 
an insulin binding capacity comparable to that of intact adipocytes. Little 
binding of insulin to nuclear or mitochondrial fractions was found and the 
soluble cellular fraction did not compete effectively with insulin binding to 
membranes (160,161). 
2. Trypsin treatment of intact adipocytes and isolated adipocyte plasma 
membranes abolishes the ability of these preparations to bind insulin (161). 
The same abolition of insulin binding to adipocytes was found after the cells 
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were exposed to trypsin covalently bound to agarose beads larger than the 
cells themselves, indicating that the insulin receptors are limited to the cell 
surface (162). 
3. Insulin covalently coupled to dextran-40 (average molecular weight = 40,000) 
stimulates glycogen synthesis and sugar transport by intact rat diaphragm (163) 
and stimulates glucose metabolism in adipose tissue (164). Insulin covalently 
coupled to dextran-2000 (average molecular weight = 2,000,000) has been found 
to stimulate glucose metabolism in adipocytes (165). 
4. Cuatrecasas attached insulin to agarose beads 60 to 300 1J m in diameter 
via the B1 a -NH2 or the B29 lysine £-NH2 group (159,166). As little as 1 to 3 
lJ U of this preparation per ml i!'"mediately stimulated glucose utilization and 
inhibited hormone-stimulated lipolysis in adipocytes 50 to 100 1J m in diameter, 
increased RNA synthesis and a -aminoisobutyrate accumulation in isolated 
mammary cells, and activated glycogen synthetase in tadpole liver slices 
(159,166-169). The increased glucose utilization by adipocytes could be com-
pletely reversed by addition of anti-insulin serum, even after prolonged incuba-
tion with insulin-Sepharose (166). 
Extensive washing of the beads with 8M urea and 6M guanidine did not 
result in liberation of free insulin (166), but Oka and Topper (170) have found 
that an insulin-like material can be extracted from insulin-Sepharose in the 
presence of 2.5% bovine serum albumin. This material elicits "super-insulin" 
responses from virgin and pregnant mouse mammary epithelial cells, consisting 
of greater than standard insulin stimulation of a -aminoisobutyrate uptake, 
DNA synthesis, and glucose-6-phosphate dehydrogenase and phosphogluconate 
dehydrogenase activities. The increment in a-aminoisobutyrate uptake, greater 
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than 5 times that obtained with insulin, is completely abolished by anti-insulin 
serum. 
5. Inverted, or "inside-out," adipocyte plasma membrane vesicles, or "ghosts," 
don't bind insulin. If such inside-out ghosts are formed in the presence of 
insulin, the vesicle-bound insulin exchanges with the medium much more slowly 
than when "right-side out" vesicles are used, but no discrepancy is seen after 
the inverted vesicles are broken {171). The observations indicate that insulin 
receptors are located on the outside of the plasma membrane. 
Although there appears to be widespread concurrence that insulin recep-
tors are confined to the plasma membrane, controversy, which is a common 
feature in many areas of insulin :'research, has arisen around this issue also. 
Goldfine and co-workers are foremost among those who postulate that 
intracellular penetration and bind;ng of insulin to receptors on organelle surfaces 
is the underlying mechanism of many insulin effects. They have reported a 
reversible, saturable binding of 125J-insulin to rat liver nuclei which they 
determined to be free of plasma membranes by electron microscopy and the 
absence of Na--K+ ATPase activity, a plasma membrane marker {172). The 
binding, which amounts to about 1096 of that found with plasma membranes, 
is abolished by trypsin treatment and inhibited by insulin analogues in proportion 
to their biologic activity and ability to inhibit binding of radiolabelled insulin 
to plasma membrane receptors. 
These investigators obtained similar results with cultured human lympho-
cytes, finding 796 of total insulin bound to cells associated ~ith purified nuclei 
{173). Using radioautographic analysis, they observed 5496 of grains over the 
Plasma membrane, 1996 over the cytosol and 2196 over the nucleus 5 minutes 
after addition of 125J-insulin to lymphocytes at 37°C. After 120 minutes, 
47 
38% of grains were observed over the plasma membrane, 27% over the cytosol, 
and 28% over the nucleus. Goldfine's group have also demonstrated intrac·enular 
uptake of insulin by cultured lymphocytes using radioautographic electron 
microscopy (17 4). They noted increasing concentrations of grains over the cell 
interior, localized mainly over the cytoplasm and nucleus, from 30 seconds to 
30 minutes after addition of 1251-insulin at 37°C. 
Several other investigators have used radioautography as a basis for 
claims of intracellular penetration of insulin. Carpentier and co-workers found 
a penetration of 1251-insulin into cultured lymphocytes of 0.9 \.lm (175) and 
into rat hepatocytes of 1.6 \.l m at 37°C (176). In the latter case, it was 
found that 1-125 activity became increasingly associated with lysosomes, possibly 
indicating a mechanism of insulin' degradation following pinocytosis. Apparent 
support for this contention may be found in the results of Bergeron et al. 
(177), who found that in rat livers removed 3 minutes after injection of 68.2 
\.l Ci (426 ng) 1251-insulin into the portal vein, radioautographic grains were 
confined to the plasmalemma, but that in livers removed 10 to 20 minutes 
after injection, a high proportion of grains were located over lysosomes, Golgi 
apparatus and other organelles. 
Properties 
The necessity of strong insulin binding to cells prior to the onset of 
the hormone's biological effects was first postulated by W .c. Stadie and co-
workers in 1949 (178) after they observed that the action of insulin on glycogen 
synthesis in diaphragm muscle, initiated during a short exposure to insulin, 
persisted after the tissue was rinsed with and transferred to insulin-free medium. 
Subsequently they found that 131J- and 35s-labeled insulin was bound by muscle 
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in proportion to the hormone's effect on glycogen synthesis (179). Narahara 
(180) also found that an immediate binding of insulin to frog sartorius muscle 
precedes the insulin-dependent acceleration of glucose transport, with an appre-
ciable interval observed between binding and the commencement of transport 
acceleration. Numerous investigators have demonstrated that the specific 
binding of insulin from various animal species, proinsulin, and several insulin 
analogues to isolated cells and cell membranes is directly proportional to the 
biologic activity of the insulin or insulin analogue, as determined by such 
criteria as glucose oxidation in adipocytes. Receptor preparations employed 
include rat liver membrane (181,182), isolated rat adipocytes (159), cultured 
human lymphocytes (183), and cultured human fibroblasts (184) . 
.' 
Although, generally, procedures that result in alterations of the insulin-
binding properties of cell receptors also cause quantitatively similar impairments 
of insulin-induced metabolic responses in these cells (159), the insulin-receptor 
interaction and the hormone's physiologic effects can be uncoupled. Insulin 
binds to frog muscle at 0°C, but does not cause the increase of glucose 
transport seen at higher temperatures (180). Treatment of cells with neuramini-
dase, which removes terminal sialic acid residues from cell-surface glycopro-
teins, abolishes insulin-induced glucose uptake and inhibition of lipolysis, but 
doesn't alter insulin binding to the cells (159,171,183,185-187). Starvation of 
rats or prior treatment with prednisone or streptozotocin reduces the metabolic 
response of fat cells to insulin, but does not affec~ the quantity or affinity of 
the receptors for the hormone (188). Furthermore, the binding of insulin to 
fat cells obtained from hamsters, rabbits, mice and guinea pigs is similar to 
that of rat adipocytes, but cells from the former group of rodents are 
significantly less responsive to insulin than are rat cells (188). It has also 
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been reported that the insulin insensitivity of large fat cells is not due to a 
reduced insulin binding (189). 
The properties of insulin-receptor interactions have been studied in a 
great variety of tissues, mainly from humans and rats. It may be seen from 
Table II that insulin receptors fall roughly into two categories: high affinity 
(Kassoc. z 109-1010 M-1)/low concentration (40-11,000 receptors per cell) and 
low affinity (Kassoc. z 107-1o9 M-1)/high concentration (1,300-250,000 recep-
tors per cell). These categories of insulin receptors, represented by curvilinear 
Scatchard plots (201), have been found in cells isolated from animal tissues, 
circulating leukocytes, cultured cells, plasma membrane preparations and solubil-
ized membrane proteins. Good; correspondence of affinities for insulin of 
different preparations from the same tissue (~.g., rat adipocytes) have been 
reported. 
Association of insulin with human erythrocytes, which are insensitive to 
the hormone, is of a decidedly lower order than the other tissues studied and 
may be due to nonspecific protein binding (202). Crofford et al. observed no 
significant binding of 1251-insulin to erythrocyte plasma membranes (203). 
Likewise, no specific binding of insulin to circulating human lymphocytes 
purified on a nylon-fiber column was found by Krug et al. (195), contrary to 
reports of insulin binding to normal circulating lymphocytes by others (196,204). 
Subsequently, it was demonstrated that the specific insulin binding observed 
using preparations of normal human mononuclear leukocytes was due to mono-
cytes, not lymphocytes (205). Lymphocytes induced to undergo blastogenesis 
in short-term culture by mitogens such as concanavalin A (195), immune 
stimulated lymphocytes (206), and malignantly transformed lymphocytes in 
continual culture, obtained from hosts suffering from lymphoproliferative dis-
'·"'""!!!"'t''~ 
TABLE II A. SOME PROPERTIES OF INSULIN RECEPTORS 
Species Tissue Preparation Temp. pH Kassoc. Kdissoc. k1* k_1t oc optimum M-1 M M-1sec.-1 sec.-1 
Human Adipose Isolated 1. 6.7 X 108 1.5 X 1o-9 
cells 
2. 1.3 X 108 8.0 X 10-9 
Fibroblasts Cultured 3. 15 4.9 X 109 2.0 X 1o-1o 1.7 X 105 3.4 x 1o-5 
cells 
Placenta Plasma 5. 30 5.(f, X 107 2.0 X 10-8 
membranes 
Particulate 6. 4 2.8 X 109 3.6 X 1o-1o 
receptors 
7. 4 2.5 X 107 4.0 X 10-8 
8. 24 2.0 X 108 5.0 X 1o-9 
9. 24 4.7 X 107 2.1 x 1o-8 
Soluble 10. 4 7.8 1.0 X 109 1.0 X 1o-9 6.6 X 103 6.6 x 1o-6 
receptors 
11. 4 3.1 X 108 3.2 x 1o-9 
12. 24 3.0 X 109 3.3 X 1o-1o 3.8 X 104 1.3 'X 10-5 
13. 24 1.5 X 108 6.7 X 1o-9 
CJ1 
0 
'1 
TABLE II A. (CONTINUED) 
Species Tissue Preparation Temp. pH Kassoc. Kdissoc. kl* k_lt oc optimum M-1 M M-lsec.-1 sec.-1 
Human Placenta Cultured 14. 15 7.6 4.8 X 109 2.1 X lo-lo 4.8 X 106 1.0 x lo-3 
cells 
15. 15 9.8 X 108 1.0 X 10-9 
Granulo- Circul. 16. 22 8.0 6.0 X 109 1.7 X lo-10 7.4 X 106 1.2 x lo-3 
cytes cells 
17. 22 2.0 X 107 5.0 X lo-8 
Lymphocytes Cultured 18. 15 7.8 1.2 X lolO 8.3 X lo-ll 1.0 X 106 8.3 X lo-5 
cells 
19. 15 1.1 X 109 9.1 X lo-10 9.2 X 105 8.3 X lo-4 
20. 30 1.5 X 109 6.7 X lo-10 1.2 X 106 8.1 X lo-4 
Erythrocytes Circul. 21. 15 8.0 2.1 X 106 4.8 X 10-7 3.7 X 102 1.8 X 10-4 
cells 
22. 15 5.8 X 102 1.7 X 10-3 
Rat Liver Isolated 23. 1.4 X lolo 7.1 X lo-11 
cells 
Membranes 24. 24 1.5 X 1o1o 6.7 X 1o-11 3.5 X 106 2.7 X 10-4 
Soluble 25. 24 7.7 X 109 1.3 X lo-lo 
receptors U1 
..... 
TABLE II A. (CONTINUED) 
Species Tissue Preparation Temp. pH Kassoc. Kdissoc. kl* k_lt oc optimum M-1 M M-lsec.-1 sec.-1 
Rat Adipose Isolated 26. 24 1.3 X lolO 8.0 X lo-u 1.5 X 107 7.4 x lo-4 
cells 
27. 24 2.0 X 109 5.0 X 10-10 
28. 24 3.3 X 108 3.0 X lo-9 
29. 37 3.3 X 108 3.0 X lo-9 4.2 X 105 1.2 X 10-3 
•. Membranes 30. 24 7.5 1.3 ·x 1010 7.5 X lo-ll 8.5 X 106 4.2 X lo-4 
31. 24 2.0 X 109 5.0 X lo-lo 
32. 24 3.3 X 108 3.0 X lo-9 
Soluble 33. 24 7.7 X 109 1.3 X 10-10 
receptors 
*Association rate constant 
tnissociation rate constant 
TABLE n B. SOME PROPERTIES OF INSULIN RECEPTORS 
Sites/~ m2 
Degradation 
Sites/Cell pmole/mg fmole/106 cells or mg·hr. Ref. 
40 15° 24° 37° 
1. 50,000 2.3 190 
2. 250,000 11.5 190 
3. 3,300 0 184 
4. 87,600 184 
5. 0.9 191 
6. 0.45 192 
7. 18.1 192 
8. - 1.4 192 
9. 4.6 192 
10. 4.2 0 2.1 15 192 
11. 6.9 192 
12. 0.6 192 
13. 6.3 192 
14. 480 0.4 0 0.36 193 
15. 50,000 36 193 CJl w 
TABLE n B. (CONTINUED) 
~m2 
Degradation 
Sites/Cell Sites/ pmole/mg fmole/106 cells or mg·hr. Ref. 
40 15° 24° 37° 
16. 40 0.07 O.Olt 1.4 194 
17. 1,300 2.3 194 
18. 350 0.12 0 0.5** 183,195 
19. 12,500 4.4 183 
20. 12,000 4.2 0 o** 196 
21. 10,500 74 0 0 o** 197 
22. 2.79 x 106 2.0 X 104 197 
23. 160 
24. 0 181 
25. 0.3 198 
26. 11,000 0 159 
27. 3,000 199 
28. 30,000 199 
29. 50,000 16 144 
30 0.2 0 200 CTI oj::o. 
TABLE II B. (CONTINUED) 
Sites/Cell Sites/ JJffi2 pmole/mg 
Degradation 
fmole/105 cells or mg·hr. Ref. 
4° 15° 24° 37° 
31. 199 
32. 199 
33. 0.63 198 
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orders (195,196), however, do po3sess specific insulin receptors and are widely 
used in studies of receptor properties and development of radioreceptor ·assays 
for insulin. 
Based on the expectation that the steady-state concentration of free 
insulin maintained in the tissues is approximately equal to the concentration 
of insulin in the peripheral circulation, the dissociation constant (K o) exhibited 
by a given set of insulin receptors will be that concentration of circulating 
insulin at which the receptors are half saturated. Thus, comparison of insulin 
concentrations necessary for half maximal stimulation of insulin-dependent 
processes with dissociation constants observed for insulin-receptor interactions 
suggests the existence of several p_opulations of receptors responsible for initiat-
' ing various insulin-dependent functions. Insulin concentrations of 5-7 x lo-ll 
M (7-10 ~.a U/ml), in the range of dissociation constants for the highest affinity 
insulin receptors, have been found to produce half-maximal stimulation of 
glucose oxidation (160,207) and lipogenesis (144), indicating that one or more 
rate-limiting steps of these processes are affected by high affinity insulin 
receptors at fasting insulin levels. 
On the other hand, much higher insulin concentrations have been neces-
sary to affect glucose transport in cells. For instance, Guidotti ~ al. (208) 
found a significant increase in glucose uptake by 10-day-old chick embryo 
hearts only at 10 mU insulin/ml (7 x to-8 M). As will be seen, large doses 
of insulin have also been required to stimulate cell proliferation (Chapter 4). 
Gammeltoft and Gliemann (144) postulated that about 2% of rat adipocyte 
receptors, for which they determined the Ko to be 3 x l·o-9 M, were bound 
to insulin when lipogenesis was half-maximally stimulated in these cells at an 
insulin concentration of 7 x to-ll M. Kono and Barham (207) found that 
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approximately 2.4% (corresponding to 4,000) rat adipocyte receptors of .K 0 = 7 
x 1o-9 M were bound to insulin when glucose oxidation was maximally stimulated 
at an insulin concentration of 40 lJ U/ml (2.8 x lo-10 M) and that 1,200 
receptors were bound at half-maximal stimulation (4.4 x lo-ll M insulin). 
Crofford et al. (209) estimated that both glucose and amino acid metabolism 
in rat adipocytes are stimulated maximally when approximately 3,000 insulin 
molecules are taken up by each cell. At about the same time that the above 
studies were published, Cuatrecasas reported the discovery of high affinity rat 
adipocyte insulin receptors with Ko = 8 x lo-ll M (159,160,200). 
Thus, it may be seen from Table III that 50% of the high affinity 
receptors will be bound to insulin when the low affinity receptors are less 
than 10% saturated. In fact, 78% of the high affinity receptors (Kassoc. = 1.25 
x 1010 M-1; Ko = 8 x lo-ll M) will be bound in the presence of 2.8 x lo-10 M 
(40 lJU/ml) insulin. At 22 \JU insulin/ml (1.6 x lo-10 M), the point at which 
maximal stimulation of glucose oxidation in adipocytes is just attained, 2.2% 
receptors of Ko = 7 x lo-9 M (Kassoc. = 1.4 x 108 M-1) are bound to insulin 
while the high affinity receptors would be two-thirds saturated. Based on 
160,000 low affinity receptors per cell reported by Kono and Barham and 400 
high affinity receptors per cell, 3,600 low affinity receptors and 270 high 
affinity receptors would be filled at this point. At 6 lJ U insulin/ml (4.4 x 
1o-l1 M), where half-maximal stimulation of glucose oxidation is attained, 
0.6%, or 980, low affinity receptors and one-third, or about 140, high affinity 
receptors would be bound to insulin. 
Until 1973, the non-linearity of the Scatchard plots describing insulin-
receptor interactions (in contrast to linear plots obtained for other hormones, 
such as somatotropin binding to cells) was routinely ascribed to receptor hetero-
TABLE III. INSULIN-RECEPTOR BINDING AT PHYSIOLOGIC INSULIN CONCENTRATIONS 
Kassoc. No receptors/cell [insulin] * % receptors boundt 
M-1 nM 11 U/ml 
1.25 X 1010 300 0.01 1.4 
0.1 14 
0.5 70 
1.0 140 
5.0 x 109 3,000 0.01 1.4 
0.1 14 
0.5 70 
1.0 140 
1.0 x 109 50,000 0.01 1.4 ··T.-, 
0.1 14 
0.5 70 
1.0 140 
* [free insulin] = [total insulin] in physiologic steady state. 
t Based on [bound receptor] = Kassoc. x [insulin]; 
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56 
86 
93 
5 
33 
71 
83 
1 
9 
33 
50 
[free receptor] 
% receptors bound = {1 -{ + [boun/ reeel!tor 1)1 ~ [free receptor] I J X 100. 
No. receptors bound/cell 
33 
168 
258 
279 
150 
990 
2,130 
2,490 
500 
4,500 
16,500 
25,000 
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geneity. At that time, however, De Meyts et al. (210) suggested that the 
curvilinear Scatchard plots characteristic of insulin-receptor interactions could 
be the result of site-site interactions among insulin receptors, or . negative 
cooperativity; that is, that binding of insulin at one site causes a decrease in 
affinity for insulin of other receptors. Indeed, Hill plots (211) for insulin-
receptor interactions yield Hill coefficients, n = 0.53 - 0. 73 (193,194,212), 
indicative of negative cooperativity (n = 1 indicates no cooperativity and n>1 
indicates positive cooperativity). However, the results of Hill plots appear to 
be contradictory. Although Podskalny et al. (193) report an average Hill 
coefficient of 0. 73 for insulin binding to cultured placental cells, the first 
three points of their plot, coverin~ the physiologic insulin range (0-100 IJU/ml), 
fall on a line of slope, n = 1, while points above 10-8 M insulin tend toward a 
Hill coefficient less than 0. 73. On the oth~r hand, Fussganger et al. (194) 
have demonstrated a Hill coefficient of 0. 7 for insulin binding to human 
granulocytes throughout the physiologic range with a sudden shift to n = 1 at 
insulin concentrations greater than 1o-7 M. 
The most compelling evidence for negative cooperativity among insulin 
receptors was introduced by DeMeyts et al. in 1973 (210): radiolabeled insulin 
is released from cells at a significantly higher rate when the cells are diluted 
with a large excess of unlabeled insulin-containing medium compared to dilution 
with insulin-free medium, indicating that the decrease in the apparent affinity 
of insulin receptors characteristic of negative cooperativity is due to an increase 
in the rate of dissociation. The insulin-induced increment in dissociation is 
unaffected by varying the dilution factor or by adding cells, and the effect is 
specific for insulin, since substitution of other hormones for unlabeled insulin 
does not accelerate dissociation. A number of insulin analogs also accelerate 
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dissociation of labeled insulin in proportion to their ability to inhibit binding 
of radiolabeled insulin to the receptors. Using this method, investigators have 
demonstrated cooperative effects among insulin receptors on cultured human 
lymphocytes {210), cultured human placental cells (193), circulating human 
granulocytes (194), cultured human fibroblasts (184), circulating human mono-
cytes (213), mouse, rat, guinea pig and chicken liver membranes (214,215), and 
turkey, frog and trout erythrocytes (215). 
Receptor binding and cooperativity can apparently also be uncoupled. 
Greatly decreased or no cooperative effect is seen with desalanine-desasparagine 
(DAA) and desoctapeptide (DOP) insulins (184,193,210), high concentrations of 
insulin (::~ . lo-4 M; 210), insulin dim~rs (possibly accounting for loss of coopera-
tivity at high insulin concentrations; 210), the plant lectin concanavalin A 
(212), urea and acid pH (216). Recently, DeMeyts et al. (217) have implicated 
a surface region of the insulin molecule as responsible for the negative 
cooperativity of insulin-receptor interactions, based on the ability of insulin 
analogues to accelerate insulin-receptor dissociation. This "cooperative" site 
is situated on the hydrophobic face that includes the putative receptor-binding 
region, borders those structures necessary for insulin dimerization, and com-
prises the B23 glycine, B24-25 phenylalanines, B26 tyrosine, and A21 asparagine. 
The finding of curvilinear Scatchard plots for and insulin-augmented 
dissociation of the hormone from solubilized insulin receptors (192,218) has 
called into question the concept of negative cooperativity as site-site interac-
tions among membrane-bound receptors. The observations of Ginsberg et al. 
(218), however, may provide a basis for negative cooperativity as a modulation 
of the insulin-receptor association at the receptor itself, initiated by insulin 
binding and resulting in an alteration of the quaternary structure of the 
61 
receptor. They found that incubation of solubilized avian erythrocyte .receptors 
with 25 ng insulin/ml (625 lJ U/ml) produced a shift of 35% receptors to the 
low affinity state. Gel chromatography revealed that about 25% of the 
receptors had shifted from molecular weight 300,000 to 75,000 daltons, 
consistent with a tetramer to monomer conversion. The fact that no more 
than one-third of the receptors are affected considerably above the physiologic 
range of insulin concentration may mean that the cooperative effect is 
physiologically unimportant and points to the need for caution in interpreting 
evidence for negative cooperativity. For example, the possibility that this 
evidence may also be produced by a receptor-associated insulinase has not 
been eliminated. Resolution.:· of the debate regarding insulin receptor 
heterogeneity versus negative cooperativity awaits definitive demonstration of 
the existence or non-existence of discrete subpopulations of cell insulin 
receptors. 
Binding of insulin to cell receptors is a specific, reversible, and saturable 
process that is dependent on time and temperature. Harrison ~ al. (192) 
found that insulin association with soluble placental receptors attained an 
apparent steady state within one hour at 37°C and 24°C, by 3 hours at 15°C 
and by 12 hours at 4°C. Gavin et al. {183) determined that maximum binding 
of insulin to cultured lymphocytes occurs at 15°C, at which temperature a 
steady state is reached by 60 minutes and is maintained for at least one hour. 
The inverse relationship between apparent association constant and temperature 
is probably due to the marked temperature-sensitivity of insulin-receptor 
dissociation, the rate of which increases with temperature to a half-life of 
about 7-10 minutes for adipocytes at 37°C {144,219). 
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The kinetics of insulin-receptor association are second-order, or bimolecu-
lar, while dissociation obeys first-order kinetics (159,181). Cuatrecasas (200) 
has determined that the free energy of association ( llG) of insulin and adipocyte 
membranes of -14 kcal/mole, based on an equilibrium constant of 2 x 1010 
M-1 at 24°C, is due to a very large decrease in enthalpy ( llH = -28 kcal/mole) 
partially offset by a large decrease in entropy ( ll S = -45 cal mole-1 deg. -1 ). 
Insulin-receptor association is also dependent on pH, but the role of 
divalent cations in the interaction is questionable. Maximum binding has been 
observed at pH 7.8 for lymphocytes (183), placental cell membranes and 
solubilized placental receptors (192), pH 7.6 for cultured placental cells (193), 
pH 7.5 for adipocyte membranes ~200), and pH 8.0 for circulating granulocytes 
(194). Binding is totally absent below pH 5.0 (183,192). Gavin et al. (183) 
found that ca++, Mg++, and ethylenediaminetetraacetate (EDTA) had no effect 
on 125J-insulin binding to cultured lymphocytes at concentrations of 1 to 10 
mM. Likewise, Harrison et al. (192) reported that 5 mM ca++, Mg++, and 
EDTA were without effect on insulin binding to soluble placental receptors. 
However, Podskalny et al. (193) noted a 25% inhibition of 125J-insulin binding 
to cultured placental cells in the presence of 1 to 5 mM CaCl2. 
The insulin receptor apparently is a highly asymmetric glycoprotein of 
molecular weight 300,000 (218,220,221), which sediments with a coefficient of 
• 11 S and behaves like a particle with a Stokes radius of about 70 A (220,222). 
The protein nature of the receptor is indicated by the fact that proteolytic 
digestion of cells or receptor preparations with such enzymes as trypsin, 
chymotrypsin and papain impairs or abolishes insulin binding and (in the case 
of cells) insulin-induced metabolic effects, while pretreatment with insulin 
protects the receptor from proteolytic agents (181). Cuatrecasas (162) has 
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found that exposure of fat cells to 10 JJ g trypsin per ml at 37°C for 15 
minutes causes a 10-fold fall in receptor affinity for insulin, while affecting 
only slightly insulin-stimulated adipocyte glucose oxidation and the cell's insulin 
binding capacity. All these functions were completely abolished in the presence 
of higher trypsin concentrations. Very similar results were obtained with 
chymotrypsin and papain. Gavin et al. (183) found that treatment of cultured 
lymphocytes with more than 100 g trypsin/ml for 15 minutes at 37°C resulted 
in significant decreases in insulin binding. Indication that the insulin receptor 
is an integral membrane glycoprotein, largely immersed in membrane phospho-
lipids, is afforded by the fact that low concentrations of trypsin even somewhat 
mimic the metabolic effects of i~sulin on adipocytes (223), that pretreatment 
of cells and membranes with phospholipases enable complete abolition of insulin 
binding at low protease concentrations that otherwise would have no significant 
effect on these preparations' ability to bind insulin (159), and that only 2 lJ g 
trypsin/ml (15 min., 37°C) is sufficient to abolish completely the ability of 
solubilized placental receptors to bind insulin (192). However, Cuatrecasas 
(220) has provided evidence that the insulin receptor is not a lipoprotein. The 
lack of functionally important nucleic acid in the insulin receptor is indicated 
by the fact that digestion of cultured human lymphocytes with ribonuclease 
and deoxyribonuclease has no ef!ect on binding of 125J-insulin to the cells (183). 
As mentioned above, neuraminidase digestion of cells indicates that sialic 
acid is unimportant to the insulin recognition function of the receptor, but is 
critical to the transmission of the insulin-binding signal from the recognition 
site to the glucose transport site. Mild a-galactosidase digestion affects 
neither cellular insulin binding nor response, but a-galactosidase treatment 
subsequent to neuraminidase digestion, which itself abolishes. insulin response, 
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results in complete abolition of cell insulin binding (222), suggesting that 
penultimate B-linked D-galactose, normally masked by terminal sialic acid (or 
terminal galactose occluded by proximal sialic acid termini), is important to 
insulin recognition. Further, Cuatrecasas (171,224) has found that the plant 
Iectins concanavalin A, which is specific for terminal a -D-mannopyranosyl or 
a -D-glucopyranosyl and internal 2-0-linked-D-mannopyranosyl residues (225, 
226), and wheat-germ agglutinin, which is specific for terminal 
N-acetylglucosamine or its dimer (di-N-acetylchitobiose; 227), in low 
concentrations produce insulin-like effects on fat cells, while at higher 
concentrations they inhibit insulin binding to the cells. 
Early claims of inhibition o~ reversal of tissue insulin effects and binding 
in the presence of sulfhydryl-blocking or disulfide disruptive agents, respec-
tively, led to postulation of a covalent bond between insulin and its receptors 
involving disulfide bonds (228-231). This notion has been discarded, however, 
due to the realization that insulin-independent metabolic effects are brought 
about by these agents, more recent studies showing no effect of disulfide 
inhibitors such as N-ethylmaleimide, iodoacetamide, iodoacetate, arsenite, dithi-
othreitol, and parachloromercuribenzoate on specific insulin-receptor associa-
tion, demonstration that insulin dissociated from receptors retains full binding, 
biological and physical properties, and the non-covalent association kinetics of 
insulin-receptor interaction (192,198,200,219,232). Cuatrecasas (200) has also 
reported that the water-soluble carbodiimide reagent, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide, which forms peptide bonds via conjugation 
with free carboxy functions, does not modify insulin binding after reaction 
with adipocyte membranes in the absence or presence of the amino ligand 
glycine-0-methyl ester. Neither is insulin binding affected by treatment of 
65 
the membranes with the tryptophan-modifying agents 2-hydroxy-5-nitrobenzyl 
bromide and 2-methoxy-5-nitrobenzyl bromide. However, treatment of 
membranes with tetranitromethane, which reacts with tyrosyl as well as 
sulfhydryl and tryptophanyl residues, results in a dramatic reduction of insulin 
binding. Diazonium-1-H tetrazole, which reacts primarily with histidyl and 
tyrosyl and to a lesser extent with tryptophanyl residues, totally abolishes the 
ability of the membrane to bind insulin. Thus, tyrosyl and possibly histidyl, 
but not sulfhydryl, free carboxyl, or tryptophanyl groups are involved in the 
specific recognition of insulin. 
As can be seen from Table II, the quantity and density of insulin receptors 
varies widely, from 40 per cell fpr granulocytes (194) to 250,000 per cell for 
human adipocytes (190), from less than 0.1 per ~m2 for granulocytes to 36 
per ~ m2 for cultured placental cells (193), and from 0.2 pmole per mg 
membrane protein for adipocytes to more than 18 pmole per mg membrane 
protein for placental cells (192). An enigmatic, but consistent observation has 
been the presence in membranes of "occult" insulin receptors unmasked at high 
ionic strength or by treatment with phopholipases. A two- to sixfold increase 
in insulin binding capacity was seen following treatment of adipocyte membranes 
(200), hepatocyte membranes (181), and cultured lymphocytes (195) with 5-100 
'llg phospholipase C/ml. A lesser increase in membrane insulin binding capacity 
can be brought about by treatment with phospholipase A in the presence of 
ca++ (181), but not with phopholipase D (222), and the phospholipase-induced 
unmasking of occult insulin receptors can be partially reversed by addition of 
exogenous phospholipid (171). Although the occult receptors (approximately 
65,000 per adipocyte; 162) are very similar to the normally exposed receptors 
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in their E..ffinity for insulin, association-dissociation kinetics and sensitiyity to 
trypsin, they are unable to trigger a biological response to the hormone. 
A very similar increase in the insulin-binding capacity of adipocyte (200) 
and hepatocyte (181) membranes was found in the presence of hypertonic salt 
solutions, attaining a maximum in 2 M NaCl and also (for adipocytes) in 2 M 
KCl or 0.5 M LiCl. The salt-induced increment in binding capacity was 
observed to be much lower after treatment of adipocyte membranes with 
phospholipase C, indicating that occult insulin receptors are also exposed at 
high ionic strength. Harrison et al. (192) also found an increase in the insulin 
binding capacity-apart from an increase in affinity-of particulate placental 
membranes at low temperature. ;' 
Regulation 
As was mentioned at the beginning of this section, it is now generally 
believed that protein hormones elicit their effects at the cell surface via 
membrane-bound receptors. Therefore, the cell must possess the means by 
which to adjust, or regulate, the magnitude of its metabolic response to a 
given external concentration of the hormone effector. Cellular regulation of 
hormone response can be envisioned to involve at least three critical aspects 
of cell function: 1) hormone recognition, at the level of the receptor; 2) 
amplitude of the signal generated by hormone-receptor association, at the level 
of one or more intracellular mediators; and 3) the magnitude of metabolic 
response to a given signal amplitude, at the level of key components of 
metabolic processes. The last two aspects will be discussed later in this 
section, under consideration of mechanism; the first aspect, that of regulation 
at the receptor level, will be dealt with here. 
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Any discussion of cellular regulation of hormone response must endeavor 
to explain how the response is initiated (cell sensitivity to the hormone), how 
the response is maintained (time-dependent magnitude of response at a given 
hormone concentration), and how the response is terminated. As was made 
evident in the foregoing discussion of receptor binding properties, similar 
hormone response at the receptor level (assuming constant signal amplitude 
and metabolic response per receptor bound) is dependent upon both the affinity 
of the receptor for the hormone and the number of receptors per cell. Thus, 
for a constant number of receptors per cell, the fraction bound, and therefore 
magnitude of response, is directly proportional to the affinity of the receptor 
for hormone; for a receptor popu~ation of given affinity, the absolute number 
bound, and therefore magnitude of response, is directly proportional to the 
number of receptors per cell. Both the sensitivity of a cell to a hormone and 
the magnitude of the cell's response to a given concentration of hormone may 
be modulated at the receptor level by varying receptor affinity for hormone 
and/or number of receptors per cell. 
A built-in decay of response, and therefore a constant duration of signal 
maximum dependent upon the magnitude of pancreatic insulin release, is 
provided by the concept of negative cooperativity, in which the affinity of 
receptor for hormone is inversely proportional to hormone concentration. It is 
to be expected that such a system would require connection of each receptor 
to mediators for all insulin-affected cell functions, with different signal ampli-
tudes and/or response/signal characteristics for different sets of functions, 
resulting in characteristic insulin sensitivities and insulin concentration-response 
profiles for each function. The same kind of variation of hormone sensitivity 
and response can be provided by discrete receptor subpopulations, each with 
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a characteristic affinity for hormone and each connected to mediators for a 
specific set of cell functions. This receptor heterogeneity model, however, 
does not provide by itself for decay of hormone response, which would have to 
be effected by other means. In fact, evidence does exist for such a separate 
mechanism of response decay via cell modulation of receptor concentration. 
The fact that cells can increase the number of surface insulin receptors 
is indicated, not only by discovery of occult receptors, but also by the emergence 
of approximately 350 insulin receptors per cell when normal circulating lympho-
cytes, which exhibit no significant insulin-binding capacity, undergo blast 
transformation in the presence of concanavalin A, phytohemagglutinin, or 
periodate (195,233). The number, of receptors increases sharply to reach a 
maximum between 24 and 46 hours after exposure of the cells to mitogen, 
coinciding with an increase in thymidine incorporation into nuclear DNA, but 
preceding the appearance of enlarged, morphologically transformed cells. A 
similar density of insulin receptors was found on giant, polynucleated cells 
resulting from transformation of circulating lymphocytes with cytochalasin B 
and on circulating leukemic lymphoblasts obtained from patients suffering from 
acute lymphoblastic leukemia, but not on chronic lymphocytic leukemia cells. 
More important to cellular regulation of the physiologic insulin response 
is evidence for a decrease in the number of cell surface insulin receptors in 
response to extracellular conditions, known as "down-regulation." A 25% 
decrease in insulin-binding capacity was observed . after cultured lymphocytes 
were preincubated with 4 ng (100 ~ U) insulin/ml for 1 hour or 16 hours at 
37°C, but 10 ~ g insulin/ml (3 hours, 37°C preincubation) was required to 
produce the same decrease in insulin-binding capacity of. adipocytes (234). A 
maximum decrease in binding capacity of 75% was seen after preincubating 
69 
lymphocytes 16 hours with 100 ng insulin/mi. A significant decrease in insulin-
binding capacity was also found for rat hepatocytes obtained from 72 hour-
fasted animals, parallel to a decrease in liver membrane phospholipids and 
despite a 3-fold increase in membrane protein (235). 
Although it is tempting to postulate an internalization of the insulin-
receptor complex followed by lysosomal degradation of both insulin and receptor, 
which would neatly explain evidence of intracellular insulin receptors, certain 
observations argue against receptor internalization prior to degradation. The 
down-regulation noted by Huang and Cuatrecasas (234) was not affected by 
· the metabolic poisons sodium fluoride and dinitrophenol, inhibitors of RNA and 
protein synthesis, or agents that interfere with phagocytosis _and microtubule 
and microfilament function. The insulin-dependent reduction of insulin binding 
also occurs with insulin analogs, such as reduced and carboxymethylated and 
synthetic B-chain, which possess no biologic activity, suggesting the triggering 
of a receptor-degrading system separate from the insulin recognition function. 
Using a radioimmunoassay for the human insulin receptor, Harrison et al. (236) 
have been able to study the fate of the receptor during down-regulation of 
cultured human lymphocytes. They found that cellular insulin binding decreased 
8896 during maximum down-regulation with 1o-6 M insulin. When the receptors 
were solubilized with 196 Triton X-100, the decrement in insulin binding was 
reduced to 6296, suggesting dilution by intracellular binding sites. The decrease 
in immunoassayable solubilized receptors was almost identical, indicating that 
down-regulation of insulin binding is due to a decrease in the number of 
receptor molecules. Establishment of the phenomenon of down-regulation as 
a physiologic mechanism for response decay is problematic, however, since 
maximum down-regulation has been seen only with pharmacologic insulin 
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concentrations, where the possibility of artifactual observations due to 
contaminating proteases is most likely. 
A separate mechanism is also required to account for termination of 
insulin response in both the negative cooperativity and receptor heterogeneity 
models. This mechanism is provided by the well-documented process of systemic 
and localized insulin degradation. 
Insulin Degradation 
The critical role of the liver in removal of insulin from systemic 
circulation was appreciated as early as 1927, when Kepinow and Dutaillis 
demonstrated that the hypoglyceJ?1iC activity of the peripheral blood of a dog 
injected intravenously with 12 units of insulin was not detectable 3 to 20 
minutes afterwards, but that hypoglycemic activity persisted beyond this time 
interval if the portal vein was anastomosed to the renal vein, bypassing the 
liver (237). Later, it was found that 8 passages through isolated bullfrog liver 
were necessary for complete removal of insulin activity (238), but that approxi-
mately half the insulin entering rat and human liver is removed in a single 
passage (239,240). The importance of hepatic uptake, or capture, of insulin 
in systemic clearance of the hormone was indicated by a rapid decrease of 
trichloroacetic acid (TCA)-precipitable 1-131 activity compared to a slow 
increase of TCA-soluble radioactivity during cyclic perfusion of 131J-insulin 
through isolated rat liver (239,241). Normally the half-life of crystalline insulin 
in human circulation is approximately 5 minutes (242). An increase in hepatic 
clearance rate of the hormone has been observed in fasted and diabetic animals 
(238,243-245). 
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By 1939, it was known that insulin degradation proceeded by two 
mechanisms: a reductive cleavage of disulfide bridges mediated by sulfhydryl 
compounds such as glutathione and cysteine and an enzymic proteolysis. The 
previous year Lehmann and Schlossmann (246} had reported a two-component 
system for reductive degradation of insulin in a cell-free muscle extract, 
consisting of a heat-stable, diffusible compound capable of catalyzing the 
reduction by a non-enzymatic mechanism and a heat-labile enzyme. The former 
component is now known to be glutathione (GSH) and the latter has been 
termed glutathione-insulin transhydrogenase (GIT), or protein-disulfide reductase 
(glutathione) (EC 1.8.4.2), in deference to the wide range of substrates it has 
been found to act upon. In liver, the enzyme is coupled to the oxidation of 
NADPH via glutathione reductase (GR) as follows: 
insulin A (S-S}2x:4 GSHX 2 NADP+ 
GIT GR 
A (SH)2 2 GS-SG 2 NADPH+2 H+ 
+ 
(247). 
Glutathione-insulin transhydrogenase is a glycoprotein of molecular 
weight 53,000-62,000 daltons and possesses amino terminal lysine, leucine, and 
valine, suggesting three polypeptide chains or subunits (248,249}. The pH 
optimum for GIT is between 7.5 and 8.5 (250}. Understandably, GIT is inhibited 
by thiol reagents (251). The enzyme is also inhibited competitively by insulin 
analogs, oxytocin and vasopressin, noncompetitively by glucagon, and both 
competitively and noncompetitively by somatotropin (252). The activity of 
GIT is enhanced by ethylenediaminetetraacetate (EDTA) (253). 
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In the rat, relative tissue concentrations of GIT have been found to be 
as follows: pancreas>liver>intestine>spleen>kidney = testis = thymus = fat = 
lung>brain>heart>diaphragm = skeletal muscle (254). The kinetics of the GIT-
catalyzed separation of insulin A and B chains is second order (255), exhibiting 
a Km of approximately 50 ).l M insulin (256). The velocity of GIT-catalyzed 
insulin degradation at 37°C using 8.4 ).l M insulin and 3 mg rat liver homogenate 
protein/ml was found to be 8.4 nmole per hour per mg wet weight homogenate 
and 5.8 pmole/hr./mg for 0.8 nM insulin and 0.5 mg liver homogenate protein 
(255,257). 
In 1949, Mirsky and Broh-Kahn (258) described a specific enzymic 
proteolysis of insulin by liver, kidn~y, and muscle tissue preparations and termed 
the enzyme responsible insulinase. Later, Brush and Kitabchi (259) demonstrated 
the presence in both soluble and particulate fractions of rat diaphragm muscle 
homogenates of an insulin-specific protease that degrades the hormone to 
oligopeptides and amino acids and is inhibited by N-ethylmaleimide. The soluble 
fraction had a Km (app.) for 1311-insulin of 2 x 1o-7 M, while the particulate 
fraction had a Km apparently 15 to 20 times higher (249). 
Probably the most physiologically significant insulinases described thus 
far are the A and B chain-degrading neutral peptidases, which are inhibited 
by EDTA, indicating a divalent metal cation requirement (255,260). Proteolytic 
A-chain degradation, which obeys first-order kinetics, also requires the presence 
of sulfhydryl compounds (255). The concentration of enzyme activity has been 
found to be greatest in kidney, followed by skeletal muscle, liver and heart 
(261). The velocity of A-chain degradation is 1.7 x 10-10 mole/hr./mg wet 
weight homogenate using 8.4 ).l M insulin and 3 mg rat liver homogenate protein 
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(255) and 2.0 x 1o-13 mole/hr./mg homogenate with 0.8 nM insulin and 0.5 mg 
homogenate protein (257). 
In contrast, the B chain-degrading enzyme recently described by Phelps 
et al. (260) is inhibited by dithiothreitol as well as potassium phosphate salts, 
--
but not by trypsin inhibitors, Trasylol, or phenylmethylsulfonyl fluoride (PMSF). 
Relative tissue concentrations of the enzyme in the rat were found to be as 
follows: kidney»intestine>pancreas == testis>liver>thymus>heart == skeletal 
muscle == diaphragm>lung == spleen>fat. The B-chain degrading activity of 
intestine and pancreas was observed to be partly inhibitable by trypsin inhibitors, 
Trasylol and PMSF, suggesting contamination with pancreatic proteases. 
Optimum activity of B-chain degrading neutral peptidase was observed at pH 
6.5-7 .0. An insulin-reversible depression of the enzyme in the kidney, liver 
and adipose tissue of streptozotocin diabetic rats was also noted. 
Varandani has presented much evidence indicating that GIT and the 
neutral peptidases constitute a stepwise mode of insulin degradation, not only 
in liver and kidney, but also generally in insulin target tissues, representing 
the primary means by which the hormone is degraded-first by reduction of 
interchain disulfide bonds and then by proteolysis-both systemically and locally 
(253,255,257 ,260,261). Although the ability of insulin analogs to inhibit insulin 
binding to and degradation by target cells is closely parallel (262), the insulin 
degradative function of cells, also a time- and temperature-dependent process 
(263), is distinct from receptor binding of the hormone (192,264). Both GIT 
and neutral peptidase activities have been found to reside in cell microsomal 
and plasma membrane fractions, near insulin receptors (265,266). 
Insulin degradation rates found for placental, granulocyte and adipocyte 
cell and membrane preparations (Table D) at 37°C range from 3.6 x 10-16 
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mole/106 cells/hr. to 1.6 x 1o-14 mole/106 cells (mg)/hr., more than an order 
of magnitude lower than degradation rates observed for hepatic tissue. PMSF-
inhibition of granulocyte insulin degradation (194) may indicate the nonspecific 
action of lysosomal proteases. 
Mechanism of Insulin Action 
While much detailed information has been obtained concerning the insulin 
receptor and the hormone's effect on its ultimate targets, such as key enzymes 
of intermediary metabolism, the means by which the two are connected remains 
elusive. Both the nature of the signal generated by insulin-receptor association 
and the mechanism by which the signal is propagated, modulated and interfaced 
' 
with well-characterized molecular effectors of the cell's biological response 
have been particularly subject to the speculation and faddism to which insulin 
research is prone. 
During the 1940s, when the pathways of intermediary metabolism were 
being elucidated, attempts were made to explain insulin's effects based on a 
putative modulation of the activity of critical enzymes involved in carbohydrate 
metabolism, most notably Carl and Gerty Cori's hexokinase theory (267). 
According to this view, insulin counteracts inhibition of hexokinase by pituitary, 
adrenal and other substances. The hexokinase theory was abandoned with the 
accumulation of evidence that insulin exerts no effect on the enzyme, that 
insulin's impact on carbohydrate metabolism actually is enhanced in hypophysec-
tomized, adrenalectomized animals, and that the hormone profoundly influences 
metabolic events independent of glucose phosphorylation (see Chapter I). 
The efforts of physiologists during the following decade resulted in 
considerably greater understanding of sugar transport across plasma membranes 
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and insulin's effect on this process. Insulin's profound enhancement of glucose 
uptake by non-hepatic target tissues, independent of other metabolic events, 
is the hormone's signature, so to speak. At that time, therefore, the belief 
that all metabolic effects on the hormone were consequential to increased 
cellular glucose uptake became prominent. Although glucose transport continues 
to be recognized as a unique and fundamental target of insulin action and 
itself has served as a basis for abandoning otherwise universal theories of 
insulin action (~.g., cyclic AMP, below) several aspects of cellular metabolism 
profoundly affected by insulin, such as amino acid and electrolyte transport, 
are known to be independent of glucose uptake. 
Perhaps the most significant development in endocrinology research 
during the 1960s was the elucidation of the role of adenosine 3',5'-monophos-
phate, or cyclic AMP, as an intracellular mediator of hormone action. After 
a somewhat complete picture had been obtained regarding the intracellular 
events commencing with binding of epinephrine or glucagon to plasma membrane 
receptors, resulting in an increase in the intracellular concentration of cyclic 
AMP, and culminating in a concomitant activation of glycogen phosphorylase 
b and inactivation of glycogen synthetase in muscle, it was logical to suppose 
that insulin, which exerts an influence on the cell largely antithetical to these 
two hormones, causes a decrease in the intracellular concentration of cyclic 
AMP. This hypothesis was largely discredited, however, by an inability to 
demonstrate a consistent insulin-induced decrement in intracellular cyclic AMP. 
There was a brief flurry of excitement early in the 1970s following 
PUblication of evidence indicating a complementary antagonism between cyclic 
AMP and cyclic GMP due to their me~:Hation of opposing cellular processes, 
With subsequent reports of insulin-induced increments in intracellular cyclic 
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GMP concentrations. Unfortunately, the results of cyclic GMP research have 
proven somewhat ephemeral, being plagued by poor reproducibility. Currently, 
the most promising hypothesis attributes a pivotal role to calcium, probably 
acting in concert with cyclic nucleotides, as an intracellular mediator of insulin 
action. 
The major concepts involved in postulated mechanisms of insulin action, 
.!:~·' membrane sugar carriers, cyclic nucleotides, and calcium, will now be 
examined in more detail. 
1. Sugar transport. Transport of monosaccharides across cell plasma 
membranes is temperature-dependent, selective, and bidirectional. The rate 
of D-glucose accumulation inside adipocyte ghosts at 25°C was found to be 
five times greater than at 4°C (268). Both hexoses and pentoses enter cells, 
but sorbitol, the alcohol analog of glucose, is excluded (269). Although many 
of the transported sugars, such as L-arabinose and 3-Q-methylglucose (30MG), 
are not metabolized by the cell, they inhibit the uptake of other, including 
metabolizable, sugars, indicating a common site of sugar entry (269). The 
affinity of this site for sugars has been found to be: glucose=30MG> 
galactose>xylose>L-arabinose (270). 
Transport of sugars across the cell membrane is also stereospecific. In 
erythrocytes, D-galactose enters the cell while L-galactose is excluded (271); 
rat epididymal adipose tissue is slightly permeable to L-glucose, but far more 
so to D-glucose (32); and the transport of 0-glucose across rat fat cell 
membranes has been found to be ten times that of L-glucose (268). The 
cellular sugar transport mechanism also favors 0-glucose in the chair conforma-
tion, with the greatest number of hydroxyl groups in the equatorial position 
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(272). That this mechanism is also capable of transporting sugars out of the 
cell is evidenced by the finding that after equilibration of cells with the 
nonmetabolizable sugars 30MG and L-arabinose, addition to the medium of D-
glucose, which is rapidly phosphorylated inside the cell, causes an efflux of 
the nonmetabolizable sugar, even against a concentration gradient (32,268-
270,273). This phenomenon, known as countertransport, provides strong support 
for the concept that sugar transport across the cell membrane does not proceed 
by simple symmetrical diffusion, but is facilitated by a mobile membrane 
carrier. Facilitated diffusion obeys Michaelis-Menten kinetics, which are 
reflected in the equation for the steady-state ratio of internal ([Si]) to external 
([S0 1) nonmetabolized sugar conceT)trations during countertransport in the pres-
ence of glucose ([ G ]): 
[Sil 1 + [Gil/Kg 
= 
1 + [G0 1/Kg (270), 
where Kg is the Michaelis constant for glucose. Thus, countertransport has 
been very useful in determining the kinetic parameters of glucose transport 
across cell membranes. 
Although the glucose uptake of most tissues, like that of working rat 
heart depicted in figure 3, obeys Michaelis-Menten kinetics and does not require 
energy expenditure by cells, some cells accumulate the sugar by mechanisms 
of active transport (273). The passage of molecules from- the capillary, through 
the extracellular spaces, to the cell surface generally takes place by a process 
of simple diffusion, resulting in a rapid equilibration of the extracellular space 
with the peripheral circulation. For instance, 80% of the equilibrium distribution 
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GURE 3. EFFECT OF GLUCOSE CONCENTRATION IN PERFUSATE AND 
:JsULIN ON GLUCOSE UPTAKE AND INTRACELLULAR GLUCOSE LEVELS 
IN THE PERFUSED RAT HEART. 
aesults are expressed per gram of dry heart. Insert in upper panel is a 
Lineweaver-Burk plot of the glucose uptake of control hearts. 
s sugar concentration (mM) 
v rate of glucose uptake ( \.l moles/g·hr.) 
(Reproduced with permission, from Ref. 185, p. 79. Copyright 1975 by Futura 
Publishing Co., Inc.) 
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of sorbitol in the extracellular volume of the perfused rat heart is attained 
within 30 seconds after the compound is added to the perfusate (269}. In such 
insulin target tissues as muscle, however, simple diffusion plays no significant 
role in sugar transport into the cell (270}. The expression for glucose transport 
into the cell is 
Tin ward = T max ( Go ) 
Go+ Kt 
where Tmax is the maximal transport rate, G0 is the glucose concentration 
outside the cell and Kt is the concentration of glucose at which the transport 
rate is half maximal. This expression is completely analogous to the Michaelis-
Menten equation for the enzyme-catalyzed reaction velocity, 
v = 
where V max is the maxim urn velocity, S0 is the initial substrate concentration, 
and Km is the Michaelis constant, the initial substrate concentration required 
for half maximal velocity. For bidirectional transport, 
(269}. 
The contention that glucose enters the cell by facilitated transport is further 
supported by the observation that the first five minutes of efflux of the sugar 
from adipocyte ghosts during countertransport conforms to zero-order kinetics 
and that glucose is not transported against a concentration gradient (268}. As 
early as 1937 it was noted that glucose uptake by canine extra-hepatic tissues 
is dependent upon blood sugar concentration, to the poiht where large 
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extracellular glucose concentrations could compensate for the lack of insulin 
in diabetes (27 4). 
The apparent Michaelis constant, Km (app.), or the glucose transport 
constant, Kt, reported for muscle and erythrocytes falls into a narrow range of 
4 to 11 mM (269,270,273,275). The reported V max' or Tmax' for perfused rat 
heart varies between 100 and 487 l1 mole glucose/g dry tissue/hr. (269,275). 
On the other hand, kinetic parameters of glucose transport in adipose tissue 
have been found to vary widely (Km = 0.2-140 mM; Vmax = 100-833 l1 mole/g•hr.) 
(32,268). 
In heart muscle, glucose transport is inhibited by free fatty acids (leading 
to preferential utilization of free :fatty acids by myocardium), serum hypoosmo-
lality, and high potassium concentrations, and is stimulated by ouabain (which 
inhibits Na+ /K+ ATPase), serum hyperosmolality, increased muscle work, and 
metabolic poisons such as dinitrophenol and salicylate (269,276). In both muscle 
and adipose tissue, the process is inhibited by the polyphenol compound phloretin 
and its glycoside phlorhizin, and nonmetabolizable sugars such as 30MG (Ki = 
16.3 mM for fat cell membranes) and is stimulated by anoxia (27% increase in 
rat heart muscle) (268-270,272,276). 
Intact transport of glucose into adipocyte ghosts (268) and intracellular 
accumulation of the sugar in the presence of inhibitors of glucose metabolism 
(277) indicate that sugar transport is not coupled to glucose metabolism. 
Furthermore, transport has been found to be the rate-limiting step in glucose 
utilization at physiologic plasma concentrations (<20 mM in adipose tissue and 
<11 mM in both normal and anoxic rat heart; 132,269) of the sugar. Consequent-
ly, intracellular glucose concentrations are normally low and glucose efflux 
from cells into which its transport is facilitated is negligible (269). 
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At greater than physiologic plasma· concentrations of glucose, when sugar 
transport approaches maximum velocity, hexokinase-catalyzed glucose phospho-
rylation, which also obeys Michaelis-Menten kinetics, becomes limiting for 
cellular glucose utilization (269). In normal rat heart, glucose phosphorylation 
has been found to have a Km of 0.6 mM and a Vmax of 81 J.J mole/g·hr. Anoxia 
is also stimulatory for glucose phosphorylation, decreasing the Km and increasing 
the Vmax (269). 
Since Levine et al. (278) outlined the transfer theory of insulin action 
in 1949, there have emerged five major lines of evidence for a discrete mobile 
membrane carrier mechanism for sugar transport: 1) the specificity and 2) 
kinetics of transport; 3) inhibition of transport by specific reactive compounds; 
4) competitive inhibition of glucose transport by certain other sugars, suggesting 
a common transport site; and 5) countertransport (273). In addition, the rate 
of glucose uptake by adipocyte ghosts has been found to be directly proportional 
to the concentration of membrane protein in the preparation (268). 
With general acceptance of the Singer-Nicholson fluid mosaic model of 
membrane structure (279), there has emerged a popular concept of the sugar 
carrier (pictured in figure 4) as an intrinsic membrane protein containing an 
interior hydrophilic channel through which sugar transport is facilitated and 
subject to allosteric regulation. Certain investigators, however, have advanced 
alternate theories of facilitated sugar transport, exemplified by Stein's dimeri-
zation concept (280), in which he considers evidence derived from erythrocyte 
studies suggesting a specific catalytic component of the membrane, termed a 
dimerizer, which could bring sugar molecules together in pairs and so orient 
them as to induce dimer formation. Since the dimers have fewer free 
hydrophilic groups they could cross the cell membrane more easily. 
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FIGURE 4. ACTIVE OR FACILITATED TRANSPORT OF MOLECULE 
THROUGH MEMBRANE PROTEIN CHANNEL VISUALIZED TWO-DIMENSION-
ALLY. 
Molecule impinges (top) on active site (shaded) of protein, following which 
some energy-yielding enzyme reaction triggers shift in subunit configuration 
(bottom) that "squeezes" the molecule through the membrane. 
(Reproduced, with permission, from Ref. 281. Copyright 1975 by HP Publishing 
co., Inc. Illustration by Bunji Tagawa.) 
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Whatever the precise mechanism of membrane carrier facHitation of 
sugar transport may be, the fact that the process is inhibited noncompetitively 
by parachloromercuribenzoate, gold and mercury indicates that one or more 
sulfhydryl groups is critically involved (272). An enhancement of cellular sugar 
transport consequent to inhibition of generation of high-energy phosphate 
compounds by anoxia, 2,4-dinitrophenol and salicylate also suggests the conver-
sion of an inactive phosphorylated carrier to an active, dephosphorylated form 
(282). 
'Much evidence exists that insulin simply enhances the cell's normal sugar 
transport mechanism. The hormone accelerates sugar transport both into and 
out of adipocyte ghosts (268) an~, heart muscle cells (269), increases the rate 
of transport of nonmetabolizable sugars such as D-galactose and L-arabinose 
(29,271), but does not induce L-glucose uptake by either muscle (270) cells or 
adipocyte ghosts (268). Crofford and Renold (32), however, reported a signifi-
cant insulin stimulation of L-glucose uptake by rat epididymal adipose tissue. 
Furthermore, countertransport also occurs in the presence of insulin (32). A 
nearly maximal (fourfold) stimulation of L-arabinose countertransport in rat 
heart muscle has been observed in the presence of 100 l.J U insulin per ml (269). 
The Michaelis-Menten kinetics of glucose transport are preserved during 
insulin stimulation of the process (269). In heart muscle, the hormone causes 
a great increase in both the Km (from 9 to 28 mM) and V max (from 100 to 
500 l.J moles/g·hr.) of glucose transport (269). On the other hand, insulin 
stimulation of glucose uptake by adipose tissue involves a 3- to 13-fold decrease 
in Km while V max remains unaffected (32). Consequently, in insulin-stimulated 
muscle tissue, glucose phosphorylation (which is unaffected by the hormone) 
becomes rate-limiting for cellular uptake of the sugar through the physiologic 
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range of plasma glucose concentrations (>50 mg/100 ml, or 2.8 mM), where 
insulin exerts its maximum effect (269,275). Under these conditions, the 
intracellular glucose concentration can increase to as much as 30% of that 
outside the cell, resulting in a significant efflux of the sugar from the cell 
(270). Since glucose phosphorylation in muscle is already rate-limiting at 
plasma glucose concentrations greater than 200 mg/100 ml (11.1 mM, attained 
in diabetes), insulin effects on cellular glucose uptake are minimal under these 
circumstances (269,275). 
Insulin enhancement of glucose uptake by muscle is independent of 
monovalent cation concentrations, but prior chelation of divalent cations with 
ethylenediaminetetraacetate rend~rs the phenomenon insensitive to the hor-
mone. Addition of ca++ or Mg++ to the medium restores transport sensitivity 
to insulin, indicating that the presence of these cations is necessary for insulin 
potentiation of glucose transport in muscle (283,284). The role of sulfhydryl 
functions is indicated again, this time in insulin potentiation of transport, by 
the fact that N-ethylmaleimide (NEM) blocks insulin stimulation of 30MG 
transport into brown fat cells without affecting basal transport rates or binding 
of the hormone to cell receptors (285). A 10-minute preincubation of the 
cells with 50 J..l U insulin/ml or agents such as hydrogen peroxide that stimulate 
glucose transport without binding to insulin receptors prevent NEM inhibition 
of insulin stimulation of transport. The mechanism of insulin stimulation of 
glucose transport appears to be unique, however, since the hormone can exert 
a striking effect on transport in muscle under anaerobic conditions (286), under 
which the Km is decreased and the Ymax is increased (269), in contrast to 
the insulin-induced increase in both Km and V max in this tissue. 
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Both the potential role of insulin as an effector of protein carrier 
dephosphorylation and the independence of insulin stimulation of glucose trans-
port from the hormone's other effects, as facilitated glucose transport is 
independent of glucose metabolism, is underscored by the observation that a 
5-minute preincubation of rat epididymal fat cells with lo-4 M ATP at 24 °C 
leads to a 2.5-fold inhibition of augmented glucose transport in the presence 
of 100 1-1U insulin/ml without affecting insulin binding to receptors, basal 
glucose oxidation, insulin inhibition of lipolysis or basal glucose transport (222). 
The effect of A TP, which consists of a blocking of the insulin-induced decrease 
of transport Km, accompanied by phosphorylation of a specific membrane 
protein, cannot be overcome by tt"le addition of large amounts of insulin. The 
S, y -methylene derivative of ATP, which cannot donate the terminal phosphate, 
not only can't suppress insulin-stimulated transport, but also inhibits both the 
ATP effect and membrane phosphorylation by ATP. Further, demonstration 
that insulin stimulation of glucose transport is dissociated from its effects on 
glycogen synthesis (287) and that high extracellular glucose concentrations do 
not reproduc-e insulin effects on cells (288) indicate that while an increase of 
glucose transport into cells is the primary effect of insulin on muscle and 
adipose tissue, it alone by no means leads to other effects of the hormone. 
Another clue to the nature of the insulin-sensitive transport mechanism 
may be supplied by the work of Guidotti (208), who postulated the existence 
of an additional, insulin-sensitive membrane based on his studies of chick 
embryo hearts. He and his co-workers found that after the 7th day of 
development, when t3 -granules first appear in the endocrine pancreas, the 
heart exhibits normal, transport-limited kinetics and are sensitive to insulin. 
Prior to that time, however, glucose uptake by heart cells is insulin insensitive 
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and proceeds at a maximal (insulin-stimulated) glucose phosphorylation-limited 
rate, suggesting the formation of an insulin-sensitive structure of facilitated 
sugar transport coincident with the development of the insulin secretory 
apparatus. 
2. Cyclic AMP. In 1957, Sutherland and Rall began studying the means 
by which glucagon and epinephrine exert their effects on liver, specifically 
the activation of glycogen phosphorylase, the enzyme catalyzing degradation 
of glycogen to its constituent glucose molecules. They found that exposure 
of liver slices to the hormones resulted in the rapid appearance of a water-
soluble heat-stable factor identified as adenosine 3' ,5 '-monophosphate (cyclic 
AMP; cAMP) via stimulation at the cell surface of a membrane-bound enzyme, 
adenylate cyclase (289-291). During the ensuing years, Sutherland and his 
associates and others succeeded in elucidating what is now considered the 
classic mechanism of cell response triggered by binding of catabolic hormones 
to cell-surface receptors, illustrated in figure 5. 
Briefly, hormone binding to a cell-surface receptor activates a proximal 
adenylate cyclase and/or inhibits the phosphodiesterase that degrades cyclic 
AMP, resulting in a transient increase in intracellular cyclic AMP concentrations 
(lo-s to lo-6 M). Cyclic AMP binds to the regulatory subunit of a cyclic 
AMP-dependent protein kinase (also termed phosphorylase b kinase kinase, 
PbKK), causing its dissociation from the now active kinase. This kinase causes 
the phosphorylation of phosphorylase b kinase (PbK), activating it. The active 
PbK then causes phosphorylation of glycogen phosphorylase b, converting it to 
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FIGURE 5. SUMMARY OF GLYCOGEN SYNTHESIS AND DEGRADATION 
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the active a-form, which causes removal of terminal glycogen residues as 
glucose-1-phosphate molecules. Meanwhile, the cAMP-dependent protein kinase 
also catalyzes phosphorylation of glycogen synthetase and glycogen phosphoryl-
ase a phosphatase, inactivating both enzymes and generally promoting glycogen 
breakdown (292-296). The same kind of cAMP-mediated activation of adipocyte 
lipase has been demonstrated to explain the stimulatory effect of epinephrine 
on lipolysis (295,296). 
One of the most striking features of this mechanism is its amplification 
potential. The action of this hormone initiates a "cascade" in which the effect 
of the original hormonal stimulus is amplified at least 100 times at each of 
the four enzymatic steps in the ;process, for a total amplification of 1 o8 or 
more; thus a single molecule of glucagon or epinephrine can theoretically 
trigger the release of about 100 million glucose molecules (296). In addition 
to glucagon and catecholamines, increases in intracellular cyclic AMP concentra-
tions have been found to accompany the mediation of adrenocorticotropin, 
luteinizing hormone, vasopressin, thyrotropin, parathyroid hormone, melanocyte-
stimulating hormone, histamine, thyrotropin-releasing hormone and certain pros-
taglandins effects (293). 
From this work evolved four criteria for establishing a cyclic nucleotide's 
role as a mediator of hormone action: 1) elevation of intracellular cyclic 
nucleotide levels by the hormone; 2) activation of the nucleotidyl cyclase by 
the hormone in broken cell preparations; 3) recapitulation of the hormone's 
effects by addition of the cyclic nucleotide or its derivatives to a target cell 
Preparation; and 4) potentiation of the hormone's effects in the presence of 
an inhibitor of the phosphodiesterase catalyzing that cyclic nucleotide's degrada-
tion (296). The fact that insulin antagonizes many cyclic AMP-mediated 
92 
hormone effects on its target tissues has led several investigators to po~tulate 
that the effects of this hormone are mediated by a decrease in the intracellular 
concentration of the cyclic nucleotide (297). 
A number of reports, in fact, seem to support this supposition. Insulin 
antagonizes the increase in cyclic AMP levels and output of glucose brought 
about by low concentrations of glucagon or catecholamines and the action of 
added cyclic AMP itself in perfused livers (297-300). Butcher et al. (301) 
showed that insulin lowers intracellular cyclic AMP levels in adipocytes. This 
effect was especially pronounced when cAMP levels had first been elevated 
by pretreatment of the tissue with epinephrine and caffeine. Also, cA'\1P-
induced K+ release from perfused ~at liver was found to be significantly reduced 
in the presence of 25 mU insulin/ml to a cAMP concentration of about 5 x 
lo-5 M (297). In vivo administration of anti-insulin serum to rats causes a 
progressive increase in hepatic cAMP levels, accompanied by an activation of 
glycogenolysis (302), and a diabetes-induced, insulin-reversible increase in rat 
liver cAMP concentrations has been observed (297). 
Insulin has been reported to alter adenylate cyclase activity in adipose 
tissue (303). Numerous investigators have described insulin inhibition of basal 
and hormone-stimulated adenylate cyclase in adipocytes (304), hepatocytes 
(304), cultured fibroblasts (305), and cell membrane preparations 
(195,222,304,306). In addition, insulin has been found to stimulate membrane-
bound cAMP phosphodiesterase, either directly (307) or after treatment of cells 
With the hormone (308,309). 
The results of experiments designed to demonstrate an effect of insulin 
on intracellular cyclic AMP levels are contradictory, however. Goldberg and 
Larner in 1967 found that in both muscle and liver cells one could obtain full 
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expression of insulin action either without any lowering of cAMP levels or 
before any lowering was detectable (296). Numerous reports demonstrating an 
inability of insulin to affect basal cAMP levels in liver, muscle and fat cells 
have appeared (219,297). Insulin does not inhibit the activation of glucose 
output in perfused liver by dibutyryl cAMP (normally a potent cAMP analog) 
(298-300) and the hormone can activate glycogen synthetase without causing 
any change in the activity of glycogen phosphorylase or a decrease in the 
concentration of cAMP (310,311), contrary to expectations for a process 
mediated by a decrease in cAMP levels. Insulin has also been found to inhibit 
cellular K+ release without affecting glycogenolysis (298,300). 
Evidently, cAMP-mediated ;mechanisms are not involved in other insulin 
effects, namely stimulation of glucose transport (312) and protein synthesis 
(313), and inhibition of urea production (298,300) and lipolysis (313,314). The 
inability to satisfy the important third and fourth criteria of cyclic nucleotide 
mediation of insulin action is exemplified by the fact that such agents as 
prostaglandins E1 and adenosine, which cause decreases in intracellular cAMP 
concentrations, do not mimic insulin's effects on glucose transport and lipolysis 
(219,315). Finally, in a number of studies using cultured cells (including human 
fibroblasts), no correlation was found between insulin binding to cells and the 
activation or inhibition of of any component of the adenylate cyclase system, 
although binding does correlate with stimulating effects on thymidine incorpora-
tion into DNA and amino acid transport (316). 
3. Cyclic GMP. Although guanosine 3',5'-monophosphate (cyclic GMP; 
CGMP) had been found in biological fluids previously, it wasn't until 1969 that 
the compound was detected in animal tissues, almost simultaneously with the 
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discovery of guanylate cyclase (317-319), because the concentration of cGMP 
in cells is as much as 100-fold less than that of cAMP (296). Development 
of highly sensitive radioimmtinoassays for the compound, however, enabled a 
spate of cGMP measurements using a wide variety of species, tissues, and 
effectors. From these studies emerged guanylate cyclase, cGMP phosphodiester-
ase and a cG MP-dependent protein kinase as predominant components of the 
cG1\1P system. The cyclase has been found in both soluble and particulate 
cell fractions (320), while the phosphodiesterase is predominantly soluble (321). 
Substrates for the kinase include histones (322), nuclear acidic proteins (323) 
and membrane proteins (324,325). 
What has also emerged from cGMP research is a tendency for cellular 
processes in opposition to those mediated by cA!\1P to be accompanied by 
increased levels of cGMP. These include uterine contraction, venoconstriction, 
platelet aggregation, polymorphonuclear leukocyte motility, lymphocytotoxicity, 
intestinal contraction, gallbladder contraction, release of lysosomal enzymes, 
ductus deferens contraction, and inhibition of lipolysis and heart contraction 
(296). One of the most important ideas resulting from these observations is 
the possibility that insulin is a cGMP agonist. 
Insulin has been found to increase intracellular cGMP concentrations in 
adipose tissue (326-328), liver (326) and intestinal mucosa (329). In the first 
case, physiologic insulin concentrations cause a marked but transient rise in 
the cellular level of cGMP and a stimulation of membrane-bound guanylate 
cyclase (222). Much information has also been gained from studies of cultured 
fibroblasts. In such cells of mouse and hamster origin insulin causes a transient 
increase in cGMP with a concomitant decrease in cAMP concentrations (330-
335), and mitogenesis induced in mouse fibroblasts by high concentrations of 
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the hormone is accompanied by li ten- to fortyfold increase in intracellular 
cGMP concentrations (332). In these cells, cAMP-induced decreases in leucine 
and hexose uptake are antagonized by addition to the medium of cGMP (336). 
Unfortunately, cGMP mediation of hormone effects is not so clear-cut 
as has been found for cAMP. Direct stimulation of guanylate cyclase by any 
cGMP agonist has not yet been observed (321,337) and dissociation of cGMP-
dependent protein kinase into catalytic and regulatory subunits by cGMP has 
proven difficult to demonstrate (321). Studies designed to establish cGMP 
mediation of insulin action are no less prone to inconsistencies than those 
involving cAMP. For instance, atropine, a potent cGMP antagonist, does not 
affect the insulin-induced increas~ in intracellular cGMP concentrations in fat 
cells (326). Furthermore, the presence of ca++ is required, not only for cellular 
processes associated with increased cG MP levels, but also for the rise in 
intracellular concentrations of the cyclic nucleotide itself (296). Indeed, this 
fact may provide a key to the elucidation of a plausible mechanism for insulin 
action. 
4. Calcium. The critical role of calcium in nerve and muscle function 
has long been known. During the past ten years, however, evidence has emerged 
implicating the ion of this metal, ca++, as a ubiquitous and pivotal mediator 
of many metabolic processes in a great variety of cells. 
While certain investigators have found it necessary to postulate an 
unsubstantiated intracellular compartmentalization of cyclic nucleotides to 
explain observed inconsistencies in the behavior of these compounds during 
manipulation of cellular processes putatively mediated by them (297), such 
compartmentalization is well documented for ca++. The cytoplasmic 
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concentration of ca++ in the typical mammaiian cell is very low (apprx. to-7 
M) compared to the extracellular (lo-3 M) and mitochondrial concentrations 
of the ion. The mitochondrion is the cell's primary repository of ca++ (except 
in muscle cells, which employ the sarcoplasmic reticulum for this purpose), in 
which the total ca++ concentration is to-2 M. Because of the high intramito-
chondrial phosphate concentration, 99% of the ca++ in this organelle is stored 
as insoluble calcium phosphate, leaving to-4 M soluble ca++, which is still 
1,000-fold greater than that of the cytoplasm. These large differences in 
ca++ concentrations are maintained by ion pumps that require cellular energy 
expenditure-membrane-localized ca++ -dependent ATPases, enabling precisely 
regulated, rapid changes in cytpplasmic ca++ concentrations (337). This 
situation is particularly significant in view of the interrelation of intracellular 
ca++ and cyclic nucleotide metabolism, exemplified by the ca++ dependence 
of cGMP metabolism already mentioned. 
The effects of ca++ on cellular metabolism-especially where related 
to cyclic nucleotides-is tissue specific, another condition necessarily imposed 
on cyclic nucleotide mediation of extracellular effectors. While ca++ antagon-
izes cAMP-mediated processes in adipose tissue, where the ion facilitates the 
conversion of the glucose-6-phosphate-dependent form of glycogen synthetase 
to the independent form (338), it stimulates the activation of glycogenolysis 
by phosphorylase b kinase in muscle (339), where an increase in free calcium 
concentrations from to-8 M to lo-4 M produces a four- to eightfold rise in 
pyruvate dehydrogenase phosphatase activity (340), leading to activation of the 
dehydrogenase and promoting glucose oxidation. 
A now-classic example of cyclic nucleotide-ca++ co-mediation of hor-
mone action is provided by the salivary gland of the blowfly, the cells of 
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which secrete isotonic potassium chloride in response to hormonal stimulation 
by serotonin at the cell surface. At first it was thought that this system 
represented a typical case of cAMP-mediated hormone effects, since it satisfied 
the experimental criteria previously iterated. The effect of serotonin on 
intracellular cAlVIP and on KCl secretion could be uncoupled, however, if the 
extracellular medium were ca++ -depleted. It has been found subsequently that 
binding of serotonin to cell membrane receptors not only activates adenylate 
cyclase, but also increases plasma membrane permeability to ca++. In turn, 
cAMP increases mitochondrial membrane permeability to ca++. Consequently, 
intracellular ca++ concentrations rise significantly. In the blowfly salivary 
gland, increased intracellular cAMP activates a K+ pump that transports the 
cation £!!!_ of the cell, against a concentration gradient, into the lumen. 
Meanwhile, ca++ mediates increased membrane permeability to Cl-. 
Furthermore, ca++ inactivates adenylate cyclase, providing a feedback loop 
which is conspicuously lacking in classic cyclic nucleotide mediation mechanisms 
(337). 
A different kind of interrelationship between ca++ and cAMP exists in 
mammalian longitudinal intestinal smooth muscle. In this tissue, acetylcholine 
causes muscle contraction by increasing intracellular ca++ concentrations while 
epinephrine causes muscle relaxation by decreasing intracellular ca++ levels. 
Both effectors cause increases in intracellular cAMP levels, however. This 
apparent discrepancy was resolved when the actual mechanisms of effector 
action were elucidated. Acetylcholine directly causes contraction by promoting 
entrance into the cell of extracellular ca++ and release of the ion from 
sarcoplasmic reticulum. Increased ca++ concentrations inhibit cAMP phosphodi-
esterase, leading to an increase of the cyclic nucleotide, which promotes uptake 
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of ca++ by sarcoplasmic reticulum. As cytoplasmic ca++ levels f~ll, the 
phosphodiesterase is again activated and cAMP returns to basal levels. Thus, 
termination of both contraction and the termination signal is provided for by 
a dual messenger mechanism. Epinephrine, on the other hand, causes relaxation 
of smooth muscle by decreasing cytoplasmic ca++ concentrations through an 
immediate increase in cAMP levels due to stimulation of adenylate cyclase by 
the hormone. The signal is terminated by degradation of cAMP by an 
increasingly more active phosphodiesterase (337). The blowfly salivary gland 
and the mammalian longitudinal intestinal smooth muscle are only examples 
of many well-documented cases of the diverse regulatory systems provided by 
a ca++ -cyclic nucleotide synergjsm that enables the exquisite tailoring of 
biologic response to external stimuli underlying the integration and subordination 
of the functions of specific cell types to the requirements of the whole organism. 
Particularly significant is the apparent role of ca++ in cellular responses 
to insulin, especially those effects that have not been associated with other 
postulated mediators. Insulin antagonizes epinephrine-induced extrusion of ca++ 
from adipocyte ghosts by ca++-dependent ATPase (341). An insulin-dependent 
material that stimulates ca++ uptake by isolated mitochondria has been extract-
ed from liver cytoplasm (342). However, McDonald et al. have found that 
insulin treatment of adipocytes does not alter total mitochondrial calcium, but 
causes an increase in the labile form of the cation and a decrease in the 
stable form (343). Procaine, lanthanum and the ca++ ionophore A23187, which 
an increase intracellular ca++ concentrations, mimic insulin's metabolic effects 
in liver and adipose tissue (344-346), satisfying an important criterion of 
hormone mediation lacking in cyclic nucleotide models of insulin action. It 
has been found that plasma membrane permeability to glucose and amino acids 
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is a function of membrane-bound ca++ (347), and that the presence o~ ca++ 
is required for insulin-induced protein synthesis (348). Furthermore, the activity 
of several enzymes involved in mediating the intracellular action of insulin is 
calcium-dependent (340,347 ,349). Seals, McDonald and Jarett (350-352), have 
demonstrated that insulin causes the activation of what may be a plasma 
membrane-associated ca++ -dependent phosphatase (M. W. 120,000) that dephos-
phorylates the alpha subunit (M. W. 42,000) of pyruvate dehydrogenase, leading 
to activation of the latter enzyme in cell-free preparations of rat adipose 
tissue. Recently, Jarett and Seals (342) reported that insulin-treated muscle 
extracts contain a factor that directly stimulates pyruvate dehydrogenase 
activity in isolated adipocyte mitochondria in the presence of ca++. 
A prime contender for the role of an insulin-mediating factor is one of 
a family of enzymically active ca++ -binding proteins exemplified by calmodulin, 
found in a great variety of tissues, and troponin C in skeletal muscle (353). 
Although these proteins tend to serve as kinases after binding ca++, the great 
variability of their specific functions in different cell types makes it possible 
that they may also act as phosphatases, an enzymic role frequently associated 
with insulin responses. 
Based on evidence available at this time, it is probable that insulin 
effects are mediated by a complex network of messengers, primarily ca++, 
ca++-binding proteins, cAMP and cGMP. ca++-mediated effects may include 
direct activation of ca++ -dependent enzymes (including nucleotidyl cyclases 
and phosphodiesterases), dephosphorylation of membrane proteins affecting 
sugar, ion and amino acid transport, and phosphorylation and dephosphorylation 
of chromosomal proteins, ribosomal proteins and cyclic nucleotide-dependent 
Protein kinases affecting enzyme induction and suppression, DNA, RNA and 
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protein synthesis, and phosphorylation-dependent enzyme activity; cyclic nucleo-
tide-mediated effects may include cell proliferation, antagonism of catabolic 
hormone effects, and termination of the calcium signal. Thus, by increasing 
the intracellular ca++ concentration (perhaps through a ca++_binding protein 
cascade commencing with one in direct proximity to the insulin receptor), 
insulin may trigger an incredibly complex train of events appropriate to a 
hormone of unequaled profundity in regard to mammalian metabolism. 
CHAPTER IV 
INSULIN ASSAYS 
An assay for insulin is herein defined as a procedure carried out for 
the specific purpose of measuring the amount of insulin present in a given 
sample. Although a great deal of research has been conducted to determine 
the physiologic and metabolic effects and physico- and immunochemical proper-
ties of insulin and the molecular mechanisms of insulin action, only the use 
of such work in the development of reproducible, reliable, quantitative assays 
for the hormone will be reviewed in this chapter. 
Ideally, any assay should ~ 1) convenient, enabling a maximum number 
of determinations with a minimum of manipulation; 2) reproducible, exhibiting 
an interassay variation of less than ten percent; 3) sensitive, being able to 
detect basal levels of the measured substance in the flui'ds being studied; 4) 
accurate, reflecting the true quantities of the substance and its actual fluctua-
tions in experimental or physiologic processes; 5) precise, with an intraassay 
variation of less than five percent; and 6) specific, measuring only what it is 
supposed to measure, relative to an appropriate standard. In the case of 
insulin, this standard is usually pure crystalline monomeric pancreatic insulin. 
Of course, few assays fully satisfy the above iterated criteria and assays 
for insulin are not among them. However, the history of insulin assays is one 
of steady progression toward this goal, hampered by certain complications, the 
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most conspicuous of which are the ignorance concerning the form of insulin 
existing in the peripheral circulation and the multiplicity of hormone properties 
that may be measured. One may assay insulin's physicochemical properties, 
immunoreactivity, or biological activity, which in most cases includes the 
integrity of the molecule's receptor-binding site. In the following account, 
the properties recognized by a given assay and the appropriate applications 
for that assay will be considered. Each assay will be evaluated in terms of 
the above criteria, with special attention devoted to the assay's sensitivity, 
precision and range of human serum insulin concentrations in normal individuals. 
IN VIVO BIOASSAYS 
The First Insulin Assays 
Even before the isolation of insulin was accomplished, Paulesco and 
Banting and Best utilized the decrease in blood sugar of dogs as an assay for 
the potency of hormone extracts. Of course, an appropriate assay is necessary 
to the isolation and characterization of any biological effector. However, the 
use of dogs proved too costly to be used on a routine basis once insulin was 
being isolated on an industrial scale. 
Rabbit Hypoglycemia Assay 
Once Banting et al. (354) found that insulin-induced convulsions in rabbits 
were usually associated with a blood glucose concentration of 45 mg/dl, this 
method was adopted for routine assay of preparative hormone potency. The 
amount of insulin that produces this concentration in 2-4 hours was first used 
as a unit of activity, but soon the unit was formally defined as one-third the 
amount required to produce this effect in a rabbit starved for 24 hours (355). 
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The First International Standard for Insulin, adopted in 1925 and based on the 
"rabbit unit," was said to have a specific activity of 8 units per mg, and 
subsequently all preparations of insulin have been assayed directly or indirectly 
in terms of it. 
By 1935, the unit was defined as 1/22 mg (356) and presently the bovine 
insulin standard of the International Union of Pure and Applied Chemistry is 
stated to have an activity of 25.0 international units (IU) per mg dry weight 
and to contain 0.439% of zinc and 14.9% nitrogen (357). With the expectation 
that the maximum specific activity of insulin has been attained, the unit is 
now based on the absolute weight of a highly purified composite preparation 
(358). 
Because considerable variation in the sensitivity of rabbits to insulin 
made these first rabbit assays unsatisfactory, Marks recommended the compari-
son of one preparation in terms of another in two similar groups of rabbits 
(359). One group received the preparation of known activity, the second the 
preparation of unknown activity. On another day, the procedure was reversed 
to complete a "cross-over" test. By averaging the hypoglycemic responses to 
each preparation over both days, the influence of the variation in sensitivity 
between rabbits was considerably reduced and an estimation using the variable 
"rabbit unit" of activity was avoided. In a later modification, two such cross-
over tests were performed, using two dose levels of both the standard and 
unknown preparations to provide an additional check on potency (360). This 
method is presently recommended by the u.s. Pharmacopeia (361), which 
requires a maximum assay deviation from the stated U.S.P. standard value of 
7.5 percent. 
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All subsequent investigations of the rabbit hypoglycemia assay have 
employed cross-over designs. The reduction in blood sugar, the final concentra-
tion, the reduction or final concentration as percentages of the initial value, 
either at a given time after insulin or averaged over a period of time, have 
been used to determine insulin activity. Lacey (362) demonstrated a linear 
relationship bet ween the log of the insulin dose and the percent reduction in 
blood sugar down to 0.4 U insulin, which brought about a 22% reduction in 
blood sugar, while Young and Romans (363) succeeded in reducing the time 
between insulin injection and determination of blood sugar to 50 minutes with 
results as precise as those obtained using longer times (364). Using three dose 
levels each of standard and test preparation and twelve rabbits in a protocol 
requiring three weeks to carry out, Bliss and Marks (365) obtained data (percent 
fall in blood sugar over 5 hours) for which coefficients of variation (C.V., the 
ratio of the standard deviation to the mean, expressed as a percent) may be 
calculated as follows: intraassay variation (bet ween rabbits), 33. 7%; interassay 
variation (bet ween days), 19 .9%. 
The rabbit hypoglycemia assay has proven satisfactory as a means of 
assessing the biologic potency of preparative quantities of insulin, but obviously 
is far too insensitive to measure concentrations of the hormone in blood. In 
addition, the assay is costly, cumbersome, extremely time-consuming, and 
relatively imprecise. 
Mouse Convulsion Assay 
Milliunit quantities of insulin injected into mice produce convulsions 
(366), and the percentage of mice responding or a mathematical function of 
the percent response, known as the normal equivalent deviation, was found to 
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increase linearly with the log of the insulin dose (355,367). Weighting coeffi-
cients were applied, the highest being given to 50% response; responses at the 
extreme ends of the dose-response curve were given the lowest values because 
of the greater range in doses producing them (368). A sensitivity of 2 mU 
insulin was attained when mice fed on bread and milk and starved overnight 
were each injected subcutaneously with 50 lJ g promethazine hydrochloride 30 
minutes before insulin administration (369). Hemmingsen obtained an interassay 
variation of 7-10% in a series of cross-over tests using 160 mice (370). 
Typically, the numbers of mice that die, exhibit frank convulsions, or 
lie still for more than 2-3 seconds when placed on their backs are recorded 
(369). In an effort to overcome possible observer error in determining positive 
responses, mice, after injection with insulin, were placed on a wire-mesh screen 
inclined at an angle of 600 (371,372) or placed within a rotating cylinder 
similarly inclined (373). Mice exhibiting convulsive symptoms are unable to 
retain their foothold and fall from the screen or cylinder and are counted as 
positive responders. This "mouse-drop" assay, however, offered no increase in 
precision compared to the more conventional method employing continuous 
observation (369). 
In a comparison of the rabbit hypoglycemia and mouse convulsion assays, 
Smith (374) found no significant difference between values for insulin standards 
obtained by the two methods. In addition, the mouse assay offers greater 
sensitivity (although still not sufficient to measure insulin in blood), while being 
more economical (four mice have an efficiency equivalent to one rabbit) and 
requiring far less time to obtain a result. Nevertheless, the rabbit assay is 
the one presently employed to determine the biologic potency of insulin prepared 
for therapeutic use (375). 
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~sulin-Sensitive Animal Assays 
Removal of the hypophysis and adrenal glands renders an animal hyper-
sensitive to insulin. Using rats prepared in this way, Gellhorn et al. (376) 
obtained a linear relationship between the blood sugar concentration and insulin 
dose from 0.3 to 1.0 mU insulin/100 g body weight. When diabetes is induced 
in these animals with alloxan, variations in response to injected insulin, caused 
by the presence of endogenous insulin, may be reduced. Employing rats from 
which the adrenal medullae had been removed, injected with alloxan and then 
hypophysectomized, Anderson et al. (377) increased the sensitivity of the assay 
to 125 ll U insulin/rat (approximately 200 g). 
The first direct measurements of human plasma insulin concentrations 
in normal individuals were made by Bornstein, who carried out total adrenalec-
tomy in the hypophysectomized rat with diabetes induced by alloxan (ADHA 
rat). He obtained a linear regression of blood sugar depression vs. insulin dose 
from 50 ll U to 500 ll U insulin. Since 0.5 ml was injected, insulin concentrations 
as low as 100 ll U/ml could be measured (378). Using this method (8 rats), 
Bornstein determined the normal fasting human plasma insulin level to be about 
100 ll U/ml (<100-130 ll U/ml) in three individuals (379). After ingestion of 50 
g glucose, plasma insulin levels were found to have risen to about 200 ll U/ml 
(<100-400 lJU/ml) at 1 hour and 340 lJU/ml (180-700 ll U/ml) at 2.5 hours, and 
then to have fallen to 220 ll U/ml (100-500 ll U/ml) at 3.5 hours, describing 
a pattern subsequently seen consistently in normal oral glucose tolerance tests. 
Intraassay variation ranged from about 1896 (C.V.) at 340 lJ U/ml to 5296 at 
100 lJU/ml. The sensitivity of the ADHA rat to insulin is not affected by 
exogenous cortisone, somatotropin or corticotropin (380). 
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Although mice are usually more sensitive than rats to insulin, r:to less 
than 250 lJ U insulin per mouse could be measured with the hypophysectomized 
alloxan-diabetic mouse (381), mainly because of an extreme lack of precision 
(c.v. = 300-400%). Since saline alone produces a fall in blood sugar, use of 
control animals is especially important in this assay. 
Insulin assays using hormone-sensitive animals proved not to be of lasting 
significance because they were most useful where they were needed least. 
They were far less precise than the traditional rabbit and mouse assays that 
are suitable for ascertaining the biological activity of preparative quantities 
of insulin and they were not sufficiently sensitive to measure accurately plasma 
insulin concentrations in normal individuals. These assays have been superseded 
by the more sensitive and precise tissue and cell bioassays, immunoassays and 
receptor assays. 
IN VITRO BIOASSA YS 
Isolated Tissue Assays 
1. Diaphragm assays. In 1952, Groen et al. (382) described an assay 
for insulin based on the net uptake of glucose from the medium by hemidia-
phragms removed from starved rats. A dose-response relationship of glucose 
decrement (from a 200 mg/dl initial concentration) above control preparations 
with increasing insulin concentration after a 90 minute incubation at 37°C was 
obtained between 100 1JU and 1.0 U insulin per ml. Valiance-owen and Hur-
lock (383) managed to improve the sensitivity of the assay to 10 U/ml. Plas-
ma from normal subjects mimics the effect of insulin in increasing glucose 
Uptake by the rat diaphragm, while plasma from depancreatized dogs has 
no such effect. Sulfhydryl agents known to inhibit the activity of crystalline 
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insulin also abolish plasma insulin-like activity in this assay (382) and inr.ulin 
antisera block the effect of plasma insulin-like activity on the diaphragm (384). 
However, the rat hemidiaphragm assay for insulin employing the metameter 
of glucose uptake has been plagued by imprecision. For an initial glucose 
concentration of 300 mg/dl, a tenfold increase in insulin concentration from 10 
to 100 f.IU/ml produces a decrement of only 2% or 4% in glucose concentration 
superimposed on a decrement of 6. 7% in the absence of insulin (385). Thus, 
in this physiologic insulin range, the insulin concentration must be increased 
about 225% to produce a 1% change in glucose concentration and in the range 
100-1,000 f.IU/ml the insulin concentration must increase by about 115% to 
produce a 1% change in glucose concentration. Consequently, any experimental 
error exercises an inordinate influence on the results of the assay. 
The precision of the hemidiaphragm assay was greatly improved by 
making glycogen synthesis the criterion of insulin activity. Incorporation of 
C-14 activity into muscle glycogen from a tracer quantity of glucose 1-[14c] 
added to the medium is determined after extraction of glycogen from hemidia-
phragms with 30% KOH in boiling water and precipitation with 66% ethanol. 
Using this method, Moody and Felber attained a sensitivity of 10 f.l U insulin/ml 
for mouse diaphragm (386); Guenther (387) obtained a linear relationship between 
CPM C-14 activity incorporated per gram rat diaphragm glycogen and insulin 
dose from 50 to 250 f.l U insulin/ml, with a correlation coefficient (r) of 0.961, 
highly significantly different from zero (P<0.001), and a coefficient of variation 
for scatter about the line (C.V. (Sy.x» of less than 6%. 
An in vivo variation of this method has also been developed (388,389). 
Rats are injected intraperitoneally with a mixture consisting of a glucose 
solution, a tracer quantity of 14c-glucose, and an insulin standard or unknown. 
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Two hours later, the rats are sacrificed, diaphragms removed, glycogen extract-
ed and incorporation of C-14 activity determined as in the in ~ assay. 
Using this technique, Guenther (387) obtained a linear relationship bet ween 
CPM/g and insulin dose up to 1 mU insulin/ml (r = 0.993, P«0.001; C.V. (Sy.x) 
= 1396) with a sensitivity of about 75 ).l U insulin/ml. Obviously, this method 
represents a considerable improvement, both in sensitivity and precision, over 
previous in vivo insulin bioassays. 
A range of 0 to 120 ).JU insulin per ml human serum has been found 
for normal fasting subjects (390,391), with a threefold increase seen in normal 
postprandial subjects (391), using the in vitro rat diaphragm assay. 
2. Fat pad assays. Insulin enhances glucose uptake, oxidation of glucose 
to C02 and incorporation of glucose carbon into ether-soluble lipid in the rat 
epididymal fat pad maintained in Krebs-Henseleit buffer (392). In 1958, Martin 
et al. reported development of the first rat epididymal fat pad assay for insulin 
based on the second of these effects, insulin induction of glucose oxidation to 
C02 in adipose tissue preferentially via the pentose phosphate pathway with 
concomitant production of NADPH and ribulose-5-phosphate (393). 
The fat pad of each fed male rat is cut into three or six equal parts 
and each piece is placed in a separate metabolism flask in buffer containing 
1-14c-glucose and insulin standard or unknown. After two hours incubation 
at 37°C in an atmosphere of 95.96 02/596 C02, with shaking, the medium is 
acidified to liberate 14co2 remaining in solution; upon contact with the Ba(OH)2 
or N aOH in the cup suspended over the reaction mixture, 14co2 is converted 
to 14co3 =. The solution in the cup is assayed for C-14 activity and the 
square root or log of CPM per gram adipose tissue is a linear function of 
insulin concentration. 
110 
Using this method, Martin et al. (393) attained a sensitivity of 10 ~ u 
insulin/ml and Guenther (387) obtained a linear relationship between log 
CPM/gram tissue and insulin dose up to 500 ~U/ml (r = 0.999, P«0.001; C.V. 
(Sy.x> = 3.1 %) with an interassay variation of 14.3%. Other metameters used 
in the fat pad assay are glucose uptake (394) and total gas exchange (395). 
A source of puzzlement for more than two decades has been the degree 
of discrepancy between the insulin values found in the sera of normal fasting 
individuals using the diaphragm and fat pad assays, the latter yielding values 
ranging from 33 to 940 ~ U/ml with levels 2-5.5 times as high after the 
administration of glucose (396). Although there can be little question that 
the fat pad is very sensitive to the action of plasma insulin, the assay utilizing 
this tissue is notoriously lacking in specificity. Human serum insulin-like 
activity (ILA), as determined using the fat pad assay, is not extractable by 
acid ethanol (397), is not neutralized by anti-insulin serum (397), and to some 
extent persists after treatment of plasma with reduced glutathione (396). 
Fasting levels of ILA persist unchanged after pancreatectomy (396-398) and 
plasma ILA of p~ncreatectomized dogs actually increases after glucose adminis-
tration (398). Although introduction of isolated tissue bioassays enabled routine 
measurement of plasma -insulin concentrations for the first time, they also 
opened the bewildering and not yet resolved issue of insulin-like activity, or 
"atypical insulin," the nature of which is discussed in Chapter v. 
Another disadvantage of isolated tissue bioassays is their particular 
sensitivity to the effects of insulin antagonists, especially catecholamines and 
free fatty acids. The addition of 0.01 ~ g epinephrine/ml significantly reduces 
the effect of 0.5 mU insulin/ml on glucose uptake by rat diaphragm (399). 
Appreciable degradation of insulin may also occur due to the general action 
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of proteases and the specific action of the insulinase system when enzymes 
are liberated from cut diaphragm preparations (400). Furthermore, the potent 
insulin antagonism of diabetic serum has proven to be due to anti-insulin 
antibodies, the study of which led to the development of the radioimmunoassay 
(385). 
The dilution of such insulin antagonists has been considered the cause of 
a disproportionate increase in the amount of ILA (as much as 24-fold) measured 
by the diaphragm assay with dilution of human sera (up to 8-fold) (391). 
However, quantitative recovery of insulin added to serum implies that the 
effect of antagonists is negligible (383,401,402). 
Cell Cultures 
The use of ·cultured cells for the assay of insulin is best exemplified by 
the free fat cell bioassay of Moody et al. (145). Short-term cultures of cells 
isolated from rat epididymal fat pads are incubated with 0.1-0.5 ~Ci 2- or 
3-3H-glucose and insulin standard or unknown for 2 hours at 37°C. Total lipids 
are then simply extracted with a toluene-based scintillation fluid and beta-
radiation assayed in a liquid scintillation spectrophotometer. Thus, one deter-
mines the conversion of glucose to lipid, which is greatly accentuated in the 
presence of insulin (125-405 times the basal value, which amounts to no more 
than 0.05% total counts). 
Sensitivity of the assay for insulin is 2.5 ~U/ml with a linear relationship 
between CPM/weight lipid and insulin dose from 4 ~ U/ml to 15 ~ U/ml and 
an intraassay variation of less than 10%. Both the well-recognized insulin 
dependence of lipid biosynthesis and the favorable comparison of biologic 
activities exhibited by insulin analogs as determined by this method and by in 
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vivo bioassays (see Table I) would lead one to expect a high degree of insulin 
-----
specificity for this technique. Therefore, cultured cell assays for insulin can 
afford a degree of sensitivity, convenience and specificity decidedly superior 
to and a measure of precision comparable to the best of the bioassays. The 
compelling advantage of delineation of insulin and other effects provided by 
cultured cells will be examined in Chapter V. 
CHEMICAL ASSAYS 
Before development of immunoassays, attempts were made to devise 
specific tests for insulin based on the physicochemical properties of the hormone 
that would possess the precision: characteristic of chemical assays. Two of 
the most promising were based on fibril formation and paper chromatography. 
Fibril Assay 
Waugh et al. (403} developed an insulin assay based on the fact that 
the precipitate formed when a solution of insulin in dilute acid is heated is 
composed of radially oriented fibrils (404}. In this method, an acid solution 
of insulin is repeatedly heated and frozen until intense flow birefringence 
occurs. The fibrils so formed are broken by expulsion through a hypodermic 
needle and used to seed the standard and test solutions of insulin. These 
solutions are stirred continuously overnight at 48oc and the precipitate formed 
is collected, washed, dried and weighed. The weight of fibrils obtained was 
found to be proportional to the amount of insulin present in the seeded solution. 
The method could not be applied to samples containing less than 11 units 
insulin/mg and the ability of the assay to reflect losses of biologic activity is 
questionable (369). 
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Chromatographic Assay 
-
In 1952, Robinson and Fehr (405) assayed the insulin content of protamine 
zinc insulin by paper chromatography. A solution of insulin was streaked across 
a paper and the chromatogram was developed with n-butanol/glacial acetic 
acid/water (3:1:4). The insulin spots were stained with bromocresol green, the 
color was intensified in ammonia vapor and the stained material was eluted 
with borate buffer. A linear relation was found between light absorption by 
the resultant solution and insulin concentration, from 0.25 to 1.5%. 
Fenton (406) separated insulin from associated impurities by ascending 
paper chromatography with 2-butanol/1% acetic acid (1:1). Insulin was stained 
with bromocresol green, the color intensified in ammonia and eluted with 0.1 
N NaOH/95% ethanol (1:1). The absorbance of eluate was shown to be linearly 
related to weight of insulin applied up to 110 ~ g, with a sensitivity of about 
0.5 unit. Good agreement of this method with the mouse convulsion assay 
was found. 
These two chemical assays are capable only of measuring preparative 
quantities of insulin and are less specific and less indicative of the hormone's 
biologic activity than in vivo bioassays. The fibril method using gravimetric 
procedures requires a large volume of solution containing at least 1 unit 
insulin/mi. Grodsky (407) found that the insulin B-chain, esterified insulin and 
carboxypeptidase-inactivated insulin also form fibrils. The chromatographic 
methods estimate between 0.5 unit and 150 units insulin, and impurities 
associated with low-grade insulin may interfere. 
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Moreover, these methods are more precise and less costly than bioassays. 
Fenton (406) calculated that a single determination of insulin potency by paper 
chromatography was equal in precision to that obtained with 960 mice. 
IM!VIUNOASSAYS 
Radioimmunoassay (RIA) 
After obtaining her Ph.D. in physics at the University of lllinois, Rosalyn 
Yalow accepted a position as physicist in the radioisotope service of the Bronx 
Veterans Administration Hospital, where in the early 1950s she began what 
was to be a profoundly fruitful association with the physician Solomon Berson. 
In order to test I.A. Mirsky's hypothesis that maturity-onset diabetes might 
not be due to a deficiency of inshlin secretion, but rather to abnormally rapid 
degradation of insulin by hepatic insulinase (408), they studied the metabolism 
of 131J-labeled insulin following intravenous administration to nondiabetic and 
diabetic subjects (409). Berson and Yalow observed that radioactive insulin 
disappeared more slowly from the plasma of patients who had received insulin, 
either for the treatment of diabetics or as shock therapy for schizophrenia, 
than from the plasma of subjects never treated with insulin. Suspecting that 
the retarded rate of insulin disappearance was due to binding of labeled insulin 
to antibodies that had developed in response to administration of exogenous 
insulin and presuming that these antibodies were likely to be present in such 
low concentrations that classic immunologic techniques would be inadequate 
to measure them, the two investigators introduced radioisotopic methods of 
high sensitivity for detection of soluble antigen-antibody complexes. Studying 
electrophoresis patterns of plasma samples after addition of 1311-labeled insulin, 
they found that in plasma from insulin-treated patients the labeled insulin is 
115 
bound to and migrates with an inter f3- Y globulin, while in control plasmas 
the radioactivity remains near the origin, as does free insulin (409,410). 
When Berson and Yalow first attempted to publish this observation as 
evidence that humans produce insulin-specific antibodies in response to insulin 
treatment, their manuscript was rejected with a request for more rigorous 
proof that the insulin-binding plasma component is an antibody (411), probably 
because of widespread scepticism among immunologists at that time regarding 
the ability of any substance below 10,000 daltons molecular weight to serve as 
an immunogen (412). Previously, many of the immunological reactions observed 
in diabetic patients were attributed to impurities in the insulin preparations 
then in use (413), but much eviden?e suggesting the existence of insulin-specific 
antibodies in humans and other animals had been reported prior to the work 
of Berson and Yalow (414). This evidence includes development of insulin 
resistance by insulin-treated humans; the ability of sera from these individuals 
to prevent or reduce insulin-induced convulsions and other hypoglycemic effects 
in mice and to abolish the effect of the hormone on glycogen deposition in 
isolated rat diaphragm; demonstration that the insulin-neutralizing component 
of these sera is associated with the globulins or Y-globulins by fractional 
precipitation and starch-block electrophoresis, is non-dialyzable and is 
thermostable; induction of insulin-resistance in rabbits, guinea pigs and other 
animals by means of repeated subcutaneous injections of insulin in Freund's 
adjuvant; and demonstration that the sera of these animals display the same 
properties as sera from insulin-resistant humans outlined above. Recently it 
has been shown that injections into rabbits of USP insulin and high molecular 
weight contaminants (including insulin aggregates and proinsulin) found in it 
produces insulin-binding antibodies, while highly purified (monocomponent) 
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insulin does not, but that even monocomponent insulin is significantly 
immunogenic in humans (415,416). 
Subsequent to Berson and Yalow's work, it was shown that erythrocytes 
coupled to insulin are agglutinated by sera from insulin-treated rabbits and 
humans (417-419) and that Y-globulin-bound labeled insulin can be precipitated 
with rabbit anti-human Y-globulin (420,421). In addition, it has been shown 
that generally the serum of insulin-treated animals fails to precipitate the 
hormone (417 ,422), confirming Berson and Yalow's suspicions. In response to 
the criticism of the reviewers, Berson and Yalow demonstrated that 
ultracentrifugation of serum to which labeled insulin has been added also shows 
that the hormone moves with the Y-globulins in the case of insulin-treated 
patients, but with the albumin fraction of serum from untreated patients, and 
that the addition of increasing amounts of unlabeled insulin to a mixture of 
insulin antibody and labeled insulin results in displacement of the labeled insulin 
(409). This latter observation led directly to development of the first 
radioimmunoassay (RIA). 
The principle of RIA, as pictured in Figure 6, is based on competitive 
protein binding rather than simple isotope dilution. A tracer quantity of a 
radiolabeled form of the antigen to be measured (usually 1-125 or 1-131 bound 
to the tyrosyl phenolic ring in the case of proteins and H-3 or C-14 substituents 
in the case of other antigens), an aliquot of highly diluted xenogeneic antiserum 
specific for the antigen (usually prepared by hyperimmunization of rabbits or 
guinea pigs with the antigen in the presence of Freund's adjuvant), and a 
standard or sample containing unlabeled antigen are mixed in quantities 
appropriate to produce approximately 5096 net binding (bound/free antigen, 
B/F =1) of labeled antigen by antibody at equilibrium in the absence of unlabeled 
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FIGURE 6. COMPETING REACTIONS THAT FORM THE BASIS OF 
RADIOIMMUNOASSAY. 
(Reproduced, with permission, from Ref. 411. Copyright 1978 by the American 
Association for the Advancement of Science.) 
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antigen. To attain this result, exceedingly small quantities, in the picogram 
to nanogram range, of antibody and antigen are required (411). Net fraction 
antigen bound, B/T, is determined as [total CPM (counts per minute) associated 
with antibody - nonspecifically bound (NSB) CPM)/[total CPM - NSB CPM) and 
net percent antigen bound, %B=B/T x 100. Nonspecifically bound antigen is 
the radioactivity found in the antibody fraction in the absence of specific 
antibody or in the presence of a large excess of unlabeled antigen. 
When unlabeled antigen is added to the mixture, this species competes 
with labeled antigen for antibody binding sites and a significant reduction in 
the amount of radioactivity specifically associated with antibody protein is 
seen. As the concentration of added unlabeled antigen is increased, antibody-
bound radioactivity decreases proportionately, resulting in a dose-response 
relation between fraction radiolabeled antigen bound to antibody (B/T) and 
concentration of unlabeled antigen, exemplified by the standard curve for 
insulin reproduced in Figure 7. The antigen concentration of an unknown 
sample may then be determined from the standard curve simply as that antigen 
dose corresponding to the proportion of net antibody-bound radioactivity 
obtained for the sample. 
Unlike isotope dilution techniques, RIA does not require that labeled 
and unlabeled antigen exhibit identical behavior in the assay system, but only 
that antigen in unknown samples be immunochemically identical to the antigen 
standard (411). Even the competitive aspects of antigen-antibody interactions 
and attainment of equilibrium need not be strictly observed since successful 
RIAs have been developed based on principles of antigen displacement from 
antibody and approach to equilibrium, utilizing preincubation of unlabeled 
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FIGURE 7. DOSE-RESPONSE CURVE FOR INSULIN RIA, IN WHICH THE 
BOUND TO FREE RATIO OF RADIOLABELED INSULIN IS PLOTTED AGAINST 
THE ADDED COLD INSULIN. 
(Reproduced, with permission, from Ref. 423. Copyright 1965 by the Endocrine 
society.) 
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antigen and antibody before addition of labeled antigen (424) and shortened 
incubation times (423), respectively. 
Obviously, the "trick" of RIA is the complete and efficient separation 
of antibody-bound from free antigen. The first RIA, that developed by Berson 
and Yalow for assay of insulin in human plasma (425), utilized paper 
electrophoresis for the separation. Another separation method based on a 
difference in the physical properties of immunoglobulins and measured antigens, 
used in early RIAs, is gel chromatography (426). These methods are laborious 
and time-consuming, however, and proved unsuitable for routine clinical use. 
More rapid and convenient separation methods based on physicochemical 
properties of antibody and antigen include nonspecific precipitation of 
immunoglobulins with ammonium 'sulfate (427), alcohol (428) and polyethylene 
glycol (429), and nonspecific adsorption of antigen with talc (430) and charcoal 
coated with plasma proteins (431), albumin (432) or dextran (423). Although 
these techniques have found widespread use in clinical RIAs, one may question 
their use for more precise applications since anomalous values are likely to 
be found for fluids differing significantly in protein composition from normal 
serum (433) and precipitation methods tend to disturb the equilibrium of the 
antigen-antibody interaction (433,434). Furthermore, relatively high values for 
nonspecific binding of labeled antigen to antibody are likely to be found, 
including spurious contributions from nonspecific trapping of free antigen in 
precipitates and inability of charcoal to adsorb "damaged" tracer which may 
nonetheless retain immunoreactivity (433). 
Immunoprecipitation of antibody with a second antibody specific for 
serum components, gamma globulins or IgG of the species in which the first 
antibody was prepared (double antibody method; 435) is well-suited to research 
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applications. Although more time-consuming, the double antibody method 
exhibits far less interference due to nonspecifically bound radioactivity and 
variation in fluid composition than nonspecific precipitation methods (433). 
Because antigen- and second antibody-binding sites are distinct (433), equilibrium 
distribution of bound and free antigen is relatively unaffected. A solid-phase 
variation of the double antibody method involves coprecipitation of first and 
second antibodies prior to addition of other components, which then require 
constant mixing with the insoluble antibody (433). 
Solid-phase antibody systems offer a potentially popular means of RIA 
separation because they are extremely convenient and easily adapted to 
automated protocols, especially the coated tube method (436). Antibody is 
adsorbed onto polystyrene or polyethylene tubes, which may then be stored in 
dry form. After appropriate incubation with labeled and unlabeled antigen, 
bound antigen is separated from the free form simply by decantation or aspira-
tion. Because the composition of the antibody phase is difficult to control, 
however, the sensitivity and precision of this method tend to be poorer than 
that of soluble antibody RIAs (433). With the development of more efficient 
means of immobilizing immunoglobulins via covalent coupling to insoluble 
matrixes, a wide variety of solid-phase RIAs have been attempted, among the 
most successful of which employs antibodies coupled to Sephadex (437 ,438). 
Although this last method exhibits a high degree of precision and accuracy 
(433,439), solid-phase RIAs tend to be costly and wasteful of antiserum (433). 
Competitive protein binding assays, including RIA, provide dose response 
curves that exhibit severe nonlinearity. Thus, numerous attempts have been 
made to linearize the relation between labeled antigen bound to antibody and 
unlabeled antigen added in order to render data reduction compatible with 
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automated, relatively simple, low-cost computer systems. The most successful 
early attempt was that of Hales and Randle (424), in which Co/Cit where c0 
is the radioactivity of the antigen-antibody complex in the absence of unlabeled 
antigen and Ci is the radioactivity of this complex at a given concentration 
of unlabeled antigen, is plotted against concentration of unlabeled antigen. An 
example of a Hales-Randle plot, obtained by Guenther (387), is shown in Figure 
8. Using a coprecipitated double antibody complex and a microfiltration 
technique for separation of bound from free insulin, Guenther obtained a linear 
relation between C0 /Ci and insulin dose up to 200 ~ U/ml with a correlation 
coefficient of 0.979 (P«0.001, C.V. (Sy•x)=13%). The sensitivity of this assay, 
however, was no better than 10 ~ U insulin/mi. 
A partial linearization of the dose response has been achieved using a 
semi-log plot of bound/total radioactivity (B/T) or percent total radioactivity 
bound (%B) vs. log unlabeled antigen added, resulting in a sigmoidal curve 
(Figure 9). Several attempts have been made to linearize this plot utilizing 
sigmoidal transformations, the most successful of which is the logit transform, 
logit Y = ln Y = 2.303 log -:-=::-y---:::-
100 - y 100 - y 
where Y=(%B/%B in the absence of unlabeled antigen) x 100=%B0 (440). When 
logit (%B0 ) is plotted against log antigen dose a linear relationship between 
10% and 90% (logit=-2.2 - +2.2) is obtained (Figure 10). It should be emphasized 
that the linear relation obtained results from mathematical manipulation of a 
non-linear function and does not necessarily reflect any intrinsic property of 
the RIA system (440). 
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FIGURE 8. DOSE-RESPONSE CURVE FOR INSULIN RIA, PLOTTED 
ACCORDING TO THE METHOD OF HALES AND RANDLE. 
Each point is the mean of 10 determinations. 
(From Ref. 387) 
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FIGURE 9. DOSE-RESPONSE CURVE FOR HUMAN LUTEINIZING HORMONE 
RIA: SEMI-LOGARITHMIC PLOT. 
Bars indicate the range of 10 replicates. 
(Reproduced, with permission, from Ref. 440. Copyright 1968 by the Endocrine 
society.) 
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FIGURE 10. DOSE-RESPONSE CURVE FOR HUMAN LUTEINIZING HORMONE 
RIA: LOGIT-LOG PLOT. . 
Data of Figure 9. 
(Reproduced, with permission, from Ref. 440. Copyright 1968 by the Endocrine 
society.) 
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Although it is technically feasible to apply linear regression analysis to 
Iogit-log plots and thereby determine the residual variance (scatter) about the 
regression line, the results of such analysis would be invalid and severely biased 
due to intensification of heteroscedasticity, or non-uniformity of the residual 
variance, by the logit transformation (440). Thus, a quality control approach 
has been found to be the most practical, expedient means of judging the 
suitability of established RIAs (440). The four most informative quality control 
parameters are B0 , the percent antigen bound in the absence of unlabeled 
antigen; the antigen dose at which 96B0 =5096 (logit Y=O); the intraassay 
variation, the coefficient of variation for sample replicates assayed at the 
same time; and the interassay variation, the C.V. for samples assayed 
repetitively at different times. 
lntraassay variation, a measure of assay precision, and interassay 
variation, a measure of assay stability and reproducibility, found for RIAs are 
typically less than 1096 and 1596, respectively (440-443). Although the 9096 
B0 x-intercept in a logit-log plot is frequently considered the sensitivity of 
an RIA, the 5096 intercept is a more suitable reflection of sensitivity for use as 
a quality control parameter, since it is situated at the center of the curve 
and thus is relatively unaffected by minor fluctuations of slope (440). As 
little as 1-3 ~U insulin/ml is commonly detected by RIA (438,443,444), with 
a sensitivity of 0.3 ~ U/ml having been reported (445). 
Before a given RIA can be considered a useful technique to which quality 
control tests may be applied, the validity of the assay must first be proven 
by certain established procedures. Assay specificity is generally verified by 
assaying dilutions of samples containing high concentrations of antigen; if the 
relation between sample dilution and 96B parallels that of the standard so that 
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assignment of an antigen concentration to the sample based on the standard 
results in the superimposibility of the sample and standard dose-response· curves, 
then one may conclude that antigen in the sample is identical to antigen in 
the standard and that the assay measures only that particular antigen in sample 
nuid (433,441-443). When an RIA is meant to measure one of a group of 
closely related antigens, such as the gonadotropins (luteinizing hormone, follicle-
stimulating hormone and chorionic gonadotropin), somatotropin and prolactin, 
insulin and proinsulin, and the steroid hormones, assay specificity is often 
determined by assaying dilutions of the possibly cross-reacting substances in 
the RIA (433,441,443). The extent of cross-reactivity may be quantitated by 
comparing the doses at which 50% B0 is attained. 
Accuracy of an RIA may be ascertained by demonstrating "recovery" of 
exogenous unlabeled antigen from sample fluid. Antigen standard is diluted 
in sample fluid which is then assayed with the RIA. If the difference between 
results obtained for this preparation and that of untreated fluid closely 
approximates the antigen concentration of the added standard, the assay is 
considered capable of measuring accurately the quantity of immunoreactive 
antigen in that fluid (441-443). If RIAs for a particular antigen have already 
been developed, one may also compare the results of a newly-developed RIA 
for antigen concentrations in fluids from normal individuals and those suffering 
from well-characterized pathologic conditions with corresponding values 
reported using previously developed RIAs. Insulin levels in human sera from 
normal fasting individuals, determined by RIA, range from 1.0 to 20 lJU/ml 
(443), with a mean of 8.44 0.35 lJU/ml (S.E.M., n=75) having been reported 
(444). Serum insulin concentrations rise four- to tenfold after ingestion of 
100 grams oral glucose (oral glucose tolerance test, OGTT), attain their 
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maximum values at 30 to 60 minutes, and thereafter gradually fall to the 
tasting level or below at two to four hours (443). 
so precise and reproducible are RIAs for insulin that it has been possible 
to discriminate among normal, pre-diabetic, maturity onset diabetic and juvenile 
onset diabetic conditions from the pattern of serum immunoreactive insulin 
(IRI) levels during OGTTs (446,447), which have also been used to assess the 
probability of diabetic angiopathy, neuropathy and renal disease in maturity 
onset diabetics (448). Furthermore, the use of insulin RIAs for determination 
of serum IRI levels after administration of glucose, tolbutamide, leucine or 
glucagon has made possible the diagnosis of insulin-secreting tumors 
(insulinomas) with a high degree of reliability (446). 
Radioimmunoassay is uns'urpassed in its sensitivity, reproducibility, 
precision and specificity for!! given antigenic species. Thus, the major drawback 
regarding RIA is the broader issue of accuracy. An antigen may lose its 
biologic activity, but retain its immunoreactivity, while a closely related or 
altered antigen may be capable of exerting a potent biologic effect, but have 
a much reduced affinity for antibody utilized in the RIA. Nowhere does this 
question have more important implications than in the fields of insulin and 
diabetes research, since there remains the possibility that insulin aggregates 
or protein-bound insulin constitute a physiologically important hormone reservoir 
that is largely undetected by RIA (see Chapter V). 
Radioimmunoassay is also extremely convenient, provided one possesses 
the appropriate equipment for carrying it out. Not every laboratory can afford 
an automated gamma ray or liquid scintillation spectrophotometer, large 
centrifuges, and even a desk computer necessary for large-scale RIAs. For 
those possessing such equipment, antigen determinations can be made on several 
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hundred samples in a single assay (411). Of special importance to clinical and 
research applications alike is the ability of RIA to measure antigen levels in 
very small sample volumes (0.1 ml or less). Furthermore, the potential 
applications of RIA to biomedical research and diagnosis appear virtually 
unlimited because of recent advances in techniques for production of haptens 
(non-immunogenic compounds rendered capable of eliciting specific antibody 
production in animals after conjugation of the compounds to immunogenic 
proteins such as albumin) and radioisotopic labeling of organic compounds. 
Thus, it is not surprising that during the past twenty years RIAs have 
been developed to measure a myriad of substances, including peptide and protein 
hormones, thyroid hormones, steroids, prostaglandins, neurotransmitters, non-
hormonal serum proteins, drugs,' vitamins, cyclic nucleotides, enzymes, viruses 
and tumor antigens (411). Plainly, RIA has had a major impact on those areas 
of study that could benefit from a striking increase in the ability to measure 
exceedingly small quantities of a given substance, and has even enabled the 
monitoring of fluctuations in intracellular concentrations of compounds reliably. 
This impact has been especially profound on the fields of endocrinology, cell 
physiology, oncology, and immunochemistry. Regarding this last application, 
RIA has been particularly useful in the immunochemical characterization of 
insulin. 
In their ability to inhibit binding of radiolabeled insulin to anti-insulin 
antibodies, insulins derived from various vertebrate species have the dual 
advantage of being extensively, but not completely, cross-reacting. Although 
the degree of inhibition per unit concentration of unlabeled insulin and thus 
the antigen-antibody affinity may differ among various insulins with a given 
antiserum, Berson and Yalow (449) found that bovine, porcine, ovine, equine 
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and human insulins were all capable of saturating antibody binding sites in 
human anti-insulin sera (inhibition curves shown in Figure 11). These 
investigators found that the kinetics of the association indicate that insulin is 
probably univalent and that there are at least two distinct orders of antibody-
combining sites. Association constants for high affinity sites ranged from 3 
x 108 M-1 (horse insulin) to 1.4 x 109 M-1 (beef insulin) and for low affinity 
sites from 3.4 x 106 M-1 to 3.2 x 107 !\1:-1 utilizing serum obtained from an 
individual treated with a combination of bovine and porcine insulins. Lower 
affinities of iodinated, nitrated, desalanine-desasparagine (DAA), and 
desoctapeptide (DOP) insulins and proinsulin for guinea pig anti-insulin antibodies 
compared to native insulin in the RIA, represented by lesser slopes in Hales-
Randle plots, have also been observed (136). 
Apparently, the ability to discriminate among insulin from different 
species is dependent mainly upon the source of the insulin used for immunization 
and for radiolabeling. Serum from humans treated with porcine insulin cannot 
discriminate among bovine, porcine, human and DOP insulins, whether 
radiolabeled porcine or bovine insulin is used (450). When these subjects are 
further treated with bovine insulin, however, their antibodies exhibit a lower 
affinity for DOP insulin compared to the animal insulins studied if an 
1311-porcine insulin tracer is used and can discriminate between bovine and 
porcine vs. human and DOP insulins if an 131J-bovine insulin tracer is used 
(450). At appropriate dilutions, sera from two of three individuals treated with 
a combination of bovine and porcine insulins can discriminate between bovine 
and porcine insulins, with bovine insulin exhibiting the greater affinity, provided 
a radiolabeled bovine or ovine insulin tracer is used (449). 
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FIGURE 11. DOSE-RESPONSE CURVES FOR INSULIN RIA USING HUMAN 
ANTI-INSULIN SERUM H.L. 
Reproduced from The Journal of Clinical Investigation, 1959, vol. 38, pp. 2017-
2025 (Ref. 449) by copyright permission of The American Society for Clinical 
Investigation. 
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The results of these experiments suggest that the AB-10 apolar amino 
acids, which are the only ones that differ among bovine, porcine, ovine and 
equine insulins, are a site of antigenic determinacy (449). The antigenicity of 
the B30 residue, however, may be dependent upon the conformation of the 
insulin molecule, since sera from individuals treated with porcine insulin cannot 
discriminate between human and porcine insulins, which differ from each other 
only in the B30 residue (alanine in the pig, threonine in man), while anti-bovine 
insulin sera do discriminate between the two insulins, suggesting that the B30 
alanine is presented in a more favorable way immunogenically by bovine insulin 
than by porcine insulin. This supposition is supported by the fact that antibodies 
to porcine insulin react well with desalanine porcine insulin and cannot 
discriminate between DOP bovine and intact insulins, while anti-bovine insulin 
sera readily distinguish DOP beef insulin from intact bovine and porcine insulins, 
but not necessarily from human insulin (450). Antisera from rabbits (whose 
insulin differs from human and porcine insulins only in containing B30 serine) 
immunized with porcine insulin also react with DOP bovine insulin (450). 
That the conformation of the insulin molecule differs among species and 
that conformational differences affect the antigenicity of the hormone are 
supported by the finding that certain human anti-porcine, bovine insulin sera 
discriminate sharply between porcine and sperm whale insulins, which possess 
identical primary structures (450,451). Several years before the discovery of 
proinsulin, Berson and Yalow interpreted this observation to mean that the 
overall protein structure may not be determined by amino acid sequence alone 
(451). The concept that protein conformation is ultimately determined by 
primary structure was vindicated, however, when the insulin portion of the 
Proinsulin molecule was shown to be in the same conformation as the free 
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insulin molecule (452). Thus, insulin conformation is dependent upon the tertiary 
structure of proinsulin, to which the primary structure of the connecting peptide 
(c-peptide, see Chapter V, ''Insulin Precursors") would be expected to make a 
major contribution and, indeed, comparison of the amino acid sequences of 
human, porcine and bovine proinsulins reveal a high degree of variance within 
the respective C-peptide segments {453). This postulate is supported by the 
fact that oxidation of reduced A and B chains of sheep insulin yielded only 
12-16% biologically active insulin {157 ,158), indicating that insulin is not in its 
thermodynamically most stable conformation, while reoxidation of fully reduced 
beef and rat proinsulins results in a high proportion of the native configuration, 
which could be converted to biologically active insulin by trypsinization {454), 
suggesting that the conformation of insulin is dictated by the thermodynamically 
most stable conformation of proinsulin. 
It may be seen from Table I that the A14 and A19 tyrosines are important 
to insulin immunoreactivity. Unfortunately, RIA is a relatively insensitive 
means of investigating the effects of changes at these positions, since they 
are prime sites of radioiodination. Monoiodoinsulin is labeled equally at A14 
tyr and A19 tyr (136), leaving half the labeled insulin intact at each site and 
able to· bind antibodies specific for these epitopes. The partial competence 
of labeled insulin at these sites is indicated by findings of 37.7 and 58.4% 
immunoreactivity for mononitro- and monoiodoinsulin, respectively, by RIA and 
corresponding values of 6.7 and 3.9% by immune hemolysis inhibition {136). 
Table I also indicates that A1 glycine and A21 asparagine may be important 
immunodeterminants, while B1 phenylalanine and B29 lysine are relatively 
unimportant. Alteration of both B1 and B29 residues, however, leads to 
significant reductions of immunoreactivity. Arquilla has suggested that a 
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significant proportion of the antibodies involved with the insulin RIA may 
combine with determinants that include B10 histidine (136). 
Previously iterated evidence for the immunogenicity of insulin, namely 
insulin resistance in animals treated with the hormone and the ability of these 
animals' sera to block insulin's biologic effects in both in vivo and in vitro 
systems, also provides a basis for the assertion that insulin immunodeterminants 
lie in or near the hormone's active site. This contention is also supported by 
the induction of experimental diabetes in animals via injection of hyperimmune 
anti-insulin sera (414). Thus, it is especially significant that the A1 glycine, 
A19 tyrosine and A21 asparagine-all associated with the insulin active site 
(135)-have ·also been implicated as insulin immunodeterminants. Although 
insulin aggregates are important to the immunogenicity of the hormone, 
immunodeterminant residues have been implicated in the hydrophobic 
aggregation regions of the monomer: B30 alanine in the dimer face and A14 
tyrosine in the hexamer face. This contention is supported by the observation 
that compromised immunoreactivity of FITC-insulin derivatives parallels the 
progressive inability of these derivatives to form aggregates (136), leading one 
to expect that large insulin aggregates should exhibit decreased 
immunoreactivity. The immunogenicity of insulin aggregates may be related 
to an increased molecular size in excess of that required for processing by 
macrophages (455), which may then "read" dissociated monomer determinants. 
Enzyme Immunoassays 
Because RIA may involve exposure to potentially dangerous radioactivity, 
requiring special handling of materials and the use of expensive equipment, 
immunoassays utilizing enzyme-labeled antigen have been developed. Among 
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those procedures collectively known as enzyme-linked immunosorbent assays 
(ELISA), this technique is based upon the same principles as RIA, but deter.mines 
quantity of labeled antigen bound to antibody by measuring enzyme activity 
in the presence of a large excess of substrate. Typically, the product of the 
enzyme reaction exhibits a characteristic color and may be quantitated in a 
simple colorimeter, giving ELISA a potentially great advantage over RIA in 
its applicability to small laboratories and fieldwork. The frequent use of 
specific antibody adsorbed to plastic test tubes or multiwell microtiter plates 
in ELISA increases the potential convenience of this assay (456,457). 
Miedema et al. developed a solid phase ELISA for insulin utilizing anti-
insulin serum adsorbed to polystyrene test tubes, insulin coupled to alkaline 
phosphatase with glutaraldehyde, and Q:-nitrophenylphosphate as substrate, the 
reaction product of which was monitored by measuring absorbance of 405 
nanometer wavelength light (A4o5) (458). The sensitivity of this assay was 
found to be no better than 75 · JJU insulin/ml, however, with a mean serum 
insulin concentration of 63 JJU/ml (below the sensitivity) for normal fasting 
individuals and a normal range of 20 to 106 JJU/ml, indicating that the 
sensitivity and precision of ELISA is far inferior to that of RIA for assay of 
insulin. 
Enzyme Immunoelectrode 
Mattiasson and Nilsson (459) described covering an oxygen electrode with 
a nylon net to which are coupled guinea pig anti-porcine insulin antibodies for 
the immunoassay of insulin. Insulin in a sample competes with glucose oxidase-
labeled insulin for antibody sites on the nylon net. After a three-minute 
incubation, substrate (glucose) is added and the signal from the electrode, 
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reflecting the change in oxygen concentration because of the enzyme-catalyzed 
reaction, is recorded on a strip chart. After the assay, antigen is dissociated 
from antibody by washing with a pH 2.2 glycine buffer, and in about three 
minutes the electrode is ready for use again. Analysis of each sample requires 
about ten minutes. The sensitivity of the assay (about 10 JJ g/ml) is many 
times poorer than that of RIA techniques and it is not yet applicable to routine 
testing (456). 
RADIO RECEPTOR ASSAYS 
It became apparent soon after systematic studies of insulin-receptor 
interactions were begun that a competitive protein-binding assay for insulin 
could be developed based on the same principles as RIA, but utilizing specific 
cell receptors for the hormone instead of antibodies. Such as assay may 
possess the sensitivity and precision of RIA while measuring the biologic activity 
of the hormone. This promise has been realized through the development of 
insulin radioreceptor assays (RRA) utilizing both particulate (membrane) and 
solubilized receptor preparations. 
Using a crude guinea pig kidney membrane fraction and 125I-porcine 
insulin with separation of membrane-bound from free insulin effected by 
Millipore membrane filtration, Suzuki et al. obtained a sensitivity of 10 JJ U 
insulin/ml with an intraassay variation of 8% (CV) and an interassay variation 
of 13% (460). Displacement of tracer from receptors by porcine proinsulin 
was 28% that of porcine insulin, while guinea pig insulin exhibited less than 
1% of the potency of the porcine hormone in the RRA. Human serum insulin 
levels during OGTTs were found to increase from a mean of 19 JJ U/ml (n=3) 
in fasting subjects to a maximum of 90 'llU/ml (n=6) at 60 min., after which 
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theY declined to 38 'IJ U/ml at 180 min. Excellent correlation between RIA 
and RRA for serum insulin was found (r=0.952) with a correspondence of 
y::0.905x+1.24, where y=serum insulin measured by RIA ( 'IJU/ml) and x=serum 
insulin measured by RRA ( 'IJ U/ml). 
Ozaki and Kalant developed RRAs for insulin utilizing a membrane 
fraction derived from fresh normal human placentas and membrane receptors 
solubilized with Triton X-100 detergent (461). Receptor-bound insulin was 
separated from free hormone by centrifugation in the case of the membrane 
assay and by adsorption of free insulin to dextran-coated charcoal in the case 
of the soluble receptor assay. With the latter assay, these investigators were 
able to attain a sensitivity of 0.5 'IJ U insulin/ml, which is understandable since 
the affinity of the receptor for i~sulin (K=1.8 x 1010 M-1) is similar to that 
of the antibody-hormone interaction using hyperimmune xenogeneic sera. The 
intraassay variation was 1.3% and the interassay variation was 10.9%, with an 
RIA correspondence of y=0.85x+2.7 (r=0.944), where the parameters are the 
same as iterated above. In this assay, proinsulin exhibits 4-5% cross-reactivity 
with the soluble receptor; thus, the reactivity of the prohormone in the RRA 
approximates its biologic activity. 
The RRA may well prove to be the ultimate assay for insulin, combining 
the best features of RIA and bioassay, but it is unlikely that it will be adopted 
for routine clinical use for the following reasons: 1) The lifetime of a receptor 
preparation is several months, compared to several years for an antiserum; 
thus, it would be necessary to prepare new receptor fairly often. Even if such 
a preparation were made available commercially, each lot may exhibit 
significantly different binding properties and require recharacterization of the 
assay. 2) Characteristic levels and fluctuations of immunoreactive insulin in 
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health and disease have already been determined and have proven more than 
adequate for clinical purposes. 3) Serum insulin concentrations determined by 
RRA are nearly identical to those found by RIA. 
Neither RIA nor RRA can be expected to exert much impact on the 
state of ignorance concerning the nature of circulating insulin, however, since 
there remains the possibility that the hormone may be bound to a carrier 
protein or itself (aggregates), masking both antibody- and receptor-binding 
structures. Investigation of serum insulin-like activity, including this possibility, 
requires a bioassay with a sensitivity within the physiologic range of 
immunoreactive insulin and the ability to discriminate bet ween "typical" insulin 
and other serum factors that mimic the effects of the hormone in the traditional 
bioassays. The use of cells in culture may provide such an assay. 
CHAPTER V 
INSULIN-LIKE ACTIVITY (ILA) 
serum insulin-like activity or "atypical" insulin is distinguished from true 
. ,monomeric or "typical" insulin by the fact that, while the former mimics the 
latter in one or more assay systems, the two differ in their physicochemical, 
: tmmunochemical, and/or particular biological properties. The properties of 
, typical and atypical insulin species discussed in the following sections are 
summarized in Table V, at the end of this chapter, to facilitate comparisons that 
may enable one to formulate conclusions regarding the nature of serum ILA. 
TYPICAL INSULIN 
Obviously, before the subject of atypical insulin may be broached, it is 
firSt necessary to define what is meant by typical insulin, which is the hormone 
possessing the physical, chemical and biologic properties described in previous 
ehapters. Reiterating some of the more important of these properties, typical 
insulin is the monomeric species of the hormone, exhibiting a molecular weight 
between 5,500 and 6,000 daltons and consisting of two polypeptide chains 
eovalently joined by two disulfide bonds. It exhibits a sedimentation coefficient 
(S2o,w> of 1.2 S, a diffusion coefficient (D2o,w> of 1.6 x 108 cm2/sec., and a 
frictional ratio (f/fo) of 1.12, indicative of a. nearly spherical molecule. This 
llpecies also has an electrophoretic mobility between that of albumin and a 1-
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globulins, is soluble in acid ethanol, forms radially oriented fibrils when heated in 
dilute acid solution and rhombohedral crystals in the presence of zinc. 
Theoretically, one mole of anti-insulin IgG antibodies will bind two moles 
of typical insulin. Thus, typical insulin will bind 13 times its weight in anti-
insulin IgG. Binding capacity of sera from insulin-resistant humans has been 
found to range from about 2 to 200 ).Jg typical insulin/ml (366), corresponding to 
25).Jg-2.5 mg anti-insulin IgG/ml, and association constants found for anti-insulin 
antibodies and typical insulin range from 106 to 1011 M-1 (428,440). Association 
of antibodies specific for determinants present on a given antigen and that 
antigen will be inhibited most efficiently by compounds structurally most similar 
to the antigen. Therefore, IRI concentrations determined by RIA (using an 
antiserum raised against pure typical insulin) relative to a typical insulin 
standard will be maximal for typical insulin. 
Binding capacity of cellular insulin receptors is 40 to 250,000 molecules 
typical insulin (TI) per cell, 0.2 to 18 pmole TI per mg membrane protein, and 0.3 
to 7 pmole TI per mg soluble receptor protein. Association constants found for 
receptor-TI interactions range from 10 7 to 1010 M-1• Because this interaction is 
dependent upon the integrity of the hormone's receptor-binding site, insulin con-
centrations determined by radioreceptor assays are directly proportional to 
specific biologic activity relative to typical insulin. 
Intravenous injection of 125 ).J g typical insulin into a 2 kg rabbit starved 
for 24 hours will cause an approximately 50% reduction in blood glucose over a 
period of 2-4 hours. Intravenous injection of 40 ng TI into a 25 g alloxan 
diabetic, hypophysectomized mouse will cause a reduction in blood glucose 
concentration of about 40 mg/dl after 20 minutes (362). Addition of 100 ).JU (4 
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ng) Tl/ml to the medium results in a 50% increase in glycogen synthesis by 
isolated rat diaphragm, while a concentration of 5 vg Tl/ml causes a 2-fold 
increase (relative to insulin-free medium) in C02 production by rat epididymal 
fat pads (368). Addition of 10 llU (0.4 ng) Tl/ml medium causes a 4-fold increase 
in conversion of glucose to total cell lipids by isolated rat fat cells (145). 
INSULIN AGGREGATES 
Insulin monomers associate non-covalently in solution to form stable 
dimers (2 monomers, M2), which associate to form tetramers (M4), which may 
combine with monomers to produce hexamers (M6), which may themselves 
associate to form larger aggregates (M6n> (462-465). As previously stated in 
Chapter m, insulin crystals consist of hexamers. 
Insulin aggregation is dependent upon insulin concentration, pH, ionic 
strength and (for M ~6) divalent cation concentration. The change in weight 
fraction of various aggregates with increasing insulin concentration at pH 2.0, 
25° C and ionic strength 0.1 is depicted in Figure 12. Under these conditions, 
disaggregation occurs below 0.1% insulin (<1 mg/ml) and the fraction of dimer 
attains a maximum between 0.1% and 0.25% insulin, declining thereafter 
concomitantly with a steady increase in the fractions of tetramer and hexamer. 
At neutral pH the average weight of zinc-free insulin ranges from the dimer to 
well above that of the hexamer in the concentration range 0.1-1.0% (466-468). 
Holladay et al. (469) found that, for zinc-free insulin at pH 7 .4, 20° C and ionic 
strength 0.368, the proportion of insulin molecules that exist as dimers follows 
the pattern of Fig. 12, attaining a maximum of 32% between 0.05 and 0.8 mg 
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FIGURE 12. APPARENT WEIGHT-AVERAGE MOLECULAR WEIGHT OF 
INSULIN AS A FUNCTION OF CONCENTRATION; pH 2, IONIC 
STRENGTH 0.1. EACH SET OF SYMBOLS REFERS TO A PARTICULAR 
EXPERIMENT. THE SOLID LINE IS CALCULATED FROM THE 
EQUILffiRIUM CONSTANTS ASSUMING NO CHARGE EFFECTS AND 
IDEALITY; THE DASHED LINE IS CALCULATED ACCOUNTING FOR 
CHARGE EFFECTS. TOP: T = 15°C; BOTTOM: T = 25°C. 
(Reproduced, with permission, from Ref. 462. Copyright 1966 by the American 
Chemical Society.) 
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insulin/mi. 
Insulin exists in the dim eric form below pH 3 at a concentration of 1% in 
o.l M sodium chloride, while the hormone is dissociated to monomers below pH 3 
at a concentration of 0.25% in 0.1 N sodium monophosphate (NaH2P04); 
dissociation of the dimer also occurs in sodium chloride at pH 2.0-2.7 below 0.1% 
insulin concentration (464). Moderately dilute solutions (0.1-o.25%) of zinc-free 
insulin dissociate to the monomers upon increasing the pH to 9.1-9.5 
(466,467 ,470). The role of increasing ionic strength promoting aggregation 
appears to lie in its effect on the net charge per monomer (number of protons 
bound less the number of counterions bound)(470). For a given degree of 
association of insulin molecules, the net proton charge (Z) has been found to 
remain the same (e.g_. 2.5/monomer at 20,000 daltons) regardless of pH between 
2.7 and 4.0, suggesting that the molecular weight of insulin in acidic media is a 
simple function of net charge and, indeed, the average molecular weight has 
been found to be a linear function of net charge over the range 7,000 daltons (Z = 
4.1/monomer) to 25,000 daltons (Z = 1.8/monomer)(470). The anion-dependence 
of insulin association in acidic media (CNS- > I - > N03- > Br- > Cl- > H2PO 41 
therefore reflects the ability of these species to serve as counterions in acidic 
media; ~·.K· the dissociation of the dimer in the presence of H2Po4- at pH 2 can 
be attributed to the poor ability of H2PO 4- to act as a counterion at this pH, 
where the charge on the monomer approaches 5 proton units (471). A similar 
inverse relation between net monomer charge and insulin aggregation has also 
been found in alkaline media (470), implying repulsion of similarly charged 
molecules. Thus, the proportion of dimers increases with decreasing pH, insulin 
concentration and ionic strength. 
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The effect of divalent cations in promoting aggregation of insulin beyond 
the tetramer stage is striking, as illustrated in Figure 13. Zinc is the only metal 
found in crystalline insulin prepared in the absence of external metal sources, 
but rhombohedral crystals also form in the presence of Cd++ , Co++ , or Ni++ , 
with 3 atoms of metal found per hexamer (464). Cu++ , Mn++ and Fe++ can also 
facilitate formation of rhombohedral insulin crystals, which requires a minimum 
of 2 metal atoms per hexamer (153, 473), while metal-free insulin crystallizes in 
orthorhombic form (474). The first 2 zinc atoms taken up in the formation of the 
hexamer appear tightly bound, but insulin-both in solution and in crystalline 
form-is capable of binding more loosely at least an additional 7 zinc atoms per 
hexamer (464). 
Insulin does not bind zinc (or other metals) below pH 3.5 (464) and the low 
incidence of hexamer in acid solution is about the same as for metal-free insulin 
in neutral solution (compare Figs. 12 and 13). Insulin binds zinc continuously 
with increasing pH above 4.5 to at least an additional 7 atoms per hexamer at pH 
8.0 (466,475). At neutral and moderately alkaline pH, the proportion of hexa-
mers increases with increasing zinc content from a few hundredths of a percent 
of zinc to about 0.35%, or 2 atoms per hexamer, where the population of 
hexamers is predominant when the insulin concentration is greater than 0.1 
mg/ml (466, 470, 472, 473). Above 2 atoms zinc per hexamer, a 72,000 dalton 
unit occurs and with further increases above 6 atoms per hexamer, a polydisperse 
distribution in the range of 200,000-300,000 daltons predominates. With 
increases of pH above 8.0 dissociation again becomes predominant even in the 
presence of high zinc content (3-6 atoms per hexamer); under these conditions a 
minimum molecular weight of 36,000 is again obtained in the pH range 9-10 
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FIGURE 13. A COMPARISON OF THE WEIGHT-FRA<;:TIONS OF MONOMER (a) 
AND HEXAMER (b) AS A FUNCfiON OF TOTAL WEIGHT 
CONCENTRATION FOR THE ZINC-FREE INSULIN ( ) AND 
ZINC-INSULIN (- - - - - -) SYSTE!\1S IN TRIS-HCI!NaCI BUFFER AT pH 
7 .0, IONIC STRENGTH = 0.2 AND 25°C. 
(Reproduced, with permission, from Ref. 472. Copyright 1977 by Elsevier 
Biomedical Press.) 
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(470). 
Although the degree of insulin aggregation in blood is unknown, study of 
the hormone's self-association behavior under various conditions strongly 
suggests a marked predominance of the monomer at physiologic insulin 
concentrations (0.1-3 ng/ml)(476). Calculations of insulin aggregate con-
centrations at pH 8.0, 25°C, ionic strength 0.1 and an insulin concentration of 
10-8M, in the presence of mammalian serum concentrations of Zn++ (1.5-3.7 x 
10-SM), based on known insulin association constants, yield values no greater 
than to-26M for the 2-Zn++ hexamer, to-13M for the 2-Zn++ tetramer and 2.1 x 
10-llM for the dimer (464). 
The physicochemical properties of insulin aggregates, including 
association constants and molecular weight, are summarized in Tables IV and V. 
The considerable enhancement of tetramer and hexamer formation in the 
presence of zinc is due to the affinity of sites on the insulin molecule for 
divalent metal ions. Two orders of affinities for the first 2 zinc ions bound and 
additional zinc binding are confirmed by equilibrium dialysis experiments at pH 
8.0, at which maximum zinc binding occurs. This method yields an association 
constant of 2 x 105M-1-s x 106M-1 for each of the first 2 zn++ bound and K = 7 x 
103M-1-3.5 x 104M-1 for each subsequent Zn ++ bound, with 10-12 insulin binding 
sites per hexamer available for the weaker associations (464, 477). 
The fact that agents known to disrupt hydrophobic interactions, such as 
guanidine hydrochloride, urea, detergents, dimethylformamide, trifiuoroacetic 
acid/ether, pyridine, dioxane, and butanol/dichloroacetic acid, induce dis-
sociation of insulin aggregates (464) indicates that such interactions play an 
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TABLE IV. SELF-ASSOCIATION OF INSULIN 
Species Process pH Kassoc. - t. G Comments Ref. 
Formed (kcal/ 
mole) 
Dimer 2M ~D 2.0 8x103M-1 462 
1.02x104 5.2 f.! = 0.1 463 
M-1 
7.0 1.1x105M-1 476 
7.4 2x105M-1 478 
2.2x104M-1 5.8 469 
8.0 2x105M-1 479 
Zinc-Free 
7.8x102M-1 Tetra mer 2D .tT 2.0 f.! = 0.1 463 
7.0 l.7x104M-1 476 
Zinc 
4M+2 Zn++ 1o29M-s Tetra mer 7.4 464 
:!TZn2 
Zinc-Free 
6.7x102M-1 Hexamer D+T :!H 2.0 f.! = 0.1 463 
3D :!H 2.0 5.3x109M-2 z = +5.0 464 
7.4 8.6x109M-2 13.3 469 
8.0 2.0x109M-2 z = -3.2 464 
Zinc 
Hexamer 6M+2Zn++ 7.4 1o32M-7 464 
:!HZn2 
Polyhexamer 2H :!H2 7.0 5x10
3M-1 476 
Abbreviations: M monomer 
D dimer 
T tetra mer 
H hexamer 
ll ionic strength 
z net charge 
156 
important role in the hormone's self-association. This supposition is verified by 
study of the molecule's tertiary structure based on x-ray diffraction analysis of 
the insulin crystal, which several lines of evidence indicate is essentially the 
same as the insulin dimer and zinc hexamer in solution (464). This x-ray 
diffraction analysis reveals that regions of contacts among insulin molecules are 
largely composed of nonpolar residues. As mentioned in Chapter III, the insulin 
monomer exhibits two faces-one involved in dimer formation and the other in 
dimer-dimer associations-each containing a number of surface apolar residues 
with their side-chains contacting solvent in the dissociated state. 
In the dimer, about 36 of 111 short atomic separations between the 
monomeric association faces involve the side chains of 10 nonpolar residues, the 
B12 valine, B16 and B26 tyrosines, and B24 and B25 phenylalanines of each 
molecule. In addition, Bll leucine, although not involved in short intermolecular 
separations, also forms part of the nonpolar core of the dimer (464). A twofold 
relationship between the molecules of the dimer means that the C-terminal 
residues of the B-chains run anti-parallel to each other, making possible the 
formation of an anti-parallel a-pleated sheet structure involving the B21-B30 
residues and containing 4 hydrogen bonds between the monomers. These 
hydrogen bonds, between the backbone amido and carbonyl functions of the B24 
and B25 phenylalanines and B26 tyrosine of each molecule, serve to stabilize the 
dimer in aqueous solution after formation due to hydrophobic interactions. In 
fact, all monomer-monomer contacts involve B-chain residues that contribute 
to a-helical and S-pleated sheet structures (143). The dimer constructed from 
0 
x-ray diffraction analysis has an oval appearance and is about 40 A from end to 
• 
end and 25 A across (143). 
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Of the 99 short intermolecular separations between dimers, about 39 
involve the nonpolar side chains of B1 phenylalanine, B14 valine, A 14 tyrosine 
and the A13, B6 and B17 leucines (464); B18 valine may also be involved in 
hydrophobic interactions as well as the other a-helical residues, B14 and B17 
(143). Dimer-dimer interactions are also stabilized by hydrogen bonds, between 
the B1 a-amino and A17 glutamate )'"'Carboxy functions and between the A14 
tyrosyl phenolic hydroxyl groups across the surface of the molecules (143,464). 
0 
The 2 tightly bound zinc ions in the hexamer lie on the threefold axis, about 18 A 
apart, each coordinated to the N3 imidazole nitrogens of 3 B10 histidines. The 
coordination of each Zn++ is completed by water molecules and is apparently 
intermediate between octahedral and trigonal prismatic (143). The 7 remaining, 
weaker metal-binding sites probably involve the B13 and A17 glutamyl y -
carboxy and the B1 a-amino functions (464). Recently, Sudmeier et al. (480) 
offered evidence from Cd-113 nuclear magnetic resonance studies that the 6 B13 
glutamyl y-carboxy functions normally form a specific Ca++ -binding site in the 
center of the 2-Zn++ hexamer. The threefold axis, consisting of B9 serine, B10 
histidine and B13 glutamate residues connected by an elaborate water structure, 
constitutes a hydrophilic core in the center of the hexamer, which has the shape 
0 0 
of a flattened disc about 50 A across and 35 A high with prominent channels 
lined with solvent molecules running between the dimers from the central zinc 
ions to the edge of the molecule (143). 
Conclusions regarding roles played by specific residues in dimer-dimer 
interactions based on x-ray diffraction analysis tend to be supported by study of 
the aggregative properties of rat insulins. Rat insulins I and D both differ from 
porcine insulin in substitutions at A4 {glu ~ asp) and B3 (asn~ lys), while rat 
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insulin I contains a further substitution at B9 (ser -+pro) and rat insulin n ~t B29 
(lys -+met). Yet rat insulin I forms hexamers less easily than rat insulin n, 
reflecting the importance to hexamer formation of the B9-B19 a-helix and BlO 
histidine conformation, which would be affected by a nonconservative 
substitution at B9 (481). 
The equatorial surface of the hexamer is smooth, but the top and bottom 
surfaces are broken by projections from residues of the AS-All loop regions on 
• each surface. Between these projections large pockets about 10 A across 
result. In the crystal these are partially filled by the A-chain loop regions from 
molecules above and below the hexamer in the direction of the 3-fold axis. The 
segregation of polar and nonpolar r~sidues is more clearly defined in the hexamer 
than in any of the subunits: the surface is largely covered with polar side chains; 
even the surface pockets and channels are lined with groups such as the B5 
histidine, B9 serine, B13 glutamate, and the hydroxyl functions of both B-chain 
tyrosine residues. The apolar residues exposed at the surface of the hexamer-
the A14 tyrosines, B25 phenylalanines and A10 isoleucines-are utilized in 
interhexamer contacts in the crystal and probably in solution, where hexamer 
associations occur at relatively high hexamer concentration. Interhexamer 
contacts are formed between the A14 tyrosine and A15 glutamine residues and 
between the A18 asparagine and B25 phenylalanine residues. Besides filling of 
the large hexamer pockets by AS-All loops, two B5 histidine residues from 
adjacent hexamers come into close contact (4S4). The importance of B29 lysine 
to the association of hexamers is illustrated by rat insulin n, which possesses a 
methionine at this position and which forms cubic instead of rhombo-hedral 
crystals in the 2-Zn ++ form (481). 
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Assessment of insulin aggregate behavior in established assay systems is 
precluded by the inability 1) to deliver solutions of lmown aggregate composition 
to tissues {due to probable dissociation in serum) in in vivo systems and 2) to 
obtain meaningful results in in vitro systems using the high concentrations of 
insulin at which significant proportions of aggregates occur. Thus, it is 
necessary to infer the insulin-like activity of aggregates in bioassays and 
immunoassays from lmowledge of the hormone's tertiary structure and from the 
effects of substituent alterations. 
Of the residues implicated in the dimerization face, B25 phenylalanine is 
known to be involved in the receptor binding site and the B30 residue may affect 
insulin immunoreactivity, while the A14 tyrosines, which make contact in dimer-
dimer interactions, are important immunodeterminants. Since chemical 
alteration of the A14 tyrosine leads to a 96% reduction in insulin 
immunoreactivity {see Table 1), it is expected that the insulin-like activity of the 
hexamer in immunoassays would be attenuated accordingly. A more precise 
estimate of aggregate activity in assay systems relative to monomeric insulin is 
provided by studies involving FITC-insulin conjugates. Mono-FITC insulin, which 
forms hexamers as well as native insulin, retains about 50% biologic activity 
{mouse convulsion assay) and 24-56% immunoreactivity {immune hemolysis 
inhibition); di-FITC insulin, which forms only monomers and dimers, possesses 4% 
biologic activity and 3.3-31% immunoreactivity; tri-FITC insulin, which exists 
only as monomers, exhibits no detectable biologic activity and 0.001-3.8% 
immunoreactivity {136). Thus, net values are bioactivity = 8%, IRI = 14-55% for 
di-FITC insulin and bioactivity = 0%, IRI = 0.2-6.8% for tri-FITC insulin. 
Furthermore, desoctapeptide {DOP; lacking B23-B30 residues, involved in 
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the wleated sheet structure of the dimer) and guinea pig insulins do not form 
aggregates; DOP insulin possesses 0-15% biologic activity and 0.08-11% 
immunoreactivity relative to native monomeric bovine and porcine insulins, 
while the corresponding values found for guinea pig insulin are 10% biologic 
activity and 0.001% immunoreactivity (136,138, 18, 217). Also, insulin dimers do 
not exhibit negative cooperativity, the site for which is situated in the receptor-
binding region of the monomer (217). Thus, insulin aggregates should be virtually 
undetectable by existing bioassays and immunoassays for insulin. Certainly, 
superhexameric aggregates are undetectable by these assays, since the A5 
glutamines, A19 tyrosines, A21 asparagines, and B25 phenylalanines, residues 
important to insulin biologic and immunologic activity that are exposed at the 
hexamer surface, are covered by interhexameric contacts. 
INSULIN PRECURSORS 
Pro insulin 
In 1965, Givol et al. (482) proposed the use of disulfide interchange 
enzyme as a probe for the thermodynamically most stable form of proteins. 
They based this proposition on their observation that treatment of oxidized 
native bovine pancreatic ribonuclease and chymotrypsinogen A with the enzyme 
and a thiol, such as s-mercaptoethanol ( s-ME), did not significantly alter the 
activity of the proteins (the latter measured after conversion to a-chymotrypsin 
with trypsin), while their tryptic digestion products, the three-chain "C-protein" 
derivative of RNase and a-chymotrypsin, rapidly lost activity under the same 
circumstances. The authors concluded that the primary structure of "stable" 
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single-chain protein precursors dictates a tertiary structure in which cy~teine 
residues are properly apposed to form the disulfide bonds of their products. 
ObServing that treatment of insulin with disulfide interchange enzyme and 13-ME 
results in chain separation and loss of immunoreactivity, they postulated that the 
hormone exists in a metastable state, which is the product of a "zymogen-like" 
conversion of a stable single-chain precursor. 
Within two years, Steiner and coworkers had reported the isolation of such 
a precursor from tumors of human islets of Langerhans and normal isolated rat 
islets (483,484). When slices of human islet cell adenoma were incubated with 
3H-L-leucine or 3H-L-phenylalanine, the acid-ethanol extractable material 
precipitated with ethanol-ether (see specific isolation procedures, below) yielded 
3 radioactive fractions upon Sephadex G-50 chromatography with 1 M acetic 
acid. The first, designated peak a, eluted with a large protein peak at the 
column exclusion volume. The third, peak c, eluted with a smaller protein peak 
and was identified as insulin. The second, "peak b", eluted at a position 
corresponding to a protein of molecular weight 10,800 daltons and possessed 
insulin immunoreactivity (determined as insulin-displacable anti-insulin globulin 
binding). Tryptic digestion of peak b material yielded a radioactive fraction 
eluting with porcine insulin and another, lower molecular weight, radioactive 
peak that was not seen following tryptic digestion of radiolabeled insulin. 
Column chromatography of peak b after sulfitolysis (which dissociates insulin A 
and B chains) revealed no generation of insulin chains or apparent change in 
molecular weight. Neither was insulin released from peak b material by 
extremes of pH, high ionic strength, 50% acetic acid, nor 8M urea (483). 
Incubation of tumor slices with 3H-L-leucine resulted in the appearance 
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on G-50 chromatography only of radioactive peaks a and b after 40 minutes, with 
the appearance and progressive increase in radioactive peak c after 80 minutes. 
When isolated rat islets were pulsed with 3H-L-leucine for 40 minutes, about 
'lO% of peak b radioactivity had shifted to peak c 140 minutes after a non-
radioactive leucine chase was begun, even in the presence of cyclohexamide, an 
inhibitor of protein synthesis. The investigators concluded that peak b 
represents an insulin precursor that is converted to the hormone by a proteolytic 
process in the S~ell with a half-life of about 1 hour, and termed the precursor 
protein proinsulin (484,485). 
The following year, Roth et al. (486) reported the discovery of a serum 
component that possesses insulin immunoreactivity, but elutes ahead of normal 
or "little" insulin on Sephadex G-50 columns. They found that this "big insulin" 
accounted for as much as 50% of total insulin immunoreactivity in normal human 
serum, in which the two species apparently are not easily interconvertible, since 
rechromatography of each fraction did not yield significant amounts of the other 
and addition of large quantities of pancreatic insulin to serum did not result in 
the recovery of increased amounts of "big insulin". These investigators 
demonstrated that the pancreas was the source of ''big" as well as "little" insulin 
by infusing a dog with glucose and collecting blood from the pancreatic vein and 
the femoral artery. At 10 minutes and 25 minutes after completion of the 
glucose infusion, pancreatic venous plasma had a more than 50-fold greater IRI 
concentration than did arterial plasma. At both times the concentrations of 
"little" and of "big" insulin were distinctly higher in the pancreatic effluent than 
in the peripheral arterial plasma. 
At about the same time, Steiner and coworkers demonstrated the 
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presence of proinsulin in human serum and urine by G-50 chromatography and 
RJAs for proinsulin and insulin (487). They observed that serum proinsulin, when 
tmmunoassayed in serial dilutions, showed immunologic identity with a standard 
of pancreatic human proinsulin and they provided evidence that the lower 
molecular weight product of proteolytic proinsulin conversion, known as 
connecting peptide (C-peptide), is secreted with insulin from the 13-cell in 
equimolar amounts (485). They found that, in a patient with an islet cell 
adenoma, the molar fraction of proinsulin in acid ethanol-extractable material 
reacting with anti-insulin serum was 52% for the tumor and 77% for fasting 
serum; the proinsulin fraction in serum did not exceed 10% after removal of the 
tumor (485). Berson and Yalow's group verified that high proportions of serum 
"big insulin" are largely limited to persons with insulinomas when they reported 
that, while "big insulin" comprised 24-55% serum IRI in such individuals, this 
fraction accounted for less than 20% serum IRI in 32 subjects without tumors, 
including obese normals, diabetics and myotonic dystrophy patients, and did not 
exceed 10% in 32 of 59 serum samples collected from these persons under 
diverse circumstances (488). 
Finally, Roth and coworkers (489) demonstrated that "big insulin" is 
indeed circulating proinsulin as follows: 1) when human "big insulin", isolated 
from plasma by G-50 chromatography, was mixed with 1251-porcine proinsulin 
and rechromatographed, the peaks of immunoreactivity and radioactivity were 
coincident; 2) when plasma was extracted by a method used for the isolation of 
insulin and proinsulin from pancreas, the location and relative proportions of 
"big" and "little" insulins upon G-50 chromatography were the same as those 
obtained by chromatography of whole plasma; 3) 90% of "big insulin" was 
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converted to "little insulin" by treatment with 20-200 l.l g trypsin; 4) 
trypsinization of human "big insulin" mixed with 125I~orcine proinsulin resulted 
in >90% conversion of both to "little insulin"; and 5) guinea pig anti~orcine 
proinsulin serum absorbed with porcine insulin bound both porcine proinsulin and 
human "big insulin", but not porcine insulin and human "little insulin". 
Steiner's recommended procedure for isolation of proinsulin from 
insulinoma tumor tissue is based on Davoren's insulin extraction method (108). 
About 170 mg tissue is homogenized with 2.2 ml acid ethanol (375 ml 95% 
ethanol + 7.5 ml cone. HCl) + 0.8 ml water. After 6 hours at 4°C, the supernate 
is decanted and 0.7 ml acid ethanol + 0.3 ml water is added to the precipitate. 
After 6 hours at 4°C, the second supernate is combined with the first, which are 
then clarified by centrifugation, adjusted to pH 8.3 with 6N NH40H, allowed to 
stand 15 minutes at 4°C, again clarified by centrifugation and adjusted to pH 5.3 
with 4N HCl. After addition of 0.025 ml 2M ammonium acetate per ml acid 
ethanol extract, insulin and proinsulin are precipitated with 3 volumes absolute 
ethanol + 5 volumes ethyl ether for 12 hours at 4°C. The suspension is then 
centrifuged at 4°C; the precipitate is dried and dissolved in 1-2 ml 3M acetic 
acid, followed by chromatography on a 1 x 50 em Bio-Gel P-30 column in the 
same solvent (485, 490). 
Islets of Langerhans are isolated from rat pancreas by digesting the 
minced tissue with collagenase and are extracted by homogenization in acid 
ethanol. The supernate is adjusted to pH 8 with 6M NH40H, clarified by 
centrifugation and adjusted to pH 5.3 with 6M HCl; 2 drops 2M ammonium 
acetate, pH 5.3, per ml extract are added, followed by 2 volumes ethanol + 4 
volumes ethyl ether. The remainder of the isolation procedure is the same as 
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that employed for tumor tissue (490). 
Proinsulin and various two-chain intermediate forms are most readily 
purified from commercial preparations of crystalline insulin with which they 
eocrystallize during preparation of the insulin; precursors represent 2-6% of this 
material, whereas they represent only about 0.0005% by weight of whole 
pancreas (453, 490). A crude precursor fraction is obtained by chromatography 
of the first crystals of bovine insulin on G-50 with 1M acetic acid or on P-30 
with 3M acetic acid. This fraction is then chromatographed on 
carboxymethylcellulose (CM-cellulose) with 0.01M sodium citrate, 7M urea, pH 
5.5, yielding the two proinsulin intermediates des arg31,arg32 proinsulin and des 
lys59,arg60 proinsulin. Further elu}ion of the column with 0.2M NaCl in starting 
buffer yields proinsulin and the insulin dimer, which are separated by DEAE-
cellulose chromatography utilizing a 400 ml linear gradient of o-o.2M NaCl in 
0.02M Tris-HCl, 7M urea, pH 7.6 (490). 
Chance (141) has isolated proinsulin and its intermediates from crystals of 
porcine insulin by a single chromatographic procedure on a 5 x 140 em column of 
DEAE-cellulose utilizing a 12-liter gradient of O-G.09M NaCl in 0.01M Tris-HCl, 
0.001M EDTA, 7M urea, pH 8.1. This procedure resulted in the isolation of 
proinsulin, des lys62 ,arg63 proinsulin, proinsulin split between residues leu54 and 
ala55' desnonapeptide proinsulin (lacking residues 55-63), arginyl insulin (+ 
arg31), 'and diarginyl insulin (+ arg31,arg32> (See discussion of proinsulin 
structure, below). Further purification of some of these fractions could be 
achieved by a subsequent step of gel filtration. The two rat proinsulins have 
been isolated from crystals of rat insulin using gel filtration, ion-exchange 
chromatography and preparative gel electrophoresis at pH 4.4 (111, 491). Similar 
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techniques have also been applied to the isolation of small amounts of pro~nsulin 
from the cod (492) and the angler fish (493). Aliquots of human serum (2-10 ml) 
are diluted with 2 volumes water and extracted with 7.5 ml acid ethanol per ml 
serum before purification and separation of IRI components as outlined for 
insulinoma tissue (490). 
The molecular weight of proinsulin has been found by gel filtration to be 
8,000-9,000 daltons (486-487). Based on the amino acid composition of human 
proinsulin (461), the molecular weight of this species is 9,430 daltons. 
Aggregation with increasing concentration at pH 7, equilibrium constants of self-
association at acid and neutral pH, and Zn++ -binding properties of proinsulin are 
the same as insulin under cprresponding circumstances (452). The 
physicochemical properties of proinsulin are summarized in Table V. 
An important early indication that proinsulin is a single-chain precursor of 
insulin was Steiner's demonstration of N-terminal phenylalanine in peak b 
material (483). It may be seen from the primary structure of porcine proinsulin, 
pictured in Figure 14, that the entire insulin B-chain makes up the N-terminal 
portion of proinsulin, followed by a 29-amino acid C-peptide segment, and that 
the entire insulin A-chain comprises the carboxy end of the molecule. The C-
peptide is connected to the insulin segments by two basic dipeptides that are 
readily removed by proteases with tryptic specificity. C-peptide lacks aromatic 
residues and cysteine, is largely composed of amino acids that can confer 
additional solubility on the molecule, and exhibits a high degree of variability in 
amino acid composition .among species (Fig. 15). More than half the C-peptide 
residues are variant among human, bovine and porcine proinsulins and only 5 
amino acids-which may be important to proper protein folding--are invariant 
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FIGURE 14. AMINO ACID SEQUENCE OF PORCINE PROINSULIN. 
(Reproduced, with permission from the American Diabetes Association, Inc., 
from Ref. 453. Copyright 1972 by the American Diabetes Association, Inc.) 
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FIGURE 15. THE C-PEPTIDE IN INSULINS OF VARIOUS SPECIES. INVARIANT 
RESIDUES ARE INDICATED BY BOLD TYPE, DELETIONS BY DASHES. · 
(Reproduced, with permission, from Ref. 104. Copyright 1975 by Ellis Horwood, 
Ltd.) 
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Val Pro Pro leu Glu Asp Thr Val Ala Arg 
Val Pro Ala Asp Val Ala Arg 
Asp Val Ala Ala Glu Gly Ala 
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among the mammalian species studied thus far. The two basic dipeptid~s are 
alsO invariant, reflecting the importance of enzymic cleavage by proteases with 
tryptic specificity. 
Evidence for the existence in the a-cell of additional enzymes with 
carboxypeptidase B (CPB) and perhaps chymotrypsin specificities comes from 
identification of bovine and porcine proinsulin intermediates isolated from 
crystalline insulins (453). Proinsulin intermediates lacking either dipeptide 
(arg31-arg32 or lys62-arg63 in porcine proinsulin) and monoarginine insulin (arg31 
attached to ala30 of the B chain), as well as insulin itself, suggest the action of 
enzymes with trypsin and CPB specificities. Diarginine insulin (+ arg31-arg32), 
porcine split proinsulin (leu54-ala55 bond cleaved), and porcine desnonapeptide 
proinsulin (lacks sequence 55-63) suggest the action of enzymes with trypsin, 
chymotrypsin, and both trypsin and chymotrypsin specificities, respectively. 
As mentioned previously, the fact that native insulin was recovered in 
poor yield after reformation of reduced disulfide bonds served as evidence that 
insulin is formed from a single-chain precursor protein in which the native 
hormone exists as the thermodynamically most stable conformation. Soon after 
its discovery, it was noted, in fact, that proinsulin reoxidizes in high yield after 
complete reduction by mercaptoethanol in urea (454). Furthermore, CD studies 
indicate that the conformation of insulin in proinsulin, as well as in split 
proinsulin and desnonapeptide proinsulin, is the same as in free insulin (452). 
Thus, it has been concluded that the main function of the C~eptide is to direct, 
interact and hold the A and B chains in a conformation favorable for correct and 
efficient pairing of cysteinyl residues (461). 
The fact that both proinsulin and split proinsulin possess no more than 
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one-third the biologic activity of desdipeptide proinsulin, desnonapeptide 
proinsulin and mono- and diarginine insulins (in which the A1 glycine is exposed), 
which exhibit nearly as great an activity as free insulin (Table V), serves as 
additional evidence that the a-amino group of the A1 glycine is an important 
part of the insulin active site (452). Cross-reaction of anti-insulin antibodies 
with proinsulin is highly variable, with 25-75% immunoreactivity compared to 
insulin being observed in early work (485, 488). When antibodies are generated 
against the proinsulin or C~eptide of a given species, they exhibit little or no 
cross-reactivity with proinsulins and C~eptides from other species. Antigenic 
determinants have been implicated within the 33-54 segment, a requirement for 
leu54 has been demonstrated, and the probable major antigenic determinant has 
been identified as the 41-54 sequence, which is an unusually hydrophobic region 
and also one of considerable variability among species, explaining the lack of 
cross-reactivity (461). The increase in IRI with anti-insulin serum following 
cleavage of the arg-A1 gly bond (Table V) also supports the contention that the 
C-peptide covers important insulin immunodeterminants, especially the A19 
tyrosine. 
Proinsulin Precursors 
In 1973, Yalow and Berson (494) reported the discovery of a high 
molecular weight insulin precursor in plasma samples from an insulinoma 
suspect. When the plasma was chromatographed on G-50 with 0.02M veronal 
buffer, pH 8.6, 45-100% of the IRI eluted in the exclusion volume. This material, 
designated "big, big" insulin", behaved similarly to y -globulin in gel 
chromatography and exhibited a sedimentation velocity between y -globulin and 
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albumin in ultracentrifugation, indicating a molecular weight of 100,000-1.50,000 
daltons. "Big, big" insulin has about one-half the mobility toward the anode of 
porcine or crystalline human insulin on starch gel electrophoresis and exhibits 
about one-third the mobility of crystalline human insulin on starch block 
electrophoresis, indicating that it is more basic than insulin. This protein 
exhibited complete cross-t'eactivity with insulin for guinea pig anti-insulin 
antibody binding sites and was more than 80% convertible to insulin by trypsin 
treatment. These investigators found that "big, big insulin" comprised 0.7-1.0% 
of the IRI extracted from human insulinoma and normal pancreatic tissue with 
acid ethanol and subjected to G-50 chromatography under the same conditions as 
the plasma samples. 
Identification, isolation and study of the human insulin gene and its 
messenger RNA (mRNA) product have revealed the true proinsulin precursor, 
termed preproinsulin, to be proinsulin with an additional 24-amino acid N-
terminal extension, which serves as a signal peptide to direct the molecule to the 
secretory machinery of the f3 -cell (495). The molecular weight of human 
preproinsulin, based on its 110-amino acid sequence, is 11,981 daltons. 
Therefore, "big, big insulin" cannot be a proinsulin precursor and most likely 
represents an aggregate form of proinsulin, since Yalow and Berson carried out 
their G-50 chromatography at pH 8.6 and they did not detect IRI where 
proinsulin would be expected to elute (494). 
The 330-nucleotide sequence for preproinsulin is completely contained 
within the human insulin gene, but in a discontinuous fashion. The mRNA 
sequence consists of 465 nucleotides, the first 59 and last 76 of which are 
untranslated, completely contained within a 1,431-nucleotide precursor (nuclear) 
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RNA sequence, which represents the immediate transcription product of the 
insulin gene. In the insulin gene, the mRNA sequence is interrupted after the 
42nd nucleotide by the first of two intervening sequences, which consists of 179 
nucleotides. The second intervening sequence, comprising 787 nucleotides, 
begins after the 246th mRNA nucleotide, which is the first nucleotide coding for 
the va163 of preproinsulin. The complete insulin gene consists of 1,726 
nucleotides, the first 260 of which comprise a "cap site" and the last 35 of which 
comprise a termination site, both untranscribed (495). 
Insulin Biosynthesis 
The present understanding ()f insulin synthesis in the pancreatic s-cell is 
as follows: 
1. The insulin gene is transcribed into a precursor RNA that is clipped and 
spliced in the nucleus to yield a messenger RNA (495, 496). 
2. The messenger RNA (mRNA) is translocated to the rough endoplasmic 
reticulum (RER), which is contiguous with the nuclear membrane. There, the 
central portion of the mRNA is translated by polyribosomes into preproinsulin 
(495-497). 
3. The amino-terminal "signal peptide" of preproinsulin enables the molecule to 
be secreted into the cisternae of the RER and directed in an energy-requiring 
step to the Golgi apparatus. The signal peptide is removed from preproinsulin 
very soon after its synthesis; in the rat, conversion of preproinsulin to proinsulin 
proceeds with a half time of about 1 minute (495-497). 
4. By the time proinsulin is packaged into vescicles in the Golgi apparatus, the 
molecule has folded into its proper conformation and disulfide bonds have been 
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formed. The vescicles, which contain immobilized on their inner membrane 
surfaces proteases with the specificities of trypsin, carboxypeptidase B and 
chymotrypsin, bud off from the Golgi apparatus (496, 497). 
s. As the vescicles traverse the cytoplasm, the proteases convert proinsulin to 
insulin through split proinsulin and arginyl insulin intermediates. The newly 
formed insulin condenses into hexameric crystals, receding from the edge of the 
vescicles and terminating the enzymic reactions before the hormone can be 
degraded to its desalanine and desoctapeptide forms (104, 496, 497). 
6. At the S-cell periphery, mature vescicles, termed secretory granules, fuse 
with the plasma membrane and release their contents-equimolar quantities of 
insulin and C-peptide and so~e unreacted proinsulin-into the lumen 
(emiocytosis), from whence they are transported into the systemic circulation 
(104, 485, 498). 
Insulin synthesis-from preproinsulin to mature secretory granules-
requires about one hour (497). An increase in the extracellular concentration of 
glucose-the most important signal for insulin secretion from S -cells-
stimulates this process at both translational and emiocytotic levels, independent 
of cAMP (497 ,499,500). Glucose stimulation of insulin release, but not 
biosynthesis, is Ca ++-dependent (497). Insulin secretion and biosynthesis can be 
stimulated further in the presence of glucose through activation of the &-cell 
adenylate cyclase system by glucagon and S-adrenergic agonists (497). 
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"BOUND INSULIN" 
The phenomenon of "atypical" insulin-like activity (ILA) was recognized 
with the development of bioassays sufficiently sensitive to measure insulin in 
serum or plasma. Using both in vivo and in vitro assays, Beigelman and 
coworkers detected ILA in f3.-globulin fractions prepared from human peripheral 
venous serum by fractional precipitation and paper electrophoresis {501-504). 
The ILA was measured by blood glucose decrement in alloxan-diabetic 
hypophysectomized {ADH) mice and stimulation of glucose uptake in rat 
epididymal fat pads. Randle and Taylor demonstrated anti-insulin serum {AIS)-
neutralizable ILA in these serum fractions by stimulation of glucose uptake and 
glycogen synthesis in isolated rat diaphragm (505-507). That the s-globulin 
form of ILA may be a transport form of insulin was suggested by the observation 
that in two samples of plasma from portal venous blood most of the ILA was in 
the albumin- a1 globulin fraction (116), an observation indicating that insulin 
may be secreted in the free form by the pancreas and become incorporated 
elsewhere into the 8-globulin fraction. 
Beigelman et al. found that Cohn Fractions IT + lll and m-o, and the 
Plasma Globulin Precipitate fraction (PGP) obtained by zinc precipitation from 
blood plasma collected in acid-citrate-dextrose solution (ACD), possessed ILA 
measured in vivo (ADH rats), but that identical plasma fractions obtained from 
blood collected not in ACD, but through cationic exchange resin were devoid of 
ILA (501,502). Antoniades and coworkers found that when human whole blood or 
serum was passed through Dowex 50 x 8 or 50 x 2 or IRC 50 cation exchange 
resins, while typical insulin was not retained by the resin, a considerable quantity 
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of ILA was retained and eluted from the resin by acid (0.1N H2so4, 0.1N HCl or 
0•2M citrate, pH 2-3) or alkali (0.1 or l.ON NH40H, pH 10.5-11) (247 ,508-510). 
This ILA, which Antoniades designated "bound insulin" (BI), was measured by 
induction of hypoglycemia in ADH rats (508, 509) and stimulation of 14co2 
production from glucose-1-14c by rat epididymal adipose tissue (509, 511); BI 
ILA in the fat pad was abolished by 20-40 mM reduced glutathione (511). 
Furthermore, this ILA was found to stimulate incorporation of uniformly labeled 
glucose carbon into muscle and adipose tissue glycogen and into fat of adipose 
tissue in intact rats (512) and into fat and glycogen of isolated rat epididymal 
adipose tissue (511). BI was observed to migrate in electrophoresis with a 
mobility similar to B-and y-globulins, to possess a molecular weight between 
60,000 and 100,000 daltons by Sephadex gel chromatography, and to precipitate 
with Cohn Fractions D + ID and m-o (compared with endogenous typical insulin 
activity, which is found in Cohn Fractions D + ID, IV-1 and V) (511-513). Unlike 
the B-globulin ILA described by Beigelman and Randle and Taylor, however, BI 
is virtually undetectable by glucose uptake in the isolated rat diaphragm and is 
unreactive with anti-insulin antibodies (247 ,509,512,514). 
Antoniades, however, observed an increase of BI ILA in the rat diaphragm 
assay after various treatments of the fraction. Treatment with acid (0.2M 
citrate, pH 2-3) or alkali (pH 9.8), an aqueous extract of rat adipose tissue, or 
acid-ethanol produced a many-fold increase in BI ILA measured by this assay 
(509,511). The diaphragm ILA increment induced by pH extremes (with 
subsequent neutralization) was especially pronounced when followed by 
centrifugation, leading Antoniades to conclude that such treatment liberated 
free insulin from an insulin-protein complex by rendering the cationic carrier 
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protein insoluble (509). A maximum adipose tissue extract (ATE)-induced 
increment in diaphragm assayable BI ILA was obtained after 30 minutes 
preincubation of the BI fraction with ATE, which exerts no effect on the ILA 
exhibited by crystalline insulin in the diaphragm assay (514). The BI ILA 
increment increased progressively with increasing ATE protein concentration, 
attaining a maximum of about 1,000 \.J U/ml eluate at an ATE nitrogen content 
of 18\.Jg/ml incubating medium (514). Further purification of ATE revealed that 
the factor responsible for the ILA increment migrates in electrophoresis with 
albumin and the a 1-globulins (514) and is heat stable, suggesting a small 
molecule (512). 
Examination of the soluble and insoluble products of resin eluates 
subjected to pH extremes provided further evidence for an insulin-protein 
complex. ILA remaining in the supernate of BI fractions treated with citrate, pH 
2.0, migrated on paper electrophoresis at pH 7.6 as an anion, in the albumin/ a1-
globulin zone (as does typical insulin), and exhibited a molecular weight below 
40,000 daltons by gel chromatography (509,512). the redissolved (O.lM acetate 
buffer, pH 4.0) precipitate obtained from BI fractions adjusted to pH 9.8 
migrated on paper electrophoresis, pH 7 .4, anodally toy-globulins and stained 
with ninhydrin, suggesting a very cationic protein with an isoelectric point near 
10 (509). The supernatant ILA was neutralized by anti-insulin serum (AIS), 
indicating that this, indeed, represented free insulin (509). No change in the 
diaphragm-assayable ILA of BI incubated with rat adipose tissue and AIS less 
than 2 hours was seen, but a significant decrease of ILA, which became greater 
with incubation time, occurred after 2 hours (511). A significant decrease in ILA 
of acid ethanol extracts of BI fractions was observed in the presence of AIS 
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within 90 minutes (511). This finding should be contrasted with the potentiation 
of Bl diaphragm-assayable ILA after treatment with acid ethanol. 
Antoniades postulated conversion of "free" to "bound" insulin in the liver 
(512), but was unable to demonstrate binding of exogenous radiolabeled insulin to 
a cationic protein in vitro or in vivo. Human serum incubated directly with 1311-
insulin or obtained from nondiabetic subjects injected with 1311-insulin showed 
no significant loss of radioactivity after passage through cation exchange resin 
(509). He determined the mean concentration of BI (400 \.lU/ml) in fasting 
nondiabetic humans to be about 10 times that of free insulin (512). It is 
noteworthy that insulin-antibody complexes were not absorbed by the cation 
exchange resin (509). 
Confirmation of Antoniades' observations came with the work of Shaw and 
Shuey, who demonstrated an AIS-neutralizable ATE-induced 12-fold increase in 
normal fasting human serum ILA, from 50 \.l U/ml to 600 ).JU/ml, measured by 
both glucose uptake and glycogen synthesis in the rat diaphragm (390). They 
obtained essentially the same results with a serum BI fraction eluted from 
Dowex 50w-x8 with 0.02M NH40H. Gundersen and Lin extended the concept of 
bound insulin by demonstrating that heparin also causes increase of BI ILA in the 
rat diaphragm to about that found with the fat pad assay (391). They found that 
addition of AIS to Bl-heparin mixtures decreased diaphragm-assayable ILA 24-
95% and fat pad-assayable ILA 25-80%. These investigators also showed a 
striking increase of ILA with dilution (to 1:8) of normal and diabetic human 
serum in both the diaphragm and fat pad. Heparin increased the ILA of dilute 
serum 8-fold in the diaphragm, but not in the fat pad. 
Several investigators pointed out apparent contradictions in the data of 
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proponents of bound insulin, however. Berson and Yalow (515) noted that the 
results of Antoniades and coworkers in three separate reports show that total 
plasma insulin ("bound" plus "free") decreases strikingly after intravenous glucose 
administration and that earlier observations by Valiance-Owen et al. (516) 
demonstrated high insulin concentrations in plasma of diabetic subjects by the 
rat diaphragm without ATE. Using rat diaphragm assays based on glucose uptake 
and glycogen production, the latter 25 times more sensitive than Antoniades' 
assay, Meade et al. (517) obtained ILA values for BI fractions intermediate 
between what Antoniades observed with and without ATE and were unable to 
increase the ILA by treatment with ATE, acid alcohol, alkali or heparin. These 
investigators also found no ILA in, vivo (mouse hypoglycemia) for BI fractions, 
whether prepared by themselves or obtained from Antoniades, they reported that 
different batches of Dowex 50-xS or 50w-x8 resin did not always yield BI, and 
they pointed out that dialysis tubing-if not properly prepared-could contribute 
to ILA. Anderson et al. (518) have extracted insulin from plasma under 
conditions that presumably would dissociate BI and found with an in vivo assay 
that the concentration of plasma insulin in the fasting dog is only 30 ).JU/ml. 
Christopher et al. (519) demonstrated that the significant quantities of 
diaphragm-assayable ILA that could not be increased by ATE, acid alcohol, alkali 
or heparin found by others in BI fractions could be due to prolonged alkalinity of 
eluates, which would lead to irreversible dissociation of BI. These investigators 
first demonstrated a 4-fold increase in undialyzed human plasma ILA (measured 
by glucose uptake in the rat diaphragm) by ATE (which exerted no effect on 
crystalline insulin ILA) to a level about equal to dialyzed plasma ILA, which was 
further increased 2.5-fold by ATE. Plasma BI fractions eluted from Dowex 50 x 
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8 resin with 0.1N NH40H, however, exhibited high ILA that could not be 
increased significantly by ATE. When the plasma was incubated 15 minutes at 
pH 10, followed by neutralization, passage through the cation exchange resin and 
alkaline elution, about 90% of the BI ILA shifted to the plasma-saline effluent 
(not adsorbed), providing additional evidence that BI represents ILA bound to a 
cationic substance. 
By 1965, proof of BI awaited only two developments: 1) demonstration of 
JRI by RIA following treatment of BI fractions in a way known to release "free" 
insulin, the ILA of which had been reported to be AIS-suppressible; and 2) 
demonstration of reversible binding of exogenous radiolabeled insulin to a serum 
protein. The latter development appeared to be achieved when several 
investigators reported migration of radioactivity with o. - and e-globulins 
following incubation of exogenous radiolabeled insulin with human serum. Using 
immunoelectrophoresis and radioautography, Clausen et al. (520) demonstrated 
binding of 1251-insulin to a 2- and ~~macroglobulins. Mitchell (521) showed 
that, while 1311-insulin alone migrated just behind albumin on cation exchange 
resin paper electrophoresis and with the e -/ y -globulins after incubation with 
AIS, the radioactivity was associated with the o.-/ S-globulins after incubation 
of the radiolabeled hormone with normal human serum. Prout et al. (522) found 
that 1311-insulin alone migrated ahead of albumin on agar electrophoresis, but in 
both agar- and immunoelectrophoresis followed by radioautography the 
radioactivity migrated with y-globulins after incubation of 1311-insulin with AIS 
and with o. 1-globulins after incubation with normal human serum. 
In several reports and reviews, however, Berson and Yalow dealt a serious 
blow to the concept of bound insulin from three directions: 
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1. Demonstration that association of radioactivity with serum protein fr:actions 
following incubation of exogenous radiolabeled insulin with human serum 
represents irreversible binding of "damaged" insulin to proteins and thus 
constitutes an artifactual observation. Berson and Yalow reported that the 
labeled insulin~rotein species observed in the studies mentioned above fail three 
primary criteria of physiologically significant hormone~rotein association: a) 
reversibility of binding, indicated by release of free labeled insulin upon addition 
of a large excess of unlabeled (cold) insulin; b) competitive inhibition of binding 
with cold insulin; and c) demonstration of labeled insulin binding to protein in 
vivo, following injection of the labeled hormone into an animal (515). Observing 
that insulin may be damaged during the radiolabeling procedure and during 
incubation with plasma, Berson and Yalow found that incubation-damaged 
radiolabeled insulin binds to a-globulins and albumin in a non-saturable and 
irreversible manner and that nearly all 131I-insulin may be damaged if incubation 
with plasma is sufficiently prolonged (515). They showed that, when care is 
taken to avoid artifactual results due to insulin damage, labeled insulin in buffer 
or normal human plasma migrates just behind albumin on starch block 
electrophoresis and is adsorbed at the site of application on paper 
electrophoresis (409). In addition, 1311-insulin sediments in the ultracentrifuge 
with the same velocity in the presence or absence of plasma (410). 
2. Inability to enhance IRI by methods employed to release "free" insulin from 
BI. Berson and Yalow (523) incubated fasting sera from 5 diabetic and 5 non-
diabetic subjects with ATE according to the method of Antoniades and were 
unable to find any increase in plasma insulin as measured by immunoassay. 
Meade et al. (524) found that serum or pancreatic extract IRI is not changed by 
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passage through a cation exchange column. Also, the cation resin eluate did not 
yield any IRI, either before or after attempts to convert "bound" to "free" 
insulin. Furthermore, Leonards (397) reported that AIS had little or no effect on 
normal human serum ILA. 
3. Inconsistencies between the concept of bound insulin and established 
observations. Plasma levels of ILA do not change following total 
pancreatectomy (515} and are then increased after glucose administration, 
despite symptoms of severe diabetes and complete absence of plasma IRI (398), 
suggesting that BI ILA is of extrapancreatic origin. Total serum insulin activity 
(TSIA, which is the diaphragm-assayable ILA found after treatment of plasma 
with acid alcohol and dialysis, yielding an insoluble suspension in which the 
diaphragm is incubated} exceeds 3 mU/ml plasma (525, 526}. Yet, Froesch et al. 
(527} reported human serum concentrations of AIS-suppressible ILA (measured by 
the rat fat pad assay} in the fasting state and after glucose almost identical to 
those found by RIA. Calculations of normal daily insulin secretion rates on the 
basis of these values and the kinetics of insulin metabolism yield estimates of 
about 50 U/day, about equal to the insulin requirements of totally 
depancreatized subjects (528, 529}. Berson and Yalow (528} also pointed out that 
the physiologic properties on insulin, namely a biologic half-life of less than 40 
minutes, which is consistent with the short-lived effects of exogenous insulin in 
vivo and the rapid onset of diabetic symptoms after pancreatectomy, are 
inconsistent with two protein-hormone models: a) thyroxine, which is 
transported by thyroxine-binding globulin in the blood. The biologic half-life of 
thyroxine is about one week and the onset of the symptoms of hypothyroidism 
occur weeks after thyroidectomy; and b) diabetics with severe insulin resistance 
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due to large concentrations of serum anti-insulin antibodies may requir~ very 
large doses of exogenous insulin for control of an acute episode of ketosis, 
following which, in the absence of any further insulin therapy, repeated insulin 
reactions may occur for days as a result of slow dissociation of insulin-antibody 
complexes. Finally, Sheps et al. (396) reported that some plasma ILA persists 
after treatment of plasma with reduced glutathione. 
Recently, however, Guenther (387) reported an increase in the IRI of BI 
fractions following treatment with heparin. He also demonstrated an increase of 
the diaphragm-assayable ILA of these fractions by biotin, implicating the 
vitamin as the active factor in ATE. Since Guenther utilized gentler cation-
exchange methods for the isolation of BI than those employed previously by 
Antoniades and others and since heparin had not been used in previous studies of 
BI IRI, the entire question of the identity of BI has again been opened to dispute. 
THE SYNALBUMIN INSULIN ANTAGONIST 
An alternate explanation for the observations leading to the postulation of 
bound insulin was advanced by Valiance-owen and coworkers based on the 
existence in blood of a substance that antagonizes the effect of insulin on 
diaphragm muscle. These investigators found significant insulin antagonism in 
this system by albumin precipitated with trichloroacetic acid from the plasma of 
nondiabetic and diabetic humans and normal cats (530-532). This antagonist, 
which they termed the "synalbumin insulin antagonist" (SIA) (533), was noted at a 
concentration of 1.2596 albumin derived from prediabetic and diabetic humans 
and 3.5-5.596 albumin derived from normal humans and cats (530-532, 534), but 
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not in 1.25% albumin from normal humans or in whole plasma from. obese, 
untreated diabetic and normal humans (383, 516, 530, 534). The SIA was noted, 
however, in the whole plasma of cats after pancreatectomy, leading Valiance-
Owen to conclude that normally SIA in whole plasma is completely masked by 
the production of adequate amounts of insulin by the pancreas (535). Since 3.5-
5.5% normal human plasma albumin completely inhibits the effect of 1,000 )..1 U 
insulin/ml on the diaphragm (531), normal human plasma apparently contains 
more than 1 m U insulin/ml, a conclusion consistent with the observation of 
Gundersen and Lin (391) that 8-fold dilution of normal and untreated diabetic 
sera yielded diaphragm-assayable ILA up to 780 and 2,100 lJ U/ml, respectively. 
Valiance-Owen and Lilley (532) reported that the albumin of two 
adrenalectomized patients was free of SIA, but in one case the antagonist 
appeared after treatment with cortisone. Valiance-Owen et al. also noted that 
the SIA disappears from the albumin of diabetic and nondiabetic humans 
following hypophysectomy (531), but Lowy et al. observed no change in SIA after 
hypophysectomy or pituitary destruction by other means and demonstrated no 
effect of albumin fractions on fat~ad assayable ILA (536). Thus, the SIA 
appears to be adrenal glucocorticoids, which are lmown to antagonize insulin-
stimulated glucose utilization by muscle (537) and which are transported in blood 
by albumin and transcortin, an a-globulin (538). 
The observation that SIA inhibits insulin action on muscle, but not on fat 
led to development of the concept that a protein-bound form of insulin in serum 
may be alternatively explained by the presence of SIA (539). When Valiance-
Owen and coworkers repeated Antoniades' experiment with serum, they found 
diaphragm-assayable ILA in the 0.1M NH40H eluate from Dowex 50-x8 resin 
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without the use of ATE. Reasoning that this ILA may represent dissociated 
"free" insulin, these investigators reapplied the neutralized eluate to the resin, 
but the ILA was again retained by the resin and NH40H elution once more 
yielded an AIS-suppressible, ATE-independent diaphragm-assayable ILA. Since 
preincubation of serum with AIS yielded no detectable ILA upon Dowex cation 
exchange resin chromatography, even in the presence of ATE, there arose the 
possibility that insulin itself may behave like a cation under the conditions of the 
experiment. They found that insulin behaves like an anion, passing through the 
resin, above pH 7 .0, but behaves like a cation and is retained by the resin below 
pH 6.6. This was verified by the observation that crystalline insulin, when 
submitted to electrophoresis, behaves like an anion above pH 6.8 and like a 
cation below pH 6.6. Furthermore, 16% of exogenous insulin added to serum was 
eluted from the resin with NH40H by the method of Antoniades (539). 
The SIA was also retained by Dowex cation exchange resin and eluted with 
NH40H. The antagonist was inactivated by preincubation with diaphragm or 
adipose tissue and with alcoholic extracts of adipose tissue (ATE) or muscle 
(MTE). It was noted that subsequent to incubation with ATE or MTE SIA eluted 
from the resin with NH40H was inactivated. Following incubation of serum with 
ATE or MTE, a significant elevation in glucose uptake by diaphragm muscle 
above serum controls was observed (539). Interpretation of Antoniades' results in 
terms of inactivation of SIA is contradicted, however, by persistence of serum 
ILA following pancreatectomy (515). 
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ATYPICAL INSULIN 
Approaching the problem from a different direction, Samaan, Fraser and 
coworkers concluded that a protein-bound form of insulin exists in the peripheral 
circulation after observing that only 30% of fat pad-assayable ILA (measured by 
conversion of 14c-glucose to 14co2 or 
14c-fatty acids) in human peripheral 
venous blood is AIS-neutralizable while about 90% of portal venous serum ILA 
was neutralized (540, 541). These investigators pointed out that, although the 
majority of peripheral serum fat pad-assayable ILA cannot be neutralized by a 
quantity of AIS capable of neutralizing 300 m U typical insulin, this entity, which 
they termed "atypical insulin" (AI)', increases the conversion of glucose to C02 
and fatty acids by adipose tissue, is acid ethanol extractable (during which some 
AI is converted to typical insulin), is abolished by 0.04 M cysteine, and is 
eliminated--along with typical insulin-from the circulation of the rat by 
injection of AIS, indicating that AI contains typical insulin (541, 542). Consistent 
with an insulin-binding protein being produced in the liver, AI was found to be 
low in liver disease, while typical insulin levels are normal or slightly elevated 
(542). AI levels were found to be one-third normal in juvenile ketotic diabetics, 
lowered in thin adult diabetics, and very high in obese adult diabetics (542). 
Samaan et al. (543) concluded that BI and AI are not the same, however, 
after observing that serum AI ~ncreases after glucose administration whereas BI 
decreases. Other observations also indicated that AI may not contain typical 
insulin. Although 90% of portal venous serum ILA is AIS neutralizable, total ILA 
concentration at this site is 5 times that of peripheral circulation, meaning that 
AI concentration is about the same in both. Likewise, infusion of 40-60 U insulin 
188 
into dogs resulted in a 100-300% increase in AI levels, but the increase in .AI was 
only 2-4% as great as the increase in typical insulin (385). Fraser and Samaan 
reported that pancreatectomy of dogs leaves some, but a reduced level of serum 
AI, along with diabetes mellitus of varying severity (542), while Leonards and 
coworkers (397, 544) found that plasma AI persisted at least 16 days after 
pancreatectomy of dogs. Also, there is little change in serum AI during glucose 
tolerance tests (542). On the other hand, hypophysectomy of dogs resulted in a 
40% reduction in serum ILA from the average preoperation value of 463 J.l U/ml 
(545), indicating a pituitary involvement. 
NONSUPPRESSffiLE INSULIN-LIKE ACTIVITY (NSILA) 
By far the most extensive investigation of atypical serum ILA has been 
carried out by a group of Swiss scientists, most notably E.R. Froesch, who 
termed fat pad-assayable (net gas exchange and glucose uptake) serum ILA in the 
presence of an excess of AIS "nonsuppressible insulin-like activity" (NSILA) 
(527). Only 7% (mean = 13 JJU/ml, range = 0-93 JJU/ml) of normal fasting 
human serum ILA (mean = 180 JJU/ml, range = 68-587 JJ U/ml, n = 22) is AIS 
suppressible (SILA) and presumably represents pancreatic IRI, since serum levels 
of SILA compare well with RIA-assayable serum insulin and nuctuate with 
varying physiologic and pathologic conditions as expected for typical insulin (527, 
546). Serum levels of NSILA don't change under physiologic or pathologic 
conditions and the species doesn't disappear after pancreatectomy (although it 
decreases considerably after alloxan induction of diabetes in rats), indicating 
that NSILA does not mimic insulin's effects in vivo (527, 546). Human studies 
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indicate that exogenous insulin is not converted to NSILA in vivo (527). 
When acetone powders prepared from lyophilized human plasma or Cohn 
fraction B, which lacks albumin and gamma globulins, were treated with acid 
ethanol, it was found that 5-10% of NSILA was soluble and this species was thus 
designated NSILA-8 (546-548). The NSILA-8 was eluted from Sephadex G-75 
with 5M acetic acid/0.15M NaCl in a sharp protein peak corresponding to 
molecular weight 6,000-10,000 daltons. When NSILA-8 was chromatographed on 
Sephadex G-100 in 0.1 M ammonium acetate, pH 7 .2, it eluted in a broad peak, 
corresponding to a protein of molecular weight 50,000-70,000 daltons. When 
rechromatographed on G-75 at neutral pH after treatment with 5M acetic 
acid/0.15M NaCl, this material eluted as a protein of molecular weight 6,000, 
indicating binding to a carrier protein rather than aggregation (547). NSILA-8 
was later determined to be a heat-stable (80°C, 3 hours) single-chain polypeptide 
of 7,500 daltons molecular weight that is 40-50% inactivated by glutathione, but 
is not inactivated by rat liver (546, 547). 
Acid ethanol-precipitable NSILA (NSILA-P), which accounts for more than 
90% serum NSILA, was found to be a heat-labile (inactivated at 80°C in 15 
minutes) protein of 100,000-150,000 daltons molecular weight that is not 
convertible to NSILA-8 and is not dissociable by acid, urea or EDTA, but is more 
than 90% inactivated by mercaptoethanol and urea (546, 547). While only 0-10% 
NSILA-P was retained by Dowex 50 cation exchange resin, 27-80% of NSILA-8 
was retained and two-thirds of the serum ILA eluted from Dowex 50 with 0.02M 
NH40H eluted from G-75 with 5M acetic acid-D.15M NaCl at the same column 
volume as NSILA-8 (547), indicating that Bl may be NSILA-8. 
NSILA-8 has been characterized more extensively than NSILA-P. In 1976, 
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Rinderknecht and Humbel (549) reported the results of a systematic purification 
and characterization of NSILA-S. Starting with a crude extract that contained 
50-80 mU NSILA-8/g, they achieved about 150-fold purification with a yield of 
85% by extraction with 0.5M acetic acid followed by G-75 chromatography in 
0.5M acetic acid. Chromatography on G-50 with 1M acetic acid yielded at least 
80% of starting NSILA-S with an average specific activity of 30 mU/mg. When 
this material was subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), 55% of total NSILA-S activity was recovered in a 
single fluorescamine-positive band. This product, with a specific activity of 300 
mU/mg, exhibited a molecular weight of 5,500-5,800 daltons by Bio-Gel A-5m 
chromatography in 6M guanidine HCl, G-50 chromatography in 1M acetic acid, 
and SDS-P AGE. No change in molecular weight was noted after reduction with 
dithiothreitol. The isoelectric point of NSILA-8 was found to be 8.2 ± 0.4. 
Ion-exchange chromatography of this material on SE-Sephadex C-25 with 
a gradient of 0.05M pyridine-acetate, pH 2.5/2.0M pyridine-acetate, pH 5.0, at 
55°C yielded two NSILA peaks. The less cationic protein was termed NSILA I 
and the more cationic fraction, after further purification by gel electrophoresis 
at pH 4.3, was termed NSILA II. Both purified NSILAs possessed a specific 
activity of about 400 mU/mg and together represented about 30% of starting 
activity. Both proteins lack histidine and tryptophane. NSILA II also lacks 
methionine. Each form of NSILA-8 was found to contain 4 cysteines per 
molecule, but no free sulfhydryl groups, indicating 2 intrachain disulfide bonds. 
Amino acid analysis also indicated a molecular weight of 5,757 daltons for NSILA 
I and 5,904 daltons for NSILA II. Biological activity of the polypeptides was fully 
conserved after heating to 70°C at pH 7.6 for 15 minutes, exposure to 8M urea, 
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6M guanidine HCI or 0.1% SDS, storage in 50% acetic acid at 4°C for several 
weeks, or repeated freezing and thawing, but was abolished by oxidation· with 
performic acid or reduction and alkylation with iodoacetate or ethyleneimine, 
indicating that the disulfide bonds are necessary for the molecules' biological 
activity. 
Determination of the amino-terminal sequences (the first 31 residues of 
52 for NISLA I and 53 for NSILA ll) of the two polypeptides revealed 73% 
identity between them through residue 30 and 47% homology between NSILA I 
and the human insulin B chain. The only B-chain invariant residue substituted in 
NSILA-8 is tyr 16. Changes in conservatively variant insulin residues include the 
B10 histidine and the B14 alanine, suggesting that NSILA-8 does not form 
aggregates in the presence of zinc, and B5 histidine. The degree of similarity 
(50%) between insulin B chains of man and coypu is the same as that between 
coypu insulin B chain and NSILA n and the highest degree of sequence identity 
(57%) is found between NSILA I and tuna fish insulin, indicating that NSILA-S 
and insulin diverged after duplication of an ancestral gene early in vertebrate 
evolution (549, 550). 
Complete sequencing of NSILA I, which was found to contain 70 amino 
acids, revealed two segments having nearly 50% (24/51) homology with the 
porcine insulin A and B chains (5-25 :::B6-B26, 42-61 :::A1-A20) with a 12-residue 
"connecting peptide" showing no homology with proinsulin and an extra 8 residues 
at the carboxy terminus (551). The arrangement of cystines in NSILA I is 
identical to that of insulin and 17 of 19 invariant insulin residues are retained. 
The homology of NSILA I to porcine insulin thus found is intermediate between 
hagfish insulin and relaxin. Insulin residues involved in dimerization are 
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conserved or are conservatively substituted in NSILA I, but B10 histidine is 
changed to glutamate 9 and 3 of 10 dimer-dimer contacts are significantly 
changed, suggesting that NSILA I probably forms dimers but not hexamers. 
The lack of NSILA immunoreactivity with AIS is explained by the fact 
that the antibody-binding regions are much altered: B5 histidine corresponds to 
threonine 4, A14 tyrosine corresponds to arginine 55, and A19 tyrosine, 
corresponding to tyrosine 60, is probably covered by the C-peptide and the 
carboxy extension. Eight of eleven receptor residues are conserved or are 
conservatively varied, but the A1 and A21 residues are not terminal. Alteration 
of these residues has resulted in retention of no more than 2% insulin bioactivity 
(see Table 1). Using computer graphic programs, Blundell et al. (551) were able 
. --
to construct a three-dimensional model of NSILA I very similar to the tertiary 
structure of insulin and possessing the same hydrophobic core. 
NSILA-8 mimics most of insulin's effects on adipose tissue and muscle in 
vitro and in vivo (552, 553). It stimulates glucose transport, C02 production and 
lipogenesis while inhibiting lipolysis, glycogenolysis and epinephrine action, 
including cyclic AMP release, in adipose tissue (527, 548, 554), and stimulates 
glucose transport and glycogen synthesis in muscle (554). NSILA-8 exhibits 20% 
of insulin activity in stimulating glucose transport in heart muscle (548), but the 
highest nonsuppressible fat pad ILA found for this species is 470 mU/mg (555), 
indicting that NSILA-8 possesses about 2% insulin activity in adipose tissue (548, 
549). This fact and the finding of normal levels of NSILA-8 in the sera of 
diabetics suggest that this substance does not exert an important physiologic 
insulin-like effect (527, 556, 557), although intravenous injection of NSILA-8 into 
normal and adrenalectomized rats elicited hypoglycemic responses (558, 559). 
193 
Other studies, however, suggest that the physiologic role of NSILA-8 is 
that of a growth factor. This substance has been found to be a potent sulfation 
factor in both chick and rat cartilage {560, 561), being 50-100 times more 
effective than insulin in stimulating [ 35s] sulfate, [ 3H) uridine and [ 3H] 
or [14cl leucine incorporation into chick cartilage and activity of ornithine 
decarboxylase {549, 561, 562). NSILA-S is also 20 times more potent than insulin 
in promoting DNA synthesis, cell proliferation, glucose uptake and lactate 
production in cultured chick embryo fibroblasts {527). Thus, NSILA-S is 
effective as a growth factor at concentrations of 0.1-10 lJU/ml, while exerting 
insulin-like effects at concentrations greater than 10 J.J U/ml {557). 
Poffenbarger {563) systematically characterized what he termed serum 
nonsuppressible insulin-like protein {NSILP), which apparently corresponds to 
NSILA-P. He isolated a NSILA protein of molecular weight 90,000 daltons, 
which under reducing conditions exhibited 2 SDS-P AGE bands corresponding to 
molecular weights of 42,000 and 56,000 daltons. NSILP has a pi of 6.2, Stokes 
radius of 42.7 A, s2o,w=4.27 x 10-
13 sec., carbohydrate content of 16%, and 
partial specific volume of 0.724 ml/g. Amino acid analysis revealed a relatively 
high proportion of glutamic acid {or glutamine), glycine, arginine and 
tryptophan. A NSILP immunoassay indicated a normal human serum 
concentration of 1.2 J.Jg/ml and anti-NSILP serum suppresses 70-80% total serum 
ILA. 
Reber and Liske {564) developed an RIA for NSILA-s that exhibited a 
sensitivity of 150 pg/ml {0.07 J.J U/ml), an intraassay variation of 8.3% and an 
interassay variation of 16.8%. They found a range of human plasma NSILA-s 
concentrations of <0.15-25 ng/ml (11.8 J.J U/ml; mean = 4 ng/ml, or 1.9 J,JU/ml) 
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for adults and <0.15-20 ng/ml (9.4 J..!U/ml) for children. These values are about 
10-20% of those determined by bioassay (527, 546). RIA of acid-ethanol extracts 
of human plasma, however, yielded a tenfold higher concentration of NSILA-8 
(564), again suggesting the existence of a plasma carrier protein for this 
substance. In contrast to humans, plasma NSILA-S in rats declines from about 20 
ng/ml at 2 weeks of age to about 8 ng/ml at 4 weeks and then rises steadily to 
about 60 ng/ml by 6 months (564). Displacement of 1251-NSILA-8 from antibody 
by goat, dog, rat and human plasma parallels the human NSILA-S standard dose-
response cu~ve, indicating that this compound is immunochemically very similar 
in all these species and thus is highly conserved through mammalian evolution. 
When Zapf et al. (556) attempted to measure human serum levels of 
NSILA-S with a solubilized fibroblast receptor assay, instead of displacement of 
radiolabeled NSILA-8, they found increased binding of label as the serum 
concentration was raised, further suggesting binding of NSILA-8 by a serum 
component. These investigators then systematically demonstrated and 
characterized a specific NSILA-S carrier protein in human serum (557). Using 
inhibition of adsorption of 1251-NSILA-8 to albumin-coated charcoal as the 
criterion for this binding, they demonstrated that a maximum of about 0.8 J.l U 
exogenous NSILA-8 is bound by 1 ml serum at a concentration of 10-20 J..!U 1251-
NSILA-8/ml. These observations and the RIA data indicate that about 90% of 
human NSILA-8 is bound at physiologic concentrations of the substance, lending 
further support to the contention that sufficient concentrations of NSILA-8 to 
exert insulin-like effects do not exist in vivo. More than 90% of 1251-NSILA-~ 
bound by 1:4 diluted human serum is displaced by 250 J..!U unlabeled NSILA-8/ml 
and efficiency of displacement is directly proportional to the biologic activity of 
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the unlabeled compound. Insulin, HGH and ACTH do not compete for the NSILA-
S binding site in serum. Chromatography of 1251-NSILA-S-serum on Sephade~ G-
200 at pH 7.5 revealed three peaks of radioactivity in the large molecular weight 
region and a fourth one corresponding to low molecular weight unbound labeled 
NSILA-S. An excess of unlabeled NSILA-s during preincubation led to the 
disappearance of the two major large molecular weight peaks and to a 
concomitant increase of the peak eluting in the low molecular weight range. 
Binding of NSILA-s is saturable and concentration dependent, with half-
maximal binding attained at 4-5 ~ U exogenous NSILA-8/ml, and is time 
dependent, with maximal binding attained after 24 hours, but is temperature 
independent between 0 and 30°C. Scatchard plots indicate a single affinity of 
association with a pH optimum of 7-8. The binding protein is not albumin, since 
2% HSA binds less than 20% of the 1251-NSILA-s bound by 1:4 human serum, is 
heat labile ( >98% inactivated at 100°C for 5 minutes), and exhibits a molecular 
weight of about 70,000 daltons in Sephadex gel chromatography (548, 557). 
NSILA-s activity in the insulin RRA using cultured human lymphocytes 
and purified rat liver plasma membranes is the same as in the insulin bioassay, 
.!·~· NSILA-s exhibits 2% cross-reactivity with the insulin receptor {548-565). 
Zapf et al. (556) demonstrated specific binding of 1251-NSILA-s to cultured chick 
embryo fibroblasts and developed an RRA for NSILA-s using solubilized 
receptors prepared from the fibroblasts by Triton X-100 extraction. Binding of 
NSILA-s to its receptor is time-, temperature-, and pH-dependent, and exhibits 
saturation kinetics. Linear Scatchard plots indicate a single binding affinity, 
with a Ko of 8 x 10-10 M { :::2 ~ U/ml; Kassoc. = 109 M-1>, which is about the 
same NSILA-s concentration {1-2 ~U/ml) at which half-maximal stimulation of 
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3H-thymidine incorporation into fibroblast DNA is achieved. A similar!~ good 
correlation between binding and the biologic activity of NSILA-8 was obtained 
with adipocytes (556) and the perfused rat heart (566). There are 18,000-24,000 
NSILA-8 binding sites per fibroblast cell and the pH optimum of binding is 
between 7.5 and 8.0. Cross-reactivity of insulin with the NSILA-8 receptor is 
0.001-1% and no displacement of 125!-NSILA-S from fibroblasts by glucagon, 
ACTH or HGH was noted. 
SOMATOMEDINS 
In 1957, Salmon and Daughaday (567) demonstrated that growth hormone 
stimulates incorporation of labeled sulfate into the costal cargilage of 
hypophysectomized rats via a secondary factor, measurable in serum, which they 
termed "sulfation factor." Sulfation factor was shown to stimulate incorporation 
of 14c-1eucine into glucosaminoglycans (568), conversion of 14c-uridine-proline 
into collagen-hydroxyproline (569), incorporation of 3H-uridine into RNA (568) 
and incorporation of 3H-thymidine into DNA (570) in rat cartilage and uptake 
of a-aminoisobutyric acid, cycloleucine and metabolizable amino acids into 
chick cartilage (571). The term somatomedin, indicative of serum factors that 
mediate the effects of somatotropin, has been applied to substances exhibiting 
the properties of sulfation factor (572) and is more generally defined as all 
growth hormone-dependent factors that exert an anabolic insulin-like action on 
their target tissues (573). Most bioassays of somatomedin measure incorporation 
of radiolabeled sulfate into chondroitin sulfate of cartilage glucosaminoglycans 
(574). Daughaday et al. (575) found a linear relation between the uptake of 
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labeled sulfate into costal cartilage of hypophysectomized rats and log of serum 
concentration. A more convenient assay, utilizing incorporation of labeled 
sulfate into cartilaginous pelvic leaflets from 11- or 12~ay-old chick embryos, 
was developed by Hall (576, 577). Numerous bioassays for somatomedins have 
also been developed based on incorporation of radiolabeled thymidine into DNA 
(578-580). 
Somatomedins have been found to be effective in the cartilage of many 
vertebrates, including monkey, horse, calf, dog, pig, sheep, rat and frog (573, 
581), but no such substances were found in the blood of the carp or atlantic 
bluefish (582, 583). somatomedins have also been found to stimulate 
incorporation of 35so4 = into polysaccharides of human fetal lung fibroblasts 
(584) and of 3H-thymidine into DNA of human glial cells in culture (585). Rat 
plasma somatomedins stimulate incorporation of radiolabeled leucine into 
hypophysectomized rat diaphragm (586), indicating that these substances are also 
effective on muscle. The somatotropin dependence of somatomedins is reflected 
in findings of high serum levels of somatomedins in human acromegalies (575-
577, 587). Total hypophysectomy in man was followed by falling levels of 
somatomedin (575, 587) and the half-life of somatomedin in three such patients 
was 9-18 hours (587). Low levels of somatomedin were found in pituitary dwarfs 
(575, 588). In retarded growth induced by other hormonal imbalances such as 
thyroid deficiency or cortisone administration normal somatomedin levels were 
obtained (577). Administration of HGH always caused a prompt rise of 
somatomedin in pituitary dwarfs (588-591). During long-term treatment of 
pituitary dwarfs with HGH a correlation was seen between serum levels of 
somatomedin and growth rate (592). Furthermore, an increase of somatomedin 
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was found in normal humans at the time of puberty by Almqvist and Rune (593). 
In newborns and children less than 4 years of age, the levels were lower than in 
adults (575, 589, 593). Somatomedin-like activity in frog serum is decreased 
following hypophysectomy and is restored to normal by administration of 
somatotropin or triiodothyronine (581). Perfusion of rat liver and kidney slices 
with growth hormone was accompanied by production of a somatomedin-like 
factor in the medium (594-596), indicating that these organs are sources of the 
substance. 
Acid-ethanol extraction of human serum yielded a 20-40% recovery of 
somatomedin activity purified 50- to 200-fold (577, 578). Further purification by 
gel chromatography, ion-exchange chromatography, isoelectric focusing and 
paper electrophoresis revealed that somatomedins migrate on electrophoresis 
with S~lobulins (573, 577, 578). Thus, 10-20% plasma somatomedins were 
recovered from acid-ethanol extraction of Cohn Fraction IV. Sephadex G-75 
chromatography with 1% formic acid containing 0.01 M 2-mercaptoethanol 
yielded a single peak of activity corresponding to molecular weight 6,000-8,000 
daltons and representing an overall purification of 20,000-50,000-fold (577). 
Further purification of this material by charge, including paper electrophoresis, 
Dowex 50 x 2 ion-exchange chromatography and isoelectric focusing yielded 
three polypeptides of about the same molecular weight (7 ,000 daltons), but 
differing in their physical and biologic properties. A neutral (pi = 7.1-7 .5) 
polypeptide that stimulates sulfate incorporation into chick cartilage was 
designated somatomedin A (SMA; 577, 585). This material was recovered from 
human plasma in a yield of 2% and a maximum specific activity of 7,000 U/mg (1 
unit SMA activity is equivalent to 200 J.l U porcine insulin; 597), representing an 
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overall purification of 1-2 x 106-fold (577). An acidic (pi= 5.9-6.4) polypeptide 
that promotes incorporation of thymidine into DNA by human glial cells was 
termed somatomedin B (SMB; 585). A basic (pi = 9-10) polypeptide that 
stimulates sulfate and thymidine incorporation by rat cartilage was designated 
somatomedin C (SMC; 598, 599). 
In addition to its effect on chick cartilage, partly purified SMA was found 
to exert a totally insulin-like effect on rat adipose tissue (600). During optimal 
stimulation of rat adipocyte lipolysis by such lipolytic hormones as epinephrine, 
norepinephrine, glucagon, ACTH, TSH, LH and parathyroid hormone SlVIA 
potentiated glycerol release, but during unstimulated and slightly stimulated 
lipolysis, SMA caused a dose-dependent depression of glycerol release. Whereas 
the adenylate cyclase-stimulating lipolytic hormones increase the uptake of 
labeled calcium by these cells, both S\1A and insulin cause an inhibition of 
calcium retention. Thus, SMA, insulin and calcitonin exert a similar effect on 
lipolysis as well as on uptake of glucose and calcium by rat adipocytes (600). 
Partially purified human plasma SlVIA also stimulates transport of a -
aminoisobutyric acid into muscle (573). In a study of both healthy children and 
children with certain growth disturbances, a correlation was found between 
serum SMA levels and dental maturity as well as body height growth (601). The 
mean serum level of SMA in 28 normal children (7-11 yrs.) was found to be 0.92 ± 
0.06 (SEM) U/ml, while those of 29 short and 9 tall children were 0.64 and 1.24 
U/ml, respectively (601). A specific RIA for SMB indicated a mean plasma 
concentration of 9.8 ± 1.7 llg/ml for normal adult males, 6.6 ±0.5 l.1 g/ml for 
17 adult males with diagnoses of chromophobe adenoma and growth hormone 
deficiency, and 19.3 ± 2.3 JJg/ml for 22 adult males with clinical acromegaly 
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and proven hypersecretion of growth hormone (602). 
Whereas purified SMB has no effect on adipose tissue, SMC has been 
shown to exert an insulin-like effect. Partially purified SMC stimulates 
oxidation of 14C-glucose to 14co2 in isolated fat cells, 1 unit of SMC being 
equivalent to 30-50 J..IU insulin (573). SMC also inhibits glycerol release in vitro 
in epinephrine-stimulated rat epididymal fat tissue. In this system 1 unit of SMC 
is equivalent to 120 J..IU porcine insulin (603). SMC, as well as somatotropin, 
stimulates hypothalmic somatostatin release, resulting in inhibition of pituitary 
somatotropin excretion, and also inhibits stimulation of somatotropin release by 
a delayed, direct mechanism that completes a negative feedback loop further 
indicating that SMC is a mediator of somatotropin action (604). A 37% inhibition 
of somatotropin release from cultured rat adenohypophyseal cells by a 
pharmacologic dose (625 J..IU/ml) of insulin was also observed (604). Amphibia is 
the most primitive class of vertebrates in which a SMC-like substance has been 
detected, but displacement of 1251-sMC from specific antibodies by frog serum 
does not parallel displacement by normal human serum. DNA synthesis and 
mitosis in frog lens epithelium is abolished by hypophysectomy and is restored by 
administration to the animals of SMC, which causes resumption of the cell cycle 
in G0 phase and continuation through S phase. Somatotropin, frog prolactin and 
thyrotropin, which enhance synthesis of SMC in mammalian liver (TSH via 
thyroid hormones), stimulate mitogenesis in hypophysectomized frog lens 
epithelium in vivo, but not in vitro. SMC also stimulates mitogenesis in vivo. 
Likewise, somatotropin and triiodothyronine restore lens cell proliferation in 
vivo, but not in vitro (581). Using a specific SMC RIA, Furlanetto et al. (582) 
found that serum SMC levels were lowest at birth (0.38 ± 0.05 (SEM) U/ml) and 
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rose dramatically during early childhood to reach 1.30 ± 0.16 U/ml by 4 years of 
age. The mean serum SMC concentration in 23 normal adults was 1.50± 0.10 
U/ml (apprx. 150 ng/ml). The levels were 6.28 ± 0.37 U/ml in 14 active 
acromegalies and <0.2 U/ml in 19 hypopituitary children. 
Experimental observations with SMA and SMC iterated above indicate 
that somatomedins exert their anabolic effects by a mechanism that antagonizes 
adenylate cyclase-activating hormones and, in fact, a partially purified 
somatomedin preparation has been found to suppress the adenylate cyclase 
activity of membrane fractions obtained from rat lymphocytes, adipocytes and 
hepatocytes, and from chick embryo cartilage (605). A similar mechanism has 
been postulated for insulin action (see Chapter ITI) and, indeed, extensive cross-
reaction of somatomedins, proportional to their ILA, has been reported. SMC 
competes with 1251-insulin for membrane binding sites on adipocytes and the 
displacement curves obtained with the two hormones are parallel. The apparent 
ratio of SMC to insulin of 50 J.IU insulin per unit of SMC is very similar to their 
relative biologic activities. Scatchard plots of 1251-insulin binding in the 
presence of both insulin and SMC are compatible with simple competition for the 
same receptor sites. SMA also competes with 1251-insulin for binding to 
adipocytes and particulate adipocyte membrane preparations (606,607). SMC has 
also been found to compete with insulin for binding to rat liver (606) and human 
placental (598,608) membranes. SMA in doses above 1 J.lg/ml displaces 1251-
insulin from placental membrane and 1 llg SMA is as potent as 1.25 ng insulin 
(4.5 J.l U ILA/U SMA) in this respect (609), but SMB up to a concentration of 10 
J.l g/ml has no effect in this system. 
Furthermore, SMA and SMC have been shown to have specific binding 
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sites on placental membrane (608-610). The specifically bound 1251-sMA was 
readily displaced by unlabeled SMA. Insulin in high doses could also displace 
oound 1251-sMA, but was 100-1,000 times less potent than SMA in this respect 
(610). The Scatchard plots for insulin and S'IIJA in this system are biphasic, 
indicating at least two types of binding sites. The calculated apparent 
association constant of the high-affinity sites is 3.8 x 108 M-1 for insulin and 2.7 
x 10 7 M-l for SMA. The corresponding amounts of binding sites are 5.4 nmole 
and 19 nmole per milligram of membrane protein, respectively (609). A 
placental membrane radioreceptor assay for SMA yieldedmean serum values of 
0.57 and 3.2 U/ml for pituitary dwarfs and acromegalies, respectively, while 
corresponding values of 0.41 and .1.61 U/ml were found using a bioassay (609). 
Despite their definition based on selectivity of biologic activity, specific binding 
of SMA to rat cartilage and of SMC to chick cartilage has been observed 
(573,608). Displacement of 1251-sMC from human placental membranes by frog 
serum also did not parallel displacement by human serum (581). 
The biologic, membrane-binding, and physicochemical properties of SMA 
and SMC are very similar to those of NSILA-8 (577 ,597 ,603). Hall and Uthne 
(573,597) found that SMA and NSILA copurified from human plasma and, in fact, 
the two are inseparable. NSILA-8 also stimulates incorporation of radiolabeled 
sulfate into rat and chick cartilage and is regulated by somatotropin (560,573). 
Serum NSILA levels are increased in acromegalies and decreased in pituitary 
dwarfs (572). In addition, evidence for somatomedin carrier proteins in serum 
has been obtained (573,585,598,602,611,612). The lack of similarity between 
SMB and other somatomedins is reflected by the fact that anti-8MB serum 
doesn't react with NSILA-8 or SMA (613). Neither SMB nor SMC compete with 
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NSILA-8 for binding to liver plasma membranes, but SMA is 10% as active as 
NSILA-8 in competing for the NSILA-S receptor (614). 
SERUM GROWTH FACTORS 
Serum has been known to be a necessary component of cell and tissue 
cultures since their inception at the beginning of this century (615). Nearly all 
animal cells in culture require serum for proliferation, although transformed 
cells (those that form tumors when injected into syngeneic animals) generally 
have lower serum requirements in vitro than do their normal counterparts (616). 
Serum has been shown to stimulate the rates of growth and DNA synthesis in 
cultures of normal chicken, mouse and hamster cells (617-620). Griffiths (621) 
found that 10% fetal bovine serum (PBS) and amino acids present in minimal 
essential medium (MEM) cause protein and DNA synthesis and cell division in 
confluent cultures of MRC-5 human diploid fibroblasts, which normally exhibit 
decreased growth, protein, DNA and RNA synthesis, and amino acid uptake at 
confiuency. Addition of amino acids at this point has no effect on DNA 
synthesis, but causes an increase in protein synthesis, while addition of serum 
stimulates DNA synthesis and amino acid uptake by the cells, but not cell 
division. Thus, the synergism of the two additives results in cell division. 
Stimulation of 3H-thymidine incorporation into the DNA of human skin 
fibroblasts was observed in the presence of 1.25% PBS, was half-maximal with 
2.5% PBS, and was maximal with 5% PBS (555). 
Plasma has been found to have little growth-promoting activity for 
cultured cells compared to serum (622-625), although factors necessary for cell 
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survival in vitro are present in both plasma and serum (616). Since cells. in vivo 
are exposed to plasma except in wounds, where they are exposed to serum, it 
may be concluded that plasma growth factors, such as NSILA-8, epidermal 
growth factor (EGF) and the somatomedins, are important to systemic growth 
requirements while serum growth factors, deriving from platelets and enzymic 
conversion of plasma precursors during clotting may be important for wound 
healing (616). 
In introducing their 1959 report of the first defined medium supporting 
growth of mammalian cells in culture at rates comparable to those obtained with 
serum, Lieberman and Ove (626) outlined three major reasons for identifying the 
growth factors of serum: 1) the desirability of better defined media for 
biochemical and other studies, 2) the elucidation of growth requirements not 
detectable in experiments with whole animals, and 3) the accumulation of a 
baseline of knowledge for future investigation of comparative biochemistry and 
nutrition on a cellular level. Using a bicarbonate-buffered basal medium 
composed of a mixture of amino acids, inorganic salts, glucose, reducing agents, 
antibiotics and vitamins, these investigators were able to replace serum with 
serum protein (flattening) factor isolated from serum, catalase, insulin and 
versene (disodium ethylenediaminetetraacetate, Na2EDTA) in supporting 
proliferation of the human epithelial cells appendix A1 and HeLa, the latter 
derived from a carcinoma of the cervix. The medium did not support long-term 
survival or cloning (propagation of single cells) of these cells, however, and, with 
the exception of the basal medium and catalase at low inocula (20,000 cells per 
flask), growth was not prevented by the omission of any single component 
(including serum). The serum protein factor was later found to be the 
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globulin fetuin, a glycoprotein of molecular weight 45,000 daltons that ~robably 
promotes cell proliferation by acting as a cationic bridge between the cells and 
their glass or plastic suport (626-628). 
It was not until the late 1960s, with the general availability of separation 
methods permiting isolation of small quantities of active polypeptides from the 
complex mixture of serum proteins and improvements in cell culture techniques 
enabling investigators other than tissue culture specialists to study the effects of 
serum factors on isolated cells in vitro, that serum growth factors such as 
multiplication stimulating activity (MSA) were identified and the growth-
promoting properties of plasma factors such as NSILA-8 and the somatomedins 
were fully elucidated. Difficulties due to mitotic inhibitors (chalones) and toxic 
factors in serum also had to be overcome (616). Prior to this time, only growth 
factors such as nerve growth factor (NGF) and EGF, which are produced in 
significant quantities by specific tissues and whose effects are demonstrable in 
vivo, were discovered. Furthermore, as indicated by the studies of Lieberman 
and Ove and others, survival factor and migration . factor activities are not 
related to the stimulation of DNA synthesis and mitosis (629). 
Since serum growth factors may appear to possess ILA in certain tissues 
due to elicitation of a positive pleiotypic response, 1·~· stimulation of metabolic 
parameters secondary to a primary induction of cell proliferation, major serum 
growth factors affecting insulin target cells in culture will be reviewed in this 
section. 
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Nerve Growth Factor 
In 1948, Bueker (630) reported the increased sensory innervation of a 
mouse sarcoma implanted in the body wall of a chick embryo and soon afterward, 
Levi-Montalcini and Hamburger (631) showed that the tumor also caused 
hypertrophy of the sympathetic ganglia of the embryo, suggesting that the 
sarcoma cells released a diffusible nerve growth factor into the circulation. In 
1954, NGF was isolated from male mouse submaxillary glands, as a factor 
capable of stimulating. the growth and differentiation of immature nerve cells 
(632). Significant quantities of this factor have also been found in snake venoms 
(633-635). NGF is secreted in .!!!.!:2. by mouse neuroblastoma cells (636), 3T3 
mouse fibroblasts (637), L"""Cells (virus-transformed 3T3) (637 ,638), rat glioma 
cells (639), and chick embryo fibroblasts (640). Synthesis of this factor is 
stimulated by androgens (641). 
In vivo, the mitogenic {!.e., processes preceeding and causing cell division, 
primarily DNA synthesis) effect of NGF is restricted to the early part of 
embryonic life (642). In vitro, the factor is vital to survival of embryonic 
sensory and sympathetic nerve cells. When it is absent, most nerve cells 
disintigrate; when it is present, nerve cells survive in excellent condition and 
axons grow vigorously (643). However, no mitogenic effect of NGF on nerve 
cells or fibroblasts has been reported (616). In the picogram range, NGF 
enhances survival of embryonic sensory and sympathetic nerve cells in culture 
(643). In the nanogram range, it stimulates neurite outgrowth (644), neurotubule 
polymerization (644), anabolic metabolism (644,645), electrical excitability (646), 
and acetylcholine sensitivity (646). In the microgram range, it induces the 
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regeneration of adrenergic fibers (647), stimulates an increase in cell-cell and 
cell-substratum adhesiveness (648), inhibits the synthesis of mucopolysaccharides 
in chondrocytes (649), and induces the enzyme systems involved in adrenergic 
neurotransmitter synthesis (650). NGF elicits a positive pleiotypic response in 
vitro that includes increased transport of glucose (651) and synthesis of RNA 
-
(645,652}, lipids (653), proteins (652), and the specific enzymes of adrenergic 
nervous transmission, especially tyrosine hydroxylase and dopamine 
S -hydroxylase (650). 
The high molecular weight NGF complex, the 7S species (M.W. 140,000), 
consists of 3 subunits termed a, Sand y (654,655). The S subunit, in which the 
biologic activity of NGF resides, consists of a dimer of two identical monomers 
of molecular weight 13,259 daltons, containing 118 amino acids and 3 disulfide 
bonds (655-658). The y subunit of 7S NGF is an arginylesteropeptidase that 
activates the S zymogen (molecular weight 22,000 daltons) by cleavage at a 
specific arginine residue (659). A 16 percent homology between the amino acid 
sequences of mouse NGF and human proinsulin suggest that both polypeptides 
evolved from a common ancestral gene (616,660). 
Epidermal Growth Factor (EGF) 
In 1962, Cohen (661) reported the isolation from male mouse submaxillary 
glands of a substance that promotes premature opening of eyes (7 days instead of 
12-14 days) and eruption of incisors (6-7 days instead of 8-10 days) in newborn 
mice. Also effective in newborn rats, this factor, which Cohen termed tooth-lid 
factor, caused stunting of mouse growth (1/3-2/3 normal weight at 10 days) and 
inhibition of hair growth (661). This epidermal growth factor (EGF) is present in 
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mouse serum at a level of 1 ng/ml and stimulation of adrenergic receptors by 
phenylephrine in normal adult mice leads to a marked increase in the serum 
level, reaching 150 ng/ml in 1 hour (662). Levels of organ EGF may be controlled 
by androgens (663). 
Mouse EGF stimulates epithelial cell proliferation in a variety of organ 
culture systems, from the cornea of chick embryo or human fetus (664,665) to 
epithelial cells of mouse mammary glands and mammary carcinomas in organ 
culture (666,667). It also stimulates keratinization and proliferation of mouse 
epidermal tissue in vivo (668). Nanogram amounts of EGF are mitogenic in vitro 
for epithelial cells of mouse mammary glands and mouse mammary carcinomas 
(666), epidermal cells from chick embryo and human fetal cornea (664,665), 
bovine corneal endothelial cells (669), human foreskin fibroblasts (670,671), 3T3 
cells (672) and human glial cells (673), stimulating DNA, RNA and protein 
synthesis (670,67 4), polyribosome formation and small molecule transport 
(including amino acids, nucleotides and sugars) and inducing ornithine 
decarboxylase (616,675). Human EGF not only induces DNA synthesis in human 
foreskin fibroblasts, but also increases the final cell density attained in the 
presence of 196 or 1096 calf serum (676). Thus EGF, by itself,cannot completely 
satisfy the serum requirement of mammalian cells in culture. EGF has also been 
shown to stimulate cell migration in aggregates of chick embryo epidermal cells 
(668) and the synthesis of prostaglandins in cultures of canine kidney cells (677), 
but is not mitogenic for WI38 human lung fibroblasts (678), nor does it exhibit 
ILA in adipocytes (652). 
Cohen (661) originally purified EGF from homogenates of male mouse 
submaxillary glands by centrifugation, streptomycin and 5696 ammonium sulfate 
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precipitations, dialysis, carboxymethyl (CM)-cellulose and DEAE-cellulose ion-
exchange chromatography, Sephadex G-75 gel chromatography and Sephadex G-
25 gel filtration, achieving a 2096 yield and 150-fold purification. The product 
was homogeneous in ultracentrifugation, paper chromatography and paper 
electrophoresis, was heat-stable (l00°C for 30 mimutes), but was destroyed by 
0.1 N sodium hydroxide at 100°C for 1 hour, 0.2 N hydrochloric acid at 100°C for 
2 hours, chymotrypsin and bacterial proteinase. It exhibited a sedimentation 
coefficient of 1.25 S and a pi of 4.2. Amino acid analysis revealed the absence 
of lysine and phenylalanine and a miminum molecular weight of about 15,000 
daltons. Taylor et al. (679,680) have isolated mouse EGF by the method of 
Cohen (661) with additional gel filtration steps and have shown it to be a single-
chain polypeptide of molecular weight 6,045 daltons, consisting of 53 amino acids 
and 3 disulfide bonds, all of which are necessary for biologic activity. It exhibits 
a pi of 4.6 and possesses no carbohydrate, lysine, phenylalanine or alanine. The 
amino acid sequence of EGF reveals no homology with insulin (681,682). Human 
urine EGF differs from mouse EGF in amino acid composition, a more neutral pi 
and lower molecular weight (5,300-5,500 daltons) (676). 
The mitogenic effect of EGF on human fibroblasts is inhibited by 
dibutyryl cyclic AMP, theophylline and cholera toxin (674), suggesting that this 
factor acts by reducing intracellular cyclic A "\fP levels. Specific EGF receptors 
have been found on human, mouse, rat and chick cells (674). Human foreskin 
fibroblasts can bind 105 EGF molecules per cell with a Kn of 2-4 x 10-10M 
(678). EGF receptors are lost after transformation of cells with murine or feline 
sarcoma viruses, but not after transformation with the DNA tumor viruses 
polyoma and SV40 (683). No other peptide hormones complete for EGF receptors 
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(674); likewise, EGF does not compete for insulin or NSILA-8 receptors 
(614,670). Mouse EGF has been shown to be associated with a high molecular 
weight carrier protein in crude homogenates of submaxillary gland. This carrier 
protein possesses arginyl esterase activity and may be responsible for the release 
of active EGF from a higher molecular weight precursor since active EGF has a 
c-terminal arginine (679,681). 
Multiplication Stimulating Activity (MSA) 
About 10 years ago, Temin suggested that, since growth factors in serum 
must be produced by some cell in the body, and since all cells in an organism 
possess the same genetic information, it might occur that cells could adapt to 
serum-free culture by producing their own growth factors. This consideration 
led Temin to investigate the components of a medium conditioned by the growth 
of Coon rat liver cells, a cell line that does not require serum. He and his co-
workers purified the growth-promoting activity in this conditioned medium, 
which stimulated DNA synthesis in chick fibroblasts, and termed it 
multiplication stimulating activity (MSA) (629). Previously, Pierson and 
Temin (684) had purified MSA from calf serum. These investigators found that 
MSA stimulates chick embryo fibroblast (CEF) DNA synthesis and mitosis, as 
well as cell proliferation. The factor also stimulates uridine, glucose and 
a - aminoisobutyrate (AlB) uptake (629). The stimulation of glucose uptake is 
primary, 1·~· it is not inhibited by actinomycin D or cycloheximide, but 
stimulation of AlB uptake was inhibited by actinomycin D, indicating that MSA-
enhancement of amino acid transport is dependent on protein synthesis. They 
found a definite correlation between stimulation of glucose uptake and DNA 
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synthesis by MSA, but not by serum, suggesting that increased glucose uptake 
does not necessarily cause DNA synthesis. MSA had no effect on leucine or 
phosphate uptake or cell migration or survival. This factor possesses sulfation 
factor activity and NSILA, leading Smith and Temin (629) to conclude that MSA 
belongs to a family of polypeptides, including insulin, NSILA-s and the 
somatomedins, that exhibits ILA. MSA was also shown to support growth of and 
exhibit mitogenic activity including stimulation of DNA synthesis (although to a 
lesser extent than serum) in rat embryo, 3T3 and human fibroblasts (685-688). 
Pierson and Temin (629) utilized Antoniades' method of BI isolation for 
initial purification of MSA from calf serum. Dowex SOw cation exchange 
chromatography of the whole serum resulted in retention of 20-3096 total CEF 
mitogenic activity by the resin. This material was further purified by gel 
filtration and polyacrylamide gel electrophoresis, yielding a fraction that was 
6,000-8,000 times more active than whole calf serum in stimulating CEF 
proliferation, but possessing only 0.596 insulin ILA. A molecular weight of 4,000-
5,000 daltons was determined for this preparation, which was stable to heat and 
acid and sensitive to periodate, chymotrypsin and dithiothreitol. When Dulak and 
Temin (685,689) purified MSA from Coon rat liver cell conditioned medium by 
salt precipitation, ion-exchange chromatography, and gel filtration, they 
obtained 4 differently charged polypeptides (pi = 5.7-7 .1), all exhibiting a 
molecular weight of about 10,000 daltons. 
Specific MSA receptors have been demonstrated in CEF and rat liver 
membranes (687 ,690). Cell binding of MSA was inhibited by NSILA-s and S'!\fA. 
Proinsulin and insulin inhibited MSA receptor binding in CEF and human 
fibroblasts, while SMB, EGF, fibroblast growth factor (FGF) and NGF had no 
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effect on MSA binding; SMC exhibited 1% cross-reactivity with MSA receptors 
(690). Cells established in culture from human fibrosarcomas were unable to 
bind MSA, but human renal cell carcinomas, chondrosarcoma and glioblastomas 
in culture retain the ability to bind MSA (691). MSA competes with insulin for 
binding at rat liver cell membranes (629) and is as active as NSILA-8 in 
competing for the NSILA-S receptor (614). 
Fibroblast Growth Factor (FGF) 
While isolating well-characterized hormones such as thyrotropin and 
luteinizing hormone from pituitary glands, several investigators noted that partly 
purified preparations exhibited growth-promoting and mitogenic effects in 3T3 
cells, but highly purified hormones did not, suggesting that the pituitary gland 
produces an active mitogen besides the familiar melange of hormones 
(618,692,693). The first isolation and purification of FGF, from bovine pituitary 
glands, was reported by Gospodarowicz in 1975 (694). A growth factor has also 
been purified from bovine brain which is physically and biologically similar to 
pituitary FGF (695}. 
FGF is a potent mitogen for cells derived from the embryonic mesoderm, 
including mouse and human fibroblasts, chondrocytes, adrenal cells, vascular 
endothelial cells, bovine myoblasts, primate smooth muscle, glial cells, cornea 
endothelial cells and amniotic cells (616,669,695-704}, but not for ectodermal 
(e.g_., epidermal and adenohypophyseal} or endodermal (e.g., liver and pancreas) 
cells (669), nor for WI38 fibroblasts (698), avian fibroblasts (including CEF} and 
myoblasts (701}, and SV40 and polyoma-transformed cells (705). 
Initiation of DNA synthesis in resting sparse cultures of 3T3 cells can be 
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obtained at concentrations of FGF as low as 10 pg/ml, and a plateau has been 
obServed at 1 ng/ml in 3T3 cells maintained quiescent in the presence of 
glucocorticoids (695). However, the effect of FGF alone on the initiation of 
DNA synthesis is 30% that of serum, and a combination of FGF and 
glucocorticoids is required to replace serum. FGF and glucocorticoids not only 
initiate DNA synthesis in 3T3 cells, but also induce cell division in both sparse 
and confluent cultures (697). In density-inhibited cultures, FGF alone or FGF 
plus glucocorticoids provokes a morphological transformation that makes the 
cells appear virus-transformed (706). Upon removal of FGF, the cells revert to 
their normal morphology. 
Human foreskin fibroblasts respond to nanogram concentrations of FGF 
(698). However, the effect of FGF on these cells differs from that observed with 
3T3 cells in two respects: 1) glucocorticoids have no effect or are inhibitory, 
and 2) the mitogenic effect of FGF is dependent on the serum concentrations in 
which the cells are maintained. In low serum ( <0.6%), FGF has little or no 
effect. In high serum (>2.5%), it has a strong mitogenic effect, additive over the 
effect of serum, and it reduces the doubling time of the human foreskin 
fibroblasts from 48 to 24 hours, indicating that the division of early passage 
fibroblasts is not controlled by the same system of steroids and macromolecules 
as is the division of 3T3 cells. 
In susceptible cells, FGF stimulates transport of sugars, nucleotides and 
amino acids, polyribosome formation, and synthesis of messenger RNA, transfer 
RNA and proteins as well as DNA (707), but the factor does not possess ILA 
(616), nor does it compete for NSILA-8 receptors on liver plasma membranes 
(614). 
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FGF purified from bovine pituitary glands by acid and ammonium sulfate 
precipitation, dialysis, and ion-exchange and gel chromatography exhibits a pi of 
9.5 and a molecular weight of 13,400 daltons (694,700). The factor does not 
inhibit adenylate cyclase, indicating that decreased intracellular levels of cAMP 
do not mediate its effects, but it may stimulate guanylate cyclase activity in 
3T3 cell plasma membranes (708). 
Other Growth Factors 
Ross et al. (624) demonstrated that addition of medium in which platelets 
had been incubated with thrombin renders plasma as effective as serum in 
supporting growth of pigtail macaque arterial smooth muscle cells. Kohler and 
Lipton (623) found that addition of platelet extract to 3T3 cells maintained in 
low concentrations of plasma induces a resumption of growth similar to that 
observed with serum. Gospodarowicz et al. (625) confirmed these results and 
showed that FGF and glucocorticoids could substitute for the platelet extract, 
suggesting that FGF could be similar to the platelet factor. Paul (709) showed 
that 3T3 DNA synthesis and cell division in response to FGF, insulin and 
dexamethasone requires the presence of two serum factors, a 158,000~alton 
survival factor and a SOO,OOO~alton serum growth factor. SV-40-transformed 
3T3, the growth of which is also serum dependent, require the serum factors but 
not the hormones for mitogenesis. 
Katsuda et al. (710) found that most serum mitogenic activity for Yoshida 
ascites tumor cells was associated with an a-globulin and the albumin fraction. 
Holmes and Wolfe (711) isolated a -globulin- and albumin -containing serum 
protein fractions with growth-1>romoting activities for HeLa and Chang 
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endothelial cells. Healy and Parker (712) found that serum growth-promoting 
activity for mouse embryo fibroblasts was associated with an a 2-macroglobulin 
and an a1-acid glycoprotein. The role of a 2-macroglobulin appears to be 
protective, since it could be replaced by nonprotein polymers. In later studies, 
these investigators isolated a serum fraction composed of three components that 
could reduce (at 250 IJg/ml) the doubling time of mouse embryo fibroblasts from 
4 days to 1 day (628). Holmes has prepared an a~lobulin from human serum 
that can stimulate (at concentrations as low as 0.4 1-1 g/ml) the proliferation of 
HeLa, conjunctiva and human heart cells, an effect that cannot be duplicated by 
insulin (713 ). 
Holley and Kiernan (714) purified a serum growth-promoting activity for 
3T3 cells from B ~lobulins by gel chromatography at low pH. This fraction, 
which stimulated 3T3 division at 11Jg/ml, exhibited a molecular weight of about 
20,000 daltons and required one or more other serum factors to elicit an effect 
comparable to that of serum. Hoffmann et al. (715) isolated from FBS two 
proteins, termed 81 and s2,that together optimally stimulated the growth of 
embryonic rat fibroblasts. s 1 was found to be a complex of insulin and an a2-
macroglobulin, both of which are necessary for growth stimulation. s 2 exhibits a 
molecular weight of 26,000 daltons and a pi of 4.9, and does not cross-react 
immunologically with 81. 
Houck and Cheng (716) purfied a serum sialoglycoprotein mitogenic for 
WI38 fibroblasts. It has a molecular weight of 120,000 daltons and a pi of 5.2-
5.4; besides sialic acid, it contains hexose and its activity is destroyed by both 
trypsin and neuraminidase. The factor comprises 0.5% of total serum protein 
and 50 IJg/ml is as effective as 10% FBS in supporting WI38 proliferation. Since 
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other serum growth factors such as MSA, EGF and FGF are roughly one-tenth 
the molecular weight and active at one thousandth the concentration, this 
species may represent a complex between a smaller active molecule and its 
carrier protein, a possibility supported by the fact that activity is partially lost 
during ion-exchange chromatography and high-current electrophoresis. 
JLA, Revisited 
When Antoniades et .!!!· (717) re-examined serum substances retained by 
Dowex 50w x 8 cation exchange resin (BI) for growth-promoting activity in vitro, 
they found that the ability of human serum to cause 3T3 division almost 
completely resides in Bl. This fraction induces DNA synthesis and mitosis in 
confiuent 3T3 cells, but does not promote cell survival and does not possess 
Insulin immunoreactivity. The mitogenic activity is heat stable (100°C, 20 min.), 
but was 75% abolished by trypsin or chymotrypsin and completely abolished by 
mercaptoethanol. The BI ILA eluted from Sephadex G-100 in a molecular weight 
range of >100,000 to about 30,000 daltons, while mitogenic activity was found 
at 10,000-35,000 daltons. Isoelectric focusing revealed at least two mitogens, 
one co-eluting with ILA (pi = 7 .3-9.4) that exhibited a pi of 8.6-8.8 and a 
molecular weight of about 30,000 daltons and the other free of ILA, with a pi of 
9.6-9.9 and a molecular weight of 13,000 daltons. About 8 ng protein (equivalent 
to 8 ml serum) from the latter fraction was sufficient to induce DNA synthesis in 
8796 of 3T3 cells in a confiuent monolayer and cell division, and to cause the 
cells to assume a random orientation characteristic of transformation. Thus, the 
latter mitogen may be FGF while the ILA fractions probably contained NSILA-8 
and somatomedins. 
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As previously mentioned, sulfation factor activity of NSILA-8 at 
concentrations found in blood and the somatotropin dependence of these 
concentrations indicate that the physiologic role of NSILA-8 is that of a growth 
factor. This substance also displays significant growth-promoting activity in 
vitro. Morell and Froesch (554) found a 1.5- to 4-fold increase in DNA synthesis 
-
by CEF 8 hours after addition of 10-100 \.1 U (21-213 ng) NSILA-S/ml. 
Furthermore, 10-100 \.1 U NSILA-8/ml caused a twofold increase in CEF glucose 
uptake and lactate production 21 hours after addition, and a twofold increase in 
cell number after 4 days in the presence of 300 \.lU NSILA-S/ml was noted, but 
NSILA-S was far less potent than FBS in this respect. Rinderknecht and Humbel 
(549) observed a linear response of thymidine incorporation into CEF DNA in the 
presence of 0.75-25 ng NSILA I or ll/ml with a maximal 4-fold stimulation 
attained at 250 ng/ml. Half-maximal stimulation occurred at 1.6 nM (9.3 
ng/ml). Stimulation of CEF ornithine decarboxylase activity by NSILA-S has also 
been demonstrated (718). 
Rechler et al. (555) showed that for human fibroblasts NSILA-8 increases 
the fraction of cell nuclei incorporating thymidine and stimulates thymidine 
uptake as well as incorporation into DNA. Stimulation of DNA synthesis was 
detected at 50 ng NSILA-8/ml, half-maximal stimulation occurred at 150 ng/ml, 
and a maximal 5.4-fold stimulation of DNA synthesis was attained at 500 ng/ml 
whereas 5% FBS induced a maximal 50-fold increase in DNA synthesis. 
Destruction of disulfide bonds by reduction and aminoethylation abolished the 
ability of NSILA-8 to stimulate DNA synthesis. Combined additon to human 
fibroblast cultures of maximally effective concentrations of insulin and NSILA-S 
did not result in additive stimulation, suggesting that insulin and NSILA-8 act at 
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a common point while serum induces DNA synthesis by a different mechanism. 
In view of its growth-promoting properties and its striking homology with 
insulin, Rinderknecht and Humbel (550) proposed a new designation for NSILA-5: 
insulin-like growth factor (IGF) and termed NSILA I and U IGF I and U. During 
purification and characterization of MSA, it became apparent that this factor 
possesses physicochemical properties very similar to NSILA (684), and 
Poffenbarger (563) found that an antiserum raised against NSILP also reacts with 
MSA. 
Salmon and Hosse (719) found that partially purified somatomedins 
prepared from calf serum stimulate the growth of HeLa cells in a defined 
medium deprived of serum. When this preparation was present in a 
concentration of 23 JJg protein/ml, cell proliferation after 3 days was twice that 
of control cultures. SMB stimulates initiation of DNA synthesis in cultured glial 
cells at a concentration of 15 J..1 g/ml, whereas 45 ng/ml is sufficient to induce a 
30% increase in lung fibroblast proliferation (720). SMB also stimulates DNA 
synthesis in fibroblasts (573). However, Heldin et al. (721) have found that the 
mitogenic effect of SMB on cultured human glial cells is neutralized by rabbit 
anti-EGF IgG and that their preparation of SMB competes with 125I-EGF for 
binding to these cells, 10 J..1g SMB containing the equivalent of about 2 ng EGF, 
indicating that SMB mitogenesis may be due to contaminating EGF. SMC is 
mitogenic for cultured human fibroblasts and fetal rat hepatocytes, with a 3- to 
4-fold stimulation of DNA synthesis by the latter cells in the presence of 0.01-1 
J..1gSMC/ml being observed (598,722). Thus, NSILA-5, SMA, SMC, MSA and 
perhaps NGF may belong to a family of closely'1"elated IGFs. 
Curiously, the oldest known growth-potentiating factor in vitro is 
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insulin. Within three years after Banting and Best isolated the hormone, Gey and 
Thalhimer reported an insulin-induced enhancement of CEF growth and glucose 
uptake in tissue culture (723). Subsequent studies demonstrated that these are 
consistent effects of the hormone on cultured fibroblasts, but pharmacologic 
doses (>0.8 mU/ml) of insulin were always required to elicit an increment in cell 
proliferation. However, several investigators reported an insulin-induced 
potentiation of fibroblast growth, but not glucose uptake, in the presence of 8-
2096 serum (724-726). 
Lieberman and Ove (626) found a fourfold stimulation of Appendix A1 and 
HeLa proliferation in culture by 40 mU insulin/mi. The same effect was obtained 
with 5-times recrystallized insulin and was abolished by treatment of insulin with 
cysteine, indicating that it was due to the hormone rather than a contaminant. 
No increment in the rate of glucose uptake by A1 cells during log'1>hase growth 
in the presence of 130 J..l U-130 mU insulin/ml was seen, but 40 mU/ml caused a 
6796 increase of this rate in confluent cultures. Temin showed that insulin (> 8 ng 
or 200 J,JU/ml) .can stimulate thymidine incorporation into CEF DNA to one~ixth 
the maximum achieved with serum, but the hormone is 250,000 times less potent 
than serum in this regard (727). He also demonstrated that both serum and 
insulin elicit their mitogenic effects by inducing cells to move out of G1 phase. 
Griffiths (621) found that 1 mU insulin/ml causes protein synthesis and 
cell division as well as DNA synthesis in confluent MRC-5 human diploid 
fibroblasts .and also potentiates the effects of serum. He postulated that the 
hormone's mitogenic effect may be due to its stimulation of amino acid uptake 
and protein synthesis. De Asua et al. (331) showed that 8 J..l g insulin/ml with 
serum could induce baby hamster kidney (BHK) cells to reach higher final 
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densities than with serum alone, while Clarke et al. (619) showed that 10 f.lg 
insulin/ml potentiates the effect of serum on BHK DNA synthesis. In 1973, 
Morell and Froesch (554) reported a 3- to 4-fold stimulation of CEF DNA 
synthesis by 10-100 mU insulin/ml as well as a 33-167% stimulation of glucose 
uptake and a 30-150% stimulation of lactate production in these cells by 1-100 
m U insulin/mI. These investigators observed a 1.5-fold increase in CEF 
proliferation after 4 days with 300 mU insulin/ml, half that obtained with 5% 
FBS, but could demonstrate no effect of physiologic insulin concentrations (<1 
mU/ml) on CEF and Wl38. Nor could they find any insulin effect on fibroblast 
growth and glucose consumption in the presence of as little as 5% FBS, contrary 
to previous studies. 
Leffert (722) showed a 3- to 6-fold stimulation of DNA synthesis in 
cultured fetal rat hepatocytes by 10 ng (250 f.! U)-10 f.lg insulin/ml, but 10% FBS 
caused a 4.5-fold greater stimulation of DNA synthesis than 10 f.lg insulin/mi. 
Rechler et al. (555) reported that stimulation of DNA synthesis in human 
fibroblasts could be detected with 20 ng insulin/ml, half-maximal stimulation 
occurred at 0.4 f.lg/ml and a maximal 2.5-fold stimulation was obtained with 20 g 
insulin/mi. Insulin also increased the fraction of cells incorporating thymidine 
and thymidine uptake. A 40% stimulation of DNA synthesis in human foreskin 
fibroblasts was observed by Hollenberg and Cuatrecasas at insulin concentrations 
as low as 40 ng/ml (222). 
The finding that pharmacologic doses of insulin exhibit sulfation factor 
activity in rat cartilage (560) supports the contention that pharmacologic doses 
of insulin exert growth-potentiating effects on cells and pharmacologic 
concentrations of IGFs exhibit ILA due to cross4'eaction with each other's 
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receptors (728) and that insulin and the IGFs derive from a single ancestral gene 
via duplication and divergence early in vertebrate evolution. 
In summary, serum ILA, or "atypical insulin," apparently is due to IGFs 
whose role in vivo is that of growth-promoting agents. However, the results of 
Guenther (387), who found heparin-induced IRI in BI fractions and heparin and 
biotin enhancement of BI ILA in the rat diaphragm assay, revive the possibility 
of a serum insulin-binding protein important to systemic, insulin-dependent 
metabolic homeostasis. Futhermore, demonstration of serum binding proteins 
for IGFs dispels the notion that polypeptide hormone binding proteins cannot 
exist and makes a serum insulin-binding protein a plausible expectation. The 
methods employed by Zapf ~ al. (557) to elucidate the NSILA-8 binding protein 
of serum should be applied to this question using heparin and biotin as possible 
potentiators of complex dissociation. These agents should also be utilized in a 
systematic study of serum fractions with an in vitro bioassay capable of 
discriminating the effects of physiologic concentrations of insulin from those of 
growth factors, the kind of assay that proved vital to the elucidation of serum 
growth factors: mammalian cells in culture. 
TABLE V. PROPERTIES OF CERTAIN COMPOUNDS EXHIBITING !LA AND OF GROWTH FACTORS 
Compound Mol. Wt. Electr. Sol. in Biol. Act. RRA IRI Reference 
(kd) Mobility acid- (% TI) (% TI) (% TI) 
or (pi) ethanol 
Typical Insulin 5-7.5 albumin- s 100 100 100 102,104,115 
ctl 116 
Insulin Aggreg. 
Dimer 10-12.3 0-15 1.1-1.9 0-11 136,138,182, 
464 
Hexamer 35.1-36 <15 <1.9 <11 143,464 
>Hexamer 72 0 0 0 143,464 
200-300 
Insulin Precurs. 
Pro insulin 8-9 s 2.5-18 20-28 45 182,452,460 
461,486,487 
489,490 
Split Proins. 3-20 45 452,461 
(leu5~-a~a; 5 bond pl1.t 
Desdipeptide 58-100 61 461 
Proinsulin t-:1 t-:1 
(lysRt-arg63 t-..~ 
abse ) 
TABLE V. (CONTINUED) 
Compound Mol. Wt. Electr. Sol. in Biol. Act. RRA IRI Reference 
(kd) Mobility acid- (% TI) (% TI) (io TI) 
or (pi) ethanol 
Desnonapeptide 60-90 61 452,461 
Pro insulin 
(sequence 55-
63 absent) 
Diarginine 60-90 80 452,461 
Insulin 
(+arg31-arg32) 
Mono arginine 60-90 67 461 
Insulin (+arg31) 
"Bound Insulin" 60-100 8-y I 8-lBa 0 390,391,501-
100 504,511-514 
NSILA oc 
NSILA-S 7.5 (8.2) s 2 2 548,549,555, 
565 
NSILA-S/ 50-70 s 547 
carrier 
NSILA I 5.8 s 1.6 ~49 
N 
NSILA II 5.9 s 1.6 549 N w 
TABLE V. (CONTINUED) 
Compound Mol. Wt. Electr. Sol. in Biol. Act. RRA IRI Reference 
(kd) Mobility acid- (% TI) (% TI) (% TI) 
or (pi) ethanol 
NSILA-P 100-150 I 546,547 
NSILP 90 (6.2) 563 
Somatomedins 6-8 a s 573,577,578 
SMA 7 (7.1-7.5) s 5.6 0.1 573,577,597, 
599,609,612 
SMB 5 Cl s <0.01 585,602,609 
(5.9-6.4) 729 
SMC 7 (9-10) s 0.8-1.4 1.4 0 573,598,599, 
606-608,612 
3.4 603 
Growth Factors 
Nerve Growth 13.3 (9.3) 656 
Factor (NGF) 
Epidermal 6.0 (4.6) 0 0 614,670,679, 
Growth Factor 680 
(EGF) N 
N 
~ 
TABLE V. (CONTINUED) 
Compound Mol. Wt. Electr. 
(kd) Mobility 
Sol. in Biol. Act. RRA 
acid- (% TI) ('7o TI) 
or (pi) ethanol 
Multiplication 10 (5.7-7.1) 0.5 
Stimulating 
Activity (11SA) 
Fibroblast 13.4 (9.5) 0 
Growth 
Factor (FGF) 
WI38 Growth 120 (5.2-5.4) 
Factor 
a. diaphragm assay 
b. fat pad assay; diaphragm assay + ATE or heparin 
c. by definition 
IRI 
('7o TI) 
0 
Reference 
629,684,685, 
689 
616,694,700 
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CHAPTER VI 
MATERIALS AND METHODS 
DEXTRAN-CHARCOAL INSULIN RIA 
The method is a modification of that described by Herbert et al. (423), 
as follows: 
Barbital-acetate buffer, pH 7 .4, consists of 1.471 grams sodium barbital, 0.971 
grams sodium acetate, 7.65 grams sodium chloride, and 50 ml 0.1 N hydro-
chloric acid per liter aqueous solution. 
Albumin buffer is prepared by adding 7 ml 5% human serum albumin ("Album-
isol", Merck, Sharp and Dohme, West Point, Pa.) to 93 ml barbital-acetate 
buffer to a final albumin concentration of 3.5 mg/ml (0.35%). 
Dextran-coated charcoal suspension consists of 2.5 grams Norit A charcoal 
(Matheson, Coleman and Bell, Norwood, Ohio) and 0.25 grams Dextran T-70 
(Pharmacia Fine Chemicals, Piscataway, N.J.) per 100 ml barbital-acetate 
buffer. 
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Antiserum 
Guinea pig anti-porcine insulin serum was a gift from Dr. Peter Wright, 
was diluted 1:1,000 with albumin buffer, divided into aliquots, and stored at -
65°C. One milliliter of this solution is mixed with 199 ml albumin buffer to 
make a working antiserum dilution of 1:200,000. One-tenth ml of working 
antiserum is added to each assay tube for a final antiserum dilution of 
1:1,600,000. 
Insulin standard is prepared by dissolving 0.58 units human insulin (lot 258-
10648-27, obtained from Dr. Mary K. Root, Eli Lilly and Co., Indianapolis, lnd) 
in 5.8 ml 0.01 N HCl. This 100 mU/ml solution is diluted 1,000-fold with 
albumin buffer to provide a 100 lJU/ml stock solution that is stored at -20°C. 
This standard is diluted with albumin buffer to produce 5, 10, 15, 20, 30, and 40 
lJ U /ml standards. 
1251 . li 
-msu n 
1251-bovine insulin was purchased from Amersham/Searle Corp., 
Arlington Heights, Til., in quantities of 5 microCuries ( ~Ci)/0.1 ~ g in 5 ml 
albumin buffer. The contents of one vial are mixed with 195 ml albumin buffer 
to make a stock label of 0.5 ng 1251-insulin/ml with an activity of approxi-
mately 8, 800 dpm/0.1 ml. 
The final incubation volume in each tube is 0.8 ml; 0.1 ml standard or 
sample (undiluted, 1:5 or 1:20 dilution of serum) is mixed with 0.1 ml 1:200,000 
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antiserum solution. Neither component is added to nonspecific binding (NS8) 
tubes for standards and 0.1 ml of an appropriate pooled serum dilution alone is 
used for NS8 tubes for samples; 0.1 ml antiserum alone is used for the zero-
standard. The volume of each tube is brought to 0. 7 ml with albumin buffer. 
After a 2-day incubation at 4°C, 0.1 ml 1251-insulin solution is added to each 
tube and incubation is continued at 4°C for another 2 days. Four-tenths ml 
dextran-charcoal suspension is then added to each assay tube, which is vortexed 
and centrifuged at 500 x g for 10 minutes. The supernate is decanted into 
another 12 x 75 mm culture tube and both are counted in an LK8 80000 gamma 
ray spectrophotometer for one minute each. 
Data Reduction 
Percent 1251-insulin bound to antibody (not adsorbed to charcoal) in 
each sample is calculated as 
CPM sample spnt.- CPM NS8 
%8= 
(CPM sample spnt. + ppt.)- CPM NS8 
%8 0 =%B standard or sample /%8 zero standard. 
X 100; 
The insulin concentration of samples was determined from a linearized dose-
response curve prepared by plotting %8
0 
of standards relative to their insulin 
concentrations on logit-log graph paper. Sample %8
0 
and insulin concentration 
in lJ U/ml were calculated from supernate and precipitate CPM using a Wang 
desk computer program into which was entered the parameters of 50% 
intercept, y-intercept, and slope from the manual plot. 
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The insulin RIA described above was employed routinely during 1974-
1975 for clinical determination of serum insulin levels for the Foster G. McGaw 
Hospital, Maywood, Illinois. 
Addition of Heparin to Insulin Standards 
Twenty or 200 mg sodium heparin (Nutritional Biochemicals, Cleveland, 
Ohio) was dissolved in 10 ml barbital-acetate buffer to produce 2 mg/ml and 20 
mg/ml solutions, respectively. Equal volumes of these solutions and insulin 
standards were mixed and incubated 3 hours at 25°C; 0.2 ml solution was added 
to assay tubes instead of 0.1 ml standard for a final heparin concentration of 
0.25 or 2.5 mg/ml. 
DOUBLE-ANTIBODY INSUUN RIA 
The assay is a modification of the method of Morgan and Lazarow (435). 
Reagents 
1. Albumin buffer: 0.35% bovine serum albumin (BSA) (Sigma Chern. Co., 
St. Louis, Mo.) in barbital-acetate buffer, pH 7 .4. 
2. EDTA: 0.1 M Na2EDTA (Mallincrodt, Inc., Paris, Ky.). 
3. Standards: 5, 10, 15, 20, 30, and 40 J.l U/ml human insulin standard 
(Burroughs Wellcome, Research Triangle Park, N.C.) in albumin buffer. 
4. Controls and unknowns: human plasma or serum samples undiluted or 
diluted appropriately with albumin buffer. 
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s. Anti-insulin serum (AIS): 1:50,000 AIS (Burroughs Wellcome) in albumin 
buffer. 
6. Trace: 0.5 ng/ml 1251-bovine insulin (New England Nuclear, Boston, 
Mass.) in albumin buffer, after purification through 25 ml Sephadex G-
50. 
7. Second antibody: 1:8 anti-guinea pig serum (Burroughs Well com e) in 
albumin buffer. 
8. Carrier protein: 1:200 guinea pig serum (Gibco, Grand Island, N.Y.) in 
albumin buffer. 
The reagents are mixed in 12 x 75 ml glass culture tubes and treated 
according to the protocol outlined in Table VI. Precipitates (antibody-bound 
radioactivity) were counted in a Picker Pace-1 automatic gamma ray spectro-
photometer (Picker Corp., Highland Heights, Ohio). 
Data Reduction 
%B = CPM sample - CPM NSB x 100. 
CPM total count - CPM NSB 
Logit-log standard curves were prepared as described for the dextran-charcoal 
assay. Insulin concentrations of samples were also calculated using a Wang desk 
computer program. 
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TABLE VI. 
DOUBLE-ANTIBODY INSULIN RADIOIMMUNOASSAY PROTOCOL 
Sample Albumin Standard Unknown or EDTA AIS 1251 . li -msu n 
buffer control 
ml added 
Total 0.9 0 0 0 0 0.1 
count 
NSB 0.8 0 0 0.1 0 0.1 
Bo 0.7 0 0 0.1 0.1 0.1 
Stds. 0.6 0.1 0 0.1 0.1 0.1 
Unknowns 0.6 0 0.1 0.1 0.1 0.1 
& Control 
Incubate 72 hr. at 4°C. 
Add 0.1 ml 1:200 guinea pig serum + 0.1 ml 1:8 anti-G PS to each tube, except 
Total Counts. 
Incubate 48 hr. at 4° C. 
Centifuge at 2,000 x g 20 min., 4° C.; aspirate supernate; wash 1X with 
barbital-acetate buffer; count precipitates (except Total Counts). 
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CATION-EXCHANGE CHROMATOGRAPHY OF HUMAN PLASMA 
The method is that described by Guenther (387). Ten grams Sephadex 
c-50 (carboxymethyl-Sephadex, Pharmacia) was allowed to swell in 900 ml 
0.005 M ammonium carbonate buffer, pH 7 .8, overnight at room temperature. 
Two units of outdated citrate-phosphate-dextrose (CPD) plasma from 
separate donors, obtained from the Foster G. McGaw Hospital blood bank, were 
pooled and centrifuged at 1,500 x g for 20 minutes, 4°C. The 450 ml recovered 
was mixed with the gel after aspiration of the supernatant buffer and stirred 
for 3 hours at 4°C. The mixture was poured over a double layer of cheesecloth 
in a Buchner funnel to which was applied mild suction. The residue was kept 
constantly covered with a wash solution of cold deionized water until the 
filtrate was clear. 
A 2.5 x 100 em glass column (Bio Rad Laboratories, Richmond, Ca.) was 
packed with the gel (column and accessory equipment were kept in a cold room 
at 4°C) and 0.005 M (NH4)2co3, pH 7 .8, was run through the column until a 
steady baseline (as monitored by an LKB Uvicord m, LKB Instruments, Inc., 
Rockville, Md, and recorded on an LKB Biocal recorder Type 6520-5) was 
obtained 
A one-liter salt gradient of 0.005 to 1.5 M potassium chloride was 
applied to the column using a two-chamber plexiglass gradient mixer and 
dispenser, specially constructed by the Experimental Medical Shop, University 
of Missouri, the flow was maintained at 30 ml per hour with an LKB 10200 
Perpex peristaltic pump, and 5 ml fractions were collected with a Buchler 
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Fracto Mette 200 automatic fraction collector (Buchler Instruments, Inc., Fort 
Lee, N.J.). The column was further eluted with 1.5 M KCl for 24 hours. 
The gradient was traced by determining the osmolality of selected 
fractions using a model 68-3L Advanced osmometer (Advanced Instruments, 
Inc., Needham Heights, Mass.). Fractions exhibiting ultraviolet absorption at 
280 nm (A280> were pooled. The protein content of each major fraction was 
estimated from A280 using E~"81 ~ = 1.0 and 2 ml of each were reserved for 
determination of ffii with and without heparin using the dextran-charcoal RIA. 
Fractions were adjusted to pH 7.3 0.1 with 0.01 or 1.0 N acetic acid or 0.001 
or 0.01 N potassium hydroxide, were then lyophilized, and were stored dessi-
cated at -20°C. Fractions exceeding 140 ml volume were concentrated through 
UM 10 membranes (molecular weight cutoff = 10,000 daltons; Amicon Corp., 
Danvers, Mass.) in an ultrafiltration cell (Amicon) to 50 ml and those exceeding 
a salt concentration of 0.3 M were diluted to 0.005 M by repeated addition of 
water and ~oncentration through UM 10 membranes before lyophilization. 
For the RIA, lyophilized fractions were dissolved or suspended in water 
at a protein concentration of 2.5-10 mg/ml and a salt concentration of 0.05-
0.31 M. Heparin was added to pooled fractions at a concentration of about 40 
JJ g/mg protein and to reconstituted fractions at a concentration of 100 lJ g/ml 
(1Q-40 JJ g/mg protein), which were then incubated at 33°C for 30 minutes and 
assayed relative to standards containing a comparable amount of heparin. 
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IMMUNOREACTIVE ENDOGENOUS INSULIN DETERMINATION AND EXOGENOUS 
- INSULIN RECOVERY FROM VARIOUS SERUM AND PLASMA SAMPLES 
serum: N- pooled normal serum 
SS (stripped serum) -pooled serum treated with Amberlite IRA 400 
(anion exchanger; J.T. Baker Chern. Co., Phillipsburg, N.J.) 24 hr. at 
4°C. 
Plasma: P- citrated plasma from a single donor (outdated) 
SP (stripped plasma) - citrated plasma from two donors, treated 
with Amberlite rnA 400 24 hr. at 4°C. 
Recoveries: 69 or 104 1-1 U of human insulin standard was added to 1.0 ml of 
each of the above samples. Significance of comparisons was determined by 
Student's t test (730). 
Heparin: 11 mg sodium heparin (Sigma) was dissolved in 1.1 ml deionized 
water. Ten 1-11 was added to 1.0 ml each of N, SS, P, SP, and 
recoveries. 
Biotin: 8 mg of D-biotin (Sigma) was dissolved in 8 ml hot saline. Ten 1-11 (10 
1-1 g) was added to 1.0 ml each of N, SS, P, SP, and recoveries. 
For replicate samples, 10 mg D-biotin was dissolved in 0.1 N NaOH 
dropwise. The alkaline solution was brought to 10 ml with barbital-acetate 
buffer, pH 7.4, for a 1 mg/ml solution. Ten 1-11 (10 llg) was added to each sample 
immediately before incubation. Separate standard curves for control, heparin 
and biotin additions were included. All assay tubes were incubated 30 minutes 
at 37°C before assay with the dextran-charcoal RIA. 
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SEPHADEX CHROMATOGRAPHY OF UNTREATED AND TREATED HUMAN SERUM 
AND PLASMA SAMPLES CONTAINING EXOGENOUS RADIOLABELED 
AND UNLABELLED INSULIN 
Initial Chromatography 
1251-insulin (10 ).l Ci) was purchased from New England Nuclear Corp. 
and was twice purified on a 25 ml Sephadex G-50 disposable column. The 
purified product was divided into three equal parts, which were lyophilized and 
stored at -20°C for no more than one week before use. A serum pool of 30 ml 
was prepared from three normal donors and stored at -20°C in three aliquots of 
9.9 ml each before use. Biotin solutions were prepared as in the recovery study 
immediately before use. A 2.6 x 90 em (477 ml) Sephadex G-200 column was 
prepared and equilibrated with barbital - acetate buffer. The column was 
calibrated with a mixture of 25 mg blue dextran (Pharmacia), 40 mg catalase (2 
ml Boehringer crystalline suspension, no. 15674, Boehringer Mannheim Bio-
chemicals, Indianapolis, Ind.), 53 mg hexokinase (Nutritional Biochemicals), 75 
mg bovine serum albumin (BSA, Sigma Fraction V), and 23 mg chymotrypsinogen 
A (Worthington Biochemicals, Freehold, N.J.) in 8 ml barbital-acetate buffer. 
All elutions were with barbital-acetate buffer at 4°C using an LKB 12000 
Varioperpex ·peristaltic pump set at 1.5 x 10 counterclockwise (flow = 17-21 
ml/hr.), an LKB Uvicord n UV monitor set for 280 nm, and an LKB 6520-3 
recorder, recording at 20 mm/hr. 
For the test runs, a serum aliquot was thawed in a 37°C water bath 
while a lyophilized 1251-insulin aliquot was reconstituted with 0.3 ml deionized, 
distilled water. The serum was added to the labeled insulin and mixed. The 
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following was added immediately: control, nothing; biotin, 0.1 ml (100 ~g) biotin 
solution. After mixing, 0.1 ml was removed for counting and the remainder 
applied to the column. The eluate was monitored as before and two-ml 
fractions were collected with an LKB fraction collector. Fractions were 
counted for radioactivity in a Searle 1185 automatic gamma-ray spectrophoto-
meter for 2 minutes each. Fractions of protein and/or radioactive peaks were 
pooled, sterilized by filtration, and stored at 4°C prior to lyophilization, after 
which they were stored dessicated at -20°C. Radioactive fractions were each 
reconstituted with 20 ml distilled water and dialyzed against 100 volumes of 
barbital-acetate buffer, pH 7.4 (3 changes in 24 hrs.). Fractions designated A 
(A1) were dialyzed through Fisher cellulose (M.W. 12,000 cutoff) and B (B1) 
fractions were dialyzed through Spectrapor membrane (M. W. 3,500 cutoff). 
Dialysis retentates were lyophilized and stored at -20°C. 
Rechromatoghraphy of Pooled A + B Fractions 
Another 475 ml Sephadex G-200 column was prepared and calibrated as 
before. All A1 and a1 fractions were reconstituted to their respective dialysis 
retentate volumes and pooled. The pool (108 ml) was concentrated to 15 ml 
through Amicon UM 2 membranes and was centrifuged at 8,000 RPM for 10 
minutes. The supernate was applied to the column and fractions collected as 
before. A 105 ml (2.5 x 21 em) G-200 column was prepared and calibrated. 
Rechromatography of the A2Fraction 
Pooled fraction A (A2) from rechromatography was concentrated to 15 
ml through UM 2 membranes and lyophilized. Two-thirds of the lyophilizate 
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was reconstituted and applied to the small column; two-ml fractions were 
collected The pooled A3 fraction was concentrated, lyophilized, reconstituted, 
and incubated with 1,000 J.l U bovine insulin before chromatography on the small 
column (A3-I). 
Chromatography of Stripped Plasma (SP) 
CPO (citrate-phosphate-dextrose) plasma from a single normal donor 
was obtained from the Foster G. McGaw Hospital blood bank after preparation 
of packed red cells, maintained continuously at 4°C. Fifty ml plasma was 
stirred with 25 grams Amberlite IRA-400 at 4°C overnight, after which the 
resin-plasma suspension was centrifuged at 1, 700 x g 20 minutes at 4°C. The 
supernate was dialyzed through cellulose (cutoff M. W. 12,000) vs. normal saline 
(3 changes of 200 volumes in 2 days) at 4°C. 
Radioiodinated insulin (1251-insulin) was obtained from New England 
Nuclear Corp. (NEX-104, lot 135-264). The contents of one vial were 
reconstituted with 0.31 ml distilled, deionized water (to 50 J.l Ci/ml + 0.050 ml 
5% bovine serum albumin (BSA, in 0.01 M phosphate-buffered saline, PBS) and 
applied to a column of Sephadex G-50 fine, bed volume 25 ml. One-ml fractions 
were collected and assayed for 1-125 activity in a Picker Pace-1 auto gamma 
counter, 0.1 min. each. After addition of 0.070 ml 5% BSA to each, insulin peak 
tubes were pooled and lyophilized 
Approximately 0.5 1JCi of this purified 1251-insulin was reconstituted 
with 0.3 ml water, mixed with 9 ml ion-depleted plasma, incubated 30 minutes 
at 37°C, and chromatographed on 477 ml Sephadex G-200 as previously 
described. In addition, 0.2 ml 5% BSA was added to each peak B tube before 
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pooling and lyophilization. The procedure was repeated with the addition of 
2.25 mU unlabeled bovine insulin to the incubation mixture (SP-1). 
Chromatography of Long-Incubated Stripped Plasma (L) 
1251-insulin (Lot 135-278) was obtained from New England Nuclear 
corp.; 14.5 J..!Ci was reconstituted with 0.3 ml distilled, deionized water + 0.1 
ml 3.5% BSA in 0.01 M phosphate-buffered saline (PBS). The resultant solution 
was applied to a 25 ml column of Sephadex G-50 fine and eluted with barbital-
acetate buffer, pH 7 .4. Each 1 ml fraction, collected in a 12 x 75 mm Falcon 
polystyrene tube, was counted 0.1 min. in a Picker Pace-1 auto gamma counter. 
Fractions from the second radioactive peak were pooled; 2.5 J..! Ci was diluted 
for the double-antibody RIA and the remaining 3.1 J..! Ci (in 6.1 ml) was dialyzed 
through Spectrapor 3 tubing vs. 3 changes of 1 liter 1/10 normal saline (0.085%) 
at 4°C. The retentate was lyophilized and reconstituted with 1 ml water. 
Normal CPD plasma from a single donor (0-neg.; #29-00236), kept at 
4°C continually after collection, was obtained from the Foster G. McGaw 
Hospital blood bank; 50 ml of this plasma was stirred with 25 grams Amberlite 
IRA-400 anion exchange resin at 4°C overnight and then was centrifuged at 
2,000 x g at 4°C. Twenty ml of the supernate was dialyzed through Fisher 
cellulose tubing vs. 3 changes of 4 liters normal saline at 4°C. Ten ml of the 
retentate was mixed with the reconstituted purified 1251-insulin, the mixture 
was sealed in a vial and kept at 4°C 5 days. Following this incubation the 
mixture (2.5 J..! Ci) was applied to a 475 ml column of Sephadex G-200. Chroma-
tography and collection of eluted fractions was carried out as for SP. 
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f_!'eparation of Rabbit Anti-HSA (human serum albumin) 
A New Zealand white rabbit (approx. 3 kg) was immunized with multiple 
subcutaneous injections of 1 mg HSA in complete Freund's adjuvant three times 
at weekly intervals. One week after the last challenge, the rabbit was 
exsanguinated by heart puncture. 
The efficacy and specificity of the serum vs. HSA was tested with 
precipitin ring tests, immunodiffusion, and hemagglutination using HSA conju-
gated to sheep red blood cells with chromic chloride (731). The serum was 
found to have an excellent titer against HSA (0.5-1.0 mg antibody/ml) and no 
detectable reactivity with bovine serum albumin (BSA). 
Immunodiffusion 
Chromatography fractions were tested for HSA using the Ouchterlony 
double diffusion technique (732). A hexagonal array of six small wells 
surrounding a larger center well is cut out of a highly purified agar plate using a 
planchet. Antiserum is put into the center well and the samples to be tested 
into the peripheral wells. If a sample contains the antigen to which the anti-
serum reacts, a precipitin band forms between that well and the center well 
within 24 hours of incubation at room temperature. The plate is then washed in 
normal saline twice in 48 hours and distilled water twice in 24 hours, allowed to 
dry 24 hours, stained with Naphthalene Black 30 minutes, and washed several 
times with acetic acid/methanol/water 1:7:2.8. The bands stain dark blue. For 
serum chromatography and rechromatography, 10 mg of each lyophilized 
fraction was dissolved in 1 ml water for testing. Unlyophilized fractions were 
used directly. 
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Amounts of radioactive'· peak C and A and protein peak n lyophilizates 
from the three CPO plasma/125I-insulin columns (control, cold insulin ~dded, 
and 5-day incubation) containing 10 mg protein each were reconstituted with 1 
ml water. The resultant solutions or suspensions were dialyzed through 
Spectrapor 3 tubing vs. 3 changes of 200 volumes normal saline at 4°C. The 
retentates (C-fractions were first centrifuged to remove insoluble material) 
were then tested without dilution (1% protein) and at 0.1% protein dilutions for 
BSA, HSA, and human IgG vs. the appropriate antisera by the Ouchterlony 
double diffusion technique. Rabbit anti-HSA, anti-BSA, and anti-human IgG 
sera were obtained from Miles Laboratories, Inc., Elkhart, Ind. 
Protein Determinations 
Protein in each fraction was assayed using the method of Lowry (733). 
Dissolved lyophilized fractions were assayed at a concentration of 0.5 mg/ml; 
partially soluble lyophilized fractions were incubated with 0.1 ml 1 N NaOH/ml 
at room temperature overnight and then diluted twenty-fold for assay; unlyo-
philized fractions were assayed directly or, if they represented a large 
absorbance peak at 280 nm, were first diluted tenfold. Total protein was 
calculated on the basis of totallyophilizate recovered or total fraction volume. 
Dextran/Charcoal Analysis of Radioactive Fractions 
Each group consisted of three 12 x 75 mm plastic culture tubes: 
1. 0.1 ml trace + 0.9 ml albumin buffer. 
2. 0.1 ml trace + 0.1 ml 1:10,000 guinea pig anti-insulin serum (AIS) + 0.8 
ml albumin buffer. 
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3. 0.1 ml trace+ 0.1 ml AIS + 0.1 ml human insulin standard (0.1 mU) + 0.7 
ml albumin buffer. 
4. 0.1 ml trace + 0.9 ml albumin buffer in 8 M urea. 
5. 0.1 ml trace + 0.1 ml AIS + 0.8 ml albumin buffer in 8 M urea. 
The above tubes were incubated 2 days at 4°C. 
For the following three groups, 78 mg (25 mg protein) of 5-day 
incubation A-fraction (AL) lyophilizate was reconstituted with 1-2 ml 
water for each group of three tubes and dialyzed through Spectrapor 3 
tubing vs. 3 changes of 200 volumes barbital-acetate buffer at 4°C 2 
days. The retentate was diluted to 3 ml (group 6) or 2. 7 ml (groups 7 
and 8). 
6. AL alone (1.0 ml). 
7. 0.9 ml AL + 0.1 ml insulin standard (0.1 mU). 
8. 0.9 ml AL + 0.1 ml 1:10,000 AIS. 
Groups 7 and 8 were further incubated 2 days at 4°C. 
9. 78 mg AL lyophilizate was reconstituted with 2 ml water and dialyzed 
through Spectrapor 3 tubing vs. 500 ml barbital-acetate buffer in 8 M 
urea at 4°C (3 changes in 2 days). The retentate was diluted to 3.0 ml 
with barbital-acetate buffer in 8 M urea and 1.0 ml was put in each of 
three tubes. 
To each of the 27 tubes was then added 0.5 ml of a cold dextran-
charcoal suspension (0.25g Dextran T-70 + 2.5g Norit A/100 ml barbital-acetate 
buffer). The contents of each tube were agitated and then centrifuged at 2,000 
RPM 10 minutes at 4°C. The supernates were decanted into 12 x 75 mm 
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culture tubes. Both supernatant ("bound") and precipitate ("free") tubes were 
assayed for 1-125 activity in the Picker Pace-1 auto gamma counter. 
_g>S Polyacrylamide Disc Gel Electrophoresis 
1. The calibration mixture consisted of 4 mg each bovine insulin, chymo-
trypsinogen A, BSA, catalase, and 8 mg glucose oxidase dissolved in 10 
ml barbital-acetate buffer, pH 7.4. 
2. Six mg (2.1 mg protein) long incubation A-peak (AL) was reconstituted 
in 0.4 ml deionized water + 0.6 ml barbital-acetate buffer (B/ A). 
3. Solutions were dialyzed vs. 500 ml 2.5% sodium dodecyl sulfate (SDS) in 
0.01 M sodium phosphate buffer, pH 7 .2, 3 hours at 25°C. 
4. Dialysis was continued in 500 ml 0.1% SDS in 0.01 M sodium phosphate 
buffer, pH 7 .2, with 1.6 M urea and 0.05% dithiothreitol 17 hours at 
25°C. 
5. Gels consisted of the following: 
A1 1%'SDS 40 ml 
1 M sodium phosphate buffer, pH 7.2 40 ml 
deionized water to 180 ml 
A2 acrylamide 40g 
bis-acrylamide 1.04g 
water to 180 ml 
B2 Ammonium persulfate 90 mg 
TEMED 0.05 ml 
water 10 ml 
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For 12 gels, 22.5 ml A1 + 22.5 ml A2 + 5 ml B2 are mixed, duaerated 30 
seconds to 1 minute, 2.5 ml poured into each glass tube, overlayed with 
water, and allowed to stand until solidified, about 30 minutes. Gels 
measured approximately 10 em length x 0. 7 em diameter. 
6. 0.1 ml of each solution was applied to duplicate gels. 
7. Gels were electrophoresed (15-20 v, 2-3 rna/gel) in 0.1% SDS in 0.1 M 
phosphate buffer 16 hours, until a bromphenol blue dye marker was 0.5 
em from the end of the gel. 
8. Gels were removed from tubes with a stream of ice water and 
transferred to a fixative solution consisting of methanol/glacial acetic 
acid/water 45:10:45. 
9. The gels were agitated 5 days at 25°C with 12 changes of fixative, until 
all residue was removed. 
10. Gels were stained with 1% fast green in fixative 2 hours at 25°C, 
washed once with tap water, and agitated in 3 changes of fixative 1-1.5 
days. 
11. The gels were destained 5-6 days in 2 changes of fixative and stored in 
fixative at 25°C. 
Affinity Chromatography 
1. Four. grams CNBr-activated Sepharose 4B (Sigma Chern. Co.) were 
swollen in 20 ml 0.001 M HCl in a scintered glass funnel 15 minutes and 
then washed with 800 ml 0.001 M HCl. 
2. The gel was then washed and resuspended to 28 ml with 0.1 M 
bicarbonate buffer, 0.5 M NaCl, pH 8.65. 
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3. The gel was divided into two equal portions; to one portion was added 
50 mg BSA in 1.5 ml bicarbonate buffer, the same concentration of HSA 
to the other. 
4. The suspensions were rocked at 4°C overnight and then washed with 
bicarbonate buffer. 
5. Each gel was resuspended in 7 ml 1 M ethanolamine, pH 8.0, and rocked 
2 hours at 25°C. 
6. The gels each were washed alternately 5 times with 0.1 M acetate 
buffer, 0.5 M NaCl, pH 4.0, and 0.1 M borate buffer, 0.5 M NaCl, pH 
8.45, followed by 0.01 M PBS, pH 7.4. 
7. The gels were resuspended to 7 ml each and stored in 0.01 M PBS with 
0.1% sodium azide before being poured into two glass columns. 
8. Fourteen ml rabbit anti-BSA (Miles lot no. R148, Miles Laboratories, 
Inc., Elkhart, Ind.) was passed through the HSA-Sepharose column to 
remove cross-reacting antibodies; the retained antibodies were eluted 
with glycine-HCI buffer, pH 3.0, and the eluate was immediately 
neutralized with 0.1 N NaOH. 
9. The first eluate (hereafter called the eluate) was then passed through 
the BSA-Sepharose column. 
10. The neutralized eluted retentate (hereafter called the retentate) was 
pooled with a second retentate obtained by passing the eluate through 
the column again, the pool was concentrated to 10 ml through a PM 10 
membrane, and dialyzed through cellulose tubing vs. 2 liters 1/10 
normal saline at 4°C with 3 changes in 2 days. 
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u. Rabbit anti-HSA (9.5 ml; Miles lot no. RHA 2) was passed through the 
HSA column and two pooled retentates were processed as was the anti-
BSA. 
12. Pure anti-BSA and anti-HSA were lyophilized after dialysis and recon-
stituted in 1 ml bicarbonate buffer each. 
13. The anti-BSA (5.8 mg) and anti-HSA (7 .6 mg) solutions were added to 
respective gel suspensions and the proteins coupled to CNBr-activated 
Sephorose 4B as described above. 
14. 312.5 mg (100 mg protein) AL was dissolved in 20.7 ml water; 5 ml was 
assayed for 1-125 activity in a Picker Pace-1 auto gamma ray spectro-
photometer in a plastic centrifuge tube. 
15. The AL solution was passed through the anti-BSA column until no 
protein was eluted with glycine-HCl, six times. 
16. The pooled anti-BSA retentates were concentrated to 8.0 ml through a 
PM 10 membrane; the resultant retentate, filtrate, and membrane were 
assayed for radioactivity (membrane activity was added to retentate 
activity). 
17. The final anti-BSA eluate was passed through the anti-HSA column 
twice and the pooled retentates concentrated to 7.2 ml through a PM 10 
membrane. 
18. The final eluate was concentrated to 9.0 ml through a PM 10 membrane 
and the resultant filtrate concentrated to 8.4 ml through a UM 2 
membrane. All fractions were assayed for radioactivity as for the anti-
BSA retenta te. 
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19. Immunochemical identification of fractions was made using the Ouch-
terlony double diffusion technique and protein was determined using the 
method of Lowry. 
Dextran-Charcoal Binding Study 
Immunoreactive insulin content of the UM 2 retentate was ascertained 
alone, with AIS, and with AIS + unlabeled insulin using dextran-coated charcoal 
as described above. 
MAINTENANCE OF HUMAN CELLS IN CULTURE 
Culture media, L-glutamine, trypsin and antibiotics (unless otherwise 
indicated) were purchased from Grand Island Biological Co. (Gibco), Grand 
Island, N.Y. Hy-Clone fetal bovine serum (FBS) was purchased from Sterile 
Systems, Inc., Logan, Utah (incubated at 56°C for 60 minutes to inactivate 
complement before use), and disposable polystyrene culture flasks were obtain-
ed from Corning Glass Works, Elmira, N.Y. 
WI38 Fetal Lung Fibroblasts 
WI38 cells in the 15th passage level were obtained in frozen ampuoles 
from the American Type Culture Collection, Rockville, Md. After thawing 
rapidly in a 37°C water bath and centrifugation in warmed Eagle's Basal 
Medium with Earle's salts (BME) containing 10% FBS and 2 rnM L-glutarnine 
(BME CM), the cells (in 5 rnl BME CM) were placed in a T-250 culture flash and 
incubated at 37°C in an atmosphere of 5% C02/95% air in a Hotpack co2 
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incubator (Hotpack Corp., Philadelphia, Pa.). Confluent monolayers were 
subcultivated in BME CM using 0.25% trypsin or 0.125% trypsin/0.01% 
Na2EDTA. Antibiotics (100 U penicillin-100 \.Jg streptomycin/ml or 100 \.J g 
gentamicin/ml) were added after the 20th passage level. The cells were used up 
to the 30th passage level (54 generations). 
SK-HEP-1 Hepatoma Cells 
Samples of this cell line were generous gifts from Dr. J~rgen Fogh at 
the Sloan-Kettering Institute for Cancer Research, Rye, N.Y. Two samples of 
SK-HEP-1 growing in glass culture tubes were transferred to a 37°C incubator 
in an atmosphere of 5% C02/95% air. The tube mouths were covered with 
sterile gauze to enable gas equilibration. Within one week, the cells were 
removed from the tubes by treatment with 0.25% trypsin (Gibco) and transfer-
red to T-250 culture flasks, which were kept in the C02 incubator. When cells 
attained confluency, they were subcultivated into other T flasks by trypsiniza-
tion as before. SK-HEP-1 was cultivated in MEM alpha medium with 15% FBS 
and 100 U penicillin/ml-100 \.Jg streptomycin/mi. 
Other Cell Lines 
LT2 squamous-cell vulvar carcinoma cells were established in continual 
culture and characterized a8 described (734). AU471 ovarian carcinoma cells 
were obtained in frozen ampuoles from W.A. Nelson-Rees, Naval Biosciences 
Laboratory, Oakland, Ca., and BeWo choriocarcinoma cells were obtained from 
R.A. Pattillo, Medical College of Wisconsin, Milwaukee. All three cell lines 
were maintained in RPMI-1640 medium with 15% FBS (CM). 
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REPLICATE CULTURE TECHNIQUES 
Cells maintained in adherent culture in 75 cm2 plastic culture flasks 
(Corning) were washed with 10 ml Dulbecco's phosphate-buffered saline (PBS) 
without Ca ++ and Mg++ and detached with 2-10 ml trypsin/EDT A for 1-15 
minutes at 37°C. The reaction was stopped by addition of at least an equal 
volume of complete maintenance medium (containing FBS) and the cell suspen-
sion was centrifuged at 400 x g for 10 minutes at room temperature. The cells 
were resuspended in 5 ml PBS; to 0.1 ml of this suspension was added an equal 
volume of 0.4% trypan blue in normal saline and number of viable cells (those 
excluding dye) was determined using a hemacytometer and a light microscope 
(American Optical Scientific Instruments, Buffalo, N.Y.) 
The cells were centrifuged once more and resuspended in maintenance 
medium to a concentration of 1 x 106 cells/mi. This suspension was further 
diluted with maintenance medium with or without varying concentrations of 
human (Wellcome) or bovine (Sigma) insulin to a concentration of 5 x 103 (WI38, 
SK-HEP-1, AU471, and BeWo) or 1 x 104 (LT2) cells/mi. One-ml aliquots were 
distributed among the center 8 wells of 24-well (2 em 2 area/well) polystyrene 
cluster plates (Costar, Cambridge, Mass.) using a Manostat (Manostat Corp., 
New York, N.Y.) dispenser. Proliferation of cells in the peripheral wells of 
these cluster plates had been found to be inconsistent and thus these wells were 
each filled with 2 ml sterile distilled water. Periodically, the medium from 2-8 
replicate wells was removed, centrifuged and assayed for glucose in a Beckman 
glucose analyzer (Beckman Instruments, Inc., Fullerton, Ca.). Aliquots were 
frozen for double-antibody insulin RIA. The cells in these wells were retrieved 
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with 1 ml trypsin/EDT A. After centrifugation, cells were resuspended in 0.1 ml 
PBS + 0.1 ml trypan blue and counted as described above. 
Log-phase growth rates (doubling time, tD) were determined from the 
linear portion (established by least-squares regression analysis) of plots of log 
viable cell number (N) vs. time. Significance of difference in growth rates with 
and without insulin was determined from t =(be- bi);/sb 2 + sb.2' where be = 
c 1 
slope of control, bi = slope with insulin and ~ is the standard error of the slope 
(730). For cells in lag phase (before log phase) and stationary phase (in medium 
lacking serum or at confluence), rate of glucose uptake, r, was determined as 
u/Nt, where u is glucose uptake in mg, N is average number of viable cells in 
millions, and t is time in days. Fo.r cells in log phase, r = u/N t, where N is the 
c g g 
geometric mean of viable cell number (in millions) = antilog {(log initial cell 
number +log final cell number)/2}. 
In addition, insulin effects on WI38 cells were examined using three 
replicate monolayer systems: 1) initial lag phase cultures. Five thousand single 
cells in one ml BME CM with or without various amounts of insulin were seeded 
in each well. At various times thereafter the supernates were assayed for 
glucose, then frozen for insulin RIA, and the cells were harvested for counting 
with trysin/EDTA; 2) log phase cultures. Twenty thousand cells were seeded in 
each well. Two days later, medium was replaced with one ml BME CM with or 
without various amounts of insulin. Supernates and cells were harvested at 
various times thereafter; 3) confluent cultures. One hundred thousand cells 
were seeded in each well. Two days later, medium was replaced with or 
without various amounts of insulin. Supernates and cells were harvested at 
various times thereafter. All operations until the final harvest were carried 
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out with sterile equipment and reagents, using sterile techniques in a laminar 
flow hood (Germfree Laboratories, Miami, Fla.). 
Efficiency oi plating (EOP) was determined by seeding duplicate Costar 
cluster wells with 100, 200, 500 and 1,000 cells in 1 ml each. After 24 hours in 
the co2 incubator, the medium was removed, the cells were washed with PBS, 
and the cells were fixed in 95% ethanol and stained with Giemsa 5 minutes 
each. The cells in each well were counted on an inverted microscope (Olympus 
Corp. of America, New Hyde Park, N.Y.). 
CULTURED FIBROBLAST INSUUN BIOASSAY 
The assay is a modification of the method of Morell and Froesch (615). 
One-ml aliquots of 2 x 104 viable WI38 cells in BME CM were distributed among 
the center 8 wells of Costar cluster dishes. After 1 day, the medium was 
aspirated, the cells were washed with 1 ml PBS/well, and 1 ml stationary 
medium (0.35% BSA in BME) was added to each well. After 2 days, medium was 
aspirated, cells washed and test samples in 1 ml stationary medium (aliquots 
reserved for glucose assay) were added to each well. After 4 days, medium was 
removed for glucose assay and cells were harvested for counting as described 
above. 
The parameters of the assay are: 
I= u/N. 
v = number viable cells in test well/number viable cells in control well 
(stationary medium alone). 
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R = rt/rc, whre rc =control rand rt =sampler= u/Ngt if Nt> Nc or ~/Nt if 
Nt ~ Nc. 
U = ut/uc. 
ILA, determined from a plot of U vs. insulin concentration. 
Specific ILA = ILAs' determined from a plot of R vs. insulin concentration. 
0.301 (t -38 hrs.) 
log (N/N
0
) 
FBS equivalent = (22 hrs./tD) x 0.1 ml. 
EFFECT OF AIS ON INSULIN-TREATED CULTURES 
Wellcome human insulin standard was reconstituted with stationary 
medium to a concentration of 100 ~ U/ml. To 2 ml of this solution was added 
0.2 ml 1:5,000 normal guinea pig serum (Gibco) or 0.2 ml 1:5,000 guinea pig 
anti-insulin serum (Wellcome). The solution were sterilized by filtration 
through 0.2 ~ m Swinny filters (Gelman Sciences, Inc., Ann Arbor, Mich.), 
incubated at 37°C for 30 minutes and then were added to WI38 cells in replicate 
wells prepared for bioassay as described above. 
CHARACTERIZATION OF CELL-SURFACE INSULIN RECEPTORS 
Tracer Determination of Cell-Surface Insulin Binding 
Radioiodinated (1251) insulin (New England Nuclear) was purified as 
described for Sephadex chromatography of plasma and serum. 
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One-ml aliquots of SK-HEP-1 cells in 0.5% BSA/MEM spinne.· culture 
medium (MEM-SC) brought to 300 mg glucose/dl with 20% dextrose/MEM-SC 
solution at concentrations of 5 x 105 - 106 viable cells/ml were distributed 
among 12 x 75 mm polystyrene culture tubes. To each tube was added 1.33 lJ U 
or 13.3 lJ U 1251-insulin and the tubes were shaken in a 37°C water bath before 
removal at 5 min., 30 min., and 5 hrs. The tubes were centrifuged at 300 x g 10 
minutes and the pellets washed once with PBS. Pellets were assayed for 1-125 
activity in a Picker Pace-1 auto gamma ray spectrophotometer. 
The same quantities of 1251-insulin were added in 1 ml aliquots of 0.5% 
BSA/MEM-alpha or CM to adherent SK-HEP-1 or LT2 cells (3.5-5.0 x 104 viable 
cells) in Costar cluster wells. After 30 minutes and 5 hours, superna tes and a 1-
ml PBS wash were pooled and assayed for activity as above. 
Cells from adherent cultures of SK-HEP-1 and LT2 were also removed 
with trypsin, washed with PBS, and treated with 1251-insulin as described for 
suspension cultures. 
Binding of 1251-insulin to Wl38 cells in suspension was studied by using 
cells harvested with trypsin/EDT A and washed twice with PBS, pH 7 .4. Four 
million cells were resuspended in 0.6 ml 5% BSA/PBS; an equal number of cells 
were resuspended in the same buffer containing 1 U bovine insulin/ml to 
ascertain non-specific binding of 1251-insulin. Aliquots of 0.05 ml cell 
suspension were t>laced in polystyrene culture tubes; 0.05 ml of various 
concentrations of 1251-insulin were then added to each tube, followed by 
incubation at 25°C for 2.5 hours with occasional shaking. Four ml PBS was then 
added to each tube, the contents were mixed, and the tubes were centrifuged at 
300 x g 10 minutes. The supernates were decanted and the precipitates assayed 
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for I-125 activity 20 minutes each in a Searle 1185 auto gamma ray spectropho-
tometer. Net percent 1251-insulin bound to cells was determined as (CPM 
without cold insulin - CPM with cold insulin)/(total CPM - CPM with cold 
insulin). 
Immunocytochemical Determination of Cell-Surface Insulin Binding 
Anti-insulin peroxidase/anti-peroxidase (PAP) staining of SK-HEP-1, 
LT2, Wl38 and BeWo cells was performed by a modification of the method of 
· Sternberger (735) as follows: 
1. Cells dispersed from adherent culture with trypsin/EDTA were resus-
pended in 1 mU or 10 mU bovine insulin in 0.5% BSA/PBS or MEM-SC at 
a concentration of 106' cells/ml and incubated 5 minutes at 37°C. 
2. The cells were washed once in PBS and resuspended in 0.1 ml FBS. Four 
smears were made on standard glass microscope slides. Subsequent 
treatments were carried out by placing 3 drops of solution on an area in 
the center of the slide, demarcated by an ink circle. Slides were 
washed in a Coplin jar. 
3. 0. 75% gelatin in 0.01 M PBS, pH 7 .6, 30 min. 25°C. Blot. 
4. 1:2,000 guinea pig anti-insulin serum (Wellcome) in 0.1% gelatin/PBS 46 
hrs. 4°C, 2 hrs. 25°C. Wash 3 times in 0.1% gelatin 5 min. each. Blot. 
5. 1:8 rabbit anti-guinea pig serum (Wellcome)/0.1% gelatin 30 min. 25°C. 
Wash 3 times (5 min.) in PBS. Blot. 
6. Two slides 1:10 goat anti-rabbit serum (Polysciences, Inc., Warrington, 
Pa.)/0.1% gelatin 30 min. 25°C, two slides 1:10 normal goat serum 
(controls); 3 x 5 min. PBS wash. Blot. 
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1. 1:50 rabbit PAP (Polysciences)/0.1% gelatin 30 min. 25° C; 3 x 5 min. 
PBS wash. Blot. 
s. 0.05% diaminobenzidine tetrahydrochloride (Sigma) in 0.0196 hydrogen 
peroxide/PBS 8 min. 25°C; 3 x 2 min. water wash. Blot. 
9. One control and one test slide were counterstained with 0.196 toluidine 
blue in 0.1 M acetate buffer, pH 4.2, 5 min.; 3 sec. rinse. 
BULK FRACTIONATION OF HUMAN SERUM 
Normal human serum in 500 ml bottles was purchased from Gibco, 
filtered through 0.2 lJm Nalgene units (Nalge Co., Rochester, N.Y.) and stored 
at 4°C; 488 ml of this serum was concentrated to 142 ml through Amicon PM 10 
(M. W. cutoff 10,000 daltons) membranes in a stirred cell under positive 
nitrogen pressure at 4°C. The filtrate was then concentrated to 52 ml through 
UM 2 (M.W. cutoff 2,000 daltons) membranes. One-half of each retentate 
(PM10r1, 3.44x cone., and UM2r1, 6.60x cone.) was lyophilized. The remaining 
PM 10 retentate was diluted to 502 ml with water and was reconcentrated 
through a PM 10 membrane to 84.5 ml {PM 10r2, 2.89x cone., 5.94x desalted); 
the remaining UM 2 retentate was diluted to 300 ml with water and was 
reconcentrated through a UM 2 membrane to 24.5 ml (UM2r2, 7 .OOx cone., 
12.24x desalted). These retentates and both UM 2 filtrates {UM2fl and UM2f2) 
were lyophilized 
For bioassay, various quantities of lyophilized fractions were reconsti-
tuted with stationary medium alone or containing 100 lJ g heparin/ml or 10 lJg 
D-biotin/ml to produce a 10% increase in medium tonicity and were then 
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sterilized by filtration. In addition, the PM10r1 fraction was assayed by further 
10-fold and 100-fold dilutions with corresponding stationary media. Various 
quantities of lyophilized fractions were also reconstituted with normal saline or 
albumin buffer for Lowry protein assay and double-antibody insulin RIA, 
respectively. 
Treatment of the PM 10 Retentate 
C (control). 64.8 mg PM10r2 was dissolved in 10 ml normal saline and 
incubated at 37°C for 30 minutes. The solution was then transferred to an ice 
bath and concentrated 10-fold through a PM 10 membrane. Both the retentate 
(CR) and filtrate (CF) were dialyzed in Spectrapor 3 tubing against 2 liters of 
1/10 normal saline with 2 changes in 48 hours at 4°C. The dialysis retentates 
were each divided into 3 equal parts and lyophilized for bioassay as described 
above. 
Equal amounts (64.8 mg) of PM10r2 were treated as above (C) with the 
following differences: 
H. The fraction was dissolved in a solution of 100 ~g heparin/ml 
normal saline. 
B. The fraction was dissolved in a solution of 10 ~g biotin/ml normal 
saline. 
U. The fraction was dissolved in 2 ml normal saline, to which was 
then added 4.805 g urea in 8 ml normal saline (final urea concentration = 8 M). 
AE. 259 mg PM10r2 was dissolved in 2.48 ml 0.1 N ammonium acetate, 
pH 7 .2, and transferred to an ice bath; 7.44 ml 96% cold ethanol was added and 
mixed vigorously, followed by addition of 0.15 ml concentrated hydrochloric 
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acid and remixing. The suspension was then incubated at 4°C for 30 minutes 
and centrifuged at 12,000 x g for 30 minutes at 4°C. The supernate was then 
treated like the control, commencing with the concentration step, and the 
precipitate (AEP) was resuspended in 2 ml normal saline and treated like the 
control, commencing with the dialysis step. 
Gel Chromatography of the PM 10 Retentate 
A 2.6 x 70 em (bed volume 371 ml) Sephacryl s-200 superfine (Phar-
macia) column was prepared according to the manufacturer's instructions (736) 
and was equilibrated with 0.01 M sodium phosphate buffer, pH 7 .4, at a flow 
rate of 26 ml/hour for 24 hours at 4°C. The column was calibrated with the 
following standards: 
Standard Amount (mg) Molecular Weight(kd) 
1. Blue Dextran 20 2,000 
2. glucose oxidase 100 186 
3. BSA 100 67 
4. chymotrypsinogen A 50 25 
5. myoglobin 50 16.9 
The standards were dissolved in 7.5 ml phosphate buffer and the solution 
was clarified by centrifugation and filtration before application to the column, 
which was then eluted with phosphate buffer at a flow rate of 23 ml/hr. The 
effluent was monitored for ultraviolet absorbence at 280 nm. 
Three grams PM10r1 were reconstituted with 10 ml deionized, distilled 
water, clarified by filtration, applied to the column and eluted as described for 
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the calibration; 2-ml fractions were collected. Twenty-four major fractions 
were prepared by pooling the contents of 5-49 collection tubes; 6 tubes were 
pooled for each of the 20 fractions (2-21) commencing with the first protein 
peak. One ml from each fraction was reserved for Lowry protein assay and 
RIA. Fractions were then lyophilized and one-third of each fraction was 
reconstituted for bioassay. 
Dextran-Charcoal Analysis of Chromatography Fractions 
One-tenth ml of each aliquot reserved from the Sephacryl fractions was 
mixed with 0.1 ml 1251-insulin + 0.6 ml albumin buffer (NSB = 0.1 ml trace + 0. 7 
ml albumin buffer) and incubated for 3 days at 4°C; 0.4 ml dextran-charcoal 
suspension was then added to each tube, which was further treated as described 
for dextran-charcoal analysis of radioactive fractions. 
Acid Treatment of Serum and Serum Fractions 
One ml serum or reconstituted fraction was mixed with 9 ml 0.05 M 
glycine-HCl, pH 2.8, adjusted to pH 3.0 with concentrated HCl, and concen-
trated tenfold through PM 10 membranes. Filtrates were neutralized with an 
equal volume of 0.05 M PBS, pH 7.4, and adjusted to pH 7.4 with 1 N sodium 
hydroxide. Retentates were dialyzed against 200 volumes 0.001 N HCl in 
normal saline, followed by PBS. Both retentates and filtrates were assayed for 
IRI and dextran-charcoal adsorption. In the latter assay, 0.6 ml 8 M urea in 
albumin buffer or 1 mU bovine insulin in 0.6 ml albumin buffer was also added 
to 0.1 ml sample + 0.1 ml trace. 
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NSILA-S Screen 
Fractions (46.3 mg fraction 9, 58.3 mg fraction 12) were each dissolved in 
0.15 M acetic acid in 0.15 M sodium chloride. Each solution was concentrated 
tenfold through PM 10 membranes. All fractions were dialyzed against 4 liters 
0.01 M phosphate buffer, pH 7 .4, in Spectrapor 3 tubing. Each fraction was 
then divided into 3 equal parts and lyophilized for bioassay. 
Comparative RIA 
Double-antibody insulin RIA of selected fractions was carried out with 
1251-labeled and unlabeled porcine insulin (Pharmacia), as well as with 1251-
bovine insulin and human insulin standard. 
GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE POWDER 
The lyophilizate from 200 ml human serum (Gibco) was suspended in 500 
ml acetone (-20°C) and stirred for 1 hour at 4°C. The suspension was filtered 
through 2 layers of Whatman no. 42 paper in a Buchner funnel and the residue 
was washed 4 times with 500 ml acetone (-20°C) and dried per ~ for 25 
minutes at room temperature and in vacuo for 45 minutes at room temperature 
(547, 737). Three grams of acetone powder were homogenized with 10 ml 0.01 
M phosphate buffer, pH 7 .4, in a 30-ml syringe. Undissolved residue was 
removed and the clarified solution was applied to a 2.6 x 71.5 em (380 ml bed 
volume) Sephacryl 8-200 column and eluted with 0.01 M phosphate buffer, pH 
7.4, at a flow rate of 25 ml/hr. Two-ml fractions were collected and pooled to 
produce 24 major fractions as described above. 
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STATISTICAL METHODS 
Means (R), standard deviations (SD), coefficients of variation (CV(%) = 
[soH~ x 100) and standard errors of the means (SEM) for RIA quality control and 
standard curve parameters and recovery data, dextran-charcoal analysis of 
affinity chromatography fractions, and cell number, glucose uptake and rates of 
glucose uptake were determined by standard variance analysis (730). Signifi-
cance of differences between means was determined by both paired and 
unpaired Student t-tests. 
Semi-log growth curve and glucose analyzer response parameters were 
determined by least-squares linear regression analysis (730). Significance of 
differences between log-phase proliferation slopes was tested as described for 
"replicate culture techniques." Normal populations were established for the 
bioassay parameters U and \) by determining these parameters for each control 
well relative to the average glucose uptake and cell number, respectively, of 
two control wells per plate. The normal range was determined from the mean 
of I control parameters -11.:!:. standard deviation x t-statistic of 95% confidence 
limit for control population degrees of freedom. Thus, any test-well parameter 
falling outside this normal range exhibited a minimum significance (high or low) 
of P<0.05. Specific ILA significance was determined relative to control r-
values. 
CHAPTER Vll 
RESULTS 
DEXTRAN-CHARCOAL INSULIN RIA 
A typical parabolic dose-response curve for this assay, obtained by plotting 
percent 125I-insulin bound to antibody (%B) relative to concentration of 
unlabeled insulin added, is reproduced in Figure 16. Plots of logit (%B0 ) relative 
to log (unlabeled insulin] (Fig. 17) were linear between 5 lJU/ml and 15-20lJ U/ml. 
Based on the 90% intercepts of logit-log plots for the 9 dextran-charcoal RIAs 
utilized in the research described herein, this assay exhibits a minimum 
sensitivity of 2.1 lJ U/ml (0.21 lJ U or 8.4 pg insulin in the assay tube). The 
interassay variance of curve parameters (slope and 50% intercept) was less than 
10% (Table Vll). 
Nonspecific binding (NSB) of 125I-insulin in albumin buffer ranged from 6-
14% and in undiluted serum (diluted 8-fold in the assay tube) from 6-38%. Where 
NSB exceeded 20%, data were obtained from dilute sera, if possible. B0 ranged 
from 38% to 50% in these assays. Interassay variance of serum controls was 
approximately 10% (Table VU) and intraassay variance of a normal serum pool 
run 12 times in one assay was 9.5% (Table XI). Recovery of 69 lJU exogenous 
insulin/ml from this pooled serum using this RIA was virtually 100% (Table X). 
The mean insulin concentration of 17 normal fasting human sera 
determined using the dextran-charcoal RIA was 6.2% 4.9 (S.D.) lJ U/ml, yielding a 
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FIGURE 16. DEXTRAN-CHARCOAL INSULIN RIA: STANDARD CURVE. 
ordinate: Free insulin is adsorbed by dextran-coated 
charcoal, while antibody-bound insulin is not. 
Therefore, % 12 5I-insulin bound to antibody, 
%B = CPM in the supernate - CPM nonspec. bound* 
Total CPM - CPM nonspecifically bound 
X 100, 
Abscissa: Concentration of unlabeled insulin added to 
the assay tube. Since 0.1 ml standard is add-
ed to each tube, the range of absolute quantity 
of unlabeled insulin in the assay tubes is 
o.s-3.0 ~u. 
* CPM in supernate in the absence of antibody or standard. 
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FIGURE 17. DEXTRAN-CHARCOAL INSULIN RIA STANDARD CURVE: 
LOGIT-LOG TRANSFORM. 
ordinate: (left) %B0 = percent of CPM specifically bound 
to antibody in the absence of unlabeled insulin. 
(right) logit (%B ) = ln %Bo 
o ~to~o~--%-B-0 
Abscissa: log 1 o (insulin concentration) 
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TABLE VII. DEXTRAN-CHARCOAL INSULIN RIA: INTERASSAY 
VARIANCE 
Number 
Mean 
Standard 
Deviation 
Coefficient 
of Variation (%) 
Number 
Mean 
Standard 
Deviation 
Coefficient of 
Variation (%) 
Logit-Log Parameters 
Slope 
9 
-2.43 
0.21 
8.8 
Normal 
Pool 
8 
42.2 
4.3 
10.1 
50% Intercept 
( f! U /ml) 
9 
13.4 
0.9 
7.0 
Serum Controls 
(f!U/ml) 
High Serum 
6 
116 
10 
8.9 
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gs% confidence range of 0-16.6 lJU/ml, close to the observed range of .0-15.4 
lJllml. This RIA also yielded values for the Phadebus Reference Serum within the 
range found by the Phadebus insulin radioimmunoassay and for sera provided by 
the College of American Pathologists within the range found by other 
laboratories using their own radioimmunoassays, and showed expected 
nuctuations in human insulin levels in response to a glucose load or tolbutamide 
administration in both normal individuals and maturity-onset diabetics. 
EFFECT OF HEPARIN ON THE DEXTRAN-CHARCOAL INSULIN RIA 
Heparin was found to inhibit binding of 1251-insulin to antibody at 
concentrations above 100 J.lg/ml in the assay tube. Although dose-response curves 
were parallel, 0.25 mg heparin/ml depressed %B 19% and 2.5 mg heparin/ml 
depressed %B 45%. 
DOUBLE - ANTffiODY INSULIN RIA 
Assay Characteristics 
The range of variability of triplicate standards in the dose response curve 
(Fig. 18) indicates a useful range for this assay of 1-30 lJU/ml with a resolution 
of 1 lJU/ml at 5 lJU/ml to 2 lJU/ml at 30 lJU/ml. The 90% intercept on the log-
logit curve (Fig. 19), which is linear between 5 and 40 lJ U/ml, indicates a 
sensitivity of 3.6 lJU/ml. NSB for both buffer and sera was consistently less than 
496. Therefore, samples and standards were not corrected for NSB in this 
assay. B0 varied between 50 and 72%. 
FIGURE 18. DOUBLE-ANTIBODY INSULIN RIA: STANDARD CURVE. 
• Insulin standards in albumin buffer 
0 Serum D.N.-CPD plasma 
• Serum D.N.-CPD plasma, diluted 10-fold with 
albumin buffer 
• Serum D.N.-CPD plasma, diluted 20-fold with 
albumin buffer 
Insulin concentration of D.N. serum was determined by 
assay of serum diluted with albumin buffer. 
267 
268 
100 
90 
80 
70 
60 
0 
~50 
0 
ID 
... 
z 
1&1 
u 40 
a: 
1&1 
A. 
30 
• 
20 
10 
10 20 30 40 
)AU INSULIN'ML 
FIGURE 19. DOUBLE-ANTIBODY INSULIN RIA STANDARD CURVE: 
LOGIT-LOG TRANSFORM. 
Range of insulin standards = 5-40 ~U/ml. 
Insulin quantity in assay tube is one-tenth of insulin 
standard concentration. 
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When a patient sample showing a high concentration of insulin (D.N ., 496 
Jl)/ml) was serially diluted with CPD plasma low in insulin, displacement of 
radiolabeled insulin was nearly superimposible on the standard curve (Fig. 18) 
over several dilutions. Recovery of exogenous human insulin standard added to 
CPD plasma was essentially 100% from about 10 \.l U/ml to 300 \.l U/ml (Table 
VID). High assay values at low concentrations indicate an actual sensitivity and 
resolution of about 4 \.1 U /ml. 
Quality Control 
Intraassay variation was determined by assaying 15 replicates of three 
human serum and plasma samples, ranging from about 7 to 500 U insulin/ml, in 
one assay. Coefficients of variation for samples exceeded 10% only at low 
insulin concentrations (Table IX). Interassay variation of curve parameters was 
less than 15%, but exceeded 15% for serum controls. The 23% CV for N1 
underscores the inaccuracy of the assay for insulin levels less than 10 \.1 U/ml. 
Patient Samples 
Fifty patient samples, including four oral glucose tolerance tests, showing 
normal glucose levels were obtained from Dr. Marion Brooks. The distribution of 
insulin concentrations determined for 27 fasting samples among these is skewed 
to the right with a median of 4.5 lJU/ml. Although the arithmetic mean is 8.8 
11U/ml, treatment of the population as a normal distribution yields a 95% 
confidence range of 0-19.4 \.1 U/ml (or approximately 0-20 \.1 U/ml), rather close 
to the observed range of 2.3-18.2 lJU/ml. 
Insulin concentrations assayed for the glucose tolerance tests show 
TABLE VIII. RECOVERY OF H~~ INSULIN STANDARD ADDED 
TO CPD PLASMA BY DOUBLE-ANTIBODY RIA 
Insulin Added 
(~U/ml) 
303 
129 
80.8 
35.8 
20.8 
6.3 
2.8 
Percent Recovered ± Standard 
Deviation 
107 10.6 
130 19.7 
106 2.5 
105 16.8 
100 20.7 
163 11.2 
236 94.8 
CPD = citrate-phosphate-dextrose 
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Each recovery determination is based on triplicate samples. 
Total ~U/ml - plasma ~U/ml 1 0 Percent recovered = Insulin added (~U/ml) x 0 · 
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TABLE IX. DOUBLE-ANTIBODY INSULIN RIA QUALITY CONTROL. 
Number Mean Std. Dev. Coeff. Var. 
(percent) 
Intraassay 
Variation 
Nl 15 7.38 0.90 12.2 
(~U/m1) 
N 1 o 15 124 10 8.1 
(~U/m1) 
D.N. 15 496 29 5.8 
(~U/m1) 
Inter assay 
Variation 
Slope 22 -2.59 0.31 12.0 
50% inter- 22 27.5 2.5 9.1 
cept (~U/ml) 
Nl 20 6.4 1.5 23.4 
(~U/ml) 
N1 o 19 121 22 18.2 
(~U/ml) 
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TABLE X. SERUM AND PLASMA IRI AND RECOVERY OF EXOGENOUS 
INSULIN BY RIA: AVERAGE OF TRIPLICATE DETERMI-
NATIONS 
Sample 
N 
p 
ss 
SP 
+ 69 
N 
p 
ss 
SP 
~U/ml 
IMMUNOREACTIVE INSULIN (~U/ml) 
(Recoveries) 
No Additions + 100 ~g/ml heparin + 10 ~g/ml 
biotin 
51.1 
0.3 
13.8 
4.4 
120 (99.9%) 
72.3 (104.3%) 
85.6 (104.1%) 
73.3 (99.9%) 
44.6 
0.3 
12.4 
4.4 
114 (100.6%) 
65.1 (93.9%) 
70.0 (83.5%) 
68.1 (92.3%) 
38.6 
1.5 
10.2 
6.7 
96.6 
58.9 
63.1 
54.4 
(84.1%) 
(83.2%) 
(76.7%) 
(69.1%) 
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TABLE XI. SERUM AND PLASMA IRI AND RECOVEI\.Y OF EXOGENOUS 
INSULIN BY RIA: STATISTICAL ANALYSIS 
UNTREATED SAMPLES 
Sample IRI % Recovery Comparison 
with % Re-
covery of N (no. JJU/ml ±S.D. (S.E.M.) 
+ 104 JJU replicates) ±S.D. (S.E.M.) 
N (12) 42.2±4.0 (1. 2) 
p (12) 0.1±0.3 (0.1) 
SP (12) 3.0±0.7 (0.2) 
ss (12) 21.2±5.1 (1.5) 
N 100 (12) 132 ±17 (4.7) 86.5±16.3 (4.5) 
p 100 (12) 
ss 100 (12) 
SP 100 (12) 
Sam:ele IRI 
N (12) 41.7 
±3.9 
74.3±7.2 (2 .1) 71.3 ±6.9 (2. 0) significantly 
lower 
(P<O.Ol) 
93.2±7.6 (2.2) 69.2 ±7.3 (2.1) significantly 
lower 
(P<0.005) 
79.9±8.9 (2.6) 73.9 ±8.6 (2.5) significantly 
lower 
(P<O. 05) 
+ 10 lJg/ML BIOTIN 
% Recover~ Comparison Comp. with Comp. 
with IRI of % Recovery with 
+99.8 lJU untreated of N % Rec 
sam:eles Untr. 
Sm:els 
no sign. 
diff. 
(1.1) (P>O. 5) 
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TABLE XI. (CONTINUED) 
Sample IRI % Recovery Comparison Comp. with Comp. 
with IRI of % Recovery with 
+ 99.8 JJU untreated of N % Rec. 
samples Untr. 
Smpls. 
p (12) 0 no sign. 
diff. 
(P>0.2) 
SP (12) 2.2 sign. 
±0.3 lower 
(0.1) (P<0.005) 
ss (12) 15.4 sign. 
±2.1 lower 
(0.6) (P<0.005) 
N 100 113 71.± 8 sign. 
(12) ±8 (2.4) lower 
(2. 4) (P<O.Ol) 
p 100 66.5 66.6±10.0 no sign. no sign. 
(12) ±10.0 (2.9) diff. diff. 
(2.9) (P>0.20) (P>O .1) 
SP 100 75.2 73.1±8.6 no sign. no sign. 
(12) ±5.9 (2.5) diff. diff. 
(1.7) (P>O. 4) (P>0.5) 
ss 100 82.1 62.9±11.6 no sign. no sign. 
(12) ±11.6 (3.3) diff. diff. 
(3.3) (P>O. 05) (P>O.l) 
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expected fluctuations and a comparison of insulin values of the 50 samples from 
this assay and from Dr. Brooks' clinical endocrinology laboratory (dextran-
charcoal RIA) by the t-test for paired data shows no significant difference (t = 
0.207; p >0.5). 
CATION-EXCHANGE CHROMATOGRAPHY OF HUMAN PLAS\IIA 
Chromatography of 450 ml CPD plasma on Sephadex C-50 was undertaken 
in order to determine the reproducibility of Guenther's observed heparin-
potentiation of IRI in cationic serum fractions. About 10 1-1 U IRI/ml plasma was 
adsorbed by the cation exchanger and 4396 of this IRI was eluted in the most 
cationic fraction (Fraction Xll), but heparin did not enhance IRI in this fraction 
or overall (Fig. 20). Heparin increased IRI 0.2- to 3-fold in Fractions I, VIT, X 
and XI, but heparin-induced IRI in no case exceeded 1 1-1 U /ml plasma. No 
significant heparin-potentiation of IRI was found in any lyophilized, 
reconstituted fraction. The fact that 4.8 mg protein/ml plasma was recovered 
from the gel suggests that most of the IgG was not eluted. 
ENDOGENOUS IRI AND EXOGENOUS INSULIN RECOVERY FROM SERUM 
AND PLASMA 
Since it was possible that insulin could be dissociated from a putative 
binding protein in CPD plasma and thus not be adsorbed by the cation exchanger, 
IRI in various serum and plasma samples was determined. Furthermore, 
reversible binding of insulin to a protein should be capable of detection by RIA as 
anomalous recovery of exogenous insulin from serum and plasma. 
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FIGURE 20. SEPHADEX C-50 CHROMATOGRAPHY OF HUMAN PLASMA. 
•--• Effluent osmolality 
Open bars: Protein 
Black bars: IRI without heparin 
Hatched bars: IRI with heparin 
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Serum and plasma were also treated with an anion exchange resin 
(Amberlite IRA 400; "stripped" serum, SS, and "stripped" plasma, SP). If free 
insulin-binding protein exists in serum or plasma or anion stripping generates 
free binding protein, then recovery of IRI from such samples should be low. If 
heparin or biotin dissociates insulin from a binding protein, an enhancement of 
IRI should be observed. 
It is evident from Table X that heparin caused no significant change in the 
IRI of any sample studied; 10 JJg D-biotin/ml caused slight increases of IRI in 
plasma and stripped plasma and a decrease of IRI in normal serum. However, 
appreciably low recoveries of IRI were seen in heparin-treated stripped serum 
and all biotin-treated samples, but recoveries from untreated samples were 
complete. Statistical analysis of IRI in replicate untreated and biotin-treated 
samples (Table XI) revealed that recovery of exogenous insulin from CPD 
plasma, stripped serum and stripped plasma was significantly lower than from 
normal serum, representing a loss of approximately 30 JJ U added insulin/ml 
sample. Biotin treatment caused a small but significant decrement of IRI in 
stripped serum and plasma and reduced recovery of IRI from normal serum to 
that seen in other samples, but did not further reduce recoveries from plasma, 
stripped serum or stripped plasma. 
GEL CHROMATOGRAPHY OF RADIOLABELED INSULIN IN HUMAN SERUM 
AND PLASMA 
Since diminished recovery of exogenous IRI could also be caused by 
enhancement of serum or plasma proteolytic activity, a systematic examination 
of human serum and plasma for an insulin-binding protein using the methodology 
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employed by Zapf et al. (557) to elucidate the NSILA-8-binding protein was 
undertaken. 
Purification of 1251-insulin + 5% BSA using Sephadex G-50 resulted in 
elution of no more than 17% radioactivity in the albumin fraction and 5% in the 
iodide fraction. G-200 calibration curves, depicted in Figure 21, indicate that 
significant differences in the elution behavior of proteins can occur with 
different columns. 
Despite differences in protein elution patterns of serum and plasma, the 
qualitative profile of 1251-insulin elution is very consistent (Fig. 22). About 90% 
of the radioactivity (peak B) eluted at volumes consistent with globular proteins 
of molecular weight 26,500-39,000 daltons (Tables xn, XIV, XV), indicative of 
tetramer-hexamer aggregation. This possibility is supported by elution of the 
final serum protein peak (V) appreciably after peak B, which eluted at a position 
between BSA and chymotrypsinogen A, while plasma peak B eluted coincident 
with the final protein peak (IV), at the position of chymotrypsinogen A. Less 
than 5% of the radioactivity (peak A) eluted coincident with protein peak m, 
corresponding to molecular weight 117,000-158,000 daltons. Less than 1% of the 
radioactivity (peak C) in plasma eluted at the exclusion volume (M.W. >360,000 
daltons). 1-125 activity nonspecifically associated with eluted protein. accounted 
for little more than 6% of recovered activity. 
Approximately 90% of Fraction B radioactivity was lost between elution 
from the first column to dialysis and another 90% of that activity was lost by 
completion of dialysis. Losses are attributed to adherence of labeled insulin to 
glass. Essentially no Fraction A activity was lost, however, from elution to 
dialysis and approximately 75% was recovered after dialysis; thus, high 
FIGURE 21. SEPHADEX G-200 CALIBRATION CURVES. 
v /V = Elution volume (ml)/Exclusion volume (elution 
e o 
volume of blue dextran) 
2.6 x 90 em columns: 
• Initial chromatography 
• Rechromatography of A1 + B1 
• Chromatography of stripped plasma and long incu-
bated stripped plasma 
2.5 x 21 em column: 
0--o Chromatography of A2 and A3-I 
Standards: a. catalase 
b. glucose oxidase 
c. hexokinase 
d. BSA 
e. chymotrypsin A 
f. ribonuclease A 
g. insulin 
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FIGURE 22. SEPHADEX G-200 CHROMATOGRAPHY OF EXOGENOUS 
125r-INSULIN IN HUMAN SERUM AND PLASMA. 
Open peaks: protein, designated by roman numerals. 
Shaded peaks: radioactivity, designated by letters. 
BD blue dextran 
cat catalase 
GO glucose oxidase 
hex hexokinase 
BSA bovine serum albumin 
chnA chymotrypsinogen A 
ve elution volume (ml) 
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TABLE XII. SEPHADEX G-200 CHROMATOGRAPHY OF 125I-INSULIN 
IN NORMAL HUMAN SERUM 
Fraction ve (ml) V /V Molecular Weight e o (daltons) 
CONTROL: 
I 162 1.0 >360,000 
II 222 1. 370 232,000 
III 314 1.938 115,000 
IV 500 3.086 28,000 
v 555 3.426 18,200 
A 312 1.926 117,000 
B 456 2.814 39,000 
BIOTIN: 
I 135 1.0 >360,000 
II 190 1.407 220,000 
III 260 1.925 117,000 
IV 420 3.111 27,000 
v 455 3.370 19,800 
A 270 2.000 106,000 
B 390 2.888 35,500 
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TABLE XIII. RECHROMATOGRAPHY OF G-200 ELUTION FRACTIONS 
Fraction ve (ml) 
A+ B Pool: 
I (Ilia) 
II (IIIb) 
III (IIIc) 
IV 
A 
B 
A Control (A2): 
I 
II 
A 
Insulin (A 3 -I): 
I 
II 
A 
142 
210 
300 
432 
306 
422 
63 
106 
59 
68 
109 
67 
Ve/Vo 
0.861 
1.273 
1. 818 
2.618 
1. 855 
2.558 
1.848 
3.109 
1.730 
1.994 
3.196 
1.965 
Molecular Weight 
(daltons) 
>360,000 
350,000 
82,000 
<20,000 
74,000 
<20,000 
62,000 
<20,000 
80,000 
47,500 
20,000 
49,500 
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TABLE XIV. SEPHADEX G-2JO CHROMATOGRAPHY OF 125I-INSULIN 
IN STRIPPED PLASMA (SP) 
PROTEIN PEAKS 
Fraction v (ml) Ve/Vo Molecular Protein (mg) e Weight 
Control 
I 162 1 >360,000 17.9 
II 222 1. 370 365,000 100 
III 298 1.840 149,000 257 
IV 444 2.741 26,000 
+ Cold 
!nsuiin 
I 161 1 >360,000 34.7 
II 220 1.366 370,000 91.8 
III 294 1. 826 151,000 235 
IV 440 2.733 26,500 
RADIOACTIVE PEAKS 
Fraction Ve (ml) Ve/Vo M.W. Percent Insulin 
Recover. equiv. 
Act. ( JJU) 
Control 
A 292 1.802 158,000 1.3 2.5 
B 440 2.716 27,500 89.9 177 
c 166 1.025 >360, 000 0.3 0.5 
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TABLE XIV. (CONTINUED) 
Fraction v (ml) V /V M.W. Percent Insulin e e o Recover. equiv. 
Act. (f.LU) 
+ Cold 
!nsulin 
A 294 1. 826 151,000 1.5 3.0 
B 432 2.683 29,000 91.1 188 
c 166 1.031 >360,000 0.2 0.5 
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TABLE XV. SEPHADEX G-200 CHROMATOGRAPHY OF CPD PLASMA/ 
125I-INSULIN AFTER FIVE DAYS INCUBATION AT 4° c 
PROTEIN PEAKS 
Fraction v (ml) Ve/Vo Molecular Weight Protein (mg) e (daltons) 
I 159 1 >360,000 63.3 
II 217 1.365 365,000 138 
III 297 1. 868 140,000 336 
IV 446 2.805 22,800 
RADlOACTIVE PEAKS 
Fraction v (ml) Ve/Vo M.W. Percent Insulin e recov. equiv. 
act. ( lJ U) 
A 294 1.849 147,000 1.7 11.1 
B 434 2.730 26,500 91.6 604 
c 162 1.019 >360,000 0.3 2.2 
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molecular weight-associated 1-125 activity is stable to dialysis. The elution 
profile (Fig. 22) resulting from G-200 chromatography of CPO plasm.a/1251-
insulin after a 5-day incubation at 4°C shows the effect of proteolysis during the 
extended incubation as an enlarged protein peak IV. Yet, the profile of 
radioactivity remains essentially the same as found for 1251-insulin in stripped 
plasma after 30 minutes incubation. 
The 1251-insulin/stripped plasma (SP) G-200 B-fraction, which contained 
approximately 3596 BSA (added after chromatography to prevent losses of 
radiolabeled insulin by adherence to glass or dialysis tubing) when applied to a 
50-ml G-50 column, yielded elution of nearly half the activity around the 
exclusion volume, indicating association of 1251-peptides with BSA. Decreased 
ability of this "damaged" labeled insulin to bind to AIS is demonstrated by 
incubation of elution fractions with AIS in the absence of unlabeled insulin (B0 ) 
in the RIA (Fig. 23). Material eluted in the second peak showed a B0 
characteristic of purified 1251-insulin (trace). No downfield 1251- peak was 
found. 
Displacement of this second peak activity and trace by increasing 
concentrations of unlabeled insulin was parallel in linear RIA dose-response 
curves (Fig. 24). Dose-response behavior of second peak material was nearly 
identical to that of trace in logit-log plots, including values for 5096 B0 x-
intercept and slope. Thus, despite elution of B-peak activity from G-200 in a 
supramonomeric position, rechromatography of this fraction yielded material 
immunochemically identical to 1251-insulin. 
Rechromatography of pooled serum A + B peaks and the A peak (Table XID) 
resulted in a shift of both peaks and their coeluting protein peaks to lower 
FIGURE 23. SEPHADEX G-50 CHROMATOGRAPHY OF FRACTION B 
(L-B). 
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The final peak of radioactivity (B-peak) eluting 
from a Sephadex G-200 column after application of a plasma/ 
125!-insulin mixture incubated for 5 days at 4° C was 
rechromatographed on a Sephadex G-50 column. 
Double-antibody radioimmunoassay: 
% NSB = % total radioactivity in "bound" fraction 
(guinea pig serum-antiguinea pig serum precipitate) in 
the absence of anti-insulin serum (AIS) and unlabeled 
insulin. 
B0 = % radioactivity specifically bound to AIS 
in the absence of unlabeled insulin: 
% B = CPM in bound fraction - NSB CPM Total CPM - NSB CPM 
Ve = elution volume (ml) 
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FIGURE 24. DOUBLE-ANTIBODY RADIOIMMUNOASSAY OF FRACTION B. 
Solid line: 125I-insulin 
Broken line: Fraction B (L-B) 
Bars: Range of triplicates 
The second peak of radioactivity eluting from the 
Sephadex G-50 column was examined in the RIA for ability 
of unlabeled insulin to displace radioactivity from AIS. 
Actual quantity of unlabeled insulin in the assay 
tube was one-tenth the concentration added (abscissa). 
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molecular weights (B <20,000, A= 74,000-80,000 daltons). Treatment of 125I-
insulin added to the serum A-peak (A3-I), to serum or to plasma with· biotin 
(Table Xll) or excess unlabeled insulin (Tables xm and XIV) resulted in no change 
in the elution pattern of radioactivity compared to controls and no shift of A-
peak radioactivity to positions consistent with free insulin, although 
chromatography of A3-I continued the trend of elution of both radioactivity and 
protein at higher elution volumes with successive rechromatography. 
DEXTRAN-COATED CHARCOAL ANALYSIS OF FRACTION A 
The data in Table XVI indicates that antibody-antigen reactions, 
represented by AIS-125I-insulin, are a good model for study of reversible protein 
associations using dextran-coated charcoal. Only 896 of 125I-insulin activity was 
not adsorbed to dextran-coated charcoal, while nearly 8496 activity was 
transferred to this supernatant "bound" fraction in the presence of 1:10,000 
AIS. Antibody binding of labeled insulin activity is nearly completely reversed 
by 0.1 m U unlabeled insulin, indicating competition for antibody binding sites by 
an immunochemically identical substance. Adsorption of more than 9096 labeled 
insulin to dextran-coated charcoal is unaffected by 8 M urea, but half the 
antibody-bound insulin is dissociated under these conditions. 
No dissociation of Fraction A activity is produced by these criteria by 
excess unlabeled insulin or 8 M urea, but a small fraction of "unbound" activity 
may have been transferred to the "bound" fraction by excess AIS. 
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TABLE XVI. ASSESSMENT OF PROTEIN-BOUND I-125 ACTIVITY 
USING DEXTRAN-COATED CHARCOAL 
Preparation "Bound" "Free" Percent "Bound" 
Fraction Fraction (± percent 
(spnt.) (ppt.) deviation*) 
CPM 
(± Eercent dev.*~ 
125I-insulin 393 4,517 8.0 
(4.2) (1.4) (5.0) 
125I-insulin 4,064 787 83.8 
+ AIS (2.1) (5 .1) (0.7) 
125I-insulin 797 4,073 16.4 
+ AIS + (5.1) (2.9) (6.7) 
cold ins. 
125I-insulin 432 4~, 4 74 8.8 
in 8 M urea (7.2) (1.4) (8.0) 
125I-insulin + 2,054 2,912 41.4 
AIS in 8M urea (4.1) (1.9) (2.4) 
Fraction A 674 471 58.8 
(5 day inc.) (21. 8) (9.1) (6.1) 
A + cold 735 369 66.6 
insulin (1. 2) (2.9) (0.8) 
A + AIS 763 275 73.5 
(7.0) (9. 0) (1.4) 
A in 8M urea 697 383 64.5 
(19.8) (18.5) (2. 0) 
determination of greatest 
* percent deviation = cliff. from mean - mean x 100 
mean 
Triplicate determinations 
cold insulin = 100 ~U unlabeled human insulin 
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IDENTITY OF HIGH MOLECULAR WEIGHT RADIOACTIVE FRACTIONS 
Immunochemical Analysis of Serum Proteins 
Ouchterlony immunodiffusion of 1251-insulin-serum G-200 fractions against 
specific antisera revealed that strong HSA reactivity resides in Fraction A. 
Protein found in Fraction B is due almost entirely to BSA added to stabilize 
insulin. Immunodiffusion of 1251-insulin-plasma (SP and L) fractions (Table XVll) 
demonstrated that maximum concentrations of HSA and BSA (added to stabilize 
tracer) were both found to reside in A-fractions (protein peak ill) and most of the 
human IgG was found in protein peak n, with lesser amounts in radioactive peaks 
A and C. 
SDS Polyacrylamide Disc Gel Electrophoresis of A-Fraction 
Rf values for SDS-PAGE bands were determined from band migration/dye 
migration from both the stained gels (Fig. 25) and densitometer scans of the 
gels. A calibration curve (Fig. 26) was constructed by plotting the Rf of the 
calibration bands vs. log M. W. An unexpected sixth band was assigned to the 
60,000 dalton subunit of catalase. 
The apparently homogeneous G-200 protein peak m (A-peak) was found to 
consist of more than seven distinct proteins, ranging in molecular weight from 
70,000 (probably albumin) to 240,000 daltons (Table XVID). A-peak albumin was 
estimated to be 9.596 AL protein from the area under the densitometer scan 
peaks. Thus, albumin comprised slightly more than 7 mg of the 75 mg recovered 
protein and 4.4 mg HSA remained after subtraction of the 2.74 mg total BSA 
retentate recovered. 
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TABLE XVII. IMMUNOREACTIVE PROTEIN CONTENT OF CPD PLASMA/ 
l25I-INSULIN SEPHADEX G-200 CHROMATOGRAPHY FRACTIONS 
Fraction vs. anti-BSA vs. anti-HSA vs. anti-
human IgG 
Control 
c + 
II +++ +++ ++++ 
A ++++ ++++ 
Insulin 
c ± ++ 
II +++ +++ ++++ 
A ++++ ++++ ++ 
Five day 
incubation 
c + ++ 
II +++ +++ ++++ 
A ++++ ++++ + 
Results of Ouchterlony immunodiffusion analysis. Scoring 
is based on intensity of band and proximity to antibody 
well, which reflects relative concentration of antigen. 
FIGURE 25. SDS POLYACRYLAMIDE DISC GEL ELECTROPHORESIS 
OF A-FRACTION. 
A-fraction was obtained by Sephadex G-200 chromatography 
of stripped plasma + 12 5I-insulin incubated for 5 days 
at 4° C. 
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Gels were stained with 1% fast green and fixed in methanol/ 
acetic acid/water (45:10:45). 
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FIGURE 26. SDS POLYACRYLAMIDE DISC GEL ELECTROPHORESIS 
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TABLE XVIII. RESULTS OF SDS POLYACRYLAMIDE DISC GEL 
ELECTROPHORESIS 
Band Rf M.W. (daltons) 
Calibration 
1 (catalase) 0.039 240,000 
2 (glue. ox.) 0.173 187,000 
3 (BSA) 0.418 67,000 
4 (catalase 0.471 60,000 
subunit) 
5 (chn A) 0.562 25,000 
6 (insulin) 0.717 5,500 
Sample 
1 0.030 243,000 
2 0.078 223,000 
3 0.191 172,000 
4 0.273 125,000 
5 0.315 106,000 
6 0.369 85,800 
7 0.414 71,700 
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_!ffinity Chromatography of the the A-Fraction 
A fraction of 41.2% activity nonspecifically bound to protein was assigned 
from extrapolation of G-200 interpeak radioactivity. Thus, NSB Rctivity for a 
given AL protein fraction was calculated as AL NSB activity (CPM) x percent 
total recovered AL protein in the fraction. The results of affinity 
chromatography and ultrafiltration, summarized in Table XIX, show that about 
five-sixths of the activity in AL was associated with BSA and HSA. The 
remaining activity exhibited a molecular weight less than 10,000 daltons and thus 
may correspond to the 20-27% radioactivity lost during dialysis of other A-
Fraction preparations. 
The 4% A-fraction radioactivity exhibiting a molecular weight between 
2,000 and 10,000 daltons may correspond to the apparent 796 IRI found for AL in 
previous dextran-charcoal binding studies, but this material did not behave like 
IRI in dextran-charcoal analysis (Table XX). 
EFFECT OF INSULIN ON PROLIFERATION AND GLUCOSE UPTAKE BY 
CELLS IN CULTURE 
WI38 fibroblasts exhibit strictly monolayer growth, elongated morphology 
and parallel orientation in confiuent adherent cell culture (Fig. 27a). Cell 
number determined for WI38 in 4 replicate wells exhibited a variance less than 
1596 when in excess of 2,500 cells per well. WI38 fibroblasts in passage 15-20 
plate with an efficiency of 4596. After an initial lag phase of about 18 hours, 
5,000 cells in a 2 cm2 cluster well enter log phase growth with a generation time 
of about 22 hours, until they attain confiuency at about 105 cells (Figs. 28 and 
29). The hepatoma line SK-HEP-1, with an efficiency of plating (EOP) of 3696, 
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TABLE XIX. PARTITION OF A-FRACTION ACTIVITY THROUGH 
AFFINITY CHROMATOGRAPHY 
Species mg protein % recov. CPM* % recov. Proj. % A-
protein act. NSB peak 
act. act. (CPM) 
BSA 2.74 3.6 1,699 31.3 80.5 50.7 
HSA 4.40 5.9 1,186 21.9 132 33.0 
Other 68.1 90.5 1,935 35.7 2,024 0 
Protein 
2,000- 1 126 2.3 3.9 
10,000 
M.W. 
<2,000 0 0 359 6.6 0 11.3 
M.W. 
* 
as of Feb. 7, 1977 
TABLE XX. DEXTRAN-CHARCOAL ADSORPTION OF 2,000 - 10,000 
DALTON MOLECULAR WEIGHT A - FRACTION 
Preparation Percent "Bound" ± S.D. (n = 4) 
UM-2 Retentate 43.8 ± 4.5 
UM-2 Retentate 45.9 ± 4.1 
+ 1:400,000 AIS 
UM-2 Retentate 40.4 ± 2.7 
+ 1:400,000 AIS 
+ 40 \..lU insulin 
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FIGURE 27. WI38 FIBROBLASTS. 
a. Adherent cell culture; 300X magnification. 
b. Detached cell, peroxidase-antiperoxidase stain for 
insulin; 350X magnification. 
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c. and d. Adherent cell culture in the presence of 6.9 mg 
human serum acetone powder Fraction 4/ml stationary 
medium; 300X magnification. 
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FIGURE 28. INSULIN EFFECTS ON WI38 CELL PROLIFERATION 
AND GLUCOSE UPTAKE IN BME WITH 10% FBS. 
e BME CM, mean of 4 determinations 
£ 100 ~U human insulin, average of duplicates 
• 10 mU bovine insulin, average of duplicates 
Solid lines: cell number 
Dashed lines: medium glucose 
Bars: standard deviation 
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FIGURE 29. INSULIN EFFECT ON WI38 CELL PROLIFERATION: 
SEMI-LOG PLOT. 
Data of Figure 28. 
• BME CM, time = 19.5-145.5 hours; n = 24, r = 0.990, 
t 0 = 22.4 hours, t = 32.7, P<O.OOl. 
£ 100 ~U human insulin, time = 3.5-167 hours; n = 16, 
r = 0.101, t 0 = 665 hours, t = 0.381, P>O.l. 
• 10 mU bovine insulin, time = 3.5-167 hours; n = 16, 
r = 0.966, t 0 = 31.9 hours, t = 13.9, P<O.OOl. 
bars: standard deviation 
n = number of points 
r = correlation coefficient 
t 0 = doubling time 
t = Student's t-statistic (significance of slope difference 
from zero 
P = probability that slope = 0 
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exhibited a log-phase tn of 26 hours, while the more differentiated squamous-
cell carcinoma cell line, LT2, exhibited a 2996 EOP and a tn of about 61 hours 
(Table XXI). LT2 cells also attain confiuence, while the less differentiated 
malignant cell lines SK-HEP-1, AU471 and BeWo did not attain confiuence within 
10 days. 
Figure 30 indicates that the Beckman Glucose Analyzer exhibits a high 
degree of accuracy and reproducibility. Glucose consumption by WI38 fibroblasts 
increased proportionately with cell growth (Fig. 28) at an overall rate of -7.7 
mg/106 cells/day (Table XXI) and slowed markedly to -o.9 mg/1o6·day at 
confluence. However, when 12,500 WI38 cells were plated in each well, log-
phase r was -4.00 mg/1o6·day, although the tn, 21.1 hours, was very similar to 
that found when 5,000 cells were plated per well. Furthermore, when glucose 
uptake was measured after 6.2 x 104 cells were allowed to attain confluence 
over a period of two days, the rate of glucose consumption was found to be only 
slightly below log phase uptake: -3.2 mg/106 cells/day. Log-phase r for other 
cell lines ranged from -3.5 to -8.6 mg/1o6·day (Table XXI). 
In the presence of 10 mU bovine insulin, WI38 cells entered log phase with 
a significantly lower generation time of about 32 hours and, in the presence of 
100 ~U human insulin, these cells remained in lag phase, exhibiting no growth 
during a 7-day interval (Figs. 28 and 29). Glucose consumption by WI38 
fibroblasts in the presence of 10 mU bovine insulin (r = -8.1 mg/106·day) is not 
significantly different from that of control cultures, but a 5096 increment in r (-
11.7 mg/to6·day) was seen with 100 ~U human insulin (Table XXI). Insulin added 
to these cells during log-phase growth had no apparent effect on growth rate, but 
glucose consumption rate followed the same pattern: no significant effect of 10 
TABLE XXI. INSULIN EFFECTS ON CELL PROLIFERATION AND GLUCOSE UPTAKE BY 
SEVERAL CELL LINES 
Cell Medium/ to Oiff. from CM vs. in- -r 
Line Additive (hrs.) zero-sloEe sulin sloEe (mg/l06~day) 
t p t p 
SK-HEP-1 CM 26.0 14.7 <0.001 3.52 
1 mU b.i. 30.0 10.3 <0.001 0.16 >0.1 3.88 
100 mU b.i. 28.7 5.67 <0.02 0.55 >0.1 4.28 
WI38 CM 22.4 32.7 <0.001 7.69 
100 llu h.i. 665 0.38 >0.1 10.8 <0.001 11.7 
1 mU b. i. 31.9 13.9 <0.001 5.77 <0.001 8.14 
AU471 CM 19.9 21.3 <0.001 4.93 
100 llu h.i. 34.5 9.8 <0.001 5.58 <0.001 8.91 
BeWo CM 27.8 14.9 <0.001 8.59 
100 llu h.i. 81.5 5.18<0.001 6.98 <0.001 52.5 , 
LT2 CM 60.8 10.9 <0.001 6.49 
100 llu b.i. 48.7 2.86 <0.05 0.56 >0.1 15.2 
10 mU b.i. 518 0.63 >0.1 4.26 <0.001 7.73 
CM = complete medium (t;/ith FBS) t 0 = doubling time 
r = rate of glucose uptake 
(-mg glucose/106 cells/day) 
b.i. = bovine insulin 
h.i. = human insulin 
FIGURE 30. BECKMAN GLUCOSE ANALYZER RESPONSE. 
e and • Separate assays 
r = 0.9998 
y = 0.987x- 1.77 
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mU bovine insulin (-4.6 mg/1o6·day) and about 5096 increment with 100 'IJU human 
msulin (-5.8 mg/106·day). Cell number was also unaffected by insulin added 
after cell confluence, while r was unaffected by 10 mU bovine insulin (-2.6 
mg/106·day) and 100 ll U human insulin caused a 2596 increase in r (to -4.2 
mg/106·day). An insulin-induced repression of cell proliferation and stimulation 
of glucose uptake rate was also observed for LT2, AU471 and BeWo, but not for 
SK-HEP-1 (Table XXI). 
CELL INSULIN RECEPTORS AND DEGRADATION 
After incubation with 1 mU bovine insulin/ml and washing, Wl38 cells 
showed strong positive staining with anti-insulin/peroxidase-antiperoxidase (Fig. 
27b). Although a mean specific 1251-insulin binding of 0.90 t 0.5196 was found, 
no progressive change in this binding was seen in the range 0.95-19.0 ll U 1251-
insulin. A specific association of about 0.2 'IJU (8 pg) insulin with 3.33 x 105 cells 
indicates a minimum of 2,400 insulin binding sites per cell for Wl38 fibroblasts. 
A consistent activity of 1-596 associated with suspended, adherent, and 
trypsinized SK-HEP-1 cells in quantities of 5 x 104-106 after 5 minutes-5 hours 
incubation with 1.33 'IJU and 13.3 ll U 1251-insulin indicates less than 200 insulin 
receptors per cell. Likewise, 0-296 activity was found associated with about 5 x 
104 adherent or 106 trypsinized LT2 cells, indicating less than 120 insulin 
receptors per cell. 
Immunocytochemical staining with PAP, able to detect less than 100 
molecules antigen/cell, was plainly negative for SK-HEP-1 cells, despite heavy 
background staining, and definitely positive for LT2 cells, with a lighter 
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background, as well as for AU471 and BeWo. 
RIA of replicate WI38 culture supernates revealed that insulin degradation 
occurred in cultures, resulting in 50% of the initial insulin concentration 
remaining after 22-48 hours in initial, log phase, and confluent cultures. The 
rate of insulin degradation decreased as medium insulin concentration decreased, 
with about 25% IRI remaining after 72 hours of log-phase growth. Bovine insulin 
RIA of supernates from SK-HEP-1 adherent cell cultures in the presence of 1 mU 
bovine insulin/ml showed no loss of immunoreactive insulin from the medium. 
WI38 ASSAYS FOR INSULIN IN THE PRESENCE OF SERU\1 
Short-form assays utilizing confluent cultures of WI38 (Table XXD) yielded 
a glucose uptake rate of 3.21 mg/106·day, which was still about half that for log-
phase cultures. Initial growth cultures reflect both glucose uptake and growth. 
Indices in all short-form assays were significantly increased in the presence of 
physiologic concentrations of human insulin. 
The rate of glucose consumption in confluent cultures was seen to increase 
progressively in an apparent dose-response relationship in the presence of 10-
100 J.lU human insulin, returning to control levels at higher insulin concentrations 
( ~1 mU). The same kind of dose-response increase in mg glucose consumed/106 
viable cells (but less pronounced) and a decrease in cell number was seen for 
cells seeded in the presence of 10-100 l-!U insulin. No progressive changes were 
seen when 10 J.lU-100 mU insulin was added to log-phase cultures. The variance 
of these parameters relative to their mean changes in these assays was too 
great, however, to enable their use as bioassays for insulin. 
TABLE XXII. EFFECTS OF INSULIN ON WI38 FIBROBLASTS IN THE PRESENCE OF SERUM 
tD -r I 6 t unpaired t paired p 
(hr.) (mg/lo
6
·d) (mg/10 ) 
±SD (n) 
Confluence 3.44 <0.005 
BME CM 3.21±0.64 
(27) 
100 llu hu. insulin 4.14±0.88 (9) 
Log Phase 9.29 <0.001 
BME CM 21.1 6.28±1.86 
(11) 
100 llu hu. insulin 21.1 7.17±1.86 (5) 
Initial Growth 2.32 <0.05 
BME CM 22.4 2.00±6.81 (6) 
100 llu hu. insulin 00 .15.2±12.2 (6) 
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CULTURED FffiROBLAST ASSAY FOR INSULIN 
Figure 31 illustrates that the stationary medium (SM,0.35% BSA in BME) 
described by Morell and Froesch (615) does, indeed, cause Wl38 fibroblasts to 
enter stationary phase 10 hours after complete medium (CM, BME with 10% FBS) 
is replaced with SM. These cells re~nter log phase 38 hours after SM is replaced 
with CM (based on a log-phase t 0 of 21.1 hours). Therefore, 38 hours were 
subsequently subtracted from the time of SM culture when calculating the 
proliferation rates of cells in the presence of serum fractions. Cell number was 
unaffected by 100 ~ U human insulin after 3 days. This quantity of insulin, 
however, caused a significant 65% increase in glucose uptake by these cells 
relative to controls and this insulin-induced increment in r was completely 
reversed by 0.1 ml 1:5,000 AIS (Table xxm). The mean r of -3.56 mg/106 
cells"day for 182 determinations, with a standard deviation of 1.20 mg/106·day 
and a two-tailed t-statistic of 1.98 at P = 0.05 (730) yields a 95% confidence 
range for control culture r of -1.18 to- 5.94 mg/106·day. The normal ranges for 
U (n = 86, i = 0.044, SD = 0.051) andv(n = 86, f = 0.11, SD = 0.084) were found to 
be 0.85-1.15 and 0.72-1.28, respectively. Thus, assay parameters falling outside 
these ranges are high or low at a minimum significance level of P < 0.05. 
Both assay parameters, U and R, show a progressive, dose-response 
increase with increasing insulin concentration (Fig. 32). The U-response is 
curvilinear and is linearized by logit transformation, permitting extrapolation 
beyond 100 ~U/ml. This parameter represents total ILA since it is independent of 
cell number and therefore includes the pleiotypic increment in glucose uptake 
due to the proliferative effects of growth factors. The R-response is directly 
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FIGURE 31. EFFECT OF STATIONARY MEDIUM, WITH AND WITHOUT 
INSULIN, ON WI38 CELL PROLIFERATION. 
CM: Complete medium, BME with 10% FBS. 
SM: Stationary medium, BME with 0.35% BSA. 
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TABLE XXIII. EFFECT OF INSULIN ON GLUCOSE UPTAKE BY 
STATIONARY-PHASE WI38 CELLS 
Medium n Mean r S.D. cv S.E.M. Comparison (-mg/ (%) with Control 
10 6 • d) t p 
SH 182 3.56 1.20 33.7 0.09 
SM + 10 5.87 1.13 19.3 0.36 6.23 <0.001 
100 ll u 
human 
insulin 
SM + 5 3.26 0.73 22.4 0.33 0.88 >0.10 
100 ll u 
human 
insulin 
+ AIS 
FIGURE 32. CULTURED FIBROBLAST BIOASSAY FOR INSULIN: 
STANDARD CURVES. 
a. Total ILA 
= glucose ultake (mg) 
U control g ucose uptake (mg) 
b. Specific ILA 
R = rate of 
contro 
Abscissa: Insulin concentration in assay well. 
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linear and represents specific ILA since it is corrected for increase in cell 
number, measuring insulin-like effects on r. Thus, this assay is capable of 
delineating the effects of growth factors and insulin, and was chosen as the in 
vitro bioassay for the systematic study of serum fractions. 
--
BULK FRACTIONATION OF HUMAN SERUM 
At least 99% of both serum proteins and IRI was retained by the 10,000-
dalton M. W .-cutoff membrane (Table XXIV A). A nearly 60-fold enhancement of 
IRI was seen in the PM10r1 fraction compared to the PM10r2 fraction. Serum 
ILA was about 180 lJU/ml (Table ~XIVB) and ILAs agreed well with this value. 
Human serum potentiation of Wl38 proliferation was 13% of FBS. The enhanced 
IRI of PM10r1 was reflected in the ILA and ILAs values for this fraction. A 10-
fold dilution of PM10r1 yielded an ILA value that agreed well with the IRI. A 
large enhancement of growth potentiation was also seen in this fraction. The 
ILAs of J;>M10r2 agreed well with IRI, while about two-thirds of serum ILA was 
recovered in this fraction, which possessed more growth-potentiating capacity 
than whole serum. Less than 2% of recovered serum ILA or ILAs was found in 
UM2 retentates and filtrates. No heparin or biotin enhancement of ILA, ILAs, or 
growth potentiation was seen in serum. Heparin enhancement of PM10r1 (100x) 
ILA, PM10r2, Ul\1:2fl and UM2f2 ILAs and PM10r1 (100x) growth potentiation and 
biotin enhancement of UM2f1 growth potentiation was also noted. 
Treatment of the PM10 Retentate 
Re-concentration of PM10r2 through a PM 10 membrane resulted in nearly 
TABLE XXIVA. BULK FRACTIONATION OF HUMAN SERUM: IRI 
Fraction Vol. mg residue Total Serum IRI 
(ml) Protein Equiv. JJU/ml JJU/mg Total % (mg) (ml) Protein JJU Total 
Human Serum 488 31,134 488 17.4 0.27 8,491 100 
PMlOrl 71.0 18,255 17,160 244 6,591 27.3 467,933 5,511 
PM10r2 84.5 17,514 16,638 244 98.2 0.50 8,294 97.7 
UM2rl 26.0 413 54 172 9.3 4.5 241 2.8 
UM2r2 24.5 101 45 172 3.4 1.9 84 1.0 
UM2fl 291 2,406 48 291 0 0 0 0 
UM2f2 275 228 6.8 24 0 0 0 0 
TABLE XXIVB. BULK FRACTIONATION OF HUMAN SERUM: BIOASSAY 
Fraction Treatment v r ILA !LAs tD FBS (-mg/10 6 'd) ~U/ml Total ~U/ml ~U/ml Total ~U/ml (hrs. )equiv. 
mU serum mU serum (ml/ml 
serum) 
Human Control 1. 26 5.49 177* 86 177 208 101 208 173 0.13 
Serum Heparin 1.31* 5.13 179')\' 87 179 88 43 88 148 0.15 
Biotin 1. 33'~( 5.33 234'~( 114 234 140 68 140 140 0.16 
PMlOrl Control 2.82* 3.71 5, 963-;\' 423 1,735 0 0 0 36.0 1. 78 
(lOx) Heparin 2.35* 3.36 2, 570'~( 1&2 748 0 0 0 43.7 1.46 
Biotin 3.28* 3.46 5,974')\' 424 1,738 0 0 0 31.5 2.03 
(lOOx) Control 1.38* 4.67 14,411'~( 1,023 4,195 3,500 249 1,018 125 5.13 
Heparin 1.85* 4.52 25,496* 1,810 7,419 2,000 142 582 65.4 9.80 
Biotin 1.58* 4.46 15, 825'~( 1,124 4,606 0 0 0 87.9 7.28 
PM10r2 Control 1. 44')\' 4.69 322'~( 27 112 115 9.7 40 102 0.22 
Heparin 1. 21 5.10 3701( 31 128 245 21 85 194 0.11 
Biotin 1.60* 4.78 535')'( 45 185 58 4.9 20 78.8 0.28 
UM2rl Control 1. Sl·k 3.20 81 2.1 12 0 0 0 90.7 0.04 
Heparin 1. J8"1'c 3.31 78 2.0 12 0 0 0 116 0.03 
Biotin 1. 48')\- 2.85 0 0 0 0 0 0 95.3 0.03 
UM2r2 Control 0.25* 10. 3')'c' 0 0 0 139 3.4 20 00 0 
Heparin 0.40* 7. 531c 0 0 0 78 1.9 11 00 0 
Biotin 0.23* 11.4')\- 0 0 0 163 4.0 23 00 0 
~ 
t-:1 
CJ:) 
TABLE XXIVB. (CONTINUED) 
Fraction Treatment v r ILA !LA tD FBS (-mg/10 6 'd) s ~U/ml Total ~U/ml ~U/ml Total ~U/ml (hrs. )equiv. 
mU serum mU serum (ml/ml 
serum) 
UM2fl Control 1.03 4.32 0 0 0 0 0 0 1,253 0.02 
Heparin 0.89 4.95 0 0 0 93 27 93 00 0 
Biotin 1.33* 3.48 0 0 0 0 0 0 130 0.18 
UM2f2 Control 0.27* 6.14* 0 0 0 3.4 0.9 39 00 0 
Heparin 0.20* 8. 74""~'( 0 0 0 8.9 2.4 102 00 0 
Biotin 0.27* 7.26* 0 0 0 5.8 1.6 66 00 0 
* Significantly different from control population. (See legend to Fig. 34.) 
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50% of IRI passing through the membrane, but less than 5% of IRI passed through 
the membrane after treatment of this fraction with heparin, biotin or urea 
(Table XXV A). Inability of these agents to enhance passage of insulin through 
PMlO membranes was reflected in ILA (Table XXVB), but ILAs was found in 
heparin, biotin and urea filtrates. Growth potentiation followed the pattern of 
ILA. Heparin enhanced ILA in the heparin filtrate and the acid-ethanol 
precipitate, ILAs in the control retentate, biotin retentate and filtrate, and urea 
filtrate and growth potentiation in the heparin filtrate. Biotin enhanced ILA in 
the control, heparin and biotin filtrates and the acid-ethanol precipitate, ILAs in 
the urea filtrate and growth potentiation in the heparin filtrate and acid-ethanol 
precipitate. 
Gel Chromatography of the P'ilO Retentate 
All of the PMlOrl IRI applied to the Sephacryl S-200 column was recovered 
in the eluate and more than 90% of the recovered IRI eluted as protein less than 
M.W. 12,000 daltons (calibration curve, Fig. 33) with a peak at about 6,500 
daltons (Table XXVIA). A minor IRI peak also occurred in Fraction 4, 
corresponding to about 240,000 daltons, possibly coincident with a peak of 
growth potentiation since v was increasing in Fraction 2. However, ILA data of 
Fractions 3-8 were obliterated due to toxicity of these fractions for WI38 cells, 
resulting in loss of all cells in Fractions 3-5 (Table XXVm, Fig. 34). 
ILAs is not depicted in Fig. 34 wherever v is significantly lower than the 
control population (resulting in spurious elevation of ILAs, which is dependent 
upon cell number), but major ILA and ILAs peaks occur at Fraction 10 (M.W. 
37 ,000), coincident with a minor IRI peak. ILA peaks at Fractions 12 (M. W. 
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TABLE XXVA. TREATMENT OF PM10r2: IRI 
Sample Vol. Serum IRI 
(ml) equiv. ~U/ml Total ~u % Recovered (ml) 
CR 1.3 0.90 10.4 13.5 43.8 
CF 10.5 0.80 0.9 9.9 32.1 
HR 1.1 0.90 5.7 6.3 20.5 
HF 10.9 0.82 0 0 0 
BR 1.1 0.90 18.0 19.8 64.3 
BF 10.9 0.82 0.1 0.9 2.9 
UR 1.5 0.90 5.4 8.1 26.3 
UF 10.5 0.79 0 0 0 
AEP 5.1 3.6 0 0 0 
c = control 
H = heparin 
B = biotin 
u = 8 M urea 
AEP = acid ethanol precipitate 
R = PM 10 membrane (M.W. cutoff = 10,000) retentate 
F = PM 10 filtrate 
TABLE XXVB.TREATMENT OF PM10r2: BIOASSAY 
Sample \) r ILA ILA tD FBS (mg/10 6 'd) JJU/ml Total JJU JJU/ml llU/ml Tota~ JJU llU/ml equiv. 
serum serum (hrs.) (ml/ml 
serum) 
CR 1. 77* 3. 55 301* 391 434 0 0 0 66.9 0.33 
heparin 1. 20 3.81 194* 252 280 59 77 86 210 0.11 
biotin 2.29* 2.97 228 297 330 0 0 0 46.1 0.48 
CF 0.99 4.30 0 0 0 0 0 0 00 0 
heparin 1.03 3.85 0 0 0 0 0 0 1,292 0.02 
biotin 1.09 4.32 6.3 66 83 0 0 0 443 0.06 
HR 2.24* 4.08 132* 145 161 0 0 0 47.4 0.46 
heparin 2.17* 3.67 74 81 90 0 0 0 49.3 0.45 
biotin 2.29* 3.77 97* 107 119 0 0 0 46.1 0.48 
HF 0.95 5.37 0 0 0 1.7 18 22 00 0 
heparin 1.93* 4. 70 7.2 78 95 0.4 4.5 5.5 61.6 0.39 
biotin 1. 25 4.77 2.6 28 34 0 0 0 182 0.13 
BR 1.38* 4.72 124* 137 152 0 0 0 126 0.17 
heparin 1.09 5.37 94* 103 115 20 23 25 470 0.05 
biotin 1.63* 4.58 152* 167 186 0 0 0 82.9 0.27 
BF 0.87 5.19 0 0 0 2.1 23 27 00 0 
heparin 0.80 5.65 0 0 0 8.7 95 115 00 0 
biotin 1.00 4. 74 2.9 31 38 0 0 0 00 0 
UR 1.55* 4.79 84* 126 140 21 32 35 92.1 0.24 
heparin 1. 68'l'C' 4. 28 64';'C' 95 11 0 0 0 77.8 0.28 w w 
biotin 2.06* 4.02 75* 112 125 0 0 0 55.9 0.39 w 
TABLE XXVB. (CONTINUED) 
Sample \) r ILA ILA tD FBS (mg/l06'd) J,JU/ml Total J.JU J.JU/ml J.JU/ml Tot a~ J,JU J.JU/ml equiv. 
serum serum (hrs.) (ml/ml 
serum) 
UF 0.88 5.03 5.2 55 69 7.7 81 103 00 0 
heparin 0.82 5.57 3.2 34 43 18 189 239 00 0 
biotin 0.77 5.82 0 0 0 23 243 308 00 0 
AEP 1.30* 4.63 21 109 30 0 0 0 177 0.12 
heparin 1.32* 5.01 55 282 78 0 0 0 168 0.13 
biotin 1.91* 3.19 56 287 80 0 0 0 71.9 0.31 
* Significantly different from control population. (See legend to Fig. 34.) 
FIGURE 33. SEPHACRYL S-200 CALIBRATION CURVE. 
v /V = elution vol. (ml)/exclusion vol. (ml) 
e o 
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TABLE XXVIA. GEL CHROMATOGRAPHY OF PMlOrl: IRI 
Fraction M.W. (kd) Total IRI Dextran/ 
Protein Total ll U/ml % Charcoal (mg) 
llu serum total % bound 
1 >250 0 22 0.6 0.03 0 
2 >250 12.2 120 3.0 0.2 1.0 
3 >250 170 918 23 1.2 4.6 
4 210->250 218 943 24 1.2 6.0 
5 137-210 211 689 17 0.9 5.6 
6 98-137 169 685 17 0.9 5.0 
7 72-98 156 449 11 0.6 4.0 
8 54-72 145 401 10 0.5 1.9 
9 42-54 152 314 7.9 0.4 2.5 
10 33-42 180 336 8.4 0.4 1.8 
11 26-33 192 271 6.8 0.4 0.4 
12 21-26 196 486 12 0.6 0.9 
13 17.5-21 182 528 13 0.7 1.6 
14 14.6-17.5 163 595 15 0.8 1.0 
15 12.2-14.6 155 818 20 1.1 1.1 
16 10.5-12.2 96.7 1,704 43 2.2 0.2 
17 9.0-10.5 52.1 3,652 91 4.8 0 
18 7.8-9.0 36.2 8,748 219 11.4 0 
19 6.8-7.8 32.5 19,296 482 25.2 0 
20 6.1-6.8 26.0 25,904 648 33.8 0.7 
21 5.5-6.1 17.8 21,484 537 28.0 0 
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TABLE XXVIA. (CONTINUED) 
Fraction M.W. (kd) Total IRI Dextran/ 
Protein Total J.IU/ml % Charcoal (mg) j.lu serum total % bound 
22 5.0-5.5 7.8 11,970 299 15.6 0 
23 <5 2.5 5,480 137 7.1 0 
24 <5 4.6 1,000 25 1.3 0.6 
Total 2,577 106,813 2,670 139 
(91.4%) 
TABLE XXVIB. GEL CHROMATOGRAPHY OF PMlOrl: BIOASSAY 
Fraction Serum \) r ILA ILA5 tD FBS % total 
equiv. (mg/10 6 ·d) Total ~U/ml '7o total Total ~U/ml equiv. 
assayed ~u serum ~u serum (hrs.) (ml/ml 
(ml) serum) 
1 1.4 1. 71* 3.46 987* 25 1.4 636 16 63.8 0.02 1.4 
neparin 1.36* 3.69 1,079-;'( 27 3.6 795 20 111 0.01 1.0 
biotin 1.38* 3.46 816* 20 1.2 564 14 106 0.01 0.7 
2 1.3 1.77* 3.13 523'>''" 13 0.8 0 0 59.9 0.03 1.6 
neparin 1.59* 3.09 387* 10 1.3 0 0 73.8 0.02 1.6 
biotin 2.19* 2.44 296 7 0.4 0 0 43.6 0.04 1.9 
3 1.4 TOXIC 
4 1.3 TOXIC 
5 1.2 TOXIC 
6 1.2 0.27* 8.62* 0 0 0 5,712 143 00 0 0 
neparin 0.51* 4. 79 0 0 0 1,572 39 00 0 0 
biotin 0.47* 5.82 0 0 0 2,687 67 00 0 0 
7 1.2 0.26* 7.36* 0 0 0 6,175 154 00 0 0 
neparin 0.26* 6.43* 0 0 0 4,973 124 00 0 0 
biotin 0.37* 5.26 0 0 0 3,429 86 00 0 0 
8 1.2 0.44* 5.75 185 5 0.3 4,670 117 00 0 0 
neparin 0.69""" 4.34 501'''" 13 1.7 2,673 67 00 0 0 
biotin 0.54* 5.70 539"''" 13 0.8 4,620 116 0 0 (.o.) 00 (.o.) 
<0 
TABLE XXVIB. (CONTINUED) 
Fraction Serum \) r !LA !LAs t 0 FBS % total 
equiv. (mg/10 6 'd) Total llU/ml % total Total llU/ml equiv. 
assayed llu serum llu serum (hrs.) (ml/ml 
(ml) serum) 
9 1.2 1.04 4.64 BOO"( 20 1.2 875 22 1,089 0.002 0.1 
lieparin 1. 24 4.29 801* 20 2.7 545 14 198 0.009 0.6 
biotin 1.65* 3.86 937* 23 1.3 132 3 85.2 0.02 1.0 
10 1.2 0.97 4.22 1,850* 46 2.7 2,311 58 00 0 0 
neparin 1.50* 3.02 1,254* 31 4.1 658 16 105 0.02 1.1 
biotin 0.16* 19.5* 463* 12 0.7 23,032 576 00 0 0 
11 1.3 0.96 2.83 618* 15 0.9 1,144 29 00 0 0 
heparin 0.67* 4.35 683"( 17 2.3 3,492 87 00 0 0 
biotin 1.09 2.40 604* 15 0.9 473 12 397 0.004 0.2 
12 1.2 1.13 2.66 794* 20 1.1 883 22 280 0.006 0.4 
heparin 0.96 3.04 766* 19 2.6 1,504 38 00 0 0 
biotin 1.01 2.98 1,004* 25 1.4 1,406 35 3,439 0.001 0.03 
13 1.2 0.74 4.38 427* 11 0.6 1,950 49 00 0 0 
neparin 0.78 3.86 321* 8 1.0 1,300 33 00 0 0 
biotin 1.06 3.41 581* 15 0.8 748 19 681 0.003 0.1 
14 1.3 1.05 3.83 532* 13 0.7 561 14 814 0.002 0.1 
neparin 1. 25 3.45 339* 8 1.1 240 6 178 0.01 0.7 
biotin 1.13 3.89 505* 13 0.7 448 11 325 0.005 0.3 
w 
""' 0 
TABLE XXVIB. (CONTINUED) 
Fraction Serum \/ r ILA ILAs t 0 FBS % 
equiv. (mg/l0 6 •d) Total ~U/ml % total Total ~U/ml equiv. total 
assayed ~u serum ~u serum (hrs.) (ml/ml 
(ml) serum) 
15 1.2 0.85 4.39 531* 13 0.8 1,618 40 00 0 0 
neparin 1.14 3.15 405* 10 1.4 219 5 303 0.006 0.4 
biotin 1.00 3.43 461* 12 0.7 472 12 00 0 0 
16 1.2 0.85 3.79 444* 11 0.6 1,311 33 00 0 0 
neparin 0.91 3.32 296 7 1.0 776 19 00 0 0 
biotin 1.04 2.99 340* 9 0.5 242 6 940 0.002 0.1 
17 1.3 0.93 3.60 389* 10 0.6 704 18 co 0 0 
neparin 0.59* 4.82 100 2 0.3 2,066 52 00 0 0 
biotin 1.09 2.79 271 7 0.4 0 0 428 0.004 0.2 
18 1.4 1.32* 3.35 434* 11 0.6 237 6 154 0.01 0.6 
neparin 0.59* 5.14 121 3 0.4 1,904 48 co 0 0 
biotin 1.04 3.54 260 7 0.4 487 12 1,088 0.001 0.07 
19 1.5 1.26 3.86 507* 13 0.7 352 9 185 0.008 0.5 
neparin 1.02 3.95 348* 9 1.2 420 11 2,156 0.001 0.05 
biotin 1.35* 3.41 292* 7 0.4 190 5 142 0.01 0.5 
20 1.5 0.03* 29.6 0 0 0 25,558 639 co 0 0 
neparin 0.63* 5.49 275* 7 0.9 2,470 62 co 0 0 
biotin 0.08* 35.1 0 0 0 30,745 769 co 0 0 
c., 
~ 
1-' 
TABLE XXVIB. (CONTINUED) 
Fraction Serum \) r !LA I LAs tD FBS % 
equiv. (mg/10 6 'd) Total ~U/ml '7o total Total ~U/ml equiv. total 
assayed ~u serum ~u serum (hrs.) (ml/ml 
(ml) serum 
21 1.8 1.06 4.39 358* 9 0.5 781 20 607 0.002 0.1 
neparin 1.35* 2.96 205 5 0.7 0 0 118 0.01 0.7 
biotin 0.95 3.88 279* 7 0.4 390 10 00 0 0 
22 2.1 0.92 3.09 183 5 0.3 166 4 00 0 0 
neparin 1.25 2.30 133 3 0.4 0 0 159 0.007 0.5 
biotin 1.16 2.44 183 5 0.3 0 0 238 0.005 0.2 
23 1.6 0.80 2.73 109 3 0.2 538 13 00 0 0 
neparin 0.90 2.35 79 2 0.3 225 6 00 0 0 
biotin 0.59* 3.72 182 5 0.3 1,700 43 00 0 0 
24 1.7 TOXIC 
Total 9,671 242 13.9 0.08 4.5 
heparin 8,093 202 25.0 0.09 6.3 
biotin 8,013 200 11.5 0.10 5.1 
* Significantly different from control population. (See legend to Fig. 34.) 
FIGURE 34. SEPHACRYL S-200 CHROMATOGRAPHY OF PMlOrl. 
Bioassay: Solid bars =no treatment 
Open bars = heparin (100 ~g/ml) 
Hatched bars = biotin (10 ~g/ml) 
b.d. = blue dextran 
g.o. = glucose oxidase 
BSA = bovine serum albumin 
Mb = myoglobin 
IRI = immunoreactive insulin (measured by RIA) 
= cell number/control cell number 
!LA = specific insulin-like activity 
s 
* Significantly higher than control population. 
A 95% confidence-limit control range was determined 
by assigning each control culture a U-value based on 
the average glucose uptake of two control cultures 
per plate. Range = l±(mean of IU-11+ {t 0 • 05x S.D.}) 
= 0.85-1.15. Therefore, cultures of U>l.l5 were 
judged to be higher than the control population at 
a minimum significance level of P<0.05. 
t Toxic 
* Control range (determined like !LA control range) 
= 0.72-1.28. 
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24,000), 14 (M. W. 16,000) and 19 (M.W. 7 ,000), and 1LAs peaks at Fractions 13 
(M.W. 19,000), 15 (M.W. 13,000), 21 (M.W. 6,000) and 23 (M.W.<5,000) were ·also 
observed. A peak of growth potentiation occurred at Fraction 18 (M.W. 8,000). 
Heparin-induced increase of 1LAs occurred in Fraction 12. Biotin-enhancement 
of both 1LA and ILAs was also seen in this fraction. Enhancement of cell 
proliferation by heparin occurred in Fraction 10 and by biotin in Fractions 2 
(M.W. >250,000) and 9 (M.W. 48,000). Fractions 20 (M.W. 6,500) and 24 (M W< 
5,000) were also toxic for W138 fibroblasts. Heparin caused inhibition of 1LA, 
1LAs and v in several fractions. Both heparin and biotin significantly decreased 
1LA and 1LAs in Fraction 10, and biotin also decreased v in this fraction. 
Because cytotoxicity of high molecular weight fractions could have been 
caused by lipidic material such as low-density lipoproteins and chylomicrons 
(738,739), bioassay was carried out on an acetone powder of Fraction 4. Loss of 
toxicity with a peak of 1LA due to a growth-potentiating effect was noted in the 
treated fraction (Table XXVll). 
Dextran-Charcoal Analysis of Fractions 
Since appearance of large quantities of monomeric 1R1 in PM10r1 is 
consistent with dissociation of the hormone from a serum binding protein, 
dextran-charcoal analysis of S-200 chromatography fractions was undertaken to 
detect appreciable binding of 1251-insulin by a liberated binding protein. A 
maximum net binding of 696 was found in Fraction 4 (Table XXVIA). 
Reversibility of this binding was tested by dextran-charcoal analysis of acid-
treated human serum, PM10r2 and PM10r1 S-200 Fraction 5 PM-10 retentates. 
Although these fractions exhibited about 2096 net binding of 1251-insulin, no 
TABLE XXVII. TREATMENT OF PMlOrl CHROMATOGRAPHY FRACTIONS 
Fraction Serum \} r ILA ILA8 tn FBS % 
equiv. (mg/ 106 ·d) Total lJ U/ml % total Total uU/ml equiv. total 
assayed vU serum uU serum (hrs.) (ml/ml (ml) serum) 
4 AP 1.3 2.00* 2.59 766* 19 1.1 90 2 57.8 0.03 1.6 
heparin 1.82* 2.64 740* 18 2.5 90 2 66.9 0.02 1.7 
biotin 1.71* 2.66 654* 16 0.9 30 1 74.6 0.02 1.1 
9 HOAcR 1.2 1.18 3.58 230 6 0.3 0 0 212 0.009 0.5 
heparin 1.17 3.56 202 5 0.7 0 0 223 0.008 0.6 
biotin 1. 21 3.20 111 3 0.2 0 0 184 0.01 0.5 
9HOAcF 1.1 1.43* 4.22 273 7 0.4 0 0 98.0 0.02 1.2 
heparin 1.12 3.79 108 3 0.4 203 5 309 0.007 0.4 
biotin 0.87 6.02* 30'1 8 0.4 756 20 00 0 0 
12HOAcR 1.2 0.67* 4.33 192 5 0.3 1,481 37 00 0 0 
heparin 0.91 3.44 248 6 0.8 461 12 00 0 0 
biotin 0.98 3.13 235 6 0.3 82 2 00 0 0 
12HOAcF 1.1 1.11 4.68 288 7 0.4 128 3 380 0.005 0.3 
heparin 1.14 4.59 309 8 1.0 0 0 303 0.007 0.5 
biotin 0.87 5.58 298 7 0.4 624 15 00 0 0 
')'c Significantly different from control population. (See legend to Fig. 34.) 
A:P acetone powder R PM 10 retentate w 
~ 
0') 
HOAc acetic acid F PH 10 filtrate 
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decrease in this binding was observed after treatment of fractions with 6M urea 
or 1 m U insulin despite apparent enhancement of monomeric IRI by acid 
treatment (Table XXVlli). 
NSILA~ Screen 
Acid treatment of PM10r1 S-200 Fraction 9 resulted in appearance of 
significant growth-potentiating activity in the PM 10 filtrate. Heparin and 
biotin did not enhance the activity of the filtrate. A biotin-enhanced !LAs was 
also seen in acid-treated Fractions 9 and 12 (Table XXVD). 
Comparative RIA 
Appearance of large amounts of IRI in PM10r1 is also consistent with 
contamination by exogenous insulin, especially since porcine insulin was being 
purified by another investigator in the same laboratory. One possible mode of 
contamination could have been through common use of lyophilization flasks. Use 
of porcine trace and standards in the insulin RIA was undertaken in order to 
discriminate dose-response behavior of human and porcine insulins. 
Unfortunately, no significant difference in displacement of porcine trace by 
human and porcine standards was found, so that this question could not be 
answered. 
GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE POWDER 
In order to examine characteristics of the important exclusion region of 
chromatographed serum, S-200 chromatography was carried out on human serum 
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TABLE XXVIII. ACID TREATMENT OF SERUM AND SERUM FRACTIONS 
Fraction Vol. IRI Dextran-Charcoal (ml) ~u % IRI % total Treatmt. % bound 
recov. recov. 
Human 
Serum 
Retentate 1.2 18.8 108 33.0 None 20.3 
6 M urea 26.0 
Insulin 30.2 
Filtrate 20.1 38.2 220 67.0 
PM10r2 
Retentate 1.2 19.9 57.8 24.7 None 21.7 
6 M urea 25.8 
Insulin 29.6 
Filtrate 20.2 60.6 176 75.3 
PMlOrl 
Fraction 5 
Retentate 1.0 131 69.0 64.5 None 20.3 
6 M urea 46.3 
Insulin 26.8 
Filtrate 19.0 72.2 38.0 35.5 
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acetone powder, the results of which are summarized in Tables XXIXA and Band 
FigUre 35. 
All of the IRI applied to the S-200 column was recovered in the eluate, but 
more than half of this material eluted at positions corresponding to molecular 
weights greater than 18,000 daltons. IRI peaks were seen at Fractions 3 (M. W. 
240,000), 7 (M.W. 57,000), 11 (M.W. 21,000), 16 (M.W. 8,000) and 20 (M.W. 
5,000). The expectation that acetone would extract toxic lipids from serum was 
realized since toxicity was completely eliminated from the exclusion fractions, 
verifying a pleiotypic ILA peak, probably at Fraction 3. Unfortunately, bioassay 
of untreated and biotin-treated Fraction 3 was unable to be completed because 
of microbial contamination. 
A peak of growth potentiation was seen in Fraction 7 (coincident with an 
IRI peak), followed by an ILA peak at Fraction 8 (M. W. 43,000) and an ILAs peak 
at Fraction 9 (M.W. 33,000). Another peak of growth potentiation occurred at 
Fraction 10 (M. W. 26,000), followed by an ILA peak at Fraction 11 and an ILAs 
peak at Fraction 12 (M.W. 17,000). An ILA peak coincident with a v peak and 
heparin- and biotin-inhibited ILAs occurred at Fraction 15 (M. W. 10,000). 
Extensive cytotoxicity was seen below M.W. 9,000, from Fraction 16. ILA peaks 
were also observed at Fractions 5 (M.W. 110,000) and 13 (M.W. 14,000), and ILAs 
peaks at Fractions 1 (M.W. >250,000) and 13. 
Heparin stimulation of cell proliferation and ILA was noted in Fraction 1 
and of ILAs in Fractions 5, 7, and 10. The compound also appeared to exert a 
sparing effect on loss of cells in Fractions 12 and 14. Biotin stimulated cell 
proliferation in Fraction 1, ILA in Fractions 5-7 and 9, and ILAs in Fractions 5, 
7, and 10. Heparin inhibited ILA in the serum acetone powder and Fractions 2 
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·rABLE XXIXA. GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE 
POWDER: IRI 
Fraction M.W. (kd) Total IRI 
Protein Total llu llU/ml % Total (mg) serum 
AP 2,032 631 17.0 100 
1 >250 0.08 0 0 0 
2 >250 32.8 20.4 0.5 3.2 
3 190->250 125 78.0 2.1 12.4 
4 130-190 126 44.4 1.2 7.0 
5 92-130 122 39.6 1.1 6.3 
6 65-92 132 24.0 0.6 3.8 
7 49-65 152 61.2 1.6 9.7 
8 37.5-49 157 46.8 1.3 7.4 
9 28.5-37.5 146 2.4 0.1 0.4 
10 23-28.5 140 0 0 0 
11 18.7-23 154 16.8 0.5 2.7 
12 14.9-18.7 158 0 0 0 
13 12.5-14.9 150 0 0 0 
14 10.7-12.5 143 0 0 0 
15 8.9-10.7 146 0 0 0 
16 7.6-8.9 125 10.8 0.3 1.7 
17 6.8-7.6 109 9.6 0.3 1.5 
18 5.9-6.8 73.2 48.0 1.3 7.6 
19 5.2-5.9 32.8 63.6 1.7 10.1 
351 
TABLE XXIXA. (CONTINUED) 
Fraction M.W. (kd) Total IRI 
Protein Total lJU lJU/ml % Total (mg) serum 
20 <5-5.2 13.4 82.8 2.2 13.1 
21 <5 3.7 75.6 2.0 12.0 
22 <5 3.1 21.6 0.6 3.4 
23 <5 2.1 14.4 0.4 2.3 
24 <5 14.1 14.6 0.4 2.3 
Total 2,261 675 18.2 107 
(111% 
recoy.) 
TABLE XXIXB. GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE POWDER: BIOASSAY 
Fraction Serum \) r ILA I LAs tD FBS % 
equiv. (mg/l06•d) Total llU/ml % total Total llU/ml equiv. total 
assayed llu serum llu serum (hrs.) (ml/ml 
(ml) serum) 
AP 0.1 1.96* 4.14 15,939* 430 100 3,875 104 58.7 0.37 1.00 
neparin 1.98* 3.66 8, 955·k 241 100 0 0 57.9 0.38 100 
biotin 2.09* 3.46 8,638 233 100 0 0 53.6 0.41 100 
1 0.9 0.90 4. 75 0 0 0 620 17 00 0 0 
'fieparin 1.41* 3.88 266 7 1.7 0 0 115 0.02 5.4 
biotin 1.37* 3.63 0 0 0 0 0 126 0.02 4.6 
2 1.7 1.45* 3.52 482* 13 3.0 197 5 106 0.01 3.3 
'fieparin 1.30* 3.58 310* 8 1.9 77 2 151 0.009 2.3 
biotin 0.31* 3.65 0 0 0 110 3 00 0 0 
3 1.5 
neparin 1.62* 4.24 661* 18 7.4 144 4 73.7 0.02 5.1 
4 1.8 1.38* 4.54 222* 6 1.4 31 1 120 0.01 2.8 
'fieparin 1.22 4.25 132 4 1.5 0 0 194 0.006 1.7 
biotin 1.38* 4.13 156 4 1.8 0 0 120 0.01 2.5 
5 1.7 1.13 3.82 380* 10 2.4 344 9 330 0.004 1.1 
'fieparin 0.90 4.52 302* 8 3.4 833 22 00 0 0 
biotin 1.00 4.26 434* 12 5.0 644 17 00 0 0 
6 1.7 0.71* 5.42 229* 6 1.4 1,287 35 00 0 0 
'fieparin 0.90 4.91 374* 10 4.2 946 25 0 0 
..., 
00 (11 
biotin 0.82 5.63 463* 12 5.4 1,430 39 0 0 ('.,) 00 
TABLE XXIXB. (CONTINUED) 
Fraction Serum v r ILA !LAs tD FBS % 
equiv. (mg/10 6 ·d) Total ~U/rnl % total Total ~U/ml equiv. total 
assayed ~u serum ~u serum (hrs.) (ml/ml 
(ml) serum) 
7 1.6 1.72* 3.80 414* 11 2.6 0 0 74.4 0.02 5.1 
neparin 1.33* 4.34 433* 12 4.8 214 6 142 0.01 2.6 
biotin 1.25 4. 70 514* 14 6.0 440 12 181 0.008 1.9 
8 1.6 1.23 4.29 581* 16 3.6 531 14 172 0.008 2.2 
neparin 1.17 3.42 242 7 2.7 150 4 226 0.006 1.6 
biotin 1.17 3.84 339* 9 3.9 219 6 226 0.006 1.5 
9 1.6 0.86 5.14 225 6 1.4 580 16 ()0 0 0 
neparin 0.88 5.27 280* 8 3.1 673 18 ()0 0 0 
biotin 1.15 4.40 317* 9 3.7 151 4 276 0.005 1.2 
10 1.6 1.32* 3.62 363* 10 2.3 124 3 139 0.01 2.6 
neparin 1.12 4.13 438* 12 4.9 407 11 340 0.004 1.0 
biotin 0.96 4.43 374* 10 4.3 610 16 00 0 0 
11 1.5 0.43* 12.02* 446 12 2.8 4,929 133 ()0 0 0 
neparin 0.65* 7.52* 224 6 2.5 2,111 57 ()0 0 0 
biotin 0. 45"~\" 9.98* 220 6 2.5 3,660 99 ()0 0 0 
12 1.5 0.58* 12.38* 237 6 1.5 3,273 88 00 0 0 
heparin 0.82 7.78* 369* 10 4.1 1,074 29 00 0 0 
biotin 0.54* 10.99* 298"(' 8 3.4 2,606 70 ()0 0 0 
(..) 
C/1 
(..) 
TABLE XXIXB. (CONTINUED) 
Fraction Serwn \1 r ILA ILA5 tD FBS % 
equiv. (mg/10 6 ·d) Total ~0/ml % total Total ~U/ml equiv. total 
assayed ~u serum ~u serum (hrs.) (ml/ml (ml) serum) 
13 1.5 0.64* 9.98* 417* 11 2.6 2,681 72 00 0 0 
heparin 0.69* 9.58* 292* 8 3.3 2,472 67 00 0 0 
biotin 0.81 8.28* 323* 9 3.7 1,771 48 00 0 0 
14 1.5 0.67* 12.05* 291* 8 1.8 1,887 51 00 0 0 
heparin 1.17 7.71* 342* 9 3.8 191 5 268 0.006 1.5 
biotin 0.72 11.58* 256* 7 3.0 1,658 45 00 0 0 
15 1.4 1.23 9.83* 632* 17 4.0 1,126 30 203 0.008 2.1 
heparin 1.05 8.72* 582* 16 6.5 676 18 861 0.002 0.5 biotin 1.35* 8.07* 645* 18 7.6 411 11 140 0.01 2.7 
16 1.5 0.40* 11.58* 0 0 0 3,138 85 00 0 0 
heparin 0.46* 10.31* 84 2 0.9 2,513 68 00 0 0 
biotin 0.57* 8.61* 76 2 0.9 1. 650 44 00 0 0 
17 1.4 0.06* 33.30* 0 0 0 16,039 432 00 0 0 
heparin 0.09* 19.71* 0 0 0 8,299 224 00 0 0 
biotin 0.11* 15.81* 0 0 0 6,088 164 00 0 0 
18 1.5 0.02* 0* 0 0 0 0 0 00 0 0 
heparin 0.05* 10.66* 0 0 0 4,209 113 00 0 0 
biotin 0.05* 1.85 0 0 0 0 0 00 0 0 
w 
c.n 
·~ 
TABLE XXIXB. (CONTINUED) 
Fraction Serum \) r ILA !LAs tD FBS % 
equiv. (mg/106 ·d) Total ~U/ml % total Total ~U/ml equiv. total 
assayed ~u serum ~u serum (hrs.) (ml/ml 
(ml) serum) 
19 1.5 0.27* 13.29* 0 0 0 4,990 134 00 0 0 
neparin 0.08* 7.60* 0 0 0 1,688 46 00 0 0 
biotin 0.07* 2.16 0 0 0 0 0 00 0 0 
20 1.4 0.06* 8.52* 0 0 0 3,296 89 00 0 0 
neparin 0.01* 70.99* 0 0 0 48,481 1,307 00 0 0 
biotin 0. 004* 0,'<' 0 0 0 0 0 00 0 0 
21 1.0 0.02* 25.72* 0 0 0 12,210 329 00 0 0 
neparin 0.01* 98.77* 0 0 0 58,127 1,567 00 0 0 
biotin 0.07* 12.52* 0 0 0 4,089 110 00 0 0 
22 1.2 0.04* 15.09* 0 0 0 9,440 254 00 0 0 
neparin 0.01* 0* 0 0 0 0 0 00 0 0 
biotin 0.04* 1. 77 0 0 0 0 0 00 0 0 
23 1.8 0.08* 13.30* 0 0 0 3,507 95 00 0 0 
neparin 0.02* 80.22* 0 0 0 32,487 876 00 0 0 
biotin 0,'<' 0,'<' 0 0 0 0 0 00 0 0 
24 1.3 TOXIC 
Fraction Serum \} r !LA I LAs tD FBS io 
equiv. (mg/l0 6 'd) Total llU/ml % total Total llU/ml equiv. total 
assayed llU serum \.IU serum (hrs.) (ml/ml 
(ml) serum) 
Total 4,919 133 30.8 0.07 18.9 
heparin 5,331 144 59.6 0.08 21.8 
biotin 4,415 119 51.1 0.06 14.4 
2 1.9 0.70* 0.85* 0 0 0 0 0 
"' 
0 0 
1.0 2.91* 5.90 88,06S"k 2,374 552 4,371 118 36.4 0.06 17.3 
0.2 1.66* 5.02 65,099* 1,755 408 15,386 415 76.7 0.15 41.0 
* Significantly different from control population. (See legend to Fig. 34.) 
FIGURE 35. SEPHACRYL S-200 CHROMATOGRAPHY OF HUMAN 
SERUM ACETONE POWDER. 
See legend to Figure 34. 
t Lost due to microbial contamination. 
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(M.W. >250,000), 4 (M.W. 160,000), 5, 8, 11 and 13, and n..As in the ac~tone 
powder and Fractions 1, 2, 4, 6 (M. W. 79,000), 8 and 15. Biotin inhibited cell 
proliferation in Fraction 2, ILA in 11, 13 and 14 (M.W. 12,000), and ILAs in the 
acetone powder and Fractions 1,2,4, 8, 9 and 15. 
SUMMARY OF RESULTS PERTINENT TO SPECIFIC OBJECTIVES 
Cation-exchange chromatography with Sephadex C-50 was carried out on 
human plasma as described by Guenther. Although about 5 \JU IRI/ml plasma was 
found in the most cationic fraction eluted from the column, significant 
quantities of heparin-induced IRI were not found in any fraction, nor did heparin 
increase IRI in normal human serum and plasma. Thus, heparin was not used in 
subsequent experiments designed to elucidate a serum insulin-binding protein. 
Sephadex G-200 gel chromatography of 125I-insulin (6.2-70\.l U/ml) added to 
normal human serum and plasma revealed that less than 5% of radioactivity was 
associated with a protein fraction that included albumin. This pattern was not 
changed by treatment of the mixture with biotin (10 g/ml) or a ten-fold excess 
of unlabeled insulin, or prolonged incubation (5 days, 4°C) of the 125I-insulin-
plasma solution. High molecular weight radioactivity was unaffected by 
rechromatography with or without excess unlabeled insulin (1 m U). Dextran-
coated charcoal analysis of the high molecular weight I-125 activity revealed 
that radioactivity was not dissociated by a thirty-fold excess of unlabeled insulin 
or 8 M urea. Affinity chromatography of this material showed that more than 
80% of radioactivity was associated with albumin and about 10% exhibited a 
molecular weight of less than 2,000 daltons. 
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In order to determine the nature of serum ILA, human cell lines were 
examined for their ability to serve as the basis for an in vitro bioassay capable of 
discriminating specific ILA and the pleiotypic effects of growth factors. I found 
that Wl38 human fetal lung fibroblasts possess cell~urface insulin receptors. 
Physiologic concentrations of insulin added to replicate culture wells in medium 
containing 10% fetal bovine serum caused a significant increase in the rate of 
glucose uptake by these cells and inhibited traversal of the cells from lag phase 
to log phase. Both of these effects were found to be dose-dependent. The three 
of four malignant human cell lines that were found to possess insulin receptors 
also showed significant increases in glucose uptake rate and inhibition of cell 
proliferation in response to various concentrations of insulin. The one cell line 
negative for insulin receptors showed neither insulin response. 
A cultured fibroblast bioassay for insulin was developed by maintaining 
Wl38 cells in stationary phase in serum-free medium in multiple-well plastic 
cluster dishes for 4 days at 37°C, after which cells were counted in a 
hemacytometer and medium glucose was measured with a Beckman Glucose 
Analyzer. Insulin or other preparation to be tested was added to medium before 
addition to cells prev~ously plated in wells. Cell number was not affected by 
physiologic concentrations (25-100 ~U/ml) of insulin after 4 days. Total ILA 
measurements were based on the curvilinear increase of the parameter U 
(glucose uptake/control glucose uptake) with increasing insulin concentration, 
while measurements of specific ILA were based on the linear increase of the 
parameter R (rate of glucose uptake/control rate of glucose uptake) with 
increasing insulin concentration. Stimulation of cell proliferation was 
determined from the parameter v(cell number/control cell number). 
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Concentration of normal human serum by ultrafiltration through a M.W. 10 
kd cutoff membrane (PM 10) apparently caused the liberation of large amounts 
of IRI in the retentate (100 times the serum level). Less than 5% of serum IRI 
passed through the membrane, even in the presence of 8 M urea, but acid 
treatment caused two-thirds of serum IRI to pass through the membrane. Values 
obtained for both total ILA and specific ILA were similar to IRI in this fraction, 
but in serum these values were ten times the IRI. Less than 1% of serum ILA 
and three-fourths specific ILA passed through the membrane after treatment of 
a retentate fraction with 8 M urea. 
On Sephacryl S-200 gel chromatography of a serum PM 10 retentate 
fraction, about 90% of the IRI apparently generated during serum concentration 
eluted at a position corresponding to proteins of M. W. <10 kd, but significant 
quantities of IRI eluted in discrete peaks at higher molecular weights. Dextran-
coated charcoal analysis of elution fractions indicated a maximum serum insulin 
binding capacity of 4 J.J U/ml. Dextran-coated charcoal analysis also revealed no 
reversible binding of 1251-insulin to acid-treated human serum and high 
molecular weight serum fractions. 
Gel chromatography of a human serum acetone powder revealed that most 
serum ILA eluted at about 250 kd M. W ., with virtually all of the serum's capacity 
to stimulate cell proliferation. Both biotin and heparin enhanced as well as 
decreased total ILA, specific ILA and cell number in various fractions. About 
half of serum IRI eluted at positions corresponding to proteins of M.W. >18 kd. 
Although only 0.5 J.J U IRI/ml serum was found at the column exclusion volume 
(Fraction 2), with large quantities of dilution-enhanced cell proliferation 
stimulation activity, dilution of this fraction also greatly enhanced specific ILA, 
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which attained a maximum of about 400 \JU/ml serum at an equivalent of 0.2 ml 
serum/ml, representing about 2096 of the total ILA in the fraction. 
CHAPTER Vlll 
DISCUSSION 
IS THERE A SERUM INSULIN-BINDING PROTEIN? 
By 1965, two major lines of evidence supported the existence of an 
insulin-binding protein in human serum: 1) AIS-suppressible ATE"'1>otentiated ILA 
in serum and BI fractions (390,511) and 2) apparent association of radiolabeled 
insulin with human serum a - Y globulins (520-522). However, Berson and 
Yalow and others were unable to enhance IRI of human serum and BI fractions by 
treatment that potentiated ILA measured by bioassays (523, 524). Furthermore, 
Berson and Yalow demonstrated that apparent association of radiolabeled insulin 
with globulins was, in fact, irreversible binding of damaged tracer to serum 
proteins, especially albumin (515). These investigators also refuted the existence 
of a serum insulin-binding protein on theoretical grounds, pointing out that the 
known effects of hormone-binding proteins are inconsistent with insulin decay 
kinetics in vivo and that insulin-binding antibodies in diabetics are highly 
disruptive of insulin~ependent carbohydrate homeostasis (528). 
On the other hand, insulin-like growth factors (IGFs), such as NSILA-8 
(IGFs I and ll) and the somatomedins, which show extensive homology with insulin 
and presumably derive from a common ancestral gene, have recently been shown 
to have serum binding proteins (557, 573, 585, 598, 602, 611, 612). Thus, an 
insulin-binding protein is a plausible expectation. Finally, Guenther's 
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demonstration of heparin-induced IRI in BI fractions {387) both confirmed 
Gundersen and Lin's observations with a rat diaphragm assay {391) and provided 
direct evidence for a human serum insulin-binding protein. 
In the present study, Sephadex C-50 chromatography of human plasma 
using Guenther's protocol resulted in elution of 10 J.l U IRI/ml plasma retained 
on the cation exchanger, about half the IRI that Guenther found in the untreated 
BI fraction. About 43% of this IRI was eluted in the most cationic fraction, but 
the same quantity of heparin employed by Guenther did not significantly increase 
the IRI in this or any other fraction. Nevertheless, this experiment confirms the 
presence of cationic IRI in human plasma. The presence of an insulin-binding 
protein in human serum and plasma was also supported by loss of approximately 
30% exogenous insulin added to CPD plasma and both plasma and serum after 
treatment with an anion-exchange resin {to remove insulin), measured by the 
dextran-charcoal RIA. However, these results could also be explained by 
potentiation of degradative enzyme activity. Again, heparin did not enhance IRI 
in any serum or plasma sample. Systematic examination of the 1251-insulin 
binding capacity of human serum and plasma using gel chromatography and 
dextran-coated charcoal as employed by Zapf et al. {557) to elucidate the 
NSILA-6 serum binding protein revealed that less than 5% of the 1-125 activity 
was associated with material in the molecular weight range 50,000-160,000 
daltons. This material was stable to dialysis and rechromatography and was 
apparently unaffected by treatment with biotin or large quantities of unlabeled 
insulin, suggesting irreversible binding of radiolabeled material. 
Dextran-charcoal analysis of this high molecular weight radioactivity 
revealed no liberation of free 1-125 activity by unlabeled insulin or 8 M urea, 
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confirming the irreversibility of the association. Subsequent dextran-charcoal 
analysis of Sephacryl S-200 fractions of a serum PM 10 retentate in which a 
large quantity of monomeric IRI was apparently liberated again revealed a 
maximum 6% binding of 1251-insulin that could not be reversed by unlabeled 
insulin or 6 M urea. If the insulin had been dissociated from a serum carrier 
protein during ultrafiltration, one or more high molecular weight fractions would 
be expected to exhibit a large reversible binding capacity for 1251-insulin. 
Immunodiffusion analysis and SDS polyacrylamide gel electrophoresis 
revealed that the high molecular weight radioactivity (peak A) consistently 
eluted with the major fraction of albumin. Affinity chromatography of A-peak 
material in fact showed that five-sixths of the 1-125 activity was bound to 
albumin and that about 10% activity exhibited a molecular weight of less than 
2,000 daltons, confirming Berson and Yalow's contention that apparent 
association of radiolabeled insulin with serum components represents irreversible 
binding of damaged tracer to proteins, particularly albumin. Thus, it must be 
concluded that no physiologically significant insulin-binding protein exists in 
normal human serum or plasma. 
WHAT IS ILA? 
The reason that findings of atypical IRI were judged to be the most 
pertinent evidence for a serum insulin-binding protein despite extensive findings 
of atypical ILA measured by various bioassays relates to the subsequent 
discovery of numerous substances that mimic insulin's effects in bioassays, but 
possess structures and physiologic roles that differ from those of the hormone. 
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The extent of the discrepancy between typical insulin and atypical ILA is 
suggested by the fact that more than 90% of serum ILA is not suppressible by 
AIS (527, 546). 
Much, if not all, of this NSILA is due to the effects of serum and plasma 
growth factors, several of which exhibit "specific" ILA (e.g_., stimulation of 
glucose uptake and lipid and glycogen synthesis) at supraphysiologic 
concentrations. These IGFs include NSILA-8 (IGFs I and ll), which comprises 
about 10% of total serum NSILA, the somatomedins and MSA (546, 547, 550, 
629). Poffenbarger (563) also showed that an antiserum raised against NSILP, 
which accounts for 70-80% human serum NSILA, reacts with MSA. In addition, 
non-IGF growth factors, such as FG:f' and EGF, may exert a pleiotypic effect on 
cells that could produce ILA in certain bioassays. For instance, BI may contain 
FGF as well as IGFs (717). 
Clearly, a bioassay capable of discriminating specific ILA and growth 
potentiation would be a very useful tool in dissecting the nature of serum ILA. 
In this study, a cultured fibroblast bioassay apparently exhibiting this 
discrimination and a double-antibody RIA for insulin were used to characterize 
human serum fractionated according to molecular size. 
The WI38 fetal lung fibroblast line is the only one of five human cell lines 
studied that was derived from a nonmalignant source. WI38 cells exhibit a 
diploid karyotype (740) and have a finite lifetime of 50 ±10 population doublings 
(741). The doubling time (tn> of 30 hours reported by Houck and Cheng (716) is 
similar to the 22-hour tn found in this study. Although these cells were used up 
to 54 generations, the consistency of tn and rate of glucose uptake (r) indicates 
that they had not become senescent. Of the five cell lines studied, SK-HEP-1 
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was the only one that was negative for insulin receptors by both 1251-insulin 
adsorption and PAP immunocytochemical staining. This cell line was also the 
only one that showed no significant increase of r in the presence of insulin. 
Although the initial study of WI38 human fetal lung fibroblast growth in 
the presence of serum indicated a decrease of r at confluence, subsequent 
studies of this cell line demonstrated that r remains relatively constant at -3 to 
-4 mg/106·day in log-phase, stationary and confluent cultures. Thus, the rate of 
glucose uptake appears to be independent of cell number and medium glucose 
concentration, contrary to other reports (554, 724-726), suggesting a facilitated 
or active glucose transport mechanism. The rate of glucose uptake exhibited by 
the other cell lines studied indicates that r is apparently independent of rate of 
cell proliferation and malignant transformation. 
Suprisingly, despite extensive documentation of insulin as a growth 
potentiator in pharmacologic doses, the hormone was found to inhibit 
proliferation of cultured cells positive for insulin receptors in this study when 
added at the time of plating in concentrations of 10 J.J U/ml-10 mU/ml. Only 
SK-HEP-1 proliferation was apparently unaffected by insulin, suggesting that 
this effect, as well as stimulation of glucose uptake, is mediated through insulin 
receptors and thus is insulin-specific, rather than being due to an insulin 
contaminant. This contention is supported by the fact that these effects are 
elicited by both human and bovine insulin preparations and is confirmed for 
enhancement of r by reversal in the fibroblast bioassay by AIS. The absence of 
toxic contaminants in insulin preparations is further indicated by the normal 
appearence of insulin-inhibited cells, which did not exhibit excessive granulation 
or floating debris, and the lack of insulin effect on cell number when the 
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hormone was added during log phase, confluence or stationary phase. Therefore, 
the concentration-dependent insulin jnhibition of cell proliferation appears to 
involve a hormone mechanism specific for lag-phase cells, in which cells are 
prevented from exiting lag phase or the subsequent log-phase cell cycle is 
somehow prolonged. 
A possible mechanism is suggested by Shapiro and Lam's observation that 
intracellular Ca ++ concentrations increase as human fibroblasts age in culture 
(742). Cultured fibroblast senescence is characterized by cessation of cell 
division (741, 743) and several investigators have provided evidence that insulin 
increases intracellular Ca ++ concentrations (see Chapter ID). Teng et al. (7 44) 
have found that 16 mU insulin/ml shortens Gr1>hase and extends the S-and G2-
phase of CEF in culture, while Koontz and Iwahashi (745) showed that physiologic 
concentrations of insulin (5 x 10-ll M) cause rat hepatoma cells to exit G1-
phase. Thus, it is unlikely that lag-phase is G1-phase. Inhibition of cell 
proliferation by insulin is also consistent with the hormone's physiologic role, 
which is to encourage energy storage through synthesis of macromolecules. 
Use of cultured Wl38 human fetal lung fibroblasts for an insulin bioassay 
is well-suited to examination of the nature and effect of human serum ILA on 
normal human cells since this cell line is diploid and well-characterized. 
Artifacts that could be encountered using malignant or non-human cells are 
exemplified by the evident loss of insulin receptors by SK-HEP-1 hepatoma cells, 
production of a growth factor (MSA) by Coon rat liver cells, rendering them 
serum-independent (629), and the fact that insulin is a much more potent 
mitogen for avian fibroblasts than for mammalian fibroblasts (616). 
In this study, a significant, specific (AIS-reversible), consistent, dose-
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dependent insulin-induced increase in rate of glucose uptake by cultured WI38 
fibroblasts is well documented. In addition, the use of stationary medium 
according to the method of Morell and Froesch (615) enables discrimination 
between specific ILA (!LAs) and the pleiotypic effects of growth factors. The 
insulin dose~ependent increase in the parameter U (glucose uptake/glucose 
uptake of control) is appropriate for measurement of total ILA since it is 
independent of cell number and does not discriminate between increments of U 
due to the stimulation of cell proliferation and those due to increase of r. !LAs is 
best measured by determination of the parameter R (r/control r), which also 
increases with increasing insulin concentration. However, because this 
parameter is dependent upon cell number, factors that cause loss of cells can 
yield artifactual enhancement of !LAs. Therefore, !LAs values were ignored 
where v (cell number/control cell number) fell below the control population 
( < 0.71). The validity of these assay parameters is indicated by the fact that 
both the ILA (177 ~U/ml) and ILAs(208 ~ U/ml) found for normal human 
serum are very close to the mean fat-pad assayable serum ILA (180 \.l U/ml) 
reported by Froesch et al. (527). 
Similar quantities of ILA were recovered in the total of Sephacryl S-200 
chromatography fractions (each assayed in 1-2 ml serum equivalents) from a 
human serum PM 10 retentate (PM10r1, M.W. >10,000, ILA recovered =242 
\.lU/ml serum) and from a human serum acetone powder (133 ~ U /ml serum). 
However, total ILA recovered from the PM10r1 fractions represents only 14% of 
the 1,735 ~ U ILA/ml serum found when PM10r1 was assayed at a 0.035 ml 
serum equivalent, a value similar to ILA concentrations obtained by Gundersen 
and Lin (391) for dilute human sera using the fat pad assay. No ILAs was 
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detected in the tenfold diluted PM10r1 preparation, suggesting the dilution-
enhanced ILA is due to attenuation of inhibitors of one of more serum growth 
factors. This possibility is supported by dilution enhancement of PM10r1 
stimulation of Wl38 cell proliferation, to 5 and 40 times the rate expected with 
equivalent amounts of FBS and human serum, respectively, based on cell 
proliferation rates in the presence of 10% concentrations of these sera. 
Furthermore, numerous S-200 fractions caused decreases in cell number relative 
to controls and several exhibited frank toxicity, evidenced by disintigration of 
cells. The possibility that high molecular weight lipidic material constitutes an 
important class of growth factor inhibitors is supported by abolition of toxicity 
in exclusion fl"actions by extraction qf fractions or serum with acetone, enabling 
measurement of cell growth stimulation by these fractions. 
About 5% recovered PM10r1 ILA eluted at 6,800-7,800 daltons, where 
free NSILA-8 would be expected. Only 5% recovered serum acetone powder ILA 
eluted around 70,000 daltons, where NSILA-8 associated with its carrier protein 
should be found. However, nearly 20% ILA, coincident with an ILAs peak, eluted 
from both columns between 30,000 and 50,000 daltons. Zapf et al. (557) reported 
that considerable amounts of serum NSILA-8-binding activity was also detected 
at molecular weight 30,000-40,000 daltons, indicating that the binding protein 
may be present in serum partly as oligomers. The results of this study support 
the contention that a 35,000-dalton protein represents the primary NSILA-8 
-binding component of human serum. About 10% ILA eluted from both columns 
between 12,500 and 17,500 daltons, suggesting a NSILA-8 dimer. All these 
putative NSILA-8 fractions contained concomitant ILAs and did not stimulate 
significant cell proliferation. The ability of the cultured fibroblast assay to 
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detect serum protein-bound NSILA-8 is supported by passage of about one-third 
PM10r2 ILA through a PM 10 membrane after treatment of the fraction with 8 M 
urea. The acetone powder ILA peak at about 10,000 daltons may be due to 
MSA. This assay, however, would not be expected to detect EGF or FGF. 
About 20% of acetone powder ILA eluted at the column exclusion volume 
with a peak of cell proliferation potentiation. This activity is very 
concentration-dependent, however. When Fraction 2 was assayed at a 1.9-ml 
serum equivalent, complete suppression of both ILA and cell growth potentiation 
was seen, but both these parameters increased markedly as the fraction was 
diluted, until at 0.2 ml serum equivalent it exhibited 1,755\.l U ILA/ml and 41% 
total acetone powder growth potentiation. In addition, 1.5-1.8 ml serum 
equivalent of Fractions 3 and 4 caused WI38 fibroblasts to form multilayered foci 
in which the cells grew in a random orientation, satisfying a morphologic 
criterion of malignant transformation (746). Thus, a serum growth factor of 
approximately 240,000 daltons molecular weight not only accounts for the entire 
potentiation of WI38 cell proliferation by human serum, but also is the apparent 
cause of serum dilution~otentiated ILA. The dilution enhancement of ILA 
and v may be due to attenuation of an inhibitory substance or a concentration 
optimum of factor-receptor interaction. This growth factor may be an 
aggregate form of NSILA-P or the WI38 growth factor, or an as-yet 
uncharacterized growth factor. However, only 8% of acetone powder ILA, with 
concomitant ILAs and without growth stimulation, eluted between 92,000 and 
130,000 daltons, where NSILA-P and WI38 growth factor would be expected, but 
a major peak of cell proliferation, containing 8% ILA and no ILAs, eluted at half 
the molecular weight, 49,000-65,000 daltons. 
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On the other hand, the exclusion-volume cell proliferation stimulating 
activity may represent aggregate forms of transforming growth factors (TGFs) 
and platelet-derived growth factors (PDGFs) bound to serum carrier proteins. 
However, only a biotin~otentiated peak of cell proliferation was found in a 
PM10rl S-200 fraction corresponding to molecular weight ::.:37,000 daltons, 
within the range of 30-40 kd reported for PDGF (747), and no stimulation of cell 
proliferation was found in the molecular weight range 10-20 kd, where TGFs 
would be expected to elute (7 48). 
IS THERE OCCULT INSULIN? 
Although the results of this study indicate that serum ILA could be due 
totally to IGFs and other growth factors, there also remains evidence for the 
existence of an occult form of insulin in human blood. Like Guenther, I found a 
significant amount of IRI (about 4 ~U/ml plasma) in highly cationic plasma 
fractions. Furthermore, more than half the IRI in a serum acetone powder 
eluted from Sephacryl S-200 at positions corresponding to proteins in excess of 
18,000 daltons molecular weight. 
If occult insulin cannot be due to an as-yet uncharacterized specific 
serum insulin-binding protein, then it most likely is due to the one known insulin-
binding protein: insulin. Elution of serum IRI peaks from Sephacryl roughly 
corresponds to what would be expected for the dimer, tetramer, hexamer, di-
hexamer and hexa-hexamer and, in fact, the ILA ascribed to IGFs could also be 
due to insulin. Since insulin aggregates, especially the hexamer and 
polyhexamers, are expected to exhibit only a small fraction of monomeric IRI, 
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this high molecular weight serum IRI could represent a much greater absolute 
amount of insulin -as much as 2 m U /ml or more, which was apparently 
"liberated" in PMlOrl. However, this phenomenon could not be reproduced 
(although the circumstances of the reproduction were not identical to the 
original conditions) and comparable quantities of IRI were not found in PM10r2 
and UM2r2, the fractions resulting from dilution and reconcentration of one-half 
PMlOrl. Unfortunately, the possibility that this IRI was an artifact due to 
contamination of the fraction with porcine insulin was unable to be tested since 
the RIAs employed were unable to distinguish between human and porcine 
insulins. The existence of insulin aggregates in human serum is also supported by 
a 2- to 3-fold enhancement of IRI and passage of two-thirds to three-fourths of 
this IRI through a PM 10 membrane after treatment of human serum or PM10r2 
with acid, whereas s; 1% untreated serum or PM10r2 IRI passes through the 
membrane. 
A specific ILA of 415 lJU/ml serum was found at a 0.2 ml serum 
equivalent of acetone powder S-200 Fraction 2, which exhibited an IRI of only 
0.5 lJU/ml serum. The ILAs in the assay well at this dilution thus was about 
80 lJ U, nearly the optimum insulin concentration for this assay. This result, 
therefore, indicates that this fraction actually contains about 1,000 times more 
insulin than the IRI (consistent with insulin aggregates, which would be expected 
to exhibit only a small fraction of the IRI of monomeric insulin) and that 
circulating insulin aggregates may account for 20-25% total serum ILA. 
The exceedingly small proportion of aggregates found in neutral aqueous 
insulin solutions at physiologic concentrations of the hormone (and of Zn ++) and 
calculations based on equilibrium association constants determined for insulin 
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aggregates has led to the general conclusion that significant quantities of insulin 
aggregates cannot exist in systemic circulation. However, these studies involved 
measurement of insulin association at equilibrium after crystalline insulin was 
dissolved at acid pH. In vivo, crystalline insulin is released into the circulation 
at pH 7 .4. Therefore, a more appropriate model of insulin aggregates in vivo 
would be measurement of crystalline insulin dissociation in dilute neutral 
solution. An example of such an experiment is measurement of the appearance 
with time of monomeric IRI in a stirred suspension of 80 ].J g crystalline zinc-
porcine insulin in one liter 596 BSA/pH 7.4 PBS at 37°C. 
The possibility that the equilibrium association constants observed for the 
formation of insulin aggregates results from rates of dissociation far slower than 
relatively slow association rates, to the extent that insulin aggregate 
dissociation in vivo is far from equilibrium is supported by examination of insulin 
aggregate characteristics iterated in Chapter V. Whereas hydrogen bond 
formation between amino acid substituents cannot be expected to contribute to 
subunit association (and, in fact, should add an unfavorable fiG increment since 
organic nitrogen and oxygen form stronger hydrogen bonds with water than with 
each other (749)), the 4 hydrogen bonds per dimer and 6 additional hydrogen 
bonds per hexamer contribute a t~G of about +2.4 kcal/mole each to dissociation 
of these aggregates (749). The net t~G of about +0.75 kcal/mole required to 
break amino acid-water hydrogen bonds and form internal hydrogen bonds during 
subunit association is reversed upon dissociation. Likewise, the ll G involved in 
displacement of water coordinated to Zn ++ by coordination of amino acid 
substituents to Zn ++ during formation of the Zn ++ tetra mer and hexamer is 
reversed during dissociation of these species. 
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Therefore, the - !::. G underlying the positive equilibrium association 
constants observed for insulin aggregation is probably due primarily to transfer 
of apolar amino acid side chains from water to an apolar environment. However, 
if the 12 apolar side chains that appear to make contacts in the dimer and the 42 
additional apolar side chains that have been implicated in the hydrophobic 
interactions of hexamer formation were completely buried, yielding a t:. G of 
about -2.5 kcal/mole each (750, 751), the resultant equilibrium association 
constants would be much higher than those observed, suggesting that these side 
chains are not completely buried. This contention is supported by the fact that 
the A14 tyrosines and B25 phenylalanines are exposed at the surface of the 
hexamer (464). 
Nevertheless, amino acid-water hydrogen bonds and Zn ++ - water 
coordinate bonds must first be broken before hydrophobic interactions can occur 
during subunit association, while not only internal hydrogen and coordinate bonds 
must be broken, but energy must also be expended to transfer apolar side chains 
to water before the - t:.G of water-bonding can be realized during aggregate 
dissociation, indicating that the rate of dissociation must be much slower than 
the rate of association. Studies of insulin aggregation in neutral solution have 
indicated that the 2-Zn ++ hexamer is essentially completely dissociated at 
concentrations below 10-7 M (472). Therefore, if hexamers exist in the systemic 
circulation at a concentration of 10-9 M, they are less than 5% dissociated. In 
other words, if significant quantities of insulin aggregates exist in the systemic 
circulation-and the results of this study indicate that they do-it can only be 
due to an extremely low rate of dissociation, much lower than the rate of 
systemic degradation of monomeric insulin so that insulin aggregate dissociation 
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is extremely limiting. Furthermore, since examination of the primary structure 
of insulin reveals that the hormone possesses a net charge of -1 per monomer at 
neutral pH, cationic IRI could represent > 2 Zn ++ tetramers and hexamers. 
The disruption of glucose homeostasis by insulin-binding proteins 
postulated by Berson and Yalow would not apply to insulin aggregates because of 
a fundamental difference between the nature of competitive protein binding, 
such as that which occurs with antibodies, carriers and receptors, and insulin 
aggregation. The former would be expected to involve high-avidity interactions, 
i,e. a very rapid association and a relatively rapid dissociation, enabling 
displacement by additional ligand or dilution, while the latter apparently involves 
a very slow dissociation and a relatively slow association. This supposition is 
supported by the fact that 8 M urea caused no generation of monomeric IRI in 
PM10r2, while acid treatment of this fraction resulted in passage of 75% IRI 
through a PM 10 membrane. Provided the systemic insulin degradative 
mechanism remains intact, monomeric insulin provided by aggregate dissociation 
will be destroyed nearly as quickly as it is generated. 
What, then, is the purpose of circulating insulin aggregates? One 
possibility is that it is the harmless consequence of an elegant mechanism of 
acute secretion of a hormone that causes the rapid utilization of nutrients, like 
the proinsulin coincidentally secreted with insulin. The other possibility is that 
circulating insulin aggregates serve a physiologic function. One possible function 
is suggested by insulin enhancement of glucose transport across the blood-brain 
barrier (752). An acute requirement for glucose by the central nervous system 
may arise during a prolonged fast, when serum insulin and glucose levels are 
basal. Although nervous stimulation of pancreatic insulin release has been 
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demonstrated, the physiologic role of this phenomenon is unclear (753). 
Certainly, neural induction of pancreatic insulin secretion during a prolonged 
fast would appear to be both wasteful and dangerous, since most of the serum 
glucose would be absorbed by peripheral tissues and a severe hypoglycemia would 
ensue before a glucagon-induced release of glucose by the liver could occur. If 
brain capillary endothelium, for instance, possessed an inducible enzyme system 
capable of dissociating insulin aggregates in situ however, insulin-stimulated 
---
glucose uptake would occur where needed and serum glucose levels would fall 
slowly enough to enable compensation by liver glucose release. In addition, a 
precedent for enzyme-mediated dissociation of macromolecular aggregates 
stabilized by hydrogen bonds and hydrophobic interactions exists within the most 
ancient forms of life: DNA polymerases. 
Besides the in vitro study of crystalline insulin dissociation mentioned 
above, the following experiments would be helpful in ascertaining the existence 
and role of circulating insulin aggregates. 
1. The existence of insulin aggregates in blood should be verified by 
further purification of gel chromatography fractions containing high molecular 
weight serum IRI, using ion-exchange chromatography; purified IRI should then 
be subjected to gel chromatography after acid treatment to determine whether 
monomeric IRI is generated. 
2. The hypothesis that insulin aggregates dissociate slowly in vivo should 
be tested by monitoring blood IRI and glucose in fasted animals infused with 
specific inhibitors of the insulinases, such as antibodies raised against the 
enzymes and biologically inactive insulin analogs ~.,A- and B-chains and DOP-
insulin). 
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3. The existence of an insulin aggregate dissociating enzyme should be 
ascertained by testing for generation of monomeric IRI in human serum during 
prolonged incubation after concentration and in the presence of tissue 
homogenates, especially of brain. 
THE EFFECTS OF HEPARIN AND BIOTIN ON SERUM ILA 
Heparin did not enhance the IRI of human serum or plasma, even after 
treatment with an anion-exchange resin, and it did not cause significant decrease 
in recovery of IRI from serum or plasma. Neither did it significantly affect the 
IRI of plasma cation exchange fractions and it did not cause IRI to be passed 
through a PM 10 membrane, indicating that heparin does not potentiate 
dissociation of insulin aggregates or a putative hormone-protein compl~ 
Heparin also did not increase serum ILA or ILAs and did not appear to dissociate 
NSILA-8 from its carrier protein, since, where it increased ILA ~., in dilute 
PM10r1), it did not increase ILAs. On the other hand, several instances of 
heparin enhancement of ILAs without increase of ILA are probably artifactual. 
The possibility that heparin enhances serum ILA by potentiating the effects of 
one or more growth factors is supported by heparin-stimulated WI38 cell 
proliferation with PM10r1, PM10r2, PM10r1 S-200 Fraction 10 (M.W. 33-42 kd), 
and human serum acetone powder S-200 Fraction 1 (M.W. >240 kd). Generally, 
it is expected that heparin, as a polyanion, will potentiate anionic effecters by 
complexing cationic inhibitors and will inhibit cationic effecters. Therefore, 
heparin would be expected to potentiate the effects of NSILP, SMB, MSA and 
WI38 growth factor, and to inhibit NSILA-8 and SMC. The expected effects on 
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ILA and/or cell proliferation were seen in fractions corresponding to free NSILA-
S and NSILA-8 bound to a carrier protein of about 30 kd M. W ., NSILP and SMC, 
but not in fractions where SMB, MSA or WI38 growth factor would be expected 
to elute. 
Biotin appeared to cause a significant decrease in the recovery of IRI 
from serum. However, S-200 chromatography of exogenous radiolabeled insulin 
in human serum after treatment with biotin showed no difference in magnitude 
or position of eluted radioactive and protein peaks relative to the control, 
indicating that biotin causes neither dissociation of an insulin-protein complex 
nor enhancement of serum proteolysis. Biotin also did not significantly stimulate 
cell proliferation or ILA of human. serum or bulk serum fractions, but did 
increase these parameters in specific serum S-200 fractions. The possibility that 
biotin enhancement of ILA in serum fractions is due to a synergistic potentiation 
of growth factor effects by the substance is supported by a report that biotin 
stimulates guanylate cyclase activity in rat tissues (754). The resultant increase 
in intracellular concentrations of cG MP is known to stimulate cell proliferation 
in many systems (296). In this study, however, biotin alone did not affect the 
RIA and neither heparin nor biotin alone affected the fibroblast bioassay. 
Finally, there remains the question of heparin-induced IRI. I found that 
heparin interferes with the RIA, causing a partial dissociation of antigen-
antibody complexes that would result in false increments of IRI, but not at the 
concentration employed by Guenther. Neither did Guenther find any effect of 
this amount (100 J.Jg/ml) of heparin on his RIA (387). For his study, however, 
Guenther employed a pool of patient sera prepared by the Foster G. McGaw 
Hospital Clinical Chemistry Laboratory, reasoning that this pool ''should thus 
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represent a good cross-section of sera". There is also an excellent possibility 
that this pool included sera from diabetics whose blood often contains hirge 
quantities of exogenous insulin complexed by anti-insulin antibodies (409). 
Although high-affinity guinea pig anti-insulin antibodies are unaffected by 100 
J.lftleparin/ml, relatively low affinity human anti-insulin antibodies (449) may be 
partially dissociated from antigen by this concentration of heparin, yielding 
' 
concentrations of free insulin that could produce the increments of IRI observed 
by Guenther. 
In conclusion, the results of this study indicate that there is no serum 
insulin-binding protein, that most ( :.: 75%) of the serum ILA observed using in 
vitro bioassays is due to the effects of growth factors, ·and that significant 
quantities of circulating insulin aggregates may exist in vivo and play a 
physiologic role in carbohydrate homeostasis. 
SUMMARY 
With the advent of in vitro bioassays for insulin, human blood components 
---
that mimic the effects of insulin in these assays, yet do not possess the 
physicochemical properties of insulin were discovered. Specifically, serum 
substances retained by cation-exchange resins were found to enhance glucose 
uptake and utilization by rat diaphragms and epididymal fat pads, but did not 
react with anti-insulin antibodies. This atypical insulin-like activity (ILA) led to 
speculation that a fraction of circulating insulin is complexed to a specific 
carrier protein. In 1974, H. Guenther (Loyola University, Chicago, Ph.D. 
Dissertation) lent support to this contention by demonstrating that insulin 
concentrations measured by radioimmunoassay (RIA; immunoreactive insulin, 
IRI) in cationic human serum fractions were increased e>y t.E-parin, a polyanion, 
and that ILA measured by in vitro bioassays in these fractions was increased by 
heparin and biotin. The present study was undertaken to test the reproducibility 
of these results and to ascertain more specifically the nature of atypical ILA in 
human serum and plasma using a cultured fibroblast bioassay capable of 
discriminating specific ILA and the pleiotypic effects of growth factors. 
Four hundred fifty milliliters normal human plasma was mixed with ten 
grams Sephadex C-50 cation exchanger after hydration of the gel, which was 
then transferred to a 2.5 x 100 em column and eluted with a 0.005-1.5 M 
potassium chloride gradient. Although about 5 J.l U IRI/ml plasma was found in 
the most cationic fraction eluting from this column, heparin did not significantly 
affect the IRI of this or any other fraction. Heparin also did not increase the IRI 
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of normal human serum or plasma, or bulk serum fractions prepared by 
ultrafiltration, nor did it significantly decrease the recovery of exogenous IRI 
from serum or plasma. 
A systematic examination of the ability of human serum and plasma 
components to bind exogenous radiolabeled insulin specifically and reversibly, 
using Sephadex G-200 gel chromatography and dextran-coated charcoal, revealed 
that less than 5% of the 1-125 activity eluted with albumin (A-peak) and less than 
1% radioactivity eluted at the column exclusion volume (C-peak, molecular 
weight >360,000 daltons), while about 90% of the added radioactivity eluted at 
positions corresponding to molecular weights less than 40,000 daltons (B-peak, 
M.W. <40 kd) and was immunochemically identical to free 1251-insulin. The size 
and relative positions of the high molecular weight radioactive peaks were 
unaffected by rechromatography, biotin or 1-2.25 mU unlabeled insulin. A 
thirtyfold excess of unlabeled insulin and 8 M urea also failed to liberate free 
insulin from A-peak material, as determined by dextran-charcoal adsorption of 1-
125 activity. Affinity chromatography of A-peak material through columns of 
anti-albumin antibodies covalently coupled to Sepharose 4B revealed that 84% of 
A-peak radioactivity was bound to albumin and an additional 11% radioactivity 
exhibited a molecular weight of less than 2,000 daltons, confirming Berson and 
Yalow's contention that exogenous radiolabeled insulin apparently associated 
with serum components represents "damaged" label irreversibly bound to serum 
proteins, particularly albumin, and that a physiologically significant insulin-
binding protein does not exist in human serum. 
Cultured human fibroblasts maintained in stationary phase in the absence 
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of serum were found to offer a means for discriminating the effects of growth 
factors from specific ILA since the rate of glucose uptake by these cells is 
significantly stimulated by insulin in a dose-dependent manner. The use of 1-ml 
cultures in multi-well plates affords a convenience of replicate determinations 
hitherto lacking in in vitro bioassays. Use of this bioassay to examine human 
serum fractionated by molecular size revealed that virtually all of the capacity 
of human serum to stimulate cell proliferation and about 95% potential serum 
ILA reside in one or more serum components of M. W. :: 240 kd. Most of the 
remaining ILA was consistent with well-characterized insulin-like growth 
factors. Half of serum IRI eluted at M. W. >18 kd, suggesting that appreciable 
amounts of insulin aggregates exist in the peripheral circulation. Both biotin and 
heparin enhanced ILA in certain serum fractions concomitant with potentiation 
of cell proliferation, but without stimulation of glucose uptake rate, indicating 
that previously reported increase of ILA by these agents is due to potentiation of 
serum growth factors. 
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